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Abstract 
The Effects of Surface Layer Proteins Isolated from Clostridium difficile on TLR4 
signalling- Kathy F. Kennedy M.Sc. 
Clostridium difficile (C. difficile) is a gram-positive, spore-forming, pathogenic 
bacterium that results in a range of gastrointestinal diseases. The incidence of C. 
difficile infection (CDI) has increased dramatically and has a significant impact on 
healthcare settings worldwide. The severity of disease may be dependent on the 
ribotype (RT) of C. difficile present. Previous research from our laboratory has shown 
that Surface Layer Proteins (SLPs) from RT 001 activate Toll-like receptor 4 (TLR4), 
with subsequent activation of downstream signalling pathways known to be important 
in the clearance of CDI. In this study we demonstrate that SLPs from RT 001 fail to 
activate IRF3 signalling, while SLPs from RT 027 activate both arms of the TLR4 
pathway. Evidence from the literature suggests that microRNAs (miRNAs) tightly 
regulate TLR4 signalling and have a role in orchestrating the host’s immune response to 
infection. The profile of miRNAs regulated in response to SLPs from C. difficile has not 
been profiled before. Subsequently we identified novel miRNAs regulated in response 
to LPS, SLPs from RT 001 and RT 027 in vitro. We found 24 miRNAs were 
differentially regulated between SLPs in response to RT 001 and RT 027 and there was 
a global down regulation of miRNAs in response to SLPs from RT 027. These miRNAs 
may modulate TLR4 signalling. Data from colonic tissue, from an in vivo murine model 
show miR-146a, miR-145, miR-155 and let-7e may have a role in regulating the host’s 
immune response during early and late stage CDI. The absence of miRNAs regulated in 
response to RT 027 may correlate to less efficient clearance by the host’s immune 
response and more persistent infection. The miRNAs are predicted to target essential 
cell processes and the impact of the modulation of the immune response by these 
miRNAs may lead to biologically relevant changes at the cell level. Further work is 
needed to fully elucidate the complexities of these miRNAs in relation to the networks 
they modulate. The effectiveness of current treatments is limited by a lack of response 
in some patients and high recurrence rates. The data generated in this study may be used 
to develop miRNA based therapy for the treatment of persistent CDI, allowing bacterial 
clearance by the host’s immune system without the need for antibiotics. 
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Chapter 1: General Introduction 
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1.1 Clostridium difficile 
Clostridium difficile (C. difficile) is a gram-positive, spore-forming, rod-shaped 
anaerobic bacterium that causes a range of gastrointestinal diseases known as 
Clostridium difficile Infection (CDI) (Bartlett, 1994; Fagan et al., 2009; Kachrimanidou 
& Malisiovas, 2011). It is the leading cause of antibiotic-associated diarrhoea 
worldwide (Dawson, Valiente, & Wren, 2009; Dubberke, 2012). C. difficile can only 
colonise the gut if the normal intestinal microbiota is disturbed or absent, in most cases 
this is achieved by the administration of antibiotics (Calabi, Calabi, Phillips, & 
Fairweather, 2002; Denève, Janoir, Poilane, Fantinato, & Collignon, 2009; Rupnik, 
Wilcox, & Gerding, 2009). The bacterium’s ability to grow in the presence of 
antibiotics in recent years has enabled its rapid spread among patients (Rupnik et al., 
2009). Antibiotic treatment diminishes commensal micro-organisms in the gut and their 
ability to mediate innate immune responses and this enables the proliferation of the 
often antibiotic resistant C. difficile (Buffie & Pamer, 2013). The bacterium can then 
dominate the mucosal surfaces and destroy cellular barriers through toxin mediated 
destruction of the epithelial cells, leading to apoptosis and cell death (Buffie & Pamer, 
2013; Denève et al., 2009).  
C. difficile is potentially a very serious condition frequently effecting hospitalised 
patients and in particular the elderly (Ausiello et al., 2006). However, not all infections 
result in disease; outcomes range from asymptomatic colonisation to mild diarrhoea. 
More serious disease symptoms include abdominal pain, fever and leukocytosis. Severe 
manifestations of the disease are characterised by inflammatory lesions see Figure 1.1.1 
and the formation of pseudo-membranes in the colon which can lead to bowel 
perforation, sepsis, shock and death. The severity of disease may also be dependent on 
the strain of C. difficile present (Goorhuis et al., 2007; Rupnik et al., 2009). Since its 
confirmation as a pathogen in 1977 (Larson, 1978), C. difficile has been one of the most 
intensively typed pathogens (Dawson et al., 2009). The most widely accepted method is 
polymerase chain reaction (PCR) ribotyping, where more than 100 distinguishable 
groups have been identified based on mutations in the 16S and 23S ribosomal RNA 
(rRNA) intergenic spacer regions (Dawson et al., 2009; Stubbs, Brazier, O’Neill, & 
Duerden, 1999). A study carried out by Ní Eidhin et al. (2006) sequenced the slpA gene 
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and flanking deoxyribonucleic acid (DNA) from C. difficile isolated from patients in St 
James’s Hospital, Dublin Ireland over a 16-month period. The most frequently 
occurring ribotypes found in this study were 001, 012 and 017 (Ní Eidhin, Ryan, Doyle, 
Walsh, & Kelleher, 2006). There is much evidence to suggest that C. difficile is 
evolving to occupy niche hospital populations and there has been rapid worldwide 
spread of ribotypes 027 and 078 (Dawson et al., 2009). Ribotypes 027 and 078 are 
known to be ‘hypervirulent’ and have been associated with more severe diarrhoea, 
higher mortality and more recurrences (Clements, Magalhães, Tatem, Paterson, & 
Riley, 2010; Dawson et al., 2009; Goorhuis et al., 2007; Loo et al., 2005). 
 
 
Figure 1.1.1 Image of ‘volcano-like’ lesions as a result of the local inflammatory 
effects of C. difficile infection in the colon (Rupnik, Wilcox and Gerding 2009) 
1.1.1  Toxin Production 
Treatment with broad-spectrum antibiotics alters the intestinal microbiota and this 
allows C. difficile to colonise the colon if present. After colonisation the bacterium 
produces and releases toxins. Toxin A (TcdA) encoded by tcdA and Toxin B (TcdB) 
encoded by tcd, are the two main toxins released by C. difficile. These toxins are located 
in a 19.6 kilobase (Kb) pathogenicity locus (PaLoc) together with three additional tcd 
open reading frames (ORFs) tcdC, tcdD and tcdE (Braun, Hundsberger, Leukel, 
Sauerborn, & Von Eichel-Streiber, 1996; Dupuy, Govind, Antunes, & Matamouros, 
2008; Hammond & Johnson, 1995). TcdA and TcdB are composed of three domains, 
the first being a carboxy-terminal domain which is responsible for binding to the host 
cell membrane (Eichel-streiber, Sauerborn, & Kuramitsu, 1992). The second domain 
  
 
 4 
contains a hydrophobic centre which has been shown to be involved in translocation 
across the cellular membrane (Pfeifer et al., 2003) and finally the third domain contains 
an amino-terminal domain that enables glucosyltransferase to be catalysed (Hofmann, 
Busch, Just, Aktories, & Prepens, 1997; Jank, Giesemann, & Aktories, 2007; von 
Eichel-Streiber, Boquet, Sauerborn, & Thelestam, 1996). TcdA binds to the apical side 
of the cell where it is endocytosed and a pore in the membrane is formed see Figure 
1.1.2. This triggers the activation of small molecular weight guanine nucleotide-
binding proteins (G-proteins), resulting in disruption of the cytoskeleton (Reineke et al., 
2007).  
 
Figure 1.1.2 Image illustrating the destruction of the cellular barriers by TcdA and 
TcdB release from C. difficile leading to the pathogenesis of CDI (Rupnik et al., 2009) 
Disruption of the cytoskeleton leads to the loosening of tight junctions in the epithelial 
barrier, enabling more toxins to cross the cell membrane (Rupnik et al., 2009). Cell 
death ensues and the dying cell produces inflammatory mediators that attract 
neutrophils. TcdB binds to the basolateral cell membrane where it acts on its cytosolic 
targets, the Guanosine Triphosphatase (GTPases) of the Rho/Rac family (Reineke et al., 
2007). TcdB induces the release of more immunomodulatory mediators resulting in 
inflammation due to the accumulation of neutrophils, phagocytes and mast cells 
(Rupnik et al., 2009). Ultimately this leads to intestinal inflammation and the onset of 
the symptoms previously described. The majority of toxigenic C. difficile strains co-
produce TcdA and TcdB (toxinotype A+B+) while only a minority of C. difficile strains 
exclusively produce TcdB (toxinotype A−B+); for instance the hypervirulent ribotype 
017 has a truncated non-functional TcdA due to a deletion in the tcdA gene (Voth & 
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Ballard, 2005). Approximately 6–10% of C. difficile strains generate a binary actin-
adenosine diphosphate (ADP) ribosylating toxin known as C. difficile transferase (CDT) 
in addition to the other toxins (Barth, Aktories, Popoff, & Stiles, 2004).  
As mentioned earlier the PaLoc contains three additional ORFs, where sequencing and 
transcription analysis suggest that TcdC and TcdD are involved in the positive and 
negative regulation of TcdA and TcdB expression (Hammond & Johnson, 1995; 
Hundsberger et al., 1997). The TcdC region of ribotype 027 contains an 18 base pair 
(bp) deletion and it is thought that this modification may lead to an altered function of 
the protein contributing to the high level of toxin expression, in consequence causing 
ribotype 027 to be ‘hypervirulent’ (Spigaglia & Mastrantonio, 2002). However a variety 
of deletions have been observed in non-virulent strains, therefore deletions may not 
always result in the loss of function. Increased virulence is not solely due to toxin 
production (Drudy et al., 2004). While the toxins of C. difficile are clearly of great 
importance in the study of its pathogenesis, other virulence factors cannot be ignored. 
1.1.2 Clostridium difficile Spores and Germination  
C. difficile is extraordinary as it is highly transmissible between humans: this is key to 
its survival and persistence (Deakin et al., 2012). The main mode of transmission of 
CDI is through the ingestion of C. difficile spores, although the timing and signals 
triggered to initiate germination following ingestion are not well understood (Jump, 
Pultz, & Donskey, 2007). Signals that prompt C. difficile sporulation in vivo or in vitro 
have not been identified, but they could be related to environmental stimuli such as 
nutrient starvation, quorum sensing and other unidentified stress factors, as seen with 
other spore forming bacteria (Higgins & Dworkin, 2012). Unlike most pathogens, C. 
difficile produces a metabolically dormant spore that is excreted by infected patients 
(Lawley, Clare, et al., 2009). Infective spores persist in the environment and are 
resistant to a wide range of physical and chemical stresses, including environmental 
oxygen and the acidic environment of the stomach (Carlson et al., 2015; Paredes-Sabja, 
Shen, & Sorg, 2014). The spores can remain on environmental surfaces for many 
months as they are highly resistant to commonly used disinfectants (Kim et al., 1981; 
Paredes-Sabja et al., 2014). The spore surface is covered by an additional surface layer 
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called the exosporium (Pizarro-Guajardo et al., 2014). The morphology of the 
exosporium is dependent on the ribotype of C. difficile, some ribotypes have a compact 
exosporium on the surface of the spore while others have exosporium layers which 
resemble hair-like projections (Joshi, Phillips, Williams, Alyousef, & Baillie, 2012; 
Paredes-Sabja et al., 2014). Although the roles of the exosporium in CDI and 
pathogenesis are unclear, recent reports have shown that the exosporium interacts with 
unidentified surface receptors on intestinal epithelium cells (Paredes-Sabja, Cofre-
Araneda, Brito-Silva, Pizarro-Guajardo, & Sarker, 2012). 
In other bacterial species, spore germination is induced when specific germinant 
receptors (GRs) sense the presence of species specific small molecule germinants 
(Paredes-Sabja et al., 2014). The binding of the germinants to GRs triggers the release 
of monovalent cations and the spore core stores of dipicolinc acid (DPA), which in turn 
activates cortex hydrolases. Cortex hydrolases degrade the peptidoglycan (PG) cortex 
layer which allows the core to hydrate and metabolism can resume (Paredes-Sabja et al., 
2014). C. difficile is unique, as it does not contain orthologs of the GerA family of GRs 
and it appears that commonly conserved germination and sporulation elements are 
differentially regulated in C. difficile compared to other spore-forming bacteria 
(Paredes-Sabja et al., 2012). C. difficile spores germinate in response to L-glycine, 
which acts as a co-germinant to specific bile salts such as Cholate and its derivatives 
Taurocholate, Glycocholate and Deoxycholate (Sorg & Sonenshein, 2008; Wheeldon, 
Worthington, & Lambert, 2011). The main components of the spore germination 
machinery of C. difficile have been identified, but further research is needed to define 
the exact signalling pathway elicited during germination. Studies have shown that the 
germination frequency of the hypervirulent ribotype 027 is different to that of a non-
epidemic C. difficile strain (Burns, Heap, & Minton, 2010b). As spores represent the 
infectious stage of C. difficile, diversity in the germination characteristics of particular 
types may also contribute to the observed differences in disease severity (Burns, Heap, 
& Minton, 2010a). 
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1.1.3 Surface Layer Proteins 
Calabi et al. (2002) found that the surface layer (S- layer) proteins play the biggest role 
in the binding of C. difficile to the host’s gastrointestinal (GI) tract allowing bacterial 
adherence to the mucosa and the delivery of toxins (Calabi et al., 2002). C. difficile 
expresses a crystalline S-layer encoded by the slpA gene, the product of which is 
cleaved to give two mature peptides which associate to form layers (Ausiello et al., 
2006; Ní Eidhin et al., 2006). These layers are commonly known as Surface Layer 
Proteins (SLPs) and are found on the outer surface on C. difficile, facilitating interaction 
with the host enteric cells (Fagan et al., 2009). SLPs have been previously described as 
virulence factors for Aeromonas salmonicida (Sara & Sleytr, 2000) and Campylobacter 
fetus (Grogono-Thomas, Dworkin, Blaser, & Newell, 2000) and as bacterial adhesions 
in Lactobacillus acidophilus (Schneitz, Nuotio, & Lounatma, 1993).  
In most bacterial species the S-layer is composed of one major protein, which is 
modified by glycosylation (Sara & Sleytr, 2000). However C. difficile is unique in that a 
single gene encodes two SLPs which are derived from post-translational cleavage of a 
single precursor slpA gene (Fagan et al., 2009). The slpA precursor protein contains a 
signal peptide that is 26 amino acids in length and it directs translocation across the cell 
membrane, after which cleavage occurs producing the mature SLPs (Calabi et al., 2001; 
Karjalainen et al., 2001). Mature SLPs contain a high molecular weight (HMW) protein 
(42 kDa) derived from the C-terminal portion of the precursor and a low molecular 
weight (LMW) partner protein (32–38 kDa) derived from the N-terminal portion of the 
precursor (Ní Eidhin et al., 2006). Fagan et al. (2009) were the first to solve the crystal 
structure of SLP from a bacterial pathogen, they solved the structure of a LMW protein 
from C. difficile ribotype 012 and this provided an insight into the architecture of SLPs. 
The HMW and LMW proteins were found to form a tightly associated non-covalent 
complex. Deletion analysis of the LMW protein demonstrated that the C-terminal 
residues are necessary for interaction with the HMW protein to form the HMW/LMW 
complex. The crystal structure of the LMW protein also revealed it had two domains, 
see Figure 1.1.3. Domain 1 adopts a two-layer sandwich architecture and domain 2 
displays a novel protein fold which has not yet been classified (Fagan et al., 2009). 
  
 
 8 
HMW proteins contain Pfam (PF04122) which are cell wall binding motifs and they are 
predicted to mediate interactions with the underlying cell wall, where the HMW protein 
can attach to the cell wall and act as an anchor to display the LMW (Calabi et al., 2002; 
Fagan et al., 2009; Karjalainen et al., 2001). More recently it has been shown that the 
LMW protein has a role in adherence to the host cells (Merrigan et al., 2013), it was 
previously thought that the HMW protein bound to the gastrointestinal tissues and 
extracellular matrix (ECM) exclusively (Calabi et al., 2002). 
 
Figure 1.1.3 3D model of the proposed structure and orientation of the HMW and 
LMW SLPs on the surface of C. difficile (Fagan et al., 2009) 
HMW proteins are highly conserved across strains of C. difficile, while the LMW 
proteins demonstrates considerable sequence diversity, and the latter have also been 
shown to be the dominant antigen (Drudy et al., 2004; Ní Eidhin et al., 2006; Sharp & 
Poxton, 1988). LMW protein on the outmost part of the bacteria may be exposed to the 
host immune system. Given the high sequence variability between strains and the fact 
that different strains induce different disease outcomes, it is plausible that this protein 
may be involved in masking the bacteria from the immune system (Lynch 2014, 
unpublished). High sequence variability may be a result of evolutionary selective 
pressures exerted by the host immune response acting on the bacteria to avoid a host 
response (Fagan et al. 2009). A change in structure or specific motifs in LMW proteins 
may result in host immune cells no longer being able to recognise C. difficile as a 
pathogen (Ausiello et al., 2006). Interestingly a recent study has shown a potential role 
for recombination in slpA between different strains (Dingle et al., 2013). Five main 
clades of C. difficile, along with twelve stable variants of a 10 Kb S-layer cassette, 
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containing slpA, were identified. The twelve S-layer cassette variants unexpectedly 
behaved as independent components of the genome, associating randomly with the five 
clades by horizontal genetic exchange. It was also shown that isolates sharing the same 
PCR ribotype can carry multiple distinct S-layer cassettes (Dingle et al., 2013). 
1.1.4 Cell Wall Proteins  
Pathogen attachment is a crucial early step in mucosal infections (Péchiné, Janoir, & 
Collignon, 2005). Cell wall proteins (CWPs) allow bacteria such as C. difficile to 
interact with the host and they can also facilitate adherence (Emerson et al., 2009). 
CWPs are not the only means by which C. difficile can attach to the mucosa, other 
adhesins such as the heat shock protein GroEL (Waligora, Hennequin, Mullany, & 
Bourlioux, 2001), the fibronectin-binding protein Fbp68 (Hennequin, 2003), the 
Flagellar cap proteins FliD and the flagellin FliC (Tasteyre, Barc, Collignon, Boureau, 
& Karjalainen, 2001) have been shown to play a role in the attachment of C. difficile to 
the mucosa. HMW SLPs and all CWPs each contain three Pfam motifs that appear to 
mediate non covalent binding to the underlying cell wall (de la Riva, Willing, Tate, & 
Fairweather, 2011). The majority of the CWPs have a second unique domain that 
specify a particular function (Emerson & Fairweather, 2009). CwpV contains a domain 
which allows for phase-variable protein expression (Emerson et al., 2009), while 
Cwp66 functions as an adhesin when the C-terminal domain is exposed to the cell 
surface- it can also act as an anchor to the cell wall via the N-terminal domain 
(Waligora et al., 2001). Cwp84 is a well characterised CWP that can degrade the host-
cell ECM (Waligora et al., 2001), it also has an important role in the cleavage of the 
immature slpA into its HMW and LMW components (Dang et al., 2010). Inhibition of 
this protease results in accumulation of immature slpA on the cell wall, which leads to a 
decreased viability of the bacterium (Dang et al., 2010). Mutations of the cwp84 gene 
were found to result in defective localisation of other CWPs and Cwp84 is itself 
regulated by Cwp13 (de la Riva et al., 2011). The high conservation of the SLP 
cleavage site between strains and low variability of Cwp84 implies a conserved process 
of SLPs maturation (Dang et al., 2010). CWPs have essential roles in the pathogenesis 
of C. difficile and are extremely important components of the S-layer. 
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1.2 Immune Response to Clostridium difficile 
The GI tract is comprised of the small intestine, the large intestine also known as the 
colon and the rectum. Shortly after birth, the GI tract becomes colonised by vast 
amounts of non-pathogenic commensal bacteria collectively known as the microbiota, 
with the greatest number residing in the distal gut (Gill et al., 2006). The microbiota 
contribute to host nutrition and energy balance as they can synthesise essential amino 
acids and vitamins, they can also process products of the diet that are otherwise hard to 
digest (Gill et al., 2006; Ley, Peterson, & Gordon, 2006; Littman & Pamer, 2011). In 
turn, the host provides the microbes with essential nutrients, ensuring their transmission 
and retention within the host species (Littman & Pamer, 2011). Alongside the exposure 
to these commensal bacteria the GI tracts is also exposed to a variety of luminal 
elements such as food/commensal bacteria and it must be able to discriminate between 
these non-pathogenic elements and antigens from pathogenic organisms (Underdown & 
Schiff, 1986). This is achieved by the interaction of the intestinal epithelium with 
lymphoid cells in order to protect against infection but at the same time avoid 
unnecessary inflammatory responses to beneficial commensals and food (Jung, Hugot, 
& Barreau, 2010). 
The Gut-Associated Lymphoid Tissue (GALT) consists of both isolated and aggregated 
lymphoid follicles and is one of the largest lymphoid organs, containing up to 70% of 
the body’s immunocytes (Neutra, Mantis, & Kraehenbuhl, 2001). Aggregated lymphoid 
follicles were originally described by Marco Aurelio Severino in 1645 in Italy. They 
were named Peyer’s Patches (PPs) after their detailed description by the Swiss 
pathologist Johann Conrad Peyer in 1677 (Jung et al., 2010). PPs are found in the small 
intestine and isolated lymphoid follicles which resemble PPs can be found in the colon. 
PPs are composed of aggregated lymphoid follicles surrounded by the follicle-
associated epithelium (FAE), which forms the interface between the GALT and the 
luminal environment. The FAE contains specialised cells named microfold cells (M-
cells) (Miller, Zhang, KuoLee, Patel, & Chen, 2007). These M-cells transport luminal 
antigens and bacteria toward the underlying immune cells, that activate or inhibit the 
immune response leading to either tolerance or systemic immune cell responses (Jung et 
al., 2010). The role of these tissues is in immune surveillance and the induction of the 
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immune response. Effector sites of the intestine are the mucosal epithelium and 
underlying lamina propria (LP). The LP contains various immune cells, including 
macrophages, dendritic cells (DCs), plasma cells, mast cells, neutrophils, T and B 
lymphocytes (Doe, 1989).  
It is well known that antibiotic treatment diminishes commensal microorganisms in the 
gut and their ability to mediate innate immune responses (Buffie & Pamer, 2013). Once 
the normal flora is disturbed and C. difficile is present the bacterial spores - which are 
the infectious agent, germinate and vegetative cells multiply producing toxins (Fagan et 
al., 2009; Rupnik et al., 2009; von Eichel-Streiber et al., 1996). These toxins are 
internalised into epithelial cells where they inhibit small molecular weight G-proteins, 
resulting in disruption of the cytoskeleton, apoptosis and cell death (Buffie & Pamer, 
2013; Denève et al., 2009; Just & Gerhard, 2004). The presence of C. difficile in the gut 
induces an acute inflammatory response and severe damage to the intestinal epithelium 
(Dawson et al., 2009). SLPs are found on the outer surface on C. difficile and facilitate 
the interaction with the host enteric cells (Fagan et al., 2009). SLPs can induce the 
production of pro-inflammatory cytokines in immune cells such as DCs, monocytes and 
macrophage (Ausiello et al., 2006; Bianco et al., 2011; Calabi et al., 2002; Collins et al., 
2014; Madan & Petri Jr, 2012; Ryan et al., 2011; Vohra & Poxton, 2012). SLPs have 
been shown to elicit an immune response and they may have a role during infection 
(Drudy et al., 2004; Péchiné et al., 2005). 
1.2.1 SLPs Activate Macrophage and Induce Bacterial Clearance  
Research from our laboratory has shown that SLPs from C. difficile activate 
macrophages and induce bacterial clearance responses. SLPs from ribotype 001 induce 
pro-inflammatory cytokines such as Interleukin (IL)-6, IL-12p40 and tumour necrosis 
factor alpha (TNFα) as well as chemokines such as macrophage inflammatory protein 2-
alpha (MIP-2) and monocyte chemo-attractant protein-1 (MCP-1). Co-stimulatory cell 
surface marker expression of CD40, CD14 and major histocompatibility complex 
(MHC) Class II were also increased, as well as the rate of phagocytosis when 
macrophages were stimulated with these SLPs (Collins et al., 2014). The highest 
numbers of intestinal macrophages are found in the colon, which is the largest reservoir 
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of macrophages in the body (Lee, Starkey, & Gordon, 1985). Intestinal macrophage 
express lower levels of co-stimulatory molecules CD80, CD86 and CD40 compared to 
their inflammatory macrophage counterparts (Rogler et al., 1998). Intestinal 
macrophage appear not to be responsive to many Toll-Like Receptor (TLRs) ligands, 
however they can express TLRs at a messenger RNA (mRNA) and protein level (Smith 
et al., 2011). They can also secrete high levels of TNFα without inducing an 
inflammatory response (Bain et al., 2013). Intestinal macrophages are capable of 
phagocytosing pathogens that display bacterial antigens (Smith et al., 2011). When 
intestinal macrophage are depleted there is an increase in inflammation (Qualls, Kaplan, 
Rooijen, & Cohen, 2006). It is now thought that the ability of SLPs to induce cell 
surface marker expression and induce cytokine production comes into effect when non-
intestinal macrophages are recruited to the site of infection (Collins et al., 2014).  
1.2.2 SLPs Induce the Maturation of Dendritic Cells  
SLPs from C. difficile induce the maturation of DCs by inducing the expression of co-
stimulatory cell surface markers: CD80, CD86 and MHCII, which leads to the induction 
of pro-inflammatory cytokines such as IL-1β and IL-6 (Ausiello et al., 2006). Research 
from our group also showed that intact SLPs containing both the HMW and LMW 
proteins were required for DC activation and this subsequently generated T helper cells 
required for bacterial clearance via Toll-Like Receptor 4 (TLR4) (Ryan et al., 2011). 
DCs along with macrophages play an important role in immunity of the GI tract, where 
populations of both cells reside in the LP behind a wall of protective epithelial cells 
(Iwasaki, 2007; Sato & Iwasaki, 2005). DCs are known as the sentinels of the immune 
system and play an essential role in deciding when to mount the appropriate immune 
response by differentiating between invading pathogens and commensal bacteria 
(Banchereau & Steinman, 1998).  
Resident mucosal DCs sample the environment via intestinal M-cells present in the 
epithelium of PPs: the antigen is taken from the lumen and transcytosed to the 
underlying DCs (Clark & Jepson, 2003; Coombes & Powrie, 2008). DCs can also 
sample antigen directly by forming tight junction structures with intestinal epithelial 
cells and extending dendrites into the lumen while preserving the epithelial barrier in 
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the mean time (Rescigno et al., 2001). This mechanism is active both with invasive and 
non-invasive bacteria and is regulated by the expression of CX3C chemokine receptor 1 
(CX3CR1) (Niess et al., 2005). The number of epithelial dendrites is increased during 
infection and requires Myeloid Differentiation primary response gene 88 (MyD88)- 
dependent signalling through TLRs to function efficiently (Rescigno et al., 2001). Upon 
antigen uptake, intestinal DCs migrate to the mesenteric lymph nodes (MLNs), where 
they can interact with naïve T and B cells and display antigens (Sato & Iwasaki, 2005). 
In the absence of pathogens, mucosal DCs either ignore the antigen or induce regulatory 
responses, upon recognition of pathogens that invade the mucosal barrier they mount a 
robust protective immune response (Iwasaki, 2007). 
1.3 Pattern Recognition Receptors 
The first cellular barriers that pathogens face in the intestine are the intestinal epithelial 
cells, they form a monolayer between the lumen of the intestine and sub-epithelial tissue 
where immune cells are located (Peterson & Artis, 2014). Epithelial cells provide a 
physical barrier, but they can also interact with pathogens present in the lumen of the 
gut and the underlying host immune cells through Pattern Recognition Receptors 
(PRRs). These receptors recognise repeating patterns of conserved molecular structures 
found on invading pathogens, that are not present in host cells (Janeway, 1989). These 
patterns are collectively known as Pathogen Associated Molecular Patterns (PAMPs). 
Some PRRs recognise PAMPs directly while others recognise products generated by 
PAMP recognition. There are three types of PPRs; Secreted proteins, transmembrane 
receptors and intracellular receptors (Medzhitov & Janeway, 1997). Of particular 
interest are transmembrane PPRs known as TLRs, which play an important role in 
pathogen recognition and they have been extensively studied. TLRs derived their name 
based on homology to the Drosophila melanogaster Toll protein (Ruslan Medzhitov, 
Preston-hurlburt, & Janeway, 1997). TLRs are glycoproteins characterised by an 
extracellular or luminal ligand binding domain containing Leucine-Rich Repeats 
(LRRs) motifs and a cytoplasmic signalling Toll/IL-1 receptor homology (TIR) domain 
(O’Neill & Bowie, 2007). Ligand binding to TLRs through PAMP-TLR interactions 
induce receptor oligomerisation, which subsequently triggers intracellular signal 
transduction (Mogensen, 2009). There are ten functional TLRs in humans and twelve 
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known in mouse, each capable of recognising distinct PAMPs, see Figure 1.3.1 (Kawai 
& Akira, 2006; Mogensen, 2009). 
 
Figure 1.3.1 Image showing TLRs and the patterns of microbial components they 
recognise (Kawai & Akira, 2006) 
TLR1, TLR2, TLR4, TLR5 and TLR6 are present on the cell surface. TLR2 forms 
heterodimers with TLR1 and TLR6 to recognise bacterial lipopeptides and lipoteichoic 
acid from gram positive cell walls (Akira & Takeda, 2004). TLR4 recognises 
lipopolysaccharide (LPS) on the outer layer of gram negative bacteria (Takeuchi et al., 
1999). TLR5 recognises flagellated bacteria (Hayashi et al., 2001). TLR3 and TLR9 
recognise PAMPs from intracellular pathogens. TLR3 recognises both single and 
double stranded viral Ribonucleic acid (RNA) (Alexopoulou, Holt, Medzhitov, & 
Flavell, 2001), while TLR9 recognises unmethylated CpG from DNA viruses (Hemmi 
et al., 2000). Nine human TLRs have been confirmed in epithelial cells of the small 
intestine to date (Otte, Cario, & Podolsky, 2004). The main TLR of interest in this thesis 
is TLR4. Despite recognising LPS in gram negative bacteria, TLR4 is the receptor 
responsible for recognising SLPs and mounting an immune response to C. difficile. It 
was also found that SLP from ribotype 001 can activate TLR4 signalling leading to the 
activation of nuclear factor κ light-chain-enhancer of activated B cells (NF-κB) through 
the MyD88-dependent signalling pathway. However, SLPs failed to induce Interferon 
Regulatory Factor 3 (IRF3) through the MyD88-independent signalling pathway (Ryan 
et al., 2011). 
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1.3.1 Toll-Like Receptor 4  
TLR4 was the first mammalian TLR to be discovered, it is expressed on the cell surface 
of innate immune cells such as macrophages, DCs, mast cells and on the surface of B 
lymphocytes (Gerondakis, Grumont, & Banerjee, 2007). TLR4 detects LPS which is 
one of the best studied components of bacteria that activates an immune response 
(Ruslan Medzhitov et al., 1997). LPS is an essential structural component of the cell 
wall of gram negative bacteria and consists of a core oligosaccharide, an O side chain 
and a highly conserved lipid A- which serves as the PAMP that activates TLR4 
(Viswanathan, Sharma, & Hecht, 2004). Cellular recognition of LPS requires several 
different molecules including LPS Binding Protein (LBP), Cluster of Differentiation 14 
(CD14), Myeloid Differentiation protein 2 (MD-2) and TLR4. LBP is present in the 
bloodstream and binds to LPS, it then transfers the LPS to the cell surface receptor 
CD14 (Wright, Ramos, Tobias, Ulevitch, & Mathison, 1990). CD14 is a glycoprotein 
expressed primarily on: macrophages, DCs and neutrophils, which contain multiple 
LRRs and are anchored to the cell membrane through phosphatidylinositol linkage 
(Haziot et al., 1988; Setoguchi et al., 1989). MD-2 is a small soluble protein that binds 
non-covalently to TLR4 and is essential for the recognition of LPS by TLR4 (Shimazu 
et al., 1999). The interaction of the CD14/LPS complex with TLR4/MD-2 causes 
receptor oligomerisation and initiates downstream signalling (Alexander & Rietschel, 
2001). 
 
Figure 1.3.2 Two distinct signalling pathways are activated following activation of 
TLR4, the MyD88-dependent and MyD88-independent signalling pathway (Akira & 
Takeda, 2004) 
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TLR4 is distinctive among TLRs in that it activates two distinct signalling pathways see 
Figure 1.3.2. The adaptor protein recruited to the receptor dictates the signalling 
pathway which ensues. TLR4 is also unique as it utilises all four TIR domain-
containing adaptor proteins. The signalling pathways activated by TLR4 are classified 
as the MyD88-dependent and MyD88-independent signalling pathways (Akira & 
Takeda, 2004). It was originally thought that these signalling pathways were initiated 
simultaneously following ligand recognition, however it was established that they are 
initiated sequentially (Kagan et al., 2008). Recognition of LPS by TLR4 initiates 
MyD88-dependent signalling and activation of transcription factors NF-κB and AP-1. 
MyD88 is recruited to the receptor at the plasma membrane with the help of the 
bridging adaptor MyD88 adaptor-like (Mal), which can also be known as TIRAP 
(Yamamoto et al., 2002). The LPS-TLR4 complex is internalised into early endosomal 
structures in a process dependent on clatherin and the GTPase dynamin (Husebye et al., 
2006). Once the LPS-TLR4 complex is endocytosed, MyD88-dependent signalling is 
abolished (Kagan et al., 2008). TIR-domain-containing adapter-inducing interferon-β 
(TRIF) is subsequently recruited to the receptor with the help of the bridging adaptor 
TRIF-related adapter molecule (TRAM) (Oshiumi et al., 2003). Recruitment of TRIF is 
dependent on endocytosis of the receptor which leads to downstream activation of 
members of the IRF family of transcription factors and the induction of Type I IFNs. 
Internalisation of TLR4 brings it into close proximity to TNF receptor associated 3 
(TRAF3) and once they interact there is downstream activation (Kagan et al., 2008). 
The LPS-TLR4 complex is then trafficked to late endosomes or lysosomes for 
degradation and loading of associated antigens into MHCII molecules for presentation 
to helper T cells (Husebye et al., 2006). Activation of TLR4 induces the expression of 
co-stimulatory molecules and can lead to the maturation of DCs which activate cells of 
the adaptive immune system (Banchereau & Steinman, 1998). 
1.3.1.1 MyD88-Dependent Signalling Pathway 
MyD88-dependent signalling is activated when MyD88 is recruited to the receptor at 
the plasma membrane with the help of the bridging adaptor Mal (Yamamoto et al., 
2002), see Figure 1.3.3. In addition to its TIR domain, MyD88 has an N-terminal death 
domain and upon recruitment it associates with members of the IL-1R associated kinase 
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(IRAK) family of protein kinases, through association of their death domains (Wesche, 
Henzel, Shillinglaw, Li, & Cao, 1997). IRAK4 is activated which in turn phosphorylates 
and activates IRAK1 through residues in the N-terminal (Shyun Li, Strelow, Fontana, & 
Wesche, 2009). After IRAK4 and IRAK1 have been sequentially phosphorylated, they 
dissociate from MyD88. In the mean time, IRAK2 becomes phosphorylated and 
dissociates from the complex. IRAK1 and IRAK2 then interact with the downstream 
adaptor, TNF-receptor associated-factor 6 (TRAF6) (Flannery & Bowie, 2010). TRAF6 
is a RING domain containing E3 ubiquitin ligase and together with other molecules: E2 
ubiquitin conjugating enzyme 13 (Ubc13) and ubiquitin conjugating enzyme E2 variant 
1 isoform A (Uev1A), it promotes lysine 63 (K63) linked polyubiquitin of target 
proteins including itself and NEMO (IKKγ) chains (Adhikari, Xu, & Chen, 2007; Chen, 
Bhatia, Chang, & Castranova, 2006). Ubiquitinated NEMO and TRAF6 recruit 
transforming growth factor-β-activated kinase 1 (TAK1) and its regulators: TAK1 
binding protein 1 (TAB1), TAB2 and TAB3 (Adhikari et al., 2007). Two further 
pathways are then activated, the mitogen-activated protein kinase (MAPK) pathway and 
also the inhibitory-κB Kinase (IKK) complex.  
MAPKs are a group of intracellular signal transducing enzymes that are phosphorylated 
and activated by a MAPK kinase (MAP2K), which are phosphorylated and activated by 
a MAPKK kinase (MAP3K). TAK1 is a MAP3K which can phosphorylate and activate 
mitogen-activated protein kinase kinase 3 (MKK3) and MKK6 (Moriguchi et al., 1996). 
MAP3Ks consecutively phosphorylate and activate the c-Jun N-terminal kinases (JNK) 
and p38 MAPK pathways. Activation of these MAPK pathways induces the 
transcription factor Activator Protein 1 (AP-1). AP-1 cooperates with NF-κB to regulate 
gene expression. The IKK complex is made up of two protein kinases IKKα and IKKβ 
along with a scaffolding protein NEMO which is essential for regulation and activation 
of the complex (Chen et al., 2006; Rothwarf, Zandi, Natoli, & Karin, 1998). 
Ubiquitinated TAK1 phosphorylates IKKβ and activates the IKK complex (Wang et al., 
2001). NF-κB in its natural state associates with IκB proteins, however when activated 
IKK complex phosphorylates IκB, they mark them as targets for ubiquitination and 
degradation in the 26S proteasome (Hayden & Ghosh, 2004). NF-κB then binds to κB 
sites in the promoter regions of its target genes, including genes encoding pro-
inflammatory cytokines and chemokines.  
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1.3.1.2 MyD88-Independent Signalling Pathway 
NF-κB and AP-1 can also be activated by a MyD88-independent pathway, involving the 
TIR domain containing adaptor protein TRIF where TRAM acts as a bridging adaptor 
between it and TLR4 (Oshiumi et al., 2003). TRIF interacts with Receptor Interacting 
Protein 1 (RIP1) following recruitment (Meylan et al., 2004). RIP1 interacts with the C-
terminal domain of TRIF and the N-terminal region contains TRAF6 binding motifs. 
Poly-ubiquitination of RIP1 causes it to form a complex with TRAF6 and TAK1 (Taro 
Kawai & Akira, 2007). As in MyD88-dependent signalling TAK1 then activates the 
IKK complex and MAPKs as previously mentioned. However, MyD88-independent 
signalling also leads to the activation of IRF3 a member of the IRF family of 
transcription factors see Figure 1.3.3. TRIF is first recruited to the receptor which leads 
to the recruitment of TRAF3 (Kawai & Akira, 2007). This leads to succeeding 
recruitment and activation of Tank Binding Kinase 1 (TBK1) and inducible IKK which 
is also known as IKKε. NF-κB activating kinase associated protein 1 (NAP1) also plays 
a role in the recruitment of these kinases (Sasai et al., 2005). TBK1 and IKKε 
phosphorylate key serine/threonine residues in the C-terminal region of IRF3 (Sharma 
et al., 2003). Phosphorylation of IRF3 promotes dimerisation and nuclear translocation 
that allows for interaction with the transcriptional co-activators cAMP responsive 
element binding protein (CBP)/p300 (Gauzzi, Del Cornò, & Gessani, 2010). CBP/p300 
acetylates IRF3 homodimers, which causes a conformational change to unmask its 
DNA binding domain (Lin, Heylbroeck, Genin, Pitha, & Hiscott, 1999). IRF3 binds to 
the promoter region and up regulates the expression of genes encoding Type I IFNs.  
  
 
 19  
 
Figure 1.3.3 Downstream signalling following activation of MyD88-dependent and 
MyD88-independent signalling pathways following TLR4 activation. Ultimately 
leading to the activation of transcription factors such as AP-1, NF-κB and IRF3 and the 
induction of pro-inflammatory cytokines, IFN and IFN-inducible genes (Mogensen, 
2009) 
MyD88-independent MyD88-dependent 
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1.3.2 NF-κB  
NF-κB was discovered in 1986 by the coincidental discovery of three proteins NFκB, v-
Rel and Dorsal (Baeuerle & Baltimore, 1988; Gilmore & Temin, 1986; Sen & 
Baltimore, 1986; Steward, Zusman, Huang, & Schedl, 1988). They have since been 
extensively studied and found to be members of the same protein family with distinct 
biological functions in immunity (NF-κB), oncogenesis (v-Rel) and development 
(Dorsal) (Gilmore, 2006). The term NF-κB can be used to describe the superfamily of 
Rel and NF-κB proteins across species, the subfamily: p100, p105 and Relish or the 
specific p50- Rel A heterodimer, which is the foremost NF-κB dimer in many cells. The 
larger NF-κB family of proteins are composed of two subfamilies: the NF-κB proteins 
and the Rel proteins. All of these proteins share a highly conserved 300 amino acid Rel 
homology domain (RHD) which is responsible for nuclear translocation, DNA-binding 
and dimerisation (Gilmore, 1990) see Figure 1.3.4.  
The Rel subfamily includes c-Rel, Rel B, Rel A also known as p65, Drosophila Dorsal 
and Dif. While the NF-κB subfamily includes p105, p100 and Drosophila Relish- which 
are distinguished by their long C-terminal domains that contain multiple copies of 
ankyrin repeats that act to inhibit proteins (Gilmore, 2006). The NF-κB proteins p100 
and p105 are processed to become shorter active DNA-binding proteins, resulting in the 
removal of their C-terminal ankyrin repeats. p105 is constitutively processed to p50 
resulting in both p50 and p105 containing dimers, while p100 processing to p52 is 
stimulus dependent and preferentially binds to Rel B (Oeckinghaus & Ghosh, 2009). 
Due to the lack of a C-terminal trans activation domains p50 and p52 homodimeric 
complexes cannot activate transcription but instead act as transcriptional repressors 
(Hayden & Ghosh, 2004). Rel subunits form homo- or heterodimers and the various 
dimeric combinations that are formed, target slightly different DNA sequences allowing 
for distinct transcriptional activity of different NF-κB dimers (Kunsch, Ruben, & 
Rosen, 1992).  
The NF-κB subfamily are generally not activators of transcription, except when they 
form dimers with members of the Rel subfamily, the predominant form of NF-κB is a 
Rel A (p65) -p50 heterodimer (Gilmore, 2006). The p65-p50 heterodimer is bound by 
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IκB and is rapidly degraded in response to NF-κB activating stimuli. IκB proteins bind 
to the NF-κB dimer through multiple ankyrin repeats and inhibit their DNA binding 
activity (Whiteside & Israel, 1997). When activated IKK complex phosphorylate IκB, 
they are marked for K48-linked ubiquitination and degradation in the 26S proteasome 
(Hayden & Ghosh, 2004). NF-κB can then bind to κB sites in the promoter regions of 
its target genes, including genes encoding pro-inflammatory cytokines and chemokines 
(Yamamoto et al., 2003). Active NF-κB promotes the expression of IκBα which is an 
important negative feedback regulatory mechanism which ensures termination of the 
NF-κB response (Klement et al., 1996). NF-κB regulates the expression of a range of 
proteins including pro-inflammatory cytokines, such as IL-1β, IL-8, IL-6 and TNFα. 
They also regulate adhesion molecules such as intracellular adhesion molecule (ICAM)-
1 and vascular cellular adhesion molecule (VCAM)-1 and inducible enzymes such as 
inducible nitric oxide synthase (iNOS) which mediate the innate immune response to 
the invading pathogen (Hayden & Ghosh, 2004; Pahl, 1999).  
 
Figure 1.3.4 Image showing the generalised structures of the two subfamilies Rel and 
NF-κB and related signalling molecules (Gilmore, 2006) 
1.3.3 Interferon Regulatory Factor 3 
IRF3 is a transcription factor belonging to the IRF family- which consists of nine 
members, it was discovered in 1995 as a regulatory component in cells infected with a 
virus and it has been shown to play an important role in type I IFN production (Au, 
Moore, Lowther, Juang, & Pitha, 1995; Honda, Takaoka, & Taniguchi, 2006). IRF3 was 
found to be a major component of the MyD88-independent pathway triggered 
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downstream of TLR4 in response to LPS (Doyle et al., 2002; Kawai et al., 2001). IRF3 
is a transcription factor that is constitutively expressed in most cell types and displays 
both nuclear export sequences (NES) and nuclear localisation sequences (NLS). IRF3 
possesses an amino N-terminal DNA-binding domain (DBD) that is characterised by a 
series of well conserved tryptophan-rich repeats (Honda & Taniguchi, 2006). The DBD 
forms a helix-turn-helix domain and can interact with interferon-stimulated response 
element (ISRE). IRF3 mainly resides in the cytoplasm due to the dominant NES but it is 
continuously shuttled between the cytoplasm and the nucleus in basal conditions 
(Kumar, McBride, Weaver, Dingwall, & Reich, 2000).  
IRF3 is activated upon the recognition of specific PAMPS leading to the activation of 
the MyD88-independent signalling pathway as previously mentioned. Phosphorylation 
of IRF3 promotes dimerisation and nuclear translocation that allows for interaction with 
the transcriptional co-activators CBP/p300 (Gauzzi et al., 2010). CBP/p300 acetylates 
IRF3 homodimers, which causes a conformational change that unmask its DNA binding 
domain, promoting the transcription of its target genes (Lin et al., 1999). IRF3 binds to 
ISRE found in the promoters of Type I IFNs and other genes involved in immunity and 
oncogenesis (Honda & Taniguchi, 2006). IRF3 is central for the induction of IFNβ, it is 
part of the enhanceosome that binds to the proximal promoter region and initiates local 
histone acetylation and nucleosomal repositioning (Agalioti et al., 2000). In 
macrophages and DCs stimulated with LPS, direct IRF3 binding is required for the 
recruitment of distinct sets of genes such as C-X-C motif chemokine 10 (CXCL10), 
regulated on activation normal T cell expressed and secreted (RANTES), IL-27a, IL-
12a and IL-15 (Ramirez-Carrozzi et al., 2009). IFNβ leads to the induction of specific 
genes that depend on other transcriptional regulators such as Interferon-stimulated gene 
factor 3 (ISGF3) and other downstream IRFs such as IRF1 and IRF5 (Ysebrant de 
Lendonck, Martinet, & Goriely, 2014). 
IL-23 and IL-27 production is strongly dependent on the set of IRF family members that 
are activated with specific ligands. IRF3 is recruited to IL-12p35 and IL-27p28 
promoter regions when DCs are stimulated with LPS (Goriely et al., 2008; Molle et al., 
2007). Formation of the ISGF3 complex is critical for amplification of the IL-27p28 
gene and may lead to late activation directly or through amplification of type I IFN 
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synthesis. The balance between IL-12, IL-23 and IL-27 production is strongly 
dependent on IRF3, which effects ensuing adaptive immune responses (Ysebrant de 
Lendonck et al., 2014). Polarization of CD4 T helper cells into distinct effector lineages 
are determined by the expression of master regulators: T-bet, Foxp3, GATA-3 or the 
orphan nuclear receptor RORγt, acting in close interaction with transcription factors 
from the signal transducer and activator of transcription (STAT) family. STAT4 is 
activated by IL-12, STAT6 is activated by IL-4, STAT3 is activated by IL-6, IL-21 or 
IL-23 and STAT5 is activated by IL-2. These are directly implicated in Th1, Th2, Th17 
or Treg development (Zhu, Yamane, & Paul, 2010). Therefore IRF3 dependent pathway 
influences the polarization of CD4 T cells see Figure 1.3.5. Activation of IRF3 within 
APCs and subsequent autocrine type I IFNs signalling limits the induction of Th17 and 
Th1 responses. This can be favourable in the context of auto-immune inflammation or 
deleterious for the host in the context of bacterial infection (Ysebrant de Lendonck et 
al., 2014). 
 
Figure 1.3.5 Illustration showing that IRF3 contributes to the balance between IL-12 
family members in antigen presenting cells. Upon activation downstream of TLR4, 
IRF3 activates the transcription of IL-12p35 and IL-27p28 through direct recruitment to 
ISRE-binding sites within the promoter regions where IRF3 is recruited to the IL-
12/23p40 promoter and enhancer regions (Ysebrant de Lendonck et al., 2014)  
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1.4 MicroRNAs 
TLR signalling pathways are strictly and finely regulated by positive or negative 
modulators at various levels to prevent excessive inflammation, they can also regulate 
tissue maintenance and homeostasis (He, Jing, & Cheng, 2014). The mechanisms 
responsible include: physical interactions, conformational changes, phosphorylation, 
ubiquitination and proteasome mediated degradation involving various regulatory 
molecules (He, Jia, Jing, & Liu, 2013; Kondo, Kawai, & Akira, 2012; O’Neill, 2008). 
MicroRNAs (miRNAs) are a newly identified family of regulators involved in the fine 
tuning of TLR signalling (Yingke Li & Shi, 2013; Ma, Buscaglia, Barker, & Li, 2011; 
Nahid, Satoh, & Chan, 2011; O’Neill, Sheedy, & McCoy, 2011; Olivieri et al., 2013). 
MiRNAs were initially identified in 1993 in C. elegans, while examining the temporal 
regulation of a gene known as lin-14, by lin-4 (Wightman, Ha, & Ruvkun, 1993). It was 
revealed that lin-4 was expressed in two forms, a non-protein coding 22 nucleotide (nt) 
small RNA and a 61 nt precursor RNA molecule- also non-protein coding. The small 22 
nt RNA molecules were found to have multiple “imperfect” complementary sites to the 
3′ Untranslated region (UTR) of lin-14 mRNA. Lin-4 was not found in any other 
species apart from C. elegans and this RNA interference mechanism was believed to be 
exclusive to this gene at the time (Lee, Feinbaum, & Ambros, 1993). Some time later it 
was discovered that a heterochronic gene let-7 regulated the products of a gene known 
as lin-41 and the regulation of this gene was similar to how lin-4 regulated the products 
of lin-14 (Reinhart et al., 2000). Unlike lin-4, the let-7 gene homolog was found in other 
species such as drosophila and humans (Hutvágner et al., 2001; Pasquinelli et al., 2000). 
These small RNA molecules were first defined as `small temporal' RNA (stRNA) 
because of their roles in developmental timing, but as more small RNAs were identified 
in regulatory roles outside of development, they were defined more generally as 
miRNAs (Lagos-Quintana, Rauhut, Lendeckel, & Tuschl, 2001; Lau, Lim, Weinstein, 
& Bartel, 2001; Lee & Ambros, 2001).  
Mature miRNAs are short double stranded RNA molecules approximately 19-23 nt in 
length. They are produced from full-length RNA polymerase II transcripts called pri-
miRNA, after cleavage by two RNase III enzymes called Drosha and Dicer (Denli, 
Tops, Plasterk, Ketting, & Hannon, 2004; Lee et al., 2003; Zhang, Kolb, Jaskiewicz, 
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Westhof, & Filipowicz, 2004). Initial cleavage by Drosha within the nuclear 
compartment produces a hairpin RNA which is approximately 65 nt, known as pre-
miRNA. Pre-miRNA is transported into the cytoplasm by exportin 5 and further 
processed by Dicer to produce the mature miRNA (Yi, Qin, Macara, & Cullen, 2003; 
Zhang et al., 2004). MiRNA actions are mediated by miRNA-induced silencing 
complex (miRISC), which is composed of many proteins including a member of the 
double-stranded RNA binding protein Argonaute (Ago) family (Liu et al., 2004; Meister 
et al., 2004). Using one strand of the miRNA called the guide strand, the miRISC either 
block mRNA translation, reduces mRNA stability or induces mRNA cleavage after 
imperfect binding to the miRNA recognition elements within the 3’ and 5’ UTR of 
target mRNA genes see Figure 1.4.1 (Doench & Sharp, 2004; Lewis, Shih, Jones-
Rhoades, Bartel, & Burge, 2003). 
 
Figure 1.4.1 Image showing the processing of pri-miRNA to pre-miRNA. Mature 
miRNA recognises elements within the 3’ and 5’ UTR of target mRNA gene (Lindsay, 
2008) 
The discovery of the first miRNA initiated a large scale search to find other novel 
miRNAs in various organisms and cell types (Hutvágner et al., 2001). The mirBase 
database was created in 2002 to name, annotate and collate all published miRNA 
sequences (Griffiths-Jones, 2004). Newly discovered miRNAs are assigned official 
gene names after experimental isolation and verification, furthermore a manuscript 
describing the discovery must be accepted for publication before being entered in this 
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official miRNA database (Lhakhang & Chaudhry, 2012). MiRNA gene names consist 
of a three or four letter prefix used to designate the species e.g. hsa for human and mmu 
for Mus musculus, followed by a sequential numerical identifier. The mirBase database 
uses ‘miR’ to identify mature miRNA molecules, whereas ‘mir’ is used to designate the 
precursor hairpin subset (Griffiths-Jones, 2010). Additionally, paralogous miRNAs 
differing in only one or two positions are given lettered suffixes e.g. hsa-miR-146a and 
hsa-miR-146b. In cases where the miRNA products are identical but expressed from 
different genomic loci, the miRNA are given numerical suffixes e.g. hsa-mir-92a-1 and 
hsa-mir-92a-2 (Griffiths-Jones, Saini, Van Dongen, & Enright, 2008). In miRNA 
identification cloning studies, two mature products are often isolated from each arm of 
the double stranded miRNA hairpin. In many cases one is a non-functional by-product 
that is referred to as the ‘star’ sequence, and these miRNAs are designated with a ‘*’ at 
the end of the gene name (Griffiths-Jones, Grocock, van Dongen, Bateman, & Enright, 
2006). However, when there is insufficient evidence to determine the functional strand 
these miRNAs are given suffixes that signify the hairpin arm of origin, either -5p or -3p 
(Griffiths-Jones et al., 2008). To date there are 28,645 miRNA hairpin precursors, 
corresponding to 35,828 mature miRNAs in 223 species (miRBASE release June 2014); 
2588 mature miRNAs are currently annotated in the human genome (Eulalio & Mano, 
2015) and it has been estimated that up to 30% of all human genes are regulated by 
miRNAs in many cell types (Bartel, 2009; Fabian, Sonenberg, & Filipowicz, 2010; 
Yates, Norbury, & Gilbert, 2013). 
1.4.1 MiRNAs Regulate TLRs  
MiRNAs act as key regulators of gene expression and the regulation of TLRs may be 
one of the most effective points to alter signalling (He et al., 2014). Thus far, several 
miRNAs have been shown to regulate TLRs including the let-7 miRNA family. It has 
been shown that let-7e and let-7i regulate TLR4 expression, studies show the over 
expression of let-7e by miRNA mimics results in the down regulation of TLR4 in 
mouse peritoneal macrophages, and inhibition of let-7e leads to up regulation of TLR4 
expression (Androulidaki et al., 2009). The myeloid-specific miR-223 is another TLR 
induced miRNA, it can regulate both TLR4 and TLR3 expression in granulocytes 
(Johnnidis et al., 2008). Another study found that miR-146a can also negatively regulate 
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TLR4, resulting in accumulation of oxidized low-density lipoprotein (oxLDL) and an 
inflammatory response in macrophages (Yang et al., 2011). In addition, miR-511 
functions as a putative positive regulator of TLR4 under cell cycle arrest conditions, it is 
likely to inhibit TLR4 expression under similar conditions in monocytes and DCs 
(Tserel et al., 2011). These studies suggest that miRNAs may play an important role in 
the expression of TLRs and in particular TLR4. See Figure 1.4.2 for a summary of 
miRNAs involved in the regulation of the TLR4 signalling pathway and their related 
regulatory molecules. 
 
Figure 1.4.2 Image illustrating the array of miRNAs involved in the regulation of the 
TLR4 signalling pathway at multiple levels involving multiple molecules (He et al., 
2014) 
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1.4.2 MiRNAs Regulate Signalling Proteins 
TLR4 recruits many types of proteins upon ligand binding as mentioned earlier in this 
chapter. These proteins include various IRAKs, MKKs, TABs, IKKs, TRAFs and the 
adaptor molecules: MyD88, TRIF, mal and TRAM. Recently all of these molecules 
have also been shown to be targeted by miRNAs, especially when TLR4 is induced 
(Broz & Monack, 2013; He et al., 2013; Kondo et al., 2012; Yingke Li & Shi, 2013; Ma 
et al., 2011; Newton & Dixit, 2012; O’Neill et al., 2011; O’Neill, 2008; Olivieri et al., 
2013). Among these miRNAs identified, miR-146a is one of the key TLR-induced 
miRNAs. MiR-146a inhibits TLR4 signalling by targeting IRAK1 kinase and TRAF6 
ligase- components of the MyD88-dependent signalling pathway, in various cell types. 
IRAK2 another component of the MyD88-dependent pathway has also been shown to 
be regulated by miR-146a (Flannery & Bowie, 2010; Hou et al., 2009; Shuo Li, Yue, 
Xu, & Xiong, 2013; Lin et al., 2013; Nahid et al., 2011; Taganov, Boldin, Chang, & 
Baltimore, 2006; Tang et al., 2010). MiR-146b- another member of the miR-146 family, 
can modulate the TLR4 signalling pathway by directly targeting TLR4, MyD88, 
IRAK1, and TRAF6 (Curtale et al., 2013). MiR-132, miR-212, and miR-146a also 
target IRAK4 which leads to diminished production of inflammatory cytokines (Nahid 
et al., 2013). 
MiR-155 another important TLR-induced miRNA, can target components of the NF-κB 
pathway such as Fas-associated death domain protein (FADD), IKKβ, IKKε 
and Receptor (TNFRSF)-interacting serine-threonine kinase 1 (RIPK1) (Ceppi et al., 
2009; Tili et al., 2007). MiR-155 has also been shown to inhibit the p38 MAPK 
signalling pathway and inflammatory cytokine production in human DCs in response to 
various microbial stimuli. In addition, miR-155 can regulate TAB2 in human monocyte-
derived DCs (Ceppi et al., 2009). MyD88 has also been shown to be regulated by miR-
155, miR-149, and miR-203 (Huang, Hu, Lin, Lin, & Sun, 2010; Tang et al., 2010; Wei 
et al., 2013; Xu et al., 2014). Another MyD88 adaptor-like protein mal has been 
identified as a target of miR-145 in hematopoietic stem/progenitor cells (Starczynowski 
et al., 2010). MiR-200b and miR-200c- members of the miR-200 family, can also 
regulate the expression of MyD88 and it has been shown that this regulation can modify 
the efficiency of the TLR4 signalling pathway effecting the host innate defences against 
  
 
 29  
microbial pathogens (Wendlandt, Graff, Gioannini, McCaffrey, & Wilson, 2012). 
Collectively, some of the key components of TLR4 associated signalling proteins are 
regulated by miRNAs. These studies suggest that miRNA activation results in the 
timely and appropriate toning down and/or termination of TLR-signalling by targeting 
critical signalling proteins once they are activated (He et al., 2014). 
1.4.3 MiRNAs Regulate Transcription Factors  
Activation of transcription factors such as NF-κB, AP-1, IRF and STAT are key 
functional steps following TLR activation (He et al., 2014). Studies have shown that 
miRNAs play a vital role in the negative feedback mechanisms that regulate these 
transcription factors (Filipowicz, Bhattacharyya, & Sonenberg, 2008; Martinez & 
Walhout, 2009). NF-κB is considered one of the most important transcription factors 
and it has been shown that a miR-9 mediated feedback mechanisms directly targets NF-
κB1 mRNA to fine tune MyD88- dependent and NF-κB signalling following activation 
with LPS (Bazzoni et al., 2009). Another study showed that miR-210 targets NF-κB1 
when induced by LPS in murine macrophages (Qi et al., 2012). Additionally, miR-329 
plays a pivotal role in the inhibition of IL-6 mRNA expression by targeting the NF-κB 
p65 complex (Garg, Potter, & Abrahams, 2013). MiR-223 has been shown to target 
STAT3, resulting in the inhibition of the pro-inflammatory cytokines IL-6 and IL-1β 
production in macrophages (Chen et al., 2012). Furthermore, miR-17-5p and miR-20a 
target STAT3 to alleviate the suppressive function of myeloid-derived suppressor cells 
(Zhang et al., 2011). A transcriptional co-repressor CCAAT/enhancer binding protein-β 
(C/EBPβ) has been identified as a target of miR-155 leading to decreased expression of 
granulocyte colony-stimulating factor and IL-6 in splenocytes (Costinean et al., 2009; 
Worm et al., 2009). Forkhead box p3 (Foxp3) - a transcription factor required for Tregs 
and E26 transformation specific sequence 2 (ETS-1) have also been identified as targets 
of miR-155 (Kohlhaas et al., 2009; Quinn et al., 2014). MiR-27b directly targets 
peroxisome proliferator-activated receptor (PPAR)γ when induced by NF-κB and miR-
27b can also inhibit TNFα secretion induced by LPS stimulation (Jennewein, von 
Knethen, Schmid, & Brüne, 2010).  
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1.4.4 MiRNAs Regulate Cytokines and Chemokines 
Activation of TLR signalling through recognition of PAMPs leads to the transcriptional 
activation of genes that encode for pro-inflammatory cytokines, chemokines, and co-
stimulatory molecules. These cytokines play an important role in eradicating infectious 
pathogens and recruiting inflammatory cells for an effective host defence (Kawai & 
Akira, 2006). Several key TLR induced cytokines including type I IFNs, TNFα, IL-6, 
IL-12, and IL-10 are regulated by miRNAs (Asirvatham, Gregorie, Hu, Magner, & 
Tomasi, 2008; Asirvatham, Magner, & Tomasi, 2009; Xiangde Liu & Rennard, 2011). 
MiR-146a sequentially suppresses the production of type I IFNs, TNFα, IL-1β and IL- 6 
by targeting IRAK1, IRAK2, and TRAF6 in macrophages during LPS tolerance (Hou et 
al., 2009; Shuo Li et al., 2013; Xie et al., 2013). MiRNA-146a can also negatively 
regulate the release of the pro-inflammatory chemokines IL-8 and RANTES (Perry et 
al., 2008). MiR-26a, miR-34a, miR-145 and let-7b directly regulate the expression of 
IFN-β by targeting the 3’-UTR region (Witwer, Sisk, Gama, & Clements, 2010; Zhou, 
O’Hara, & Chen, 2011). Type I IFNs can also affect miRNA expression, it has been 
shown that the activation of IFN-β can suppress miR-378 and miR-30 which allows the 
release of cytolytic mRNAs resulting in augmented natural killer (NK) cell cytotoxicity 
(Wang et al., 2012). IκBξ, is a master regulator for the transcription of two key 
cytokines IL-6 and IL-12p40, it is indirectly targeted by miR-187, it was also shown 
that miR-187 directly targets TNFα mRNA (Rossato et al., 2012). When IL-6 is targeted 
by miRNAs including miR-16, miR-365 and miR-142-3p, there is a reduction in 
endotoxin induced mortality through a feedback mechanism (Sun et al., 2015; Xu et al., 
2011; Zhou et al., 2011). IL-12p35 mRNA contains target sites for miR-21 in 
macrophages and DCs leading to restricted adaptive Th1 responses (Lu, Munitz, & 
Rothenberg, 2009). In contrast, miR-29 suppresses the immune response against 
intracellular pathogens by targeting IFN-γ (Ma et al., 2011). 
1.4.5 MiRNAs Regulate Other Regulatory Molecules 
MiRNAs can also target other regulatory molecules known to modulate TLR signalling 
pathways. MiR-132 targets acetyl cholinesterase (ACHE) which negatively regulates 
the TLR signalling pathway (Shaked et al., 2009). MiR-21 can target tumour suppressor 
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protein programmed cell death 4 (PDCD4), an inhibitor of eukaryotic translation 
initiation factor 4F in macrophages, thus enhancing innate immune responses in the 
early stages of infection by a pathogen. The inhibition of PDCD4 increases IL-10 
secretion, suggesting a role for TLR induced cytokine production during infection (Loh 
et al., 2009; Sheedy et al., 2010; Yang et al., 2003). Src homology 2 domain-containing 
inositol-5’-phosphatase 1 (SHIP1), a negative regulator of TLR signalling and the 
inflammatory response, is a target of miR-155 (Costinean et al., 2009; Cremer et al., 
2009). Studies have also shown that when macrophage are stimulated with LPS, there is 
a down regulation of SHIP1 and increased expression of miR-155 (Gabhann et al., 
2010; Loh et al., 2009; Worm et al., 2009; Yang et al., 2003). MiR-155 has also been 
shown to target suppressor of cytokine signalling 1 (SOCS1), which is another negative 
regulator of TLR signalling. However, IL-10 can inhibit miR-155 expression leading to 
an increase in SHIP1 and SOCS1 expression, thus mitigating TLR signalling 
(Androulidaki et al., 2009; McCoy et al., 2010). Notch1 on the other hand is a known 
positive regulator of IL-12p70 production in DCs and miR-146a targets IL-12p70 in 
DCs stimulated with TLR9 (Bai et al., 2012). MiR-148a/b and miR-152 inhibit the 
expression of calcium/calmodulin dependent protein kinase II (CaM-kinase II) to 
regulate TLR signalling (Liu et al., 2010). Together these studies suggest that miRNAs 
are responsible for regulating regulatory molecules to fine tune TLR-signalling 
pathways and downstream events (He et al., 2014). 
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Table 1.4.1 Summary of miRNAs that regulate TLR4 signalling 
Target mRNA MiRNA(s) Reference 
Receptor   
TLR4 let-7i, let-7e miR-
223, miR-146a, miR-
146b, miR-511 
Androulidaki et al., 2009; Curtale et al., 
2013; Johnnidis et al., 2008; Tserel et 
al., 2011; Yang et al., 2011 
Signalling Proteins 
IKKβ miR-155 Ceppi et al., 2009; Tili et al., 2007; 
Wendlandt et al., 2012 
IKKε miR-155 Ceppi et al., 2009; Tili et al., 2007 
IRAK1 miR-146a, miR-146b 
miR-148b, miR-21 
Curtale et al., 2013; Hou et al., 2009; 
Shuo Li et al., 2013; Lin et al., 2013; Liu 
et al., 2010; Taganov et al., 2006 
IRAK2 miR-146a Hou et al., 2009; Taganov et al., 2006 
IRAK4 miR-146a, miR-132, 
miR-212 
Nahid et al., 2013 
Mal miR-145 Starczynowski et al., 2010 
MyD88 miR-146b, miR-155, 
miR-200b, miR-200c, 
miR-21, miR-203, 
miR-149 
Curtale et al., 2013; Huang et al., 2010; 
Tang et al., 2010; Wei et al., 2013; 
Wendlandt et al., 2012 
RIPK1 miR-155 Ceppi et al., 2009; Tili et al., 2007 
TAB2 miR-155 Ceppi et al., 2009; Tili et al., 2007 
TRAF6 miR-146a, miR-146b Curtale et al., 2013; Hou et al., 2009; Liu 
et al., 2010; Taganov et al., 2006 
Transcription Factors 
C/EBPβ miR-155 Costinean et al., 2009 
ETS-1 miR-155 Quinn et al., 2014 
Foxp3 miR-155 Kohlhaas et al., 2009 
NF-κB1 miR-9, miR-210 Bazzoni et al., 2009; Qi et al., 2012 
NF-κBp65 miR-329 Garg et al., 2013 
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p38 MAPK miR-155 Ceppi et al., 2009 
PPARγ miR-27b Jennewein et al., 2010 
STAT3 miR-17-5p, miR-20a, 
miR-223 
Chen et al., 2012; Zhang et al., 2011 
Cytokines and Chemokines 
IFN-β miR-26a, let-7b, 
miR-34a, miR-145, 
miR-378, miR-30 
Witwer et al., 2010; Zhou et al., 2011 
IFN-γ miR-29 Ma et al., 2011 
IL-10 miR-21, miR-155 Androulidaki et al., 2009; Loh et al., 
2009; McCoy et al., 2010; Sheedy et al., 
2010; H. Yang et al., 2003 
IL-12p35 miR-21 Lu et al., 2009 
IL-12p40 miR-187 Rossato et al., 2012 
IL-1β miR-223 Chen et al., 2012 
IL-6 miR-16, miR-365, 
miR-142-3p, miR-
187, miR-329, miR-
223 
Chen et al., 2012; Garg et al., 2013; Sun 
et al., 2015; Xu et al., 2011; Zhou et al., 
2011 
IL-8 miR-146a Jing et al., 2005; Perry et al., 2008 
RANTES miR-146a Perry et al., 2008 
TNFα miR-187, miR-27b Jennewein et al., 2010; Rossato et al., 
2012 
Regulatory Molecules 
ACHE miR-132 Shaked et al., 2009 
CaM-Kinase II miR-148a/b, miR-152 Xingguang Liu et al., 2010 
Notch1 miR-146a Bai et al., 2012 
PDCD4 miR-21 Loh et al., 2009; Yang et al., 2003 
SHIP1 miR-155 Costinean et al., 2009; Cremer et al., 
2009 
SOCS1 miR-155 Androulidaki et al., 2009; McCoy et al., 
2010 
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1.5 Aims and Objectives 
C. difficile can induce severe inflammation in the gut and the severity of disease 
depends on the ribotype causing the infection. SLPs coat the outer layer of C. difficile 
and the LMW protein varies between ribotypes. Previous research focused on SLPs 
from ribotype 001 which activate innate and adaptive immunity suggesting an important 
role for SLPs in the recognition of C. difficile by the immune system. Given the 
differences in clinical symptoms between strains of C. difficile, SLPs may modulate the 
immune response and this may differ between ribotypes. SLPs from ribotype 001 
activate TLR4 signalling with subsequent downstream activation of NF-κB, however 
they fail to induce IRF3 signalling. MiRNAs are a newly identified family of regulators 
involved in the fine tuning of TLR4 signalling. There is mounting evidence that 
miRNAs orchestrate immune regulation and host responses to pathogens during 
infection. To date nobody has studied miRNAs regulated by SLPs from C. difficile. Our 
hypothesis states SLPs from various ribotypes of C. difficile may activate different 
immune responses to infection and signalling downstream of TLR4. MiRNAs may be 
expressed in response to SLPs, which perhaps modulate TLR4 signalling leading to the 
differences in severity of infection between ribotypes. 
To address the above, the aims of this thesis were: 
 To examine the immune response of various ribotypes of C. difficile and to 
determine downstream signalling following TLR4 activation with SLPs from the 
various ribotypes 
 Establish and optimise a protocol to examine miRNAs  
 Compare miRNA profiles regulated by SLPs from ribotype 001 and 027 in vitro 
 Identify miRNAs switched on and off during infection by examining colonic 
tissue in a mouse model of C. difficile in vivo 
 Analyse functionality of miRNAs induced by SLPs from ribotype 001 and 027 
in TLR4 signalling 
 Identify biologically relevant gene targets using bioinformatic target prediction 
tools 
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2.1 Materials 
Table 2.1.1 Tissue cell culture 
Material  Source 
15ml and 50ml centrifuge tubes Sarstedt 
Blasticidin  Invivogen™ 
Brightline Haemocytometer Sigma-Aldrich® 
Cell Titer® 96 AQueous One Solution Promega 
DMEM-6429 Gibco® 
Foetal Bovine Serum (FBS) Invitrogen™ 
GM-CSF expressing cell line J558 GM-CSF 
Hygrogold™ Invivogen™ 
LPS (E. Coli serotype R515) Enzo Lifesciences 
Mr. Frosty freezing container Thermo Fisher Scientific 
Penicillin Streptomycin/ Glutamine Gibco® 
Presept tablets VWR International Ltd. 
rGM-CSF(G0282) Sigma-Aldrich® 
RPMI-1640 Gibco® 
Sterile dH2O Sigma-Aldrich® 
Sterile petri dishes Nunc™ 
Tissue culture flasks T-25cm
2 
and T-75cm
2
 Nunc™ 
Tissue culture plates 6, 24 and 96-well Nunc™ 
Trypan Blue (0.4% w/v) Sigma-Aldrich® 
Trypsin/ EDTA Sigma-Aldrich® 
α-MEM alpha Invitrogen™ 
Table 2.1.2 Characterisation of SLPs 
Material  Source 
Bicinchoninic acid (BCA) Protein Assay Kit. Pierce™ 
ToxinSensor™ Chromogenic LAL Endotoxin Assay Kit Genscript 
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Table 2.1.3 SDS-PAGE 
Material  Source 
Acetic Acid CH3CO2H Sigma-Aldrich® 
Ammonium persulphate (APS) Sigma-Aldrich® 
Bicinchoninic acid (BCA) Protein Assay Kit. Pierce™ 
Bis-acrylamide 30% Sigma-Aldrich® 
Bromo-blue Sigma-Aldrich® 
Coomassie Brilliant blue Sigma-Aldrich® 
Fermentas PageRuler™ plus Pre stain protein ladder Thermo Fisher Scientific 
Glycine Sigma-Aldrich® 
Methanol Lennox 
N,N,M’- Tetramethylethylenediamine (TEMED) Sigma-Aldrich® 
Propan-2-ol (Isopropanol) VWR International Ltd. 
Sodium dodecylsulphate (SDS) Sigma-Aldrich® 
Table 2.1.4 Enzyme Linked Immunosorbent Assay (ELISA) 
Material  Source 
96- well micro titre plate Nunc™ 
Bovine serum albumin (BSA) Sigma-Aldrich® 
Dulbecco’s Phosphate Buffered Saline (PBS) Gibco® 
DuoSet® ELISA kits R&D systems 
Streptavidin-HRP R&D systems 
Trizma base Sigma-Aldrich® 
VersaMax™ microplate reader Molecular Devices 
3,3’,5,5’-tetramethyl-benzidine (TMB) Sigma-Aldrich® 
Tween® 20 Sigma-Aldrich® 
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Table 2.1.5 Flow Cytometry 
Material  Source 
APC hamster anti-mouse CD11c antibody BD 
BD buffer BD 
FACS Clean BD 
FACS flow BD 
FACS Rinse BD 
FACS tubes Sarstedt 
FITC rat anti-mouse CD14 antibody eBioscience 
FITC rat anti-mouse CD86 antibody BD 
PE rat anti-mouse CD40 antibody BD 
PE rat anti-mouse CD80 antibody BD 
Proprodium Iodide (PI) BD 
Sodium Azide (NaN3) Sigma-Aldrich® 
Wash buffer (PBS+ 0.1% Tween) BD 
Table 2.1.6 Plasmid DNA preparation and transfection 
Material  Source 
Ampicillin 100 mg/mL Sigma-Aldrich® 
hsa- let-7e mirVana miRNA mimic (MC 12304) Ambion® 
Empty Vector control construct pcDNA3.1 Invitrogen™ 
hsa-miR-145-5p mirVana miRNA mimic (MC11480) Ambion® 
hsa-miR-146a-5p mirVana miRNA mimic (MC10722) Ambion® 
hsa-miR-155-5p mirVana miRNA mimic (MC12601) Ambion® 
Inoculation Loops Cruinn 
Lipofectamine 2000 reagent Thermo Fisher Scientific 
Lysogeny broth (LB) Broth Sigma-Aldrich® 
mirVana miRNA mimic miR-1 positive control Ambion® 
mirVana miRNA negative control #1 Ambion® 
NF-κB construct Gift 
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Opti-Mem Reduced Serum Medium Gibco® 
pFA-IRF3 construct Gift 
pFR construct Gift 
Qiagen plasmid DNA Hi-speed midi kit Qiagen 
phRL-TK (TK renilla construct) Gift 
Table 2.1.7 Luciferase gene reporter assay 
Material  Source 
Acetyl Co Enzyme A (Lithium salt)  Sigma-Aldrich® 
ATP Sigma-Aldrich® 
Coelenterazine Biotium 
Dithiothreitol (DTT) Sigma-Aldrich® 
D-Luciferin firefly Sigma-Aldrich® 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich® 
GloMax® Microplate Luminometer Promega 
Luciferase cell culture lysis 5x reagent Promega 
Magnesium Carbonate Hydroxide Pentahydrate 
(MgCO3)4Mg(OH)2.5H2O 
Sigma-Aldrich® 
Magnesium Sulfate Heptahydrate MgSO4.7H2O Sigma-Aldrich® 
Sodium Hydroxide NaOH Sigma-Aldrich® 
Tricine Sigma-Aldrich® 
Table 2.1.8 RNA and DNA integrity by gel electrophoresis  
Material  Source 
Agarose Thermo Fisher Scientific 
Fermentas 6X DNA Loading Dye Thermo Fisher Scientific 
Gene Ruler 1 kb Plus DNA ladder Thermo Fisher Scientific 
RNA Sample Loading Buffer Sigma-Aldrich® 
SYBR® Safe DNA Gel Stain Invitrogen™ 
TAE Sigma-Aldrich® 
  
 40  
Table 2.1.9 RNA isolation, cDNA synthesis and qPCR. (Complete list of miRNA 
sequences and assays numbers see Appendix E) 
Material  Source 
96 well PCR plates Applied Biosystems™ 
Diethyprocarbonate (DEPC) H2O Invitrogen™ 
DNA Zap Invitrogen™ 
Megaplex PreAmp Primers, Human Set v2.0 (A & B)  Applied Biosystems™ 
Megaplex RT Primers Human Set v2.0 (A & B) Applied Biosystems™ 
MicroAmp Optical Adhesive film Applied Biosystems™ 
mirVana miRNA isolation kit Ambion® 
Taqman Array cards, 31 +1 MC format 32 Applied Biosystems™ 
TaqMan Array Human miRNA Cards Set v2.0 (A & B) Applied Biosystems™ 
Taqman MicroRNA Individual Assays Applied Biosystems™ 
TaqMan miRNA Reverse Transcription Kit Applied Biosystems™ 
TaqMan Pre Amp Master Mix Applied Biosystems™ 
Taqman Universal Master Mix II, no UNG Applied Biosystems™ 
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2.2 Methods 
2.2.1 Characterisation of SLPs 
C. difficile culture and the purification of all SLPs used in this project were carried out 
by Dr. Mark Lynch and Dr. Izabela Marszalowska- members of the Immunolodulation 
research group, DCU as part of their PhD research projects. SLPs were purified from 
frozen C. difficile spores from patient samples attending St. James hospital, Dublin. The 
C. difficile spores from the varying ribotypes were a gift from Prof. Thomas Rogers 
from the Department of Clinical Microbiology, School of Medicine, Trinity College, 
Dublin.  
The strains used in this study included R13537 (ribotype 001) and R12885 (ribotype 
014). The sequence of the slpA gene of these strains had been previously determined 
(accession numbers DQ060626 and DQ060638 respectively). To determine the slpA 
gene sequences of our clinical strains, whole-genome sequencing was performed. DNA 
was extracted from C. difficile using the Roche High-pure PCR template preparation kit 
(Roche, West Sussex, UK). Nextera XT library preparation reagents (Illumina, 
Eindhoven, The Netherlands) were used to generate multiplexed sequencing libraries of 
C. difficile genomic DNA, and resulting libraries were sequenced on an Illumina 
MiSeq®. Short-read data obtained has been deposited in the European Nucleotide 
Archive (ENA); project accession number PRJEB6566. Genome assemblies were 
performed using the Velvet short read assembler and slpA gene sequences were 
retrieved for each isolate using BLAST (Altschul, 1990).  
All microbial cell culture was carried out using aseptic techniques in a BIOMat class II 
microbiological safety cabinet in the Institute of Molecular Medicine (Trinity College, 
Dublin), based in St. James hospital. The SLPs were purified from cultures grown 
anaerobically at 37°C in Brain Heart Infusion (BHI) broth/0.05% Sodium thioglycolate 
with 0.5% Hemin and 0.1% Vitamin K. Cultures were harvested and the S-Layer 
protein was purified from the surface of the bacteria. Crude extracts were dialysed and 
samples applied to MonoQ HR10/10 anion exchange column attached to an AKTA 
FPLC. SLPs were eluted with a linear gradient of 0–0.3 mol/L NaCl at a flow rate of 4 
mL/min. Fractions containing pure SLPs were collected and concentrated down to a 
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volume of approximately 200 μL using an Amicon Ultra- 4 filter unit centrifuge tubes. 
Samples were collected and exposed to a UV light for 15 min to ensure sterilisation. 
SLPs were then aliquoted and stored at -20°C until ready for use (Lynch 2014, 
unpublished; Marszalowska 2015, unpublished).  
Table 2.2.1 Accession numbers for the slpA gene for each ribotype used in this study, 
sequences from GenBank 
Ribotype Accession number Length of sequence 
RT 001 DQ060626 AA: 756 
Nuc: 2271 
RT 005 DQ060630 AA: 610 
Nuc: 1833 
RT 027 R20291 AA: 758 
Nuc: 2277 
RT 031 DQ060641 AA: 739 
Nuc: 2220 
RT 078 DQ060643 AA: 726 
Nuc: 2181 
RT 014 DQ060638 AA: 732 
Nuc: 2199 
2.2.1.1 SDS-PAGE 
Sodium Dodecylsulphate-Polyacrylamide Electrophoresis (SDS-PAGE) was carried out 
to visualise the HMW and LMW SLPs that were extracted from the C. difficile cultures. 
The loading buffer containing SDS applies a uniform negative charge to the samples 
which migrate in an electrical field towards the positive electrode. The proteins are 
separated primarily by size as a result of the mass to charge ratio following binding of 
the SDS. Pure and crude samples of each of the SLPs from the differing ribotypes were 
diluted in 5x Loading Buffer (see Appendix A) which was supplemented with 
Dithiothreitol (DTT) and heated to 96°C for 5 min to denature any protein structures. 
The samples were allowed to cool to room temperature. Acrylamide resolving gels 
(12%) and stacking gels (5%) (see Appendix A) were made - the APS (10%) and 
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TEMED were added last and swirled gently to induce setting. The Acrylamide gels 
were cast between a pair of 10 x 100 mm glass plates. Once set the gels were fixed to 
the electrophoresis unit using a spring clamp. Gels were submerged in 1X electrode 
running buffer (see Appendix A), 15 μL of sample was loaded into each well. 
PageRuler Plus Prestained Protein ladder is a molecular weight protein ladder ranging 
from 10-250 kDa, it was added to lanes either side of the SLPs as a size indicator. Gels 
were run at 30 mA per gel for approximately one hour or until the dye front reached the 
base of the gel. Once electrophoresis was complete, the gels were washed with dH2O 
and submerged in 10 mL of Coomassie Blue stain (see Appendix A). The gels were left 
on a rocker for one hour to stain any protein bands present. Following staining the gel 
was washed briefly with dH2O and 10 mL of destain solution (see Appendix A) was 
added to the gels. The gels were placed on the rocker for 10 min before replacing the 
buffer with fresh destain, this was repeated four times. The gels were then left to agitate 
gently in destain overnight at 4°C. Gels were examined for the presence of SLPs. The 
HMW band was expected to be seen at 44 kDa while the LMW band was expected to be 
seen between 32-35kDa. 
2.2.1.2 Protein Concentration of SLPs 
The total protein concentration of the SLPs was determined using a Bicinchoninic Acid 
(BCA) protein assay kit (Pierce). The assay uses the well documented reduction of Cu
+2
 
to Cu
+1
 by protein in a base, where colorimetric detection of Cu
+1
 can be measured. A 
purple colour is observed in the presence of protein- darker colours signify a higher 
concentration of protein. Standards ranging from 0-2,000 μg/mL were made from 
Bovine Serum Albumin (BSA). Each standard and sample was added to a 96 well plate 
in triplicate. BCA working reagent was added to each well and the plate was covered 
and incubated at 37°C for 30 min. Samples were allowed to cool to room temperature 
and absorbance was read at 562 nm on the VersaMax™ microplate reader (Molecular 
Devices). A standard curve was constructed using the blank corrected absorbance values 
for each standard (see Appendix B).  
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2.2.1.3 Endotoxin Assay  
SLPs were tested for the presence of endotoxin, to ensure any observed immune 
response was not due to contaminants. The ToxinSensor™ Chromogenic LAL 
Endotoxin Assay Kit (GenScript) was used and instructions were followed according to 
manufacturer’s specifications. Limulus amebocyte lysate (LAL) reacts with bacterial 
endotoxin and lipopolysaccharide (LPS). A synthetic colour producing substrate is used 
to detect this endotoxin chromogenically. A series of standards were made from 1 
EU/mL (endotoxin unit/mL) endotoxin stock solution ranging from 0.01-0.1 EU/mL. 
Subsequently 100 μL of standards and samples were placed in specific endotoxin-free 
vials in triplicate. A blank of LAL reagent water was also prepared. LAL was added to 
each vial and the samples were incubated at 37°C for 10 min. Chromogenic substrate 
solution was then added, the samples were gently mixed and incubated for 6 min. Stop 
solution and colour stabiliser were added and samples were gently swirled to avoid 
generation of bubbles. Samples were transferred to a 96 well plate and the absorbance 
was read at 545 nm on the VersaMax™ microplate reader (Molecular Devices). A 
standard curve was constructed using the absorbance values for each standard where 4 
EU/mL equates to 1 ng/mL therefore the concentrations of endotoxin present in the 
unknown samples could be calculated (see Appendix B). 
2.2.2 Cell Culture Techniques 
All cell culture was carried out using aseptic technique in a class II laminar airflow unit 
(Holten 2010-ThermoElectron Corporation, OH, USA). Cell cultures were maintained 
in a 37°C incubator with 5% CO2 and 95% humidified air (Model 381- Thermo 
Electron Corporation OH USA). Cell cultures were maintained in media supplemented 
with heat inactivated (HI) Fetal Bovine Serum (FBS) at 56°C for 30 min where stated. 
Cells were visualised with an inverted microscope (Olympus CKX31, Olympus 
Corporation, Toyko, Japan). 
2.2.2.1 Revival of Frozen Stocks 
A cryovial was removed from liquid nitrogen and thawed rapidly by gentle agitation in 
a 37°C water bath. As soon as contents were thawed, the vial was sprayed with 70% 
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ethanol and the contents were removed under aseptic conditions. The cells were 
transferred into 9 mL complete medium (depending on the cell line used) and 
centrifuged for 5 min at 250 x g. The pellet was re-suspended in 10 mL complete 
medium and placed in a pre-warmed T25 cm
2
 culture flask. The flask was incubated at 
37°C and 5% CO2. 
2.2.2.2 Cell Enumeration and Viability Assessment  
Cell viability was assessed using trypan blue dye exclusion analysis. This test is based 
on the principle that viable cells maintain intact cell membranes and they can exclude 
trypan blue dye from entering the cell. In contrast dead cells cannot maintain intact cell 
membranes and allow the dye to enter the cell. Viable and non-viable cells can be 
visualised under the microscope. We placed 100 µl of cells in suspension were mixed 
with 150 µl PBS and 250 µl trypan blue solution (0.4% (v/v). A glass coverslip was 
mounted onto the shoulders of a Brightline Neubauer Haemocytometer and 10 μL of the 
mixture was applied at the edge of the coverslip and drawn across the counting chamber 
underneath by capillary action. Cells were examined under high power magnification 
(x40) and cells were counted in the areas marked 1-4 see Figure 2.2.1. The number of 
cells in the 16 squares equates to the number of cells x 10
4
/mL, therefore the total 
number of cells was calculated using the following formula: Cell/mL = N x D x 10
4
 
Where, N = average cell number counted in each square , D = dilution factor of cells in 
PBS.  
 
Figure 2.2.1 Representation of the Neubauer haemocytometer used to count cells. Areas 
1-4 on the diagram show where cells were counted. Cells touching the left or top 
boundary were not counted 
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2.2.2.3 Cryogenic Preservation of Cell Line Stocks 
To maintain reserves of cell lines, the cells were cryogenically preserved in liquid 
nitrogen. Cells were grown to a state of sub-confluency and counted (see Section 
2.2.2.2) and re-suspended at 5x10
6 
cells/mL in of complete medium with 5% (v/v) 
DMSO. Aliquots of 1 mL were transferred to labelled cryovials and placed in a Mr 
Frosty freezing container in a -80°C freezer. Mr Frosty freezing container provides a 
1°C/min cooling rate which is required for successful cryopreservation of cells. After 
three hours the cryovials were then transferred for storage to the liquid nitrogen vessel. 
2.2.3 Bone Marrow Derived Dendritic Cell Isolation and Culture 
Lutz et al. (1999) developed a technique to isolate large quantities of pure bone 
marrow-derived dendritic cells (BMDCs) from mouse bone marrow (Lutz et al., 1999). 
Bone marrow was isolated aseptically from the tibiae and femurs of BALB/c mice 
purchased from Charles River (U.K.) aged 10–14 weeks. The animals had ad libitum 
access to animal chow/water and were housed in a Specific Pathogen Free (SPF) unit in 
the licensed Bioresource facility at Dublin City University. The mice were culled in 
accordance with European Union (Protection of Animals used for scientific purposes 
regulations 2012) S.I No.543 of 2012 & directive 2010/63/EU of the European 
Parliament. The hind legs were removed and flesh/muscle was carefully removed from 
the leg bones, the bones were stored in RPMI media on ice. The femur was cut above 
the knee and below the hip to expose the bone marrow. A syringe with a 27.5 G needle 
was filled with RPMI and used to flush the bone marrow out of the femur into a sterile 
50 mL falcon. The same process was repeated for the tibia. All bone marrow was 
collected together and a sterile 10 mL syringe with a 19 G needle was used to break up 
the bone marrow. The 50 mL falcon was centrifuged at 250 x g for 5 min and the pellets 
were re-suspended in 1 mL media for every bone used in the experiment e.g. 2 legs 
equals 4 bones therefore cells re-suspended in 4 mL media. Enough complete RPMI 
media (see Appendix A) supplemented with Granulocyte macrophage colony-
stimulating factor (GM-CSF) was added to the cells to load 10 mL of total media per 
sterile petri dish: 1 mL of cells to 9 mL RPMI. Cells were incubated at 7°C in 5% CO2 
in a humidified incubator. After 3 days 7 mL of media was removed from each petri 
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dish and 10 mL of fresh RPMI/GM-CSF was added. Cells were incubated for a further 
four days before being removed from the petri dishes, a sterile cell scraper was used to 
detach any adherent cells. The cells were collected in a sterile 50 mL centrifuge tube 
and centrifuged at 250 x g for 5 min. Cells were counted (see Section 2.2.2.2) and 
plated at 1x10
6
 cells/mL for experiments. 
2.2.4 Hek-293 and Hek TLR4/MD2/CD14 Cell Culture 
Human Embryonic Kidney 293 (Hek-293) and human Hek-293 TLR4/MD2/CD14 cell 
lines were a gift from Prof. Paul Moynagh, The Institute of Immunology, National 
University of Ireland Maynooth, Maynooth Co. Kildare. The cells were maintained in 
complete DMEM (see Appendix A) in T-75 cm
2 
flasks. The human Hek 
TLR4/MD2/CD14 cells are derived from Hek-293 cells but have the machinery for 
TLR4 signalling, as they are stably co-transfected with the pUNO-TLR4 that express 
human TLR4 genes and the pDUO2-MD2-CD14 plasmid which express human MD2 
with CD14 genes. Cell monolayers were passaged at a confluency of 80% (every 4-5 
days). Cells were detached from the flask surface by scraping with sterile cell scrapers 
in the presence of PBS. For subculture cells were split 1:3 in complete medium. Cells 
were counted (see Section 2.2.2.2) and plated at 1x10
6
 cells/mL for experiments. 
2.2.5 JAWS II Dendritic Cell Line Culture 
The Murine JAWS II DC cell line (CRL-11904) were bought from the ATCC and 
maintained in complete α-MEM (see Appendix A) in T75cm2 flasks. JAWS II DCs are 
an immature dendritic cell line derived from p53 growth suppressor gene deficient 
C57BL/6 mice. The cell line can be induced to become an activated dendritic cell line 
with the ability to stimulate T cells to proliferate (MacKay & Moore, 1997). JAWS II 
DCs are a mixed culture of attached and suspension cells. After seven days of growth 
the suspension cells were transferred to a 50 mL falcon before adherent cells were 
washed with PBS and detached with 0.25% trypsin-0.53 mM EDTA. All cells were 
pooled and centrifuged at 200 x g for 10 min and sub cultured at a 1:5 ratio in T75cm
2
 
flasks and incubated at 37°C in 5% CO2. Cells were counted (see Section 2.2.2.2) and 
plated at 1x10
6
 cells/mL for experiments. 
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2.2.6 Cell Stimulation 
Cells were seeded at 1x10
6
 cells/mL and incubated overnight or until adherent cells 
adhered to the base of each well. Cells were stimulated with 20 µg/mL SLPs which 
were isolated from various ribotypes (RT) of C. difficile. Cells were also stimulated 
with 100 ng/mL LPS from a 1 mg/mL stock of E. coli serotype R515 as a positive 
control. Control cells were incubated in media alone. The cells were incubated for a 
period of time ranging from 1-24 hours depending on the experimental set up. 
2.2.7 Cytotoxicity Assay 
Cell titer 96 Aqueous One solution contains (3- 4,5-dimethylthialzol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium, known as MTS. This 
compound can be used to measure the quantity of formazan produced by cells, to 
measure cell viability. The quantity of formazan produced is directly proportional to the 
number of living cells in culture. Hek TLR4/MD2/CD14 cells were counted and plated 
at 0.1x10
6
 cells/100 μL in complete DMEM media in a 96 well plate overnight (see 
Section 2.2.2.2). Cells were transfected with miRNA mimics, NF-κB and IRF3 plasmid 
DNA constructs (see Section 2.2.11). Post transfection (18 hours) cells were stimulated 
with LPS and SLPs (see Section 2.2.6). We placed 20 μL of Cell Titer96 AQueous One 
Solution to each well and incubated at 37°C in 5% CO2. After 4 hours the absorbance 
was read at 490 nm on the VersaMax™ microplate reader (Molecular Devices). The cell 
viability of each sample was expressed as a percentage of the control cells and 
compared to cells treated with 10% DMSO which is known to effect cell viability.  
2.2.8 Enzyme Linked Immunosorbent Assay (ELISA) 
Enzyme linked Immunosorbent assay (ELISA) was used to quantify numerous 
cytokines and chemokines in cell supernatants from both murine and human cells 
depending on the experiment. DuoSet ELISA kits from R&D Systems with antibodies 
specific for murine or human samples were used according to the manufacturer’s 
specifications (see Appendix A). Capture antibody (100 µl) specific for the cytokine of 
interest was bound to each well in a 96 well plate by incubation overnight at room 
temperature. Excess or unbound antibodies were removed by washing with wash buffer. 
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Assay diluent (300 µl) was added to each well and incubated for one hour before being 
washed, the diluent acts as a blocking buffer preventing non-specific binding. A stock 
solution of standards at a known concentration of the cytokine/chemokine in question 
was prepared and a 1:2 serial dilution was carried out to make a range of known 
standards. Samples were prepared and diluted in reagent diluent where required. We 
placed 100 µl samples and standards into the 96 well plate and incubated at room 
temperature for 2 hours. The plates were washed again to remove any unbound sample 
and 100 µl biotinylated detection antibody specific for the assay of interest was added to 
each well on the plate. Streptavidin has a high affinity for biotin, therefore 100 µl 
streptavidin-HRP was added to each well. After 20 min the plate was washed with wash 
buffer to remove any excess and 100 µl Tetramethylbenzidine (TMB) was added to 
each well on the plate. The colour was allowed to develop as Streptavidin catalyses the 
oxidation of TMB which forms a blue colour, the intensity of colour is proportional to 
the concentration of the cytokine/chemokine being measured. The reaction was stopped 
after approximately 20 min by the addition of 50 µl sulphuric acid 2N H2SO4 (see 
Appendix A) which turns the colour of the assay from blue to a yellow. The absorbance 
of each of the samples and standards was read at 450 nm on the VersaMax™ microplate 
reader (Molecular Devices). The optical density (OD) at 450 nm of the set of known 
standards was plotted against their corresponding known concentrations, making a 
standard curve. The absorbance of samples being tested was calculated by interpolating 
the absorbance readings into the standard curve equation to determine the concentration 
of cytokine/chemokine in the cell supernatant. 
2.2.8.1 Detection of Murine/Human Cytokines & Chemokines 
The cytokines, murine (m) IL-6, mIL-10, mTNFα, mIL-12p40, mIL-12p70, mIL-23, 
mIL-27p28 and chemokines mRANTES, human (h) RANTES, mMCP-1 and mMIP-2 
were quantified according to manufacturer’s recommendations. 1% (w/v) BSA/PBS 
was used as a blocking buffer and reagent diluent. Washing buffer consisted of 0.05% 
Tween-20 in PBS made from 10X PBS (see Appendix A). 
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2.2.8.2 Detection of IL-1β and IL-8 
The cytokines mIL-1β and hIL-8 were quantified according to manufacturer’s 
recommendations. BSA/PBS 1% (w/v)  was used as a blocking buffer and 0.1% 
BSA/TBS + 0.05% (v/v) Tween-20 were used as reagent diluent. Washing buffer 
consisted of 0.05% Tween-20 in PBS made from 10X PBS. 
2.2.9 Flow Cytometry 
Flow cytometry is a technique that allows the analysis of multiple parameters of cells in 
a heterogeneous cell population. Cells in suspension are passed through a 100 μm 
nozzle which allows one cell at a time to pass through a laser light. The light scattered 
and the fluorescence emitted from positively stained cells can be read by detectors. The 
detector in front of the laser beam measures the forward scatter which determines cell 
size and the detector to the side measures side scatter which determines the granularity. 
When cells have been stained by flurochromes, light will be emitted at a certain 
wavelength when excited by a laser at the corresponding excitation. The emitted light is 
detected by photomultiplier tubes (PMTs) which convert the energy of a photon into an 
electrical signal called a voltage. Each voltage pulse equates to an “event” and 100,000 
of these are recorded on average. In order to investigate an antigen on the surface of a 
cell, the cell is incubated with a fluorescently labelled monoclonal antibody specific to 
the antigen of interest. These flurochromes are excited by a laser and emit light at 
specific wavelengths. In this study we used three-colour polychromatic flow cytometry 
using the following flurochromes; Fluorescein Isothiocyanate (FITC), Phycoerythrin 
(PE) and Allophycocyanin (APC). FITC excites at 495 nm and emits at 520 nm. PE 
excites at 465 nm and emits at 578 nm. APC excites at 635 nm and emits at 660 nm. 
2.2.9.1 Cell Surface Staining of BMDCs 
The bone marrow from BALB/C mice were isolated (See Section 2.2.3) and grown for 
7 days in the presence of GM-CSF. The cells were counted (see Section 2.2.2.2) and 
seeded at 2 x10
6
 cells in 2 mL of media on 6 well plates. The cells were then stimulated 
with LPS and SLPs for 24 hours (see Section 2.2.6). The supernatants were aspirated 
from each well and collected for further analysis by ELISA (see Section 2.2.8). The 
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cells were washed with 2 mL of sterile PBS and a cell scraper was used to gently detach 
cells from each well. The cells were transferred to 15 mL centrifuge tubes. An equal 
amount of FBS was added to each tube to block non-specific binding and cells were 
incubated at room temperature for 15 min. Cells were centrifuged at 250 x g for 5 min 
and re-suspended in FACS buffer (see Appendix A). We used 1 mL of buffer per 2x10
6
 
cells. We transferred 200 µl of each sample to a round bottom 96-well plate. Plates were 
centrifuged at 250 x g for 5 min. The relevant antibody was added to each well at a 
concentration of 0.5 µg/1x10
6
 cells. Antibody stock was diluted in FACS buffer as 
required. Cells were incubated at 4˚C for 30 min. Cells were then washed with 200 µl 
FACS buffer, and centrifuged at 250 x g for 5 min. This was repeated three times. Cells 
were re-suspended in FACS buffer and transferred to labelled FACS tubes for analysis. 
Samples were then acquired immediately on the Becton Dickinson (BD) FACSAria™ I 
Cell Sorter and analysed using FlowJo software (Tree Star) with cells gates applied to 
CD11c
+
 BMDC population. 
2.2.10 Purification of Plasmid DNA  
Glycerol stocks of chemically competent DH5α E. coli transformed with NF-κB, pFA-
IRF3, pFR phRL-TK renilla and pcDNA3.1 empty vector ligated DNA (see Appendix 
C) were a gift from Prof. Paul Moynagh, The Institute of Immunology, National 
University of Ireland Maynooth, Maynooth, Co. Kildare and all plasmids were 
authenticated by sequencing. Plasmid DNA from the individual glycerol stocks were 
inoculated into separate conical flasks containing 500 mL LB broth supplemented with 
100 μg/mL Ampicillin and grown overnight at 37 °C in a shaking incubator. Further 
glycerol stocks were made by aseptically mixing 930 μL bacterial culture and 70 μL of 
DMSO and storing at -80ºC. The rest of the bacterial culture was harvested by 
centrifugation at 6000 x g for 40 min at 4 °C. Microgram quantities of plasmid DNA 
were purified using a Qiagen plasmid DNA Hi-speed midi kit (Qiagen) according to 
manufacturer’s instructions. This kit utilises the alkaline lysis procedure. The 
supernatant was removed from the pellet which was then re-suspended using 6 mL of 
chilled P1 buffer. We added 6 mL of P2 buffer and mixed vigorously for 30 seconds to 
lyse the bacterial cells before they were incubated at room temperature for 5 min. We 
added 6 mL of P3 buffer to neutralise the lysing effect of the P2 buffer, and solution 
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was mixed vigorously again for 30 seconds. The cell lysate was then poured into the 
barrel of a QIA midi-cartridge and incubated at room temperature for 10 min to allow 
cell debris settle. Using the QIA filter the cell lysate was filtered into a previously 
equilibrated hi speed midi-prep tip where the DNA was allowed bind to the resin 
column. Bacterial cell proteins were removed by washing the column with 20 mL of QC 
buffer and then precipitated with 3.5 mL room temperature Isopropanol which was 
gently mixed by inversion. The DNA was then allowed to precipitate by incubation at 
room temperature for 5 min. The Isopropanol mixture was then added to the QIA-
precipitator and filtered through. Plasmid bound to the precipitator was then washed 
with 2 mL 70% (v/v) ethanol, air dried and eluted into a 1.5 mL micro- centrifuge tube 
using 700 µl sterile TE buffer. Lastly, the eluted DNA was flushed through the 
precipitator once again to remove any unbound DNA. The DNA was quantified using a 
NanoDrop® ND-1000. The purity of the DNA was determined by measuring the ratio 
of absorbance at 260 nm and 280 nm. Pure DNA which has no bound protein impurities 
should have an A260/A280 ratio of 1.8-1.9. Stocks were aliquoted and stored in the -
20ºC freezer and used for transfection. A 500 mL culture typically yielded 1-2 µg/mL of 
plasmid DNA.  
2.2.11 Transient Transfection of Cells 
Hek-293 or Hek TLR4/MD2/CD14 cells were cultured (see Section 2.2.4) and counted 
(see Section 2.2.2) before they were seeded at 0.2 x10
6
 cells/mL in 200 μL DMEM 
media per well in a 96 well plate. Cells were allowed to adhere for 18 hours to 
approximately 60% confluency. Cells were transfected using Lipofectamine 2000 which 
is a cationic liposome that functions by complexing with nucleic acid molecules, 
allowing them to overcome the electrostatic repulsion of the cell membrane and to be 
taken up by the cell (Dalby, 2004). For each well to be transfected, 25 µl of OptiMEM 
was mixed with DNA. DNA mixes were made up for the appropriate construct (see 
Sections 2.2.11.1 – 2.2.11.3). Lipofectamine 2000 (0.4 μL) was diluted in OptiMEM 
and made up to 25 µl per sample. The reaction was mixed gently and left at room 
temperature for 5 min. After incubation, the Lipofectamine/OptiMEM solution was 
added to the DNA/OptiMEM mix for a total volume of 50 µl per well to be transfected. 
The combined reaction was mixed gently and incubated at room temperature for 20 min. 
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The transfection mixture was then added to each well and mixed gently by tapping the 
side of the plate. Cells were placed back in the incubator at 37°C 5% CO2 for 18-24 
hours depending on the experiment. 
2.2.11.1 NF-κB assays 
To measure activation of the NF-κB pathway, cells were transfected with NF-κB 
regulated firefly luciferase reporter plasmid (80 ng) and constitutively expressed Renilla 
luciferase reporter construct phRL-TK (20 ng). An empty vector control reaction was 
set up in parallel using the same concentrations of NF-κB and IRF3 constructs with the 
additions of pcDNA3.1 empty vector (50 ng). Firefly luminescence readings were 
corrected for Renilla activity and expressed as fold stimulation over empty vector 
control. 
2.2.11.2 IRF3 assays 
To measure the activation of IRF3, cells were transfected with pFR-Luc (60 ng), the 
trans-activator plasmid pFA-IRF3 (IRF3 fused downstream of the yeast Gal4 DNA 
binding domain, (30 ng) and phRL-TK (20 ng). An empty vector control reaction was 
set up in parallel using the same concentrations of pFR, IRF3 and TK constructs with 
the additions of pcDNA3.1 empty vector (50 ng). Firefly luminescence readings were 
corrected for Renilla activity and expressed as fold stimulation over empty vector 
control. 
2.2.11.3 MiRNA mimics 
MiRNA mimics are small chemically modified double-stranded RNAs that mimic 
endogenous miRNAs and enable miRNA functional analysis as they can up-regulate 
miRNA activity. We examined the effect of over-expressing miRNAs on NF-κB and 
IRF3 gene expression. 0-100 nM of individual miRNA mimics/ miRNA controls (see 
Appendix A) were added to DNA/OptiMEM mix of NF-κB (see Section 2.2.11.1) and 
IRF3 (see Section 2.2.11.2). The volume of OptiMEM was adjusted to give a 50 µl total 
volume at the time of transfection (see Section 2.2.11). 
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2.2.12 Luciferase Assays 
Firefly luciferase is a 61 kDa monomeric protein that does not require post-translational 
processing for enzymatic activity. Firefly luciferase catalyzes an oxidative reaction 
involving ATP, firefly Luciferin and molecular oxygen, yielding an electronically 
excited oxyluciferin species and this excited species emits visible light (Baldwin, 1996). 
Thus it functions as a genetic reporter immediately upon translation when expressed 
under an experimental promoter, in this case NF-κB of IRF3. This assay enabled us to 
examine NF-κB and IRF3 signalling induced by the SLPs from differing ribotypes of C. 
difficile using the luciferase assay. Both sets of plasmid DNA were co-transfected with 
constitutively expressed TK renilla luciferase construct. Renilla luciferase is a 36 kDa 
monomeric protein where post-translational modification is not required for its activity 
and the enzyme may function as a genetic reporter immediately following translation 
however it is expressed under the control of a constitutive promoter (Matthews, Hori, & 
Cormier, 1975; Shifera & Hardin, 2010). The utility of an internal control plasmid is 
dependent on the fact that the encoded protein is expressed in a constitutive manner 
without being influenced by experimental factors and can therefore be used to normalise 
the transfection efficiency (Shifera & Hardin, 2010). 
Hek-293 or Hek TLR4/MD2/CD14 cells were cultured (see Section 2.2.4) and counted 
(see Section 2.2.2.2) before being seeded at 0.2 x10
6
 cells/mL in 200 μL DMEM media 
per well in a 96 well plate and allowed to adhere for 18 hours to approximately 60% 
confluency. Cells were transiently transfected (see Section 2.2.11) with NF-κB (see 
Section 2.2.11.1), IRF3 (see Section 2.2.11.2) and in some cases combined with 
miRNA mimics (see Section 2.2.11.3). 18-24 hours post transfection (depending on the 
experiment) cells were stimulated with LPS and SLPs (see Section 2.2.4) for 18-24 
hours (depending on the experiment). Media was aspirated from each well and 100 µl 
1X luciferase lysis buffer (see Appendix A) was added. The plates were covered in foil 
and placed on a rocker for 20 min at room temperature. The plates were then placed in 
the -80°C freezer for a minimum of 1 hour. Samples were then thawed at room 
temperature, for a maximum of 2 hours, to release the contents of the cell. Lysed cells 
were transferred to white plates. Firefly luciferase activity was assayed by the addition 
of 40 μL of luciferase assay mix (see Appendix A) to each sample. Renilla luciferase 
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was made by diluting Coelenterazine in PBS to give a 1:1000 dilution. 40 µl Renilla 
luciferase was also added to duplicated samples on each plate. The luminescence was 
read using a GloMax® Microplate Luminometer (Promega). Firefly luminescence 
readings were corrected for Renilla activity and expressed as fold stimulation over 
empty vector control. 
2.2.13 RNA Isolation  
A dedicated RNase-free environment specific for RNA work was established with 
specific gloves and pipettes used with filter tips, to ensure the quality of RNA starting 
product. Prior to any RNA work, surfaces and equipment were cleaned down with DNA 
Zap (Invitrogen). DNA Zap is a potent nucleic acid degrading solution which can 
degrade any contaminating genomic DNA  
2.2.13.1 Total Isolation from Cell Lines 
Hek TLR4/MD2/CD 14 cells (see Section 2.2.4) and JAWS II cells (see Section 2.2.5) 
were cultured and counted (see Section 2.2.2.2) before they were seeded at 2x10
6
 
cells/mL in 2 mL media. Cells were stimulated with LPS and SLPs (see Section 
2.2.2.6). Cells were harvested after 8 hours and total RNA was isolated using the 
mirVana™ miRNA Isolation Kit (Ambion) as per manufacturer’s instructions, Figure 
2.2.2 shows a summary of this procedure. The cells were scraped in media and 
transferred to 15 mL falcons, the tubes were centrifuged at 250 x g for 5 min. The 
supernatants were removed and the pellets washed with 5 mL sterile PBS. The samples 
were diluted in lysis solution and vortexed for 1 min to obtain a homogenous lysate. 
The volume was recorded and used to calculate the volume of miRNA homogenate 
additive to add in (1/10). The solution was mixed by vortexing for 30-60 seconds and 
incubated on ice for ten min. The volume prior to addition of the miRNA homogenate 
additive was used to calculate the volume of acid-phenol chloroform to add in, making 
sure to take the bottom phase. The lysate solution was again vortexed for 30-60 seconds 
before being centrifuged for 5 min at 10,000 x g at room temperature to separate the 
aqueous and organic phases. Following centrifugation, the lysate solution was checked 
for a compact interphase and if this was not evident the centrifugation step was 
repeated. The upper aqueous phase was transferred to a fresh tube taking care not to 
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disturb or carryover any of the bottom organic phase. The volume of upper aqueous 
phase recovered was noted and 1.25 X of this volume of room temperature 100% high 
grade ethanol was added to the fresh tube. A maximum of 700 µl of this lysate/ethanol 
mixture was pipetted onto a glass-fibre filter cartridge, which was placed in a fresh tube. 
This was centrifuged at 10,000 x g for 15 seconds to pass the mixture through the filter. 
This step was repeated until all of the lysate/ethanol had been passed through making 
sure to discard the flow through each time. 700 µl of wash buffer 1 was then added to 
the filter column and passed through by centrifugation at 10,000 x g for 15 seconds. 
This was repeated using 500 µl of wash buffer 2/3 again with the flow through being 
discarded each time. After the third wash the filter column was centrifuged at 10,000 x 
g for 1 min to dry off the filter column and prevent ethanol carry over to the new tube in 
which filter column was placed. The total RNA was then eluted into a fresh collection 
tube by centrifugation at 10,000 x g for 30 seconds using 100 µl elution solution which 
was pre-heated to 95°C. The RNA was quantified and qualified on the NanoDrop® ND-
1000 Spectrophotometer. The purity of the RNA was analysed by measuring the 260nm 
and 280 nm absorption wavelengths, where RNA with an A260/A280 ratio between 
1.8- 2.1 is considered pure. The RNA samples where then run on a 1% agarose gel 
where the 28S and 18S ribosomal RNA bands were assessed for integrity (see Section 
2.2.14). 
 
Figure 2.2.2 Summary of the RNA Isolation procedure. Image modified from 
mirVana™ miRNA Isolation Kit protocol (Life Technologies, 2011) 
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2.2.13.2 Enrichment of Total RNA Derived from C. difficile Infection model 
All procedures were carried out in accordance with the Health Products Regulatory 
Authority. The in vivo C. difficile infection model was carried out in collaboration with 
Pat Casey and Professor Colin Hill in the Alimentary Pharmabiotic Centre, University 
College Cork. Isolation of colonic samples were carried out by Dr Maja Kristek, Dr 
Mark Lynch and Dr Joseph deCourcey. Total RNA samples were generated by Dr. 
Mark Lynch, a member of the Immunolodulation Research group (DCU), as part of his 
PhD research project. C57BL/6J mice were infected with C. difficile using an antibiotic-
induced model of mouse infection (Chen et al., 2008). Mice were treated for three days 
with an antibiotic mixture of Kanamycin (400 μg/mL), Gentamicin (35 μg/mL), Colistin 
(850 U/mL), Metronidazole (215 μg/mL) and Vancomycin (45 μg/mL) in the drinking 
water. Mice were subsequently given autoclaved water. On day 5, mice were injected 
intraperitoneally with Clindamycin (10 mg/kg). Mice were infected with 10
3
 C. difficile 
spores on day six by oral gavage. Initial studies determined infection with 10
3
 spores of 
C. difficile R13537 caused mild transient weight loss and diarrhoea in wild-type 
C57BL/6J strain mice. Animals were weighed daily and monitored for overt disease, 
including diarrhoea. Moribund animals with >15% loss in body weight were humanely 
culled. The colon was harvested from uninfected and infected mice at days three and 
seven of infection. Squares of tissue from the distal colon roughly 5 mm
3
 were cut for 
the preparation of RNA. This tissue was stored in RA1 buffer until required, it was 
homogenised using a rotor-stator homogeniser. RNA was isolated using the 
NucleoSpin® RNA II Total RNA Isolation Kit (Macherey-Nagel) as per manufacturer’s 
instructions. The RNA was quantified using a NanoDrop Spectrophotometer and then 
stored in the -80°C freezer until ready for use (Lynch 2014, unpublished). 
For this study small RNAs were enriched from 50 µg Total RNA samples from the C. 
difficile infection model using the mirVana™ miRNA Isolation Kit (Ambion) as per 
manufacturer’s instructions. Total RNA samples were mixed with 5 volumes of 
lysis/binding buffer and 1/10 volume of miRNA homogenate additive before being 
placed on ice for 10 min. 1/3 volume of 100% ethanol was added to each sample and 
pipetted onto a filter cartridge. The filter cartridge was placed in a collection tube and 
spun at 5000 x g for 1 min. The filtrate was collected and 2/3 volume of 100% ethanol 
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was added to each sample. The filtrate/ethanol mixture was pipetted onto a new filter 
cartridge and spun at 5000 x g for 1 min. The flow through was discarded and the filter 
was washed sequentially with 700 µl miRNA Wash solution 1, followed by two 500 µl 
Wash solution 2/3 using the centrifugation method where the filter cartridge was spun at 
5000 x g for 1 min in between washes. Following the last wash the filter cartridge was 
placed in a fresh collection tube and 50 µl Elution solution (which had been heated to 
95°C) was added to the centre of the filter and incubated at room temperature for 2 min. 
The filter cartridge and collection tube were then spun at 10,000 x g for 1 min. The flow 
through contained the RNA enriched for the small RNA fraction. RNA was quantified 
using a NanoDrop Spectrophotometer and RNA integrity was assessed by analysing the 
A260/A280 ratio. RNA with a ratio between 1.8- 2.1 was considered of good quality. 
2.2.14 Agarose Gel Electrophoresis to Assess RNA Integrity 
To assess the integrity of the RNA, 1 µg of total RNA from each sample was used for 
visualisation. Briefly, 1% agarose gel was prepared in 100 ml of 1X TAE buffer made 
from 50X TAE (see Appendix A). To visualise the RNA, 10 µl of SYBR Safe was 
added to cooled agarose solution and poured into a sealed gel cassette with the comb set 
in place. The gel was left to set for 30 min covered in tin foil to prevent photo 
bleaching. Samples were prepared by in 5X loading buffer and heated to 65°C for 10 
min. The apparatus consisted of a horizontal rig which housed the gel cassette and 
comb. The rig was then filled with 1X TAE buffer. Samples along with 1 kb ladder 
were loaded into the wells created by the comb. The gel was electrophoresised at 150 V 
for approximately 30 min or until the loading dye ran three quarters of the way down 
the rig. The gel was then visualised using the G-Box Gel Imagine System. Intact total 
RNA has two clear bands, corresponding to 28S and 18S subunits. The ratio of intensity 
of 28S to 18S should be 2:1. 
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2.2.15 cDNA Synthesis 
 
Figure 2.2.3 Image depicting RNA-specific stem-looped reverse transcription primers 
(Life Technologies, 2013) 
Reverse transcription is used to convert single stranded RNA into complementary DNA 
(cDNA). Standard and quantitative Polymerase Chain Reaction (PCR) methods require 
a template that is at least two times the length of either of the specific forward or reverse 
primers, each typically 20 nucleotides (nt) in length. Thus, the target minimum length is 
≥ 40 nts, making miRNAs too short for standard reverse transcription qPCR methods. 
They require primers that contain a highly stable stem-loop structure see Figure 2.2.3, 
that lengthen the target cDNA. The forward PCR primer adds additional length with nt 
that optimise its melting temperature (T(m)). Assay specificity is further optimised by 
placement of the probe over much of the original miRNA sequence, and the probe T(m) 
is optimised by addition of a minor groove binding (MGB) moiety (Kramer, 2011).  
2.2.15.1 cDNA Synthesis for Pool A and B TLDA Cards 
Single stranded cDNA was synthesised using TaqMan® micoRNA Reverse 
Transcription Kit (Applied Biosystems™) which utilises stem-loop technology and 
creates cDNA from mature miRNAs only and not precursors. For a full miRNA profile 
two reverse transcription reactions were needed incorporating RNA-specific stem-
looped primers for both pool A and pool B miRNA panels. Total RNA from Hek 
TLR4/MD2/CD14 cells stimulated with LPS and SLPs for 8 hours were isolated (see 
Section 2.2.13.1). The final volume for each reaction was 7.5 μL where either 350 ng or 
500 ng in 3 μL total volume was added to 4.5 μL master mix see Table 2.2.2. For the no 
template control (NTC) 3 µl of nuclease water was added instead of total RNA. The 
samples were then run on the bench top thermocycler (PTC-200 DNA Engine cycler, 
Biorad) see Table 2.2.3 for the conditions. 
  
 60  
Table 2.2.2 Recipe for cDNA synthesis for pool A and pool B TLDA cards 
Mix Components Volume for 
1 sample 
(μL) 
Volume for 10 
samples (μL) * 
Megaplex RT Primers (10✕) 0.8 9.0 
dNTPs with dTTP (100 mM) 0.2 2.3 
MultiScribe Reverse Transcriptase (50 U/µl) 1.5 17.0 
10✕ RT Buffer 0.8 9.0 
MgCl2 (25 mM) RNase 0.9 10.1 
RNase Inhibitor (20 U/µl 0.1 1.1 
Nuclease-free water 0.2 2.3 
Total 4.5 50.8 
*Includes 12.5% excess for volume loss from pipetting. 
Table 2.2.3 Thermocycler conditions for cDNA synthesis for pool A and B TLDA 
cards 
Stage Temperature Time 
Cycle 
(40 Cycles) 
16 °C 2 min 
42 °C 1 min 
50 °C 1 sec 
Hold 85 °C 5 min 
Hold 4 °C ∞ 
2.2.15.2 cDNA Synthesis for Custom TLDA Cards and Individual miRNA assays 
Custom pools of 5X RT primers were made in 1X TE buffer. Total RNA from Hek 
TLR4/MD2/CD14 cells and JAWS II cells (see Section 2.2.13.1) and RNA enriched for 
miRNAs from the C. difficile model (see Section 2.2.13.2) was taken out of the -80°C 
freezer and thawed on ice. The final volume for each reaction was 15 μL where 350 ng 
total RNA in 3 μL (total volume) was added to 12.0 μL master mix see Table 2.2.4. For 
the NTC 3 µl of nuclease water was added instead of total RNA. The samples were then 
run on the bench top thermocycler (PTC-200 DNA Engine cycler, Biorad) see Table 
2.2.5 for the conditions. 
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Table 2.2.4 Recipe for cDNA synthesis for custom TLDA cards and individual miRNA 
assays 
Mix Components Volume for 1 sample 
(μL) 
RT Primers ǂ 6.0 
dNTPs with dTTP (100 mM) 0.3 
MultiScribe Reverse Transcriptase (50 U/µl) 3.0 
10✕ RT Buffer 1.5 
RNase Inhibitor (20 U/µl) 0.2 
Nuclease-free water 1.0 
Total 12.0 
ǂ 10 µl of each 5X RT primer added to 1X TE for a final volume of 1 mL to give final 
0.05X concentration in each reaction tube. 
Table 2.2.5 Thermocycler conditions for cDNA synthesis for custom TLDA cards and 
individual miRNA assays 
Stage Temperature Time 
Hold 16 °C 30 min 
Hold 42 °C 30 min 
Hold 85 °C 5 min 
Hold 4 °C ∞ 
2.2.16 Pre-amplification of cDNA 
Pre-amplification of cDNA was used to uniformly amplify desired cDNA by increasing 
the amount on starting template (Noutsias et al., 2008). This increases sensitivity of the 
miRNAs detected without biasing the estimation of miRNA expression ratio (Chen, 
Gelfond, McManus, & Shireman, 2009) 
2.2.16.1 Pre-amplification Reaction for Pool A and pool B TLDA Cards 
The pre-amplification reaction had a final volume of 25 µl containing 2.5 μL cDNA 
product originally isolated from Hek TLR4/MD2/CD14 cells (see Section 2.2.15.1) and 
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22.5 μL PreAmp reaction mix see Table 2.2.6. The samples were then run on the bench 
top thermocycler (PTC-200 DNA Engine cycler, Biorad) see Table 2.2.7 for the 
conditions. Following this the reaction samples were diluted with 0.1X TE pH 8.0. 
Table 2.2.6 Recipe for pre-amplification master mix for pool A and B TLDA cards 
 Volume for 1 
Sample (µl) 
Volume for 10 
Samples (µl)* 
TaqMan PreAmp Master Mix (2X) 12.5 140.62 
Megaplex PreAmp Primers (10X) 2.5 28.13 
Nuclease-free water 7.5 84.37 
Total 22.5 253.12 
*Includes 12.5% excess for volume loss from pipetting. 
Table 2.2.7 Thermocycler conditions for pre-amplification  
Stage Temperature Time 
Hold 95 °C 10min 
Hold 55 °C 2 min 
Hold 72 °C 2 min 
Cycle  
(12 Cycles) 
95°C 15 sec 
60°C 4 min 
Hold 99.9 °C 10 min 
Hold 4°C ∞ 
2.2.16.2 Pre-amplification for Custom TLDA Cards and Individual miRNA 
Assays 
The pre-amplification reaction had a final volume of 25 µl containing 2.5 μL cDNA 
product originally isolated from Hek TLR4/MD2/CD14 cells, JAWS II cells and 
miRNAs enriched from the C. difficile model (see Section 2.2.15.2). The cDNA 
products were mixed with 22.5 μL PreAmp reaction mix see Table 2.2.8. The samples 
were then run on the bench top thermocycler (PTC-200 DNA Engine cycler, Biorad) see 
Table 2.2.7 for the conditions. Following this the reaction samples were diluted with 
0.1X TE pH 8.0. 
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Table 2.2.8 Recipe for pre-amplification master mix for custom TLDA cards and 
individual miRNA assays 
 Volume for 1 sample 
(µl) 
TaqMan PreAmp Master Mix (2X) 12.5 
PreAmp Primer Poolǂ 3.75 
Nuclease-free water 6.25 
Total 22.5 
ǂ 10 µl of each 20X individual Taqman miRNA assay was added to 1X TE for a final 
volume of 1 mL to give final 0.2X concentration in each reaction tube. 
2.2.17 Running Taqman® Low Density Arrays (TLDA) cards 
DNA polymerase from the TaqMan® Universal PCR Master Mix amplifies the target 
cDNA using sequence specific primers and a probe on the TaqMan microRNA array. 
The presence of the target is detected in real time through cleavage of the TaqMan 
probe by the polymerase 5’-3’ activity. Pre-amplified cDNA (see Section 2.2.16.1) was 
added to the following master mix see Table 2.2.9. During optimisation, cDNA product 
(see Section 2.2.15.1) originating from 350 ng and 500 ng starting RNA was 
investigated, therefore cDNA product was added to the following master mix see Table 
2.2.10. Pool A and B TLDA cards were allowed to come to room temperature before 
100 µl of the mix was dispensed into each port on the cards. The cards were centrifuged 
twice in specialised Sorvall/Heraeus buckets at 200 x g for 1 min to fill each of the 384 
wells on the array card. The card was then sealed using the Micro Fluidic Card Sealer 
which uses a precision stylus assembly to isolate and seal the channels of the micro 
fluidic card. The loading chambers were cut off and the card was run on the Applied 
Biosystems 7900HT Fast Real-Time PCR System using the default parameters 
contained within the SDS setup file on the supplied CD specific for either pool A or 
pool B as shown in Table 2.2.11. 
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Table 2.2.9 Recipe for cDNA with pre-amplification for running on pool A and B 
TLDA cards 
Component  Volume for one 
array 
TaqMan® Universal PCR Master Mix No AmpErase® UNG, 2x 450 
Diluted PreAmp product 9 
Nuclease-free water 441 
Total 900 
Table 2.2.10 Recipe for cDNA without pre-amplification for running on pool A and B 
TLDA cards 
Component  Volume for one 
array 
TaqMan® Universal PCR Master Mix No AmpErase® UNG, 2x 450 
Megaplex™ RT product 6 
Nuclease-free water 444 
Total 900 
Table 2.2.11 Default thermocycler parameters for running pool A and B TLDA cards 
Stage Temperature Time 
Cycle 
(40 Cycles) 
16 °C 2min 
42 °C 1 min 
50 °C 1 sec 
Hold 85°C 5 min 
Hold  4°C ∞ 
2.2.18 Running Custom TLDA cards 
Following the profiling study with pool A and B TLDA cards, a list of 31 miRNAs of 
interest were generated. We commissioned custom 384 well microRNA cards to be 
made by Applied Biosystems™ containing our 31 miRNAs of interest and an 
endogenous control U6 snRNA (see Appendix E). Pre-amplified cDNA originally from 
Hek TLR4/MD2/CD14 cells (see Section 2.2.16.2) were added to the master mix for 96 
reactions for 4 replicates see Table 2.2.12. Each custom card was allowed to come to 
room temperature before 513 µl of the mix was dispensed into each port on the array. 
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The card was centrifuged twice for 1 min at 200 x g to fill each of the 384 wells on the 
array card. It was then sealed using the Micro Fluidic Card Sealer and the loading 
chambers were cut off. The cards were run on the Applied Biosystems 7900HT Fast 
Real-Time PCR System using the parameters shown in Table 2.2.13 
Table 2.2.12 Recipe for reaction mix for Custom TLDA cards 
 Volume for 1 
sample (µl) 
Volume for 96 
reactions x 4 
replicates (µl)* 
20X Taqman microRNA Assays Mix 0.5 Pre-loaded on array 
Diluted PreAmp Product 0.08 34.60 
TaqMan® Universal PCR Master Mix No 
AmpErase® UNG, 2x 
5.0 2160.0 
Nuclease-free water 4.42 1900.80 
Total 10.0 4104.0 
*Includes 12.5% excess for volume loss from pipetting.  
Table 2.2.13 Thermocycler conditions for custom TLDA cards 
Stage Temperature Time 
Hold 95 °C 10 min 
Cycle  
(12 Cycles) 
95°C 15 sec 
60°C 1 min 
Hold 4°C ∞ 
2.2.19 Running Individual Taqman miRNA Assays 
In order to validate the results generated in the miRNA custom TLDA cards, individual 
Taqman assays were carried out for human and murine miRNAs. Pre-amplified cDNA 
from Hek TLR4/MD2/CD14 cells, JAWS II cells and miRNAs enriched from the C. 
difficile model (see Section 2.2.15.2) were added to the master mix see Table 2.2.14. 19 
µl of master mix was added to each well on a 96 well PCR plate before 1 µl of either 
human or murine 20X TaqMan® MicroRNA Assays was added (see Appendix E). 
snRNA U6 was used as the endogenous control for the human Hek TLR4/MD2/CD14 
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cells, while snoRNA202 was used as the endogenous control for the murine JAWS II 
cells and samples from the murine C. difficile model. The plates were run on the 
Applied Biosystems 7900HT Fast Real-Time PCR System using the parameters shown 
in Table 2.2.15. 
Table 2.2.14 Recipe for reaction mix for individual TaqMan® microRNA Assays 
 Volume for 1 sample (µl) 
Diluted PreAmp Product 0.20 
TaqMan® Universal PCR Master Mix No 
AmpErase® UNG, 2x 
10.0 
Nuclease-free water 8.80 
Total 19.00 
Table 2.2.15 Thermocycler conditions for Individual TaqMan® microRNA Assays 
Stage Temperature Time 
Hold 95 °C 10 min 
Cycle  
(12 Cycles) 
95°C 15 sec 
60°C 1 min 
Hold 4°C ∞ 
2.2.20 MiRNA Data Analysis following qPCR 
Following the completion of each run the SDS files were exported from the Applied 
Biosystems 7900HT Fast Real-Time PCR System and opened in ExpressionSuite 
Software v1.0.3. Quantitative real time PCR (qPCR) data was analysed. The max Ct 
was set to 37.0 and a manual threshold of 0.1 was set to ensure Ct determination 
consistency across each miRNA target. Each assay was pre-designed from Applied 
Biosystems™ therefore the efficiency (100%) and limit of detection (10 copies) are 
guaranteed by the manufacturer. We implemented a number of quality control measures 
outlined in Figure 2.2.4. Samples that did not meet these criteria were omitted from the 
study. We then went through each amplification curve to ensure the curves were 
sigmoidal in shape and ones which were found not to be were also omitted from the 
study. The reference group was set to the control samples.  
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Figure 2.2.4 Screen shot from ExpressionSuite software of quality control criteria for 
TLDA card data 
2.2.20.1 MiRNA Data Analysis of Targets from Pool A and B TLDA Cards 
Data from pool A and pool B was combined in the one study file and sample groups 
were assigned. Global normalisation was carried out where the median Ct of common 
assays were used as the normaliser on a per sample basis (Mestdagh et al., 2009). The 
normalised reporter ‘Rn’ value for each target was integrated into the calculations for 
global normalisation. The Rn value was calculated by dividing the fluorescence of the 
passive ROX dye by the fluorescence of the FAM reporter dye to normalise the 
reaction. Relative gene expression values were calculated using Expression Suite 
Software. The Benjamini-Hochberg false discovery rate (FDR) was used to adjust p-
values to account for the number of tests being performed. To ensure data was normally 
distributed box plots for each sample were then constructed using the ExpressionSuite 
software where the box for each sample contained the middle 50% of the data, the black 
horizontal line indicated the median Ct value and the black dot denoted the mean Ct. 
The end of the vertical lines indicated the minimum and maximum Ct values and the 
outliers were the points outside the ends of the whiskers. Following this a student’s t-
test was applied and values of p≤ 0.05 were considered statistically significant 
compared with the control group. Ct scatter plots were constructed to see if there were 
differences between groups. However to determine differences in individual miRNA 
targets a volcano plot was made where the log of the fold change was plotted on the x-
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axis and the negative log10 of p-values was plotted on the y-axis. The fold change 
boundary was set to 1.0 and the p-value boundary was set to p≤ 0.05. 
2.2.20.2 MiRNA Data Analysis of Targets from Custom TLDA Cards 
The endogenous control U6 snRNA was used to correct for variation of RNA input and 
relative gene expression values were calculated using the ExpressionSuite software. To 
ensure data was normally distributed box plots for each sample were then constructed 
using the ExpressionSuite software where the box for each sample contained the middle 
50% of the data, the black horizontal line indicated the median Ct value and the black 
dot denoted the mean Ct. The end of the vertical lines indicated the minimum and 
maximum Ct values and the outliers were the points outside the ends of the whiskers. 
Following this a student’s t-test was applied and values of p≤ 0.05 were considered 
statistically significant compared with the control group. Ct scatter plots were 
constructed to see if there were differences between groups. However to determine 
differences in individual miRNA targets a volcano plot was made where the log of the 
fold change was plotted on the x-axis and the negative log10 of p-values was plotted on 
the y-axis. The fold change boundary was set to 1.0 and the p-value boundary was set to 
p≤ 0.05. A heat map was also generated incorporating Pearson’s product moment 
Correlation Coefficient (PCC) using average linkage as a clustering method of miRNA 
profiles between pairs of samples analysed in this study. The heat map shows the 
corresponding relative miRNA expression levels rendered in a green-red colour scale, 
red represents high expression level, green represents low expression level and black 
being absence of detection. Each row represents a single miRNA and each column 
represents an individual sample. Dendograms indicate the correlation between groups of 
samples and miRNAs. 
2.2.20.3 MiRNA Analysis of Targets from Individual miRNA Assays 
U6 snRNA was used as the endogenous control for the human Hek TLR4/MD2/CD14 
cells, while snoRNA202 was used as the endogenous control for the murine JAWS II 
cells and samples from the murine C. difficile model to correct for variation of RNA 
input (see Appendix F). Relative gene expression values were calculated using the 
ExpressionSuite software. A Mann Whitney U-test was applied in experiments 
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comparing miRNA expression in the Hek TLR4/MD2/CD14 and JAWS II cells. 
However a student’s t-test was used to compare miRNA expression derived from tissue 
from differing mice. Values of p ≤0.05 were considered statistically significant. Error 
bars were presented in all graphs as standard error of the mean (SEM).  
2.2.21 MiRNA Gene/Target/Pathway Predictions using Bioinformatics 
In the literature it is suggested that to select consensus targets, they must be identified 
by different prediction tools (Sun, Julie Li, Huang, Shyy, & Chien, 2010). We choose 
DIANA miRPath (Vlachos et al., 2012) to carry out our searches as this prediction tool 
highlights targets that are also predicted by miRanda and TargetScan, two well-known 
prediction tools or targets which are verified experimentally in TarBase v6.0 
(Paraskevopoulou et al., 2013). See Appendix G for Web links to the databases used in 
this study. 
The list of 24 miRNA targets induced by SLPs from ribotype 001 and 027 were inputted 
into miRConvertor on the miRSystem database (Lu et al., 2012). This was to ensure we 
had an up to date name for each of the miRNAs according to the version of miRBASE 
used by DIANA miRPath which is version 18 (see Appendix G). DIANA miRPath 
v2.0 is a free web-server which utilises miRNA targets in coding regions and 3’-UTR 
regions provided by the DIANA-microT-CDS algorithm (Vlachos et al., 2012). The 
lists of 24 miRNAs of interest were inputted into the prediction tool where a posteriori 
analysis was performed where the significance levels between all possible miRNA 
pathway pairs were calculated using enrichment analysis. The previously calculated 
significance levels where combined with this to provide a merged p-value for each 
pathway by applying Fisher’s combined probability method (Vlachos et al., 2012).  
DIANA-miRPath enables the analysis of gene targets in the Kyoto Encyclopaedia of 
Genes and Genomes (KEGG) (Kanehisa & Goto, 2000) which generates graphical 
representations of pathways interactions. The web server also allows the generation of 
heat maps, the heat map is based on significance levels where the darker colours 
represent lower significance values and the adjacent dendrograms depict hierarchical 
clustering results for miRNAs and the pathways respectively. Gene lists that were 
targeted in the KEGG pathways were analysed and the 3’UTR region of gene was 
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crossed check in TargetScan (see Appendix G). TargetScan predicts biological targets 
of miRNAs by searching for the presence of 8mer, 7mer, and 6mer sites that match 
the seed region of each miRNA see Figure 2.2.5. Predictions are ranked by their 
probability of conserved targeting (PCT) (Friedman & Jones, 2009) and considers 
matches to human 3' UTRs and their orthologs, as defined by UCSC whole genome 
alignments. 
 
Figure 2.2.5 Diagrammatic representation of the types of miRNA matches predicted in 
TargetScan (Lewis, Burge, & Bartel, 2005) 
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Chapter 3: Characterising the Immune 
Response of SLPs from C. difficile in 
BMDCs 
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3.1 Introduction  
C. difficile is the leading cause of antibiotic-associated diarrhoea worldwide, called 
Clostridium difficile infection (CDI) (Dawson et al., 2009; Dubberke, 2012). It can only 
colonise the gut if the normal intestinal microbiota is disturbed or absent- which, in 
most cases is achieved by the administration of antibiotics (Calabi et al., 2002; Denève 
et al., 2009; Rupnik et al., 2009). The bacterium’s ability to grow in the presence of 
antibiotics in recent years has enabled its rapid spread among patients (Rupnik et al., 
2009). Antibiotic treatment diminishes commensal micro-organisms in the gut and their 
ability to mediate innate immune responses, which enables the proliferation of the often 
antibiotic resistant C. difficile (Buffie & Pamer, 2013). The bacterium can then 
dominate the mucosal surfaces and destroy cellular barriers through toxin mediated 
destruction of the epithelial cells leading to apoptosis and cell death (Buffie & Pamer, 
2013; Denève et al., 2009). CDI is potentially a very serious condition frequently 
effecting hospitalised patients and in particular the elderly (Ausiello et al., 2006). The 
severity of CDI may be dependent on the strain of C. difficile present (Goorhuis et al., 
2007; Rupnik et al., 2009) which is illustrated in Figure 3.1.1. Ribotype 001 is 
associated with a milder CDI and efficient bacterial clearance compared with ribotype 
027 which is known to be a ‘hypervirulent strain’. Infection with ribotype 027 has been 
associated with more severe diarrhoea, higher mortality and more recurrences 
(Clements et al., 2010; Dawson et al., 2009; Goorhuis et al., 2007; Loo et al., 2005). 
 
 
Figure 3.1.1 Illustration of the range of clinical symptoms associated with CDI, 
comparing ribotype 001 with ribotype 027 
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Calabi et al. (2002) found that S-layer proteins are considered to play the biggest role in 
the binding of C. difficile to the hosts gastrointestinal (GI) tract allowing bacterial 
adherence to the mucosa and the delivery of toxins (Calabi et al., 2002). S-layer proteins 
have been detected in all C. difficile strains examined so far (Drudy et al., 2004). C. 
difficile express a crystalline S-layer encoded by the slpA gene, the product of which is 
cleaved to give two mature peptides which associate to form layers (Ausiello et al., 
2006; Ní Eidhin et al., 2006). These layers are commonly known as Surface layer 
proteins (SLPs) which are predominantly found in outer surface proteins in C. difficile. 
SLPs contain a HMW protein derived from the C-terminal portion of the precursor and 
a LMW partner protein derived from the N-terminal portion of the precursor, which 
form a tightly associated non-covalent complex (Fagan et al., 2009; Ní Eidhin et al., 
2006). The HMW protein (42 kDa) is highly conserved between strains of C. difficile, 
while the LMW protein (32–38 kDa) demonstrates considerable sequence diversity and 
is a dominant antigen of the precursor (Drudy et al., 2004; Ní Eidhin et al., 2006; Sharp 
& Poxton, 1988).  
SLPs have been shown to activate immune cells (Bianco et al., 2011; Calabi et al., 
2002; Madan & Petri Jr, 2012; Vohra & Poxton, 2012). Previous research from our 
laboratory has shown that SLPs activate macrophages and induce bacterial clearance 
responses. SLPs from ribotype 001 activate pro-inflammatory cytokines and 
chemokines in a murine macrophage cell line. Furthermore SLPs increase co-
stimulatory cell surface marker expression on macrophage and they display enhanced 
phagocytosis and migration (Collins et al., 2014). In addition, other studies have shown 
that SLPs induce the maturation of DCs by inducing the expression of co-stimulatory 
cell surface markers which leads to the induction of pro-inflammatory cytokines 
(Ausiello et al., 2006). Research from our group also have shown that intact SLPs from 
ribotype 001 containing both HMW and LMW proteins were required for DC activation 
and subsequently generated T helper cells required for bacterial clearance via TLR4 
(Ryan et al., 2011). Consequently SLPs isolated from ribotype 001 can activate innate 
and adaptive immunity. This would suggest, an important role for SLPs in the 
recognition of C. difficile by the immune system (Collins et al., 2014; Ryan et al., 
2011).  
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SLPs from ribotype 001 evoke a similar response to that of LPS through TLR4 
signalling. Ryan et al. (2011) showed that these SLPs induce MyD88-dependent 
signalling which leads to the activation of NF-κB and Collins et al., (2014), 
demonstrated that the SLPs induced downstream activation of p38 (Collins et al., 2014; 
Ryan et al., 2011). NF-κB regulates the expression of a range of proteins including pro-
inflammatory cytokines such as IL-1β, IL-8, IL-6 and TNFα which mediate the innate 
immune response to the invading pathogen (Hayden & Ghosh, 2004; Pahl, 1999). It is 
well known that severe complications of infection result from excessive immune 
activation and there is an essential role for immunoregulatory components of the 
immune response in limiting pathology. Consequently nearly all major TLR signalling 
pathways are implicated as targets for suppression by anti-inflammatory cytokines 
(Williams, Ricchetti, Sarma, Smallie, & Foxwell, 2004). IL-10 is an anti-inflammatory 
cytokine that inhibits MHC class II and co-stimulatory molecules on monocytes and 
macrophages. IL-10 limits the production of pro-inflammatory cytokines including IL-
1β, IL-6, IL-12, TNFα and chemokines such as MCP-1, RANTES, IL-8 and MIP-2 (Lee 
& Kim, 2007; Williams et al., 2004). During infection IL-10 inhibits the activity of Th1 
cells, NK cells and macrophages (Couper, Blount, & Riley, 2008), all which are 
required for optimal pathogen clearance (Andoh et al., 2007). During infections, the 
absence of IL-10 can be accompanied with immunopathological tissue damage that is 
potentially harmful to the host, whereas excessive IL-10 always results in chronic 
infectious diseases caused by less clearance of pathogens (Lin et al., 2013).  
Both MyD88-dependent and independent mechanisms are required for the development 
of full host response to bacterial challenge (Carrigan et al., 2010). SLPs isolated from 
ribotype 001 did not induce the MyD88-independent signalling pathway via IRF3 (Ryan 
et al., 2011). IRF3 is central for the induction of IFN-β and the balance between IL-12, 
IL-23 and IL-27 production is strongly dependent on IRF3. The production of IL-12 and 
IL-23 cytokines directly influence the development of Th1 and Th17 cells respectively 
and the ensuing immune response is therefore affected by the subset of T cell induced. 
This may be favourable in the context of auto-immune inflammation but deleterious for 
the host in the context of bacterial infection (Ysebrant de Lendonck et al., 2014; Zhu et 
al., 2010). Studies have shown the importance of IRF3 and type I IFNs in the 
modulation of host defence and bacterial clearance (O’Connell et al., 2004). 
  
 75  
Additionally, the production and signalling of type I IFN is required for LPS induced 
IL-10 up-regulation (Chang, Guo, Doyle, & Cheng, 2007). 
Given the differences in clinical symptoms between strains of C. difficile, the aim of 
this chapter is to investigate the immune response to SLPs from various ribotypes of C. 
difficile. Firstly we will examine the ability of a variety of C. difficile ribotypes to 
induce the maturation of DCs. Secondly, we will measure co-stimulatory cell surface 
marker expression using flow cytometry and quantify the production of key cytokines 
using ELISA. It has been previously shown that SLPs from ribotype 001 activate TLR4 
signalling; therefore we will examine downstream signalling of SLPs in Hek 
TLR4/MD2/CD14 cells, as they possess intracellular mechanisms necessary for TLR4 
signalling. Finally, we will examine MyD88-dependent signalling by measuring NF-κB 
activation and MyD88-independent signalling by measuring IRF3 activation- using the 
luciferase gene reporter assay to measure gene expression. 
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3.2 Results 
3.2.1 Characterisation of SLPs from C .difficile 
SLPs were purified from cultures grown anaerobically at 37°C in BHI/0.05% 
thioglycolate broth. Cultures were harvested and crude extracts of the SLPs were 
dialysed and applied to an anion exchange column attached to an AKTA FPLC. The 
pure SLPs were eluted with a linear gradient of 0-0.3 mol/L NaCl at a flow rate of 4 
mL/min. Crude fractions of SLPs and peak fractions corresponding to pure SLPs were 
run on 12% SDS–PAGE gels, which were then stained with Coomassie blue see Figure 
3.2.1. The gels were imaged and protein bands were examined. Two distinct bands were 
seen on the gel, the first HMW band was seen at 44 kDA and the second LMW band 
was seen at approximately 35-37 kDa. The HMW proteins were the same size for each 
of the five ribotypes. However the LMW protein differed between ribotypes (RT), for 
example SLPs from RT 005 and RT 001 had a larger LMW protein compared to the 
purified SLPs from RT 031, RT 027 and RT 078. Once we confirmed that pure SLPs 
were extracted we determined the total protein concentration using a BCA assay, (see 
Appendix B). Previous research in our laboratory established that 20 μg/mL was the 
concentration of SLPs required to evoke an optimum immune response (Ryan et al., 
2011), therefore we used this concentration in experiments thereafter. In order to 
confirm that activity by SLPs was attributed to the SLPs alone and not an endotoxin 
contaminant from another bacterial source, a LAL assay was carried out (see Appendix 
B). There was no endotoxin activity detected in samples containing SLPs compared to 
LPS which was used as a positive control. 
3.2.2 SLPs Modulate Cell Surface Marker Expression on BMDCs. 
BMDC maturation is characterised by increased expression of cell surface markers such 
as CD40, CD80 and CD86 (Higgins et al., 2003; Lavelle et al., 2003). Flow cytometry 
was used to examine the cell surface marker expression on BMDCs which were 
stimulated with LPS and SLPs. BMDCs isolated from the bone marrow of BALB/c 
mice were differentiated in the presence of GM-CSF for 7 days and plated at 1x10
6 
cells/mL. Cells were stimulated with either 100 ng/mL LPS or 20 µg/mL SLPs from RT 
001 for 18 hours. BMDCs from each treatment group were counted and separated into 
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different staining groups. These staining groups consisted of PI and fluorescently 
labelled antibodies; Group 1) FITC rat anti-mouse CD14, PE rat anti-mouse CD40 and 
APC hamster anti-mouse CD11c, and Group 2) FITC rat anti-mouse CD86, PE rat anti-
mouse CD80 and APC hamster anti-mouse CD11c.  
Firstly, we assessed the viability of cells stimulated with LPS or SLPs from RT 001. 
Cells were stained with PI and analysed within 30 minutes on the BD FACs Aria I. 
Viable (PI negative) cells were identified by assessing the dot plot of forward scatter 
(FSC) against PI stained BMDCs see Figure 3.2.2. We gated on the PI negative cells 
and found that un-stimulated control BMDCs were 75.5% viable, BMDCs stimulated 
with LPS were 69.3% viable and cells stimulated with SLPs from RT 001 were 66.8% 
viable. Viability was not notably affected by the treatment with LPS or SLPs from RT 
001. We also wanted to make sure that we were getting pure BMDC populations, the 
integrin CD11c
 
is expressed on the cell surface of BMDCs and is an established 
phenotypic marker for pure BMDC populations. Figure 3.2.3 shows dot plots of FSC 
and APC hamster anti-mouse CD11c stained BMDCs. We gated on CD11c
+
 cells and 
obtained 70-73.3% pure populations of BMDCs, this is in line with the average for our 
laboratory. 
We then examined the expression of CD14 and CD40 cell surface markers as shown in 
Figure 3.2.4. Cell surface marker expression was examined by measuring the mean 
fluorescence intensity (MFI) of treated cells and comparing them to stained control 
cells. As expected the expression of CD14 (MFI 1851 V 1098) and CD40 (MFI 989 V 
303) were up regulated in BMDCs stimulated with LPS as seen by increased 
fluorescence compared to the control cells. The expression of CD14 (MFI 1469 V 1098) 
and CD40 (MFI 588 V 303) were also up regulated in BMDCs stimulated with SLPs 
from RT 001. We then examined the expression of CD80 and CD86 cell surface 
markers, as shown in Figure 3.2.5. As expected the expression of CD80 (MFI 6832 V 
1310) and CD86 (MFI 1394 V 428) were up regulated in BMDCs stimulated with LPS 
compared to the control cells. The expression of CD80 (MFI 2808 V 1310) and CD86 
(MFI 465 V428) were also up regulated in BMDCs stimulated with SLPs from RT 001 
as seen by increased fluorescence compared to the controls cells.  
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We then went on to examine these parameters in response to SLPs from other ribotypes. 
Firstly, we gated on CD11c
+ 
cells and obtained 70-75% pure populations of BMDCs see 
Figure 3.2.6. The expression of CD14 was up regulated in BMDCs stimulated with 
LPS (MFI 2275 V 2066) and SLPs from RT 005 (MFI 2664 V 2066) and RT 031 (MFI 
2431 V 2066) as seen by increased fluorescence compared to the control cells. 
However, the expression of CD14 was slightly down regulated in BMDCs stimulated 
with SLPs from RT 027 (MFI 1916 V 2066) see Figure 3.2.7. In addition the 
expression of CD40 was up regulated in BMDCs stimulated with LPS (MFI 860 V 262) 
and SLPs from RT 005 (MFI 752 V 262), RT 031 (MFI 868 V 262) and RT 027 (MFI 
630 V 262) as seen by an increase in fluorescence compared to the control cells in 
Figure 3.2.8. Furthermore the expression of CD80 was up regulated in BMDCs 
stimulated with LPS (MFI 9186 V 3306) and SLPs from RT 005 (MFI 6516 V 3306), 
RT 031 (MFI 7585 V 3306), and RT 027 (MFI 8146 V 3306) as seen by increased 
fluorescence compared to the control cells in Figure 3.2.9. We then examined the 
expression of CD86 and found it was also up regulated in BMDCs stimulated with LPS 
(MFI 2246 V 1322) and SLPs from RT 005 (MFI 1460 V 1322), RT 031 (MFI 1708 V 
1322) and RT 027 (MFI 1838 V 1322) seen by increased fluorescence compared to the 
control cells in Figure 3.2.10. 
3.2.3 SLPs Induce Cytokine Production in BMDCs 
When BMDCs are activated they mature and produce inflammatory cytokines. We used 
ELISA to measure cytokines secreted in the supernatant of BMDCs stimulated with 
LPS and SLPs. BMDCs isolated from the bone marrow of BALB/c mice were 
differentiated in the presence of GM-CSF for 7 days and plated at 1x10
6 
cells/mL and 
stimulated with either 100 ng/mL LPS or 20 µg/mL SLPs from RT 001, RT 005, RT 
031 and RT 027. After 18 hours the supernatants were collected and cytokines including 
IL-1β, IL-6, IL-12p40, IL-10, IL-12p70, IL-23 and TNFα were measured using ELISA, 
see Figure 3.2.11. IL-1β was produced at low levels in control BMDCs. However IL-1β 
was produced at higher levels in cells stimulated with LPS and SLPs from RT 001, RT 
005, RT 031 (p≤ 0.001) and RT 027 (p≤ 0.001) compared to the control cells. SLPs 
from RT 027 produced the most IL-1β. IL-6 was not produced in control BMDCs. IL-6 
was produced in BMDCs stimulated with LPS (p≤ 0.001) and SLPs from RT 001 (p≤ 
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0.001), RT 005 (p≤ 0.001), RT 031 (p≤ 0.001) and RT 027 (p≤ 0.001). It would appear 
that SLPs from RT 031 and RT 027 produced more IL-6 than cells stimulated with LPS. 
IL-10 was not produced in control BMDCs. IL-10 was produced in BMDCs stimulated 
with LPS (p≤ 0.01) and SLPs from RT 001 (p≤ 0.001), RT 005 (p≤ 0.001), RT 031 (p≤ 
0.001) and RT 027 (p≤ 0.001), compared to the control cells. BMDCs stimulated with 
SLPs from RT 031 and RT 027 appeared to produce more IL-10 compared to cell 
stimulated with SLPs from RT 001, RT 005 and LPS. IL-12p40 was produced at low 
levels in control BMDCs however levels of IL-12p40 was increased in BMDCs 
stimulated with LPS (p≤ 0.001) and SLPs from RT 001 (p≤ 0.001), RT 005 (p≤ 0.001), 
RT 031 (p≤ 0.001) and RT 027 (p≤ 0.001), compared to the control cells. The level of 
IL-12p40 induced by SLPs from the various ribotypes was comparable to the response 
induced by LPS. IL-23 was not produced in control BMDCs. IL-23 was produced in 
BMDCs stimulated with LPS (p≤ 0.001) and SLPs from RT 001 (p≤ 0.001), RT 005 (p≤ 
0.001), RT 031 (p≤ 0.001) and RT 027 (p≤ 0.001), compared to the control cells. The 
level of IL-23 induced by SLPs from the various ribotypes was comparable to the 
response induced by LPS. TNFα was produced at low levels in control BMDCs. 
However levels of TNFα were increased when BMDCs were stimulated with LPS (p≤ 
0.01) and SLPs from RT 001 (p≤ 0.01), RT 005 (p≤ 0.001), RT 031 (p≤ 0.001) and RT 
027 (p≤ 0.001), compared to the control cells. Cytokine production induced by SLPs 
from the various ribotypes was also comparable to the response induced by LPS. IL-
12p70 was not produced in control BMDCs. IL-12p70 was produced in BMDCs 
stimulated with LPS (p≤ 0.001) and SLPs from RT 001, RT 005 (p≤ 0.001), RT 031 (p≤ 
0.001) and RT 027 (p≤ 0.001), compared to the control cells. BMDCs stimulated with 
SLPs from RT 031 appeared to produce more IL-12p70 then cells stimulated with LPS 
and SLPs from the various ribotypes. 
3.2.4 SLPs from RT 027 Activate NF-κB and IRF3 
It was previously shown in our laboratory that SLPs from RT 001 activate immune cells 
through TLR4 and induce NF-κB signalling downstream of this, however it fails to 
induce IRF3 signalling (Ryan et al., 2011). Given the difference observed in the 
immune response to SLPs from different ribotypes, we wanted to determine if there 
were any differences in the activation of transcription factors. Hek TLR4/MD2/CD14 
  
 80  
cells were used to assess the activation of NF-κB and IRF3 via TLR4 by measuring 
gene expression via firefly and renilla luciferase activity. Hek-293 cells do not express 
TLR4 and they were used in this study as an internal control. Firstly, we carried out a 
time course experiment on Hek TLR4/MD2/CD14 cells stimulated with LPS over 
multiple time points during an 18 hour period to identify the optimal time point to 
examine NF-κB and IRF3 signalling, see Figure 3.2.12. The Hek TLR4/MD2/CD14 
cells were transfected with either NF-κB (80 ng) or IRF3 fused downstream of yeast 
GAL4 DNA binding domain known as pFA-IRF3 (30 ng) with pFR-regulated firefly 
luciferase (60 ng). Both sets of plasmid DNA were co-transfected with constitutively 
expressed TK renilla luciferase (20 ng). Post transfection cells were stimulated with 100 
ng/mL LPS. Lysates were generated and assayed for firefly and renilla luciferase 
activity, where the TK renilla luciferase plasmid was used to normalise for transfection 
efficiency in all experiments. We show that the expression of NF-κB increased 2.0 fold 
after 4 hours; expression increased steadily over time and reached 8.5 fold at 12 hours 
which was maintained at 18 hours. The expression of IRF3 followed a similar pattern, 
where expression increased 2.0 fold after 4 hours; this steadily increased over time and 
reached 8.1 fold after 18 hours. IL-8 and RANTES also known as Chemokine (C-C 
motif) ligand (CCL5) are indicative of NF-κB and IRF3 signalling respectively (Lin et 
al., 1999; Mukaida, Okamoto, Ishikawa, & Matsushima, 1994). Therefore, we measured 
human IL-8 and RANTES expression from the cell supernatants using ELISA see 
Figure 3.2.13. IL-8 was secreted after 4 hours and steadily increased over time until 12 
hours where it reached 7700 pg/mL which was maintained after 18 hours. RANTES 
secretion was low between 4-8 hours, it increased slightly at 12 hours however 50 
pg/mL was reached at 18 hours. The 18 hour time point was chosen for experiments 
thereafter.  
We first examined the expression of NF-κB and IRF3 in Hek TLR4/MD2/CD14 and 
Hek-293 cells stimulated with 100 ng/mL LPS and 20 ng/mL SLPs from RT 001 see 
Figure 3.2.14. Cells stimulated with LPS induced the expression of NF-κB 6.0 fold (p≤ 
0.001) in Hek TLR4/MD2/CD14 cells compared to the control cells. Cells stimulated 
with SLPs from RT 001 induced the expression of NF-κB 3.0 fold (p≤ 0.01) in Hek 
TLR4/MD2/CD14 cells compared to control cells. Cells stimulated with LPS induced 
the expression of IRF3 6.0 fold (p≤ 0.001) in Hek TLR4/MD2/CD14 cells compared to 
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control cells. SLPs from RT 001 did not induce the expression of IRF3 in Hek 
TLR4/MD2/CD14 cells. There was no expression of NF-κB or IRF3 in Hek-293 cells 
when stimulated with either LPS or SLPs as expected since they do not contain the 
machinery for TLR4 signalling. The profile at gene level was also reflected in cytokine 
production. We measured human IL-8 and RANTES using ELISA see Figure 3.2.15. 
There were low levels of IL-8 produced by the control Hek TLR4/MD2/CD14 cells, 
however IL-8 production was increased when cells were stimulated with LPS (p≤ 
0.001) and SLPs from RT 001 (p≤ 0.01) compared to control cells. There were low 
levels of RANTES produced in Hek TLR4/MD2/CD14 cells however RANTES 
production was increased in cells stimulated with LPS (p≤ 0.001) compared to the 
control cells. There was no significant increase in RANTES in Hek TLR4/MD2/CD14 
cells stimulated with SLPs from RT 001. IL-8 and RANTES was not produced in Hek-
293 cells when stimulated with either LPS or SLPs from RT 001 as expected.  
To this end, it was decided to investigate the expression of NF-κB and IRF3 in response 
to stimulation with SLPs from the other ribotypes, see Figure 3.2.16. It was shown that 
LPS (p≤ 0.01) and SLPs from RT 001 (p≤ 0.05), RT 014 (p≤ 0.01), RT 027 (p≤ 0.01) 
and RT 078 (p≤ 0.01) induced the expression of NF-κB in Hek TLR4/MD2/CD14 cells 
compared to control cells. Cells stimulated by SLPs from RT 027 appeared to induce 
higher levels of NF-κB than the cells stimulated with LPS. However SLPs from RT 
001, RT 014 and RT 078 did not induce the expression of IRF3 in Hek 
TLR4/MD2/CD14. IRF3 expression was induced by Hek TLR4/MD2/CD14 cells 
stimulated with LPS (p≤ 0.001) and interestingly SLPs from RT 027 (p≤ 0.01) 
compared to the control cells. There was no expression of NF-κB or IRF3 in Hek-293 
cells when stimulated with either LPS or SLPs as expected. The profile at gene level 
was also reflected in cytokine production when we measured human IL-8 and RANTES 
using ELISA from cell supernatants see Figure 3.2.17. There were low levels of IL-8 
produced by the control Hek TLR4/MD2/CD14 cells, however, IL-8 production was 
increased when cells were stimulated with LPS (p≤ 0.001), SLPs from RT 001 (p≤ 
0.001), RT 014 (p≤ 0.001) and RT 027 (p≤ 0.001). There was an increase in IL-8 when 
cells were stimulated with SLPs from RT 078 but it was not statistically significant. 
There were low levels of RANTES produced in Hek TLR4/MD2/CD14 cells however 
RANTES production was increased when cells were stimulated with LPS (p≤ 0.001) 
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and SLPs from RT 027 (p≤ 0.05). There was no significant increase in RANTES when 
cells were stimulated with SLPs from RT 001, RT 014 and RT 078. RANTES was not 
produced, while minute levels of IL-8 was produced in Hek-293 cells when stimulated 
with either LPS or SLPs as expected.  
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Figure 3.2.1 SLPs from RT 005, RT 027, RT 031, RT 078 and RT 001 contain a 
conserved HMW protein at 44kDA and variable LMW band ranging from 35-37 
kDA. SLPs were purified from cultures grown anaerobically at 37°C in BHI/0.05% 
thioglycolate broth. Cultures were harvested and crude extracts of SLPs were dialysed 
and applied to an anion exchange column attached to an AKTA fast protein liquid 
chromatography (FPLC). Pure SLPs were eluted with a linear gradient of 0-0.3 mol/L 
NaCl at a flow rate of 4 mL/min. Crude fractions of SLPs and peak fractions 
corresponding to pure SLPs were run on 12% SDS–PAGE gels, which were then 
stained with Coomassie blue stain. The gels were imaged and protein bands were 
examined. Bands at 44 kDa represent the HMW protein and the bands at approximately 
35-37 kDa represent LMW proteins respectively. 
RT 005           RT 027          RT 031        RT 078          RT 001   
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Figure 3.2.2 BMDCs stimulated with LPS and SLPs from RT 001 do not notably 
affect cell viability. Bone marrow from BALB/c mice was isolated and BMDCs 
differentiated in the presence of GM-CSF for 7 days. Cells were plated at 1x10
6 
cells/mL and stimulated with 100 ng/mL of LPS or 20 µg/mL SLPs from RT 001. After 
18 hours, cells were stained with Propidium Iodide (PI) and cells were analysed within 
30 minutes on the BD FACs Aria I. Data was analysed using Flowjo software. Dot plot 
showing forward scatter (FSC) and PI stained BMDC’s. Data shows the percentage PI 
negative viable cells. Profiles are shown for a single experiment however are 
representative of three independent experiments. 
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Figure 3.2.3 CD11c
+
 population of BMDCs range from 70-73% when stimulated 
with LPS and SLPs from RT 001. Bone marrow from BALB/c mice was isolated and 
BMDCs differentiated in the presence of GM-CSF for 7 days. Cells were plated at 
1x10
6
 cells/mL and stimulated with 100 ng/mL of LPS or 20 µg/mL SLPs from RT 001. 
After 18 hours, cells were stained with fluorescently labelled APC hamster anti-mouse 
CD11c. Cells were analysed on the BD FACs Aria I and data was analysed using 
Flowjo software. Dot plot showing forward scatter (FSC) and APC hamster anti-mouse 
CD11c. Data represents the percentage of BMDCs stained for CD11c. Profiles are 
shown for a single experiment however are representative of three independent 
experiments. 
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Figure 3.2.4 SLPs from RT 001 modulate the expression of CD40 and CD14 on 
BMDCs. Bone marrow from BALB/c mice was isolated and BMDCs differentiated in 
the presence of GM-CSF for 7 days. Cells were plated at 1x10
6
 cells/mL and stimulated 
with 100 ng/mL of LPS or 20 µg/mL SLPs from RT 001. After 18 hours, cells were 
stained with fluorescently labelled antibodies FITC rat anti-mouse CD14, PE rat anti-
mouse CD40 and APC hamster anti-mouse CD11c. Cells were analysed on the BD 
FACs Aria I and data was analysed using Flowjo software. Cells were gated on the 
CD11c
+
 BMDC population. Histograms represent the mean fluorescent intensity (MFI) 
of conjugated A) CD14 and B) CD40, with unstained cells (grey) overlaid with control 
cells (blue line) and stimulated cells (red line). MFI values on the histogram show the 
stimulated cells (red) and the control cells (blue). Profiles are shown for a single 
experiment however are representative of three independent experiments.  
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Figure 3.2.5 SLPs from RT 001 modulate the expression of CD80 and CD86 on 
BMDCs. Bone marrow from BALB/c mice was isolated and BMDCs differentiated in 
the presence of GM-CSF for 7 days. Cells were plated at 1x10
6
 cells/mL and stimulated 
with 100 ng/mL of LPS or 20 µg/mL SLPs from RT 001. After 18 hours, cells were 
stained with fluorescently labelled antibodies FITC rat anti-mouse CD86, PE rat anti-
mouse CD80 and APC hamster anti-mouse CD11c. Cells were analysed on the BD 
FACs Aria I and data was analysed using Flowjo software. Cells were gated on the 
CD11c
+
 BMDC population. Histograms represent the mean fluorescent intensity (MFI) 
of conjugated A) CD86 and B) CD80, with unstained cells (grey) overlaid with control 
cells (blue line) and stimulated cells (red line). MFI values on the histogram show the 
stimulated cells (red) and the control cells (blue). Profiles are shown for a single 
experiment however are representative of three independent experiments. 
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Figure 3.2.6 CD11c
+
 population of BMDCs range from 70-75% when stimulated 
with LPS and SLPs from RT 005, RT 027 and RT 031. Bone marrow from BALB/c 
mice was isolated and BMDCs differentiated in the presence of GM-CSF for 7 days. 
Cells were plated at 1x10
6
 cells/mL and stimulated with 100 ng/mL of LPS or 20 µg/mL 
SLPs from RT 005, RT 031 and RT 027. After 18 hours, cells were stained with 
fluorescently labelled APC hamster anti-mouse CD11c. Cells were analysed on the BD 
FACs Aria I and data was analysed using Flowjo software. Dot plot showing forward 
scatter (FSC) and APC hamster anti-mouse CD11c. Data represents the percentage of 
BMDCs stained for CD11c. Profiles are shown for a single experiment however are 
representative of three independent experiments. 
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Figure 3.2.7 SLPs from RT 005, RT 031 and RT 027 modulate the expression of 
CD14 on BMDCs. Bone marrow from BALB/c mice was isolated and BMDCs 
differentiated in the presence of GM-CSF for 7 days. Cells were plated at 1x10
6
 
cells/mL and stimulated with 100 ng/mL of LPS or 20 µg/mL SLPs from RT 005, RT 
031 and RT 027. After 18 hours, cells were stained with fluorescently labelled 
antibodies FITC rat anti-mouse CD14 and APC hamster anti-mouse CD11c. Cells were 
analysed on the BD FACs Aria I and data was analysed using Flowjo software. Cells 
were gated on the CD11c
+
 BMDC population. Histograms represent the mean 
fluorescent intensity (MFI) of conjugated CD14 with unstained cells (grey) overlaid 
with control cells (blue line) and stimulated cells (red line). MFI values on the 
histogram show the stimulated cells (red) and the control cells (blue). Profiles are 
shown for a single experiment however are representative of three independent 
experiments. 
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Figure 3.2.8 SLPs from RT 005, RT 031 and RT 027 modulate the expression of 
CD40 on BMDCs. Bone marrow from BALB/c mice was isolated and BMDCs 
differentiated in the presence of GM-CSF for 7 days. Cells were plated at 1x10
6
 
cells/mL and stimulated with 100 ng/mL of LPS or 20 µg/mL SLPs from RT 005, RT 
031 and RT 027. After 18 hours, cells were stained with fluorescently labelled 
antibodies PE rat anti-mouse CD40 and APC hamster anti-mouse CD11c. Cells were 
analysed on the BD FACs Aria I and data was analysed using Flowjo software. Cells 
were gated on the CD11c
+
 BMDC population. Histograms represent the mean 
fluorescent intensity (MFI) of conjugated CD40 with unstained cells (grey) overlaid 
with control cells (blue line) and stimulated cells (red line). MFI values on the 
histogram show the stimulated cells (red) and the control cells (blue). Profiles are 
shown for a single experiment however are representative of three independent 
experiments. 
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Figure 3.2.9 SLPs from RT 005, RT 031 and RT 027 modulate the expression of 
CD80 on BMDCs. Bone marrow from BALB/c mice was isolated and BMDCs 
differentiated in the presence of GM-CSF for 7 days. Cells were plated at 1x10
6
 
cells/mL and stimulated with 100 ng/mL of LPS or 20 µg/mL SLPs from RT 005, RT 
031 and RT 027. After 18 hours, cells were stained with fluorescently labelled 
antibodies PE rat anti-mouse CD80 and APC hamster anti-mouse CD11c. Cells were 
analysed on the BD FACs Aria I and data was analysed using Flowjo software. Cells 
were gated on the CD11c
+
 BMDC population. Histograms represent the mean 
fluorescent intensity (MFI) of conjugated CD80 with unstained cells (grey) overlaid 
with control cells (blue line) and stimulated cells (red line). MFI values on the 
histogram show the stimulated cells (red) and to the control cells (blue). Profiles are 
shown for a single experiment however are representative of three independent 
experiments. 
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Figure 3.2.10 SLPs from RT 005, RT 031 and RT 027 modulate the expression of 
CD86 on BMDCs. Bone marrow from BALB/c mice was isolated and BMDCs 
differentiated in the presence of GM-CSF for 7 days. Cells were plated at 1x10
6
 
cells/mL and stimulated with 100 ng/mL of LPS or 20 µg/mL SLP from RT 005, RT 
031 and RT 027. After 18 hours, cells were stained with fluorescently labelled 
antibodies FITC rat anti-mouse CD86 and APC hamster anti-mouse CD11c. Cells were 
analysed on the BD FACs Aria I and data was analysed using Flowjo software. Cells 
were gated on the CD11c
+
 BMDC population. Histograms represent the mean 
fluorescent intensity (MFI) of conjugated CD86 with unstained cells (grey) overlaid 
with control cells (blue line) and stimulated cells (red line). MFI values on the 
histogram show the stimulated cells (red) and the control cells (blue). Profiles are 
shown for a single experiment however are representative of three independent 
experiments. 
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Figure 3.2.11 SLPs from RT 001, RT 005, RT 031 and RT 027 induce the 
production of murine IL-1 β, IL-6, IL-12p40, IL-10, IL-23, TNFα and IL-12p70 in 
BMDCs. Bone marrow from BALB/c mice was isolated and BMDCs differentiated in 
the presence of GM-CSF for 7 days. Cells were plated at 1x10
6
 cells/mL and stimulated 
with 100 ng/ml of LPS or 20 µg/mL SLPs from RT 001, RT 005, RT 031 and RT 027. 
Supernatants were recovered after 18 hours and assessed for levels of cytokines using 
ELISA. The results show the mean (± SEM) measured in triplicate, one-way ANOVA 
followed by Newman-Keuls analysis was used to determine if differences between 
treatment groups were significantly different compared to the control, where * p≤ 0.05, 
** p≤ 0.01 and *** p≤ 0.001. The results are indicative of three independent 
experiments. 
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Figure 3.2.12 Time course analysis shows that the optimal time point is after 12 
hours for examining the expression of NF-κB and IRF3 expression in Hek 
TLR4/MD2/CD14 cells stimulated with LPS. Hek TLR4/MD2/CD14 cells were 
plated at 1x10
6
 cells/mL and allowed to adhere for 18 hours to approximately 60% 
confluency. The cells were then transfected with A) NF-κB (80 ng) B) pFA-IRF3 
(30ng) and pFR-regulated firefly luciferase (60 ng). Both sets of plasmid DNA were co-
transfected with constitutively expressed TK renilla luciferase (20 ng). 12-18 hours post 
transfection cells were stimulated with 100 ng/mL of LPS for 4, 6, 8, 12 and 18 hours. 
Lysates were generated and assayed for firefly and renilla luciferase activity. The TK 
Renilla luciferase plasmid was used to normalize for transfection efficiency in all 
experiments. The results show the mean (± SEM) measured in triplicate and the results 
are indicative of three independent experiments. 
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Figure 3.2.13 Time course analysis shows 18 hours is the optimal time for 
examining the expression of human IL-8 and RANTES expression in Hek 
TLR4/MD2/CD14 cells stimulated with LPS. Hek TLR4/MD2/CD14 cells were 
plated at 1x10
6
 cells/ml and allowed to adhere for 18 hours to approximately 60% 
confluency. The cells were then transfected with NF-κB (80 ng) or pFA-IRF3 (30 ng) 
and pFR-regulated firefly luciferase (60 ng). Both sets of plasmid DNA were co-
transfected with constitutively expressed TK renilla luciferase (20 ng). 12-18 hours post 
transfection cells were stimulated with 100 ng/mL of LPS for 4, 6, 8, 12 and 18 hours. 
Supernatants were recovered and levels of A) IL-8 and B) RANTES were measured 
using ELISA. The results show the mean (± SEM) measured in triplicate. The results 
are indicative of three independent experiments. 
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Figure 3.2.14 SLPs from RT 001 activates NF-κB but it does not activate IRF3 
downstream of TLR4. Hek TLR4/MD2/CD14 cells or Hek-293 cells were plated at 
1x10
6
 cells/mL and allowed to adhere for 18 hours to approximately 60% confluency. 
The cells were then transfected with A) NF-κB (80 ng) B) pFA-IRF3 (30 ng) and pFR-
regulated firefly luciferase (60 ng). Both sets of plasmid DNA were co-transfected with 
constitutively expressed TK renilla luciferase (20 ng). 12-18 hours post transfection 
cells were stimulated with 100 ng/mL of LPS or 20 µg/mL SLPs from RT 001 for 18 hr. 
Lysates were generated and assayed for firefly and renilla luciferase activity. The TK 
Renilla luciferase plasmid was used to normalise for transfection efficiency in all 
experiments. The results show the mean (± SEM) measured in triplicate, one-way 
ANOVA followed by Newman-Keuls analysis was used to determine if differences 
between groups were significantly different compared to the control, where * p≤ 0.05, 
** p≤ 0.01 and *** p≤ 0.001. The results are indicative of three independent 
experiments. 
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Figure 3.2.15 SLP from RT 001 activates NF-κB but do not activate IRF3 
downstream of TLR4. Hek TLR4/MD2/CD14 or Hek-293 cells were plated at 1x10
6
 
cells/mL and allowed to adhere for 18 hours to approximately 60% confluency. The 
cells were then transfected with NF-κB (80 ng) or pFA-IRF3 (30 ng) and pFR-regulated 
firefly luciferase (60 ng). Both sets of plasmid DNA were co-transfected with 
constitutively expressed TK renilla luciferase (20 ng). 12-18 hours post transfection 
cells were stimulated with 100 ng/mL of LPS or 20 µg/mL SLPs from RT 001 for 18 
hours. Supernatants were recovered and levels of human A) IL-8 and B) RANTES were 
measured using ELISA. The results show the mean (± SEM) measured in triplicate, 
one-way ANOVA followed by Newman-Keuls analysis was used to determine if 
differences between groups were significantly different compared to the control, where 
* p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. The results are indicative of three independent 
experiments. 
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Figure 3.2.16 SLPs from RT 001, RT 014, RT 027 and RT 078 activate NF-κB. 
SLPs do not activate IRF3 with the exception of SLPs from RT 027. Hek 
TLR4/MD2/CD14 cells or Hek-293 cells were plated at 1x10
6
 cells/mL and allowed to 
adhere for 18 hours to approximately 60% confluency. The cells were then transfected 
with A) NF-κB (80 ng) B) pFA-IRF3 (30 ng) and pFR-regulated firefly luciferase (60 
ng). Both sets of plasmid DNA were co-transfected with constitutively expressed TK 
renilla luciferase (20 ng). 12-18 hours post transfection cells were stimulated with 100 
ng/mL of LPS or 20 µg/mL SLPs from RT 001, RT 014, RT 078 and RT 027 for 18 
hours. Lysates were generated and assayed for firefly and renilla luciferase activity. The 
Renilla luciferase plasmid was used to normalise for transfection efficiency in all 
experiments. The results show the mean (± SEM) measured in triplicate, one-way 
ANOVA followed by Newman-Keuls analysis was used to determine if differences 
between groups were significantly different compared to the control, where * p≤ 0.05, 
** p≤ 0.01 and *** p≤ 0.001. The results are indicative of three independent 
experiments. 
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Figure 3.2.17 SLPs from RT 001, RT 014, RT 027 and RT 078 activate NF-κB 
downstream of TLR4. SLPs do not activate IRF3 downstream of TLR4 with the 
exception of RT 027. Hek TLR4/MD2/CD14 cells or Hek-293 cells plated at 1x10
6
 
cells/mL and allowed to adhere for 18 hours to approximately 60% confluency. The 
cells were then transfected with NF-κB (80 ng) or pFA-IRF3 (30 ng) and pFR-regulated 
firefly luciferase (60 ng). Both sets of plasmid DNA were co-transfected with 
constitutively expressed TK renilla luciferase (20 ng). 12-18 hours post transfection 
cells were stimulated with 100 ng/mL of LPS or 20 µg/mL SLPs from RT 001, RT 014, 
RT 027 and RT 078 for 18 hours. Supernatants were recovered and levels of human A) 
IL-8 and B) RANTES were measured using ELISA. The results show the mean (± 
SEM) measured in triplicate, one-way ANOVA followed by Newman-Keuls analysis 
was used to determine if the difference between groups were significantly different 
compared to the control, where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. The results are 
indicative of three independent experiments. 
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3.3 Discussion 
C. difficile is a gram-positive, spore-forming, rod shaped anaerobic bacterium, that 
causes a range of gastrointestinal diseases known as CDI (Bartlett, 1994; Fagan et al., 
2009; Kachrimanidou & Malisiovas, 2011). CDI is characterised by tissue injury and an 
acute intestinal inflammatory response where both pathogen and host play a major role 
in disease pathogenesis. C. difficile toxins cause direct injury to the intestinal epithelium 
leading to a robust host inflammatory response (El Feghaly et al., 2013). Approximately 
15-25% of all cases of antibiotic-associated colitis are caused by C. difficile and patients 
with severe disease have elevated faecal IL-1β, and IL-8 (Solomon, 2013; Steiner, 
Flores, Pizarro, & Guerrant, 1997). C. difficile has been one of the most intensively 
typed pathogens and to date there are more than 100 distinguishable ribotypes (Dawson 
et al., 2009; Stubbs et al., 1999). A study carried out by Ní Eidhin et al. (2006) 
sequenced the slpA gene and flanking DNA from C. difficile isolated from patients in St 
James’s Hospital, Dublin Ireland over a 16-month period. The most frequently 
occurring ribotypes found in this study were 001, 012 and 017 (Ní Eidhin et al., 2006). 
There is evidence in the literature which suggests that C. difficile is evolving to occupy 
niche hospital populations and there has been rapid worldwide spread of ribotypes 027 
and 078 (Dawson et al., 2009).  
We had access to ribotypes 001, 005, 027, 031, 078 and 014 in this study. Evidence 
from the literature suggests that Ribotype 031 does not produce toxins and cause less 
severe infection, clinical outcomes range from asymptotic colonisation to mild 
diarrhoea. In comparison ribotype 014 and 005 produce both toxins and are considered 
toxigenic, clinical symptoms range from mild to severe diarrhoea (Yakob et al., 2015). 
Some ribotypes are more ‘hypervirulent’ than others, ribotype 027 and 078 have been 
associated with more severe diarrhoea, higher mortality and more reoccurrences, 
compared to ribotype 001 which is associated with a milder infection (Clements et al., 
2010; Dawson et al., 2009; Goorhuis et al., 2007; Loo et al., 2005). Evidence from the 
literature has shown that ribotype 027 induces more severe colitis and tissue injury than 
any other ribotype examined so far (Yakob et al., 2015). Increased virulence might be 
due to genetic mutations in tcdC a toxin regulator gene, leading to hyper production of 
toxins A and B (Barbut et al., 2007). Ribotype 027 also produces a binary toxin 
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associated with severe diarrhoea and isolates from recent epidemics have shown this 
ribotype acquired a resistance to fluoroquinolones, common antibiotics used to treat 
CDI (Cartman, Heap, Kuehne, Cockayne, & Minton, 2010). Studies carried out in a 
human gut model found that ribotype 027 germinates more readily, remains in a 
vegetative form and produced cytotoxin for substantially longer than ribotype 001 
(Freeman, Baines, Saxton, & Wilcox, 2007). A Canadian study showed that the 30 day 
mortality rate for patients with ribotype 027 CDI was twice that for those infected with 
ribotype 001 (Labbé et al., 2008).  
C. difficile expresses a crystalline S-layer encoded by the slpA gene, the product of 
which is cleaved to give two mature peptides which associate to form layers (Ausiello et 
al., 2006; Ní Eidhin et al., 2006). These layers are commonly known as SLPs and are 
found on the outer surface of C. difficile, facilitating interaction with the host enteric 
cells (Fagan et al., 2009). HMW proteins are highly conserved across strains, while the 
LMW proteins demonstrates considerable sequence diversity, and the latter have also 
been shown to be the dominant antigen (Drudy et al., 2004; Ní Eidhin et al., 2006; 
Sharp & Poxton, 1988). Research from our laboratory has shown that SLPs from 
ribotype 001 can induce the maturation of BMDCs and the response this elicits is 
comparable to that of LPS (Ryan et al., 2011). LPS is a well-known TLR4 agonist that 
activates both NF-κB and IRF3 signalling (Akashi et al., 2003; Taro Kawai & Akira, 
2007; Laird et al., 2009). However, while SLPs from ribotype 001 activate NF-κB 
through TLR4 signalling, they fail to induce IRF3 signalling. SLPs from ribotype 001 
can activate pro-inflammatory cytokines and chemokines in a murine macrophage cell 
line with an increase in cell surface marker expression, enhanced phagocytosis and 
migration (Collins et al., 2014). Therefore, SLPs from ribotype 001 can activate innate 
and adaptive immunity, suggesting an important role for SLPs in the recognition of C. 
difficile by the immune system and possible bacterial clearance (Collins et al., 2014; 
Ryan et al., 2011). The goal of this chapter was to investigate the immune response of 
SLPs from various ribotypes of C. difficile and to examine NF-κB and IRF3 signalling 
particularly, to see if there were any differences in signalling that could account for the 
differences in clinical symptoms between differing ribotypes.  
  
 102  
BMDCs are known as the sentinels of the immune system and play an essential role in 
deciding when to mount the appropriate immune response, by sampling their local 
environment for antigens to present to T lymphocytes (Banchereau & Steinman, 1998), 
which require MyD88-dependent signals during infection (Chieppa, Rescigno, Huang, 
& Germain, 2006; Niess et al., 2005). BMDCs have traditionally been defined by 
phenotypic markers, such as the expression of the integrin CD11c on the cell surface, as 
well as other functional characteristics (Helft et al., 2015). BMDCs are relatively short 
lived and they are continuously replenished from bone marrow, blood or tissue derived 
precursors (Laar, Coffer, & Woltman, 2012). The first part of this study was to isolate 
and grow BMDCs from bone marrow in the presence of GM-CSF, a well-known 
stimulus for driving murine BMDC formation in vitro (Inaba et al., 1992). Before each 
experiment we assessed the cell surface of the BMDCs for the presence of the integrin 
CD11c using flow cytometry. Flow cytometry allows cells in solution to be individually 
analysed by focusing a stream of cells through a laser, one cell at a time. Specific cell 
surface markers can be targeted and analysed using monoclonal antibodies conjugated 
to flurochromes, which absorb and emit light at specific wavelengths (Herzenberg et al., 
2002). Our data shows we isolated pure BMDC populations as they expressed CD11c 
on the surface and we were able to gate on these cell populations to look at other cell 
surface markers when we stimulated BMDCs with SLPs from the various ribotypes of 
C. difficile. 
BMDC maturation is characterised by increased expression of cell surface markers such 
as CD40, CD80 and CD86 (Higgins et al., 2003; Lavelle et al., 2003). Co-receptors are 
molecules on the surface of T-cells that send signals to drive cell activation, without 
these signals they may become unreactive or die by programmed cell death. The main 
co-receptors for T-cell activation are CD80, CD86 and CD40 which bind to CD28, 
Cytotoxic T-lymphocyte Associated protein 4 (CTLA-4), and CD40 ligands 
respectively on the T-cell. Activated BMDCs are the most potent stimulators of naive 
T-cells (Janeway, Travers, Walport, & Schlomchik, 2001; Parkin & Cohen, 2001; 
Sharpe & Freeman, 2002). CD14 was the first identified PRR that bound directly to 
LPS (Wright et al., 1990) and is known to chaperone LPS molecules to the TLR4-MD2 
signalling complex (da Silva Correia, Soldau, Christen, Tobias, & Ulevitch, 2001; 
Gioannini et al., 2004; Moore et al., 2000). Our flow cytometry data shows that SLPs 
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from ribotypes 001, 005, 031, 027 induce CD80, CD86 and CD40 expression on the 
surface of BMDCs. The expression of CD14 was induced by LPS and SLPs from 
ribotypes 001, 005 and 031, however, BMDCs stimulated with SLPs from ribotype 027 
exhibited slightly lower CD14 expression compared to the control cells. CD14 sits at 
the apex of all cellular responses and functions to induce an innate immune trafficking 
cascade that involves the transport of both TLR4 and its ligand (Zanoni et al., 2011). It 
is possible that ribotype 027 utilises the slight down regulation of CD14 to delay the 
innate immune trafficking cascade in order to evade the host immune response. Our data 
confirms the results previously seen with SLPs from ribotype 001 and we show that 
SLPs from ribotypes 005, 031, 027 induce BMDC maturation in a similar manner, the 
response seen is also comparable to the response by LPS.  
Maturation of BMDCs are also characterised by the production of cytokines such as IL-
12p70, TNFα, IL-23 and IL-6. Cytokines play a central role in the modulation of the 
immune system and they can have pro-inflammatory or anti-inflammatory functions 
(Gerhard & Andus, 1998). Our data demonstrates that SLPs from ribotypes 005, 031 
and 027 induce the production of IL-12p40, IL-23 TNFα and IL-6 in BMDCs to a 
similar level to that of LPS and in a similar way to SLPs from ribotype 001. The IL-12 
family of cytokines which include IL-23 and IL-12p40 play a major role in the 
inflammatory response (Parkin & Cohen, 2001). TNFα also acts on BMDCs, promoting 
migration to the lymph nodes where an adaptive immune response can be initiated and 
it has also been shown to induce bacterial clearance (Bekker et al., 2000). IL-6 plays a 
crucial role in the differentiation of BMDCs and is an important modulator to maintain 
the balance between Th1 and Th2 effector functions (Jego et al., 2003; Yao et al., 2014). 
Both IL-6 and IL-23 are required to drive Th17 responses and Th17 cells have a role in 
the clearance of bacteria from the gut (Khader, Gaffen, & Kolls, 2009; Zhang, Clarke, 
& Weiser, 2009). It has been shown previously that SLPs can induce the production of 
pro-inflammatory cytokines in immune cells such as BMDCs, monocytes and 
macrophage (Ausiello et al., 2006; Bianco et al., 2011; Calabi et al., 2002; Collins et al., 
2014; Madan & Petri Jr, 2012; Ryan et al., 2011; Vohra & Poxton, 2012) and the data 
presented in this chapter supports these claims. 
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However, our findings show differences in the potency of the immune response between 
ribotypes, with regard to the induction of IL-1β, IL-12p70 and IL-10 in BMDCs which 
has not yet been reported in the literature. Our data shows that BMDCs stimulated with 
ribotype 027 and 031 appeared to produce more IL-1β than BMDCs stimulated with 
LPS and SLPs from the other ribotypes examined in this study. IL-1β is an important 
pro-inflammatory mediator that is generated at sites of injury or immunological 
challenge (Schroder & Tschopp, 2010). IL-1β has also been shown to be critical in 
bacterial infection and clearance in vivo (Miller et al., 2014). Our data also demonstrates 
that BMDCs stimulated with SLPs from ribotypes 005, 031 and 027 produced IL-12p70 
to a similar level as the response induced by LPS. However BMDCs stimulated with 
SLPs from ribotype 001 appeared to produce much less IL-12p70 than BMDCs 
stimulated with LPS and the other SLPs examined in this study. IL-12p70 part of the 
IL-23 family helps induce T-cells to differentiate into Th1 cells thus aiding the 
inflammatory response (Parkin & Cohen, 2001). Our data also shows that SLPs from 
ribotype 031 and 027 appeared to produce more IL-10 in BMDCs, compared to BMDCs 
stimulated with LPS and SLPs from the other ribotypes in this study. IL-10 is an anti-
inflammatory cytokine that inhibits MHC class II and co-stimulatory molecules on 
monocytes and macrophages. IL-10 limits the production of pro-inflammatory 
cytokines including IL-1β, IL-6, IL-12, TNFα and chemokines such as MCP-1, 
RANTES, IL-8 and MIP-2 (Lee & Kim, 2007; Williams et al., 2004). The production of 
and signalling by type I IFN is required for LPS induced IL-10 up regulation (Chang et 
al., 2007). STAT3 is an important player mediating the anti-inflammatory effect of IL-
10, studies have shown that IL-10 production is abolished in STAT3 -/- mice (Takeda et 
al., 1999). STAT3 is activated by the IL-23 family of cytokines, we know from the 
literature that the production of the IL-23 family of cytokines is strongly dependent on 
IRF3 (Goriely et al., 2008; Molle et al., 2007).  
During infection IL-10 inhibits the activity of Th1 cells, NK cells and macrophages 
(Couper, Blount, & Riley, 2008), all which are required for optimal pathogen clearance 
(Andoh et al., 2007). The absence of IL-10 can be accompanied with 
immunopathological tissue damage that is potentially harmful to the host, whereas 
excessive IL-10 production always results in chronic infectious diseases caused by less 
clearance of pathogens (Lin et al., 2013). Furthermore other organisms such as Brucella 
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abortus and Mycobacterium tuberculosis have been shown to utilise IL-10 to avoid 
clearance in host cells and mediate long term infection (Redford, Murray, & O’Garra, 
2011; Xavier et al., 2013). It is possible that the ability of ribotype 027 to induce pro-
inflammatory tissue damaging responses and anti-inflammatory responses is beneficial 
for the pathogen. Ribotype 027 could increase tissue damage to potentially invade 
deeper into the gut resulting in a more persistent disease while switching off powerful 
immune cell responses. Ribotype 001 on the other hand induces a less potent 
inflammatory response. The ability of SLPs from certain ribotypes to induce anti-
inflammatory responses and others to induce more potent pro-inflammatory responses 
may account for the variability of symptoms and severity of disease experienced by 
patients who contract C. difficile.  
We have previously shown that SLPs from ribotype 001 activate TLR4 (Ryan et al., 
2011). TLR4 initiates downstream signalling which in turn activates NF-κB and IRF3 
via MyD88-dependent and -independent pathways (Akira & Takeda, 2004). Activation 
of the MyD88 dependant pathway is mainly an event initiated at the plasma membrane, 
while induction of IRF3 via the MyD88- independent pathway is dependent on the 
endocytosis of TLR4 and requires the presence of CD14 and subsequently TRIF (Jiang 
et al., 2005; Kagan et al., 2008). IRF3 induce type I IFNs which have an important role 
in bridging innate and adaptive immunity by mediating the induction of co-stimulatory 
molecules on antigen presenting cells in response to pathogen associated molecules 
(Hoebe & Beutler, 2004). Both MyD88-dependent and independent mechanisms are 
required for the development of full host response to bacterial challenge and LPS can 
activate both NF-κB and IRF3 signalling pathway (Carrigan et al., 2010). Given the 
similarity of the response of SLPs from ribotype 001 with LPS and the induction of DC 
maturation, it was not surprising to us that the response activated TLR4 signalling with 
downstream activation of p38 and NF-κB signalling (Collins et al., 2014; Ryan et al., 
2011). What was surprising was SLPs from ribotype 001 did not induce IRF3 signalling 
(Ryan et al., 2011).  
The next part of this study was to investigate if there were differences between SLPs 
from the different ribotypes in signalling downstream of TLR4. We used HEK-293 cells 
which were stably transfected with TLR4, MD2 and CD14 receptors on the surface as 
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these cells have the machinery necessary for TLR4 signalling. The luciferase gene 
reporter assay enabled us to examine NF-κB and IRF3 signalling induced by the SLPs 
from differing ribotypes of C. difficile. Both sets of plasmid DNA were co-transfected 
with constitutively expressed TK renilla luciferase construct. The utility of an internal 
control plasmid is dependent on the fact that the encoded protein is expressed in a 
constitutive manner without being influenced by experimental factors and can therefore 
be used to normalise the transfection efficiency (Shifera & Hardin, 2010). Our data 
shows that SLPs from ribotypes 001, 014, 078 and 027 activate NF-κB signalling 
downstream of TLR4 and with subsequent production of IL-8. We also show that SLPs 
from ribotypes 001, 014 and 078 do not induce IRF3 activation, whereas SLPs from 
ribotype 027 induced IRF3 signalling with independent production of RANTES by the 
cells. Therefore, there are key signalling differences between SLPs from ribotype 027 
which is known to be hypervirulent and other ribotypes of C. difficile such as ribotype 
001. SLPs from ribotype 027 can induce both NF-κB and IRF3 signalling and we know 
from the literature that activation of both arms of the TLR4 signalling pathway is 
required for full bacterial clearance. Yet clearance of ribotype 027 appears more 
difficult given the clinical symptoms of CDI, even though both arms of the TLR4 
pathway are activated. It is possible that there is another level of regulation influencing 
bacterial clearance induced by the SLPs from ribotype 027. SLPs from ribotype 001 did 
not induce IRF3 signalling, this could account for the reduced IL-12p70 and IL-10 
production in BMDCs as there is a link between IL-10 production, IL-12p70 a member 
of the IL-23 family and IRF3 expression and thus warrants further investigation.  
The differences between SLPs isolated from differing C. difficile ribotypes is the amino 
acid sequence changes in the LMW protein (Lynch 2014, unpublished). Consequently, 
this variability in SLPs sequence may be an important mechanism in C. difficile 
escaping the host’s response (Fagan, et al. 2009, Ryan, et al. 2011). Sequence 
differences could affect the recognition of SLPs by the immune system and therefore 
may explain why some strains of C. difficile cause severe infection and have a higher 
frequency of reoccurrence and yet others are associated with minimum clinical 
symptoms and varying pathology (Ryan, et al. 2011). Given the continuing challenge 
that C. difficile poses, understanding how it activates the immune response by either 
switching on or off certain arms of the pathway may ultimately provide insights for 
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novel therapies to improve clearance in patients and prevent reoccurrence of infection 
(Collins et al., 2014; Ryan et al., 2011). It has now emerged that TLR pathways are 
tightly regulated by miRNAs (He et al., 2014; O’Neill et al., 2011). In the next chapter 
we hope to elucidate further differences between miRNA profiles of cells stimulated 
with LPS and SLPs via the TLR4 signalling pathway. 
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Chapter 4: Profiling the MiRNAs 
Induced by SLPs from C. difficile 
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4.1 Introduction  
The inflammatory response to infection involves the induction of several hundred 
genes, a process that must be tightly regulated to achieve pathogen clearance and at the 
same time avoid consequences of deregulated gene expression such as uncontrolled 
inflammation or cancer (Sonkoly, Ståhle, & Pivarcsi, 2008). The innate immune 
response is the first line of defence against pathogens (Janeway, 1989). It is initiated by 
the binding of microbial ligands to membrane-associated pathogen recognition receptor 
proteins known as TLRs as previously described in the general introduction (Mogensen, 
2009). Mature microRNAs (miRNAs) are short double stranded RNA molecules 
approximately 19-23 nt in length that pair to protein coding genes. They can block 
mRNA translation, reduce mRNA stability or induce mRNA cleavage after imperfect 
binding to the miRNA recognition elements within the 3’ and 5’ untranslated region 
(UTR) of target mRNA genes (Bartel, 2004). MiRNAs have been shown to be involved 
in innate immunity by regulating TLR signalling and ensuing cytokine response by 
targeting a variety of signalling proteins, regulatory molecules and transcription factors 
(Dalal & Kwon, 2010; He et al., 2014; Sonkoly et al., 2008). They can also regulate 
central elements of the adaptive immune response such as antigen presentation, T cell 
receptor signalling and the interferon system (Cullen, 2006; Sonkoly et al., 2008).  
In recent times, unique miRNA expression profiles have been described in epithelial 
cells of patients with active ulcerative colitis, Crohn’s ileitis, and Crohn’s colitis, as 
well as in the peripheral blood of patients with active ulcerative colitis and Crohn’s 
disease (Dalal & Kwon, 2010). There is also mounting evidence that miRNAs 
orchestrate immune regulation and host responses to pathogens during infection. 
Bacterial pathogens manipulate cellular functions and modulate signal transduction 
pathways and pro-inflammatory responses through the delivery of effectors into host 
cells. Each pathogen can use different molecular strategies to subvert the complex 
pathways that regulate the host immune response (Staedel & Darfeuille, 2013). C. 
difficile are no different and key effector molecules have been identified that can drive 
towards a protective anti-inflammatory response or a damaging pro-inflammatory 
response (Solomon, 2013). To date no one has examined miRNAs profiles induced in 
response to SLPs from C. difficile.  
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The severity of C. difficile infection may be dependent on the strain present (Goorhuis 
et al., 2007; Rupnik et al., 2009). Some ribotypes are more ‘hypervirulent’ than others, 
this is the case with ribotype 027 which has been associated with more severe diarrhoea, 
higher mortality and more recurrences (Clements et al., 2010; Dawson et al., 2009; 
Goorhuis et al., 2007; Loo et al., 2005). In comparison infection with ribotype 001 is 
associated with a milder infection and a more efficient clearance of the bacteria 
(Clements et al., 2010; Dawson et al., 2009; Goorhuis et al., 2007; Loo et al., 2005). In 
the previous chapter we determined that SLPs from ribotype 001 and 027 activate NF-
κB signalling. SLPs from ribotype 027 activate IRF3 signalling downstream of TLR4, 
while SLPs from ribotype 001 fail to induce this response. Given the role of miRNAs in 
the regulation of TLR4 signalling and during infection, we hypothesise that SLPs 
induce miRNAs and that profiles differ between ribotypes, which may explain the 
differences we see in signalling downstream of TLR4 signalling and ultimately the 
immune response to C. difficile. 
Quantitative Real-Time PCR (qPCR) is the gold standard for detecting miRNAs 
(Schmittgen et al., 2009). However, many properties that are unique to miRNA pose 
challenges for their accurate detection and quantification using this method (Wark, Lee, 
& Corn, 2008). Their short length makes it difficult for traditional primers to anneal for 
reverse transcription. Unlike mRNA, miRNA lack a common structure/ sequence, such 
as a poly adenylated (poly-A) tail which is typically used for enrichment or as a binding 
site for primers. The poly-A tail is cleaved by the Drosha/DGCR8 microprocessor 
complex during biogenesis (Gromak et al., 2013). MiRNAs within a seed family also 
pose difficulties for qPCR as they may only differ from one another by as little as one 
nucleotide making specificity of the primer particularly crucial. Stem loop primers 
differentiate between mature and pre/pri miRNA as well as miRNA which differ by 
only a single nucleotide. This method has shown to have a high specificity and dynamic 
range of at least 7 logs and is capable of detecting as few as 7 copies of product in a 
qPCR reaction (Chen et al., 2005; Kramer, 2011).  
Taqman chemistry utilises an oligonucleotide probe constructed from a fluorgenic 
labelled reporter fluorescent dye and a quencher dye see Figure 4.1.1. While the probe 
is intact, the proximity of the quencher dye greatly reduces the fluorescence emitted by 
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the reporter dye by fluorescence resonance energy transfer (FRET). If the target 
sequence is present, the probe anneals downstream from one of the primer sites and is 
cleaved by the 5' nuclease activity of Taq DNA polymerase as this primer is extended. 
Cleavage of the probe separates the reporter dye from the quencher dye, increasing the 
reporter dye signal. Removing the probe from the target strand, allows primer extension 
to continue to the end of the template strand. Additional reporter dye molecules are 
cleaved from their respective probes with each cycle, resulting in an increase in 
fluorescence intensity proportional to the amount of PCR product produced. The 
development of this mature TaqMan technology has led to an innovative design of 
Taqman Low Density Arrays (TLDA), a medium throughput method for qPCR that uses 
384 well microfluidic cards pre-loaded with miRNA primer probes. Applied 
Biosystems™ have developed TLDA cards containing different pools of known human 
miRNAs found in pool A and lesser characterised miRNAs found in pool B, thus 
enabling the screening of over 756 miRNA targets found in miRBase. 
 
Figure 4.1.1 Stem loop primers for miRNA detection and PCR using TaqMan 
chemistry (Chen et al., 2005) 
The aim of this chapter is to profile and compare miRNA expression induced by SLPs 
from ribotypes 001 and 027. Initially miRNAs induced in response to LPS and SLPs 
from ribotype 001 will be screened using TLDA cards to validate our method and 
narrow down the target list. This target list will be further validated using custom made 
to order TLDA cards. The differences in miRNA profiles between ribotype 001 and 027 
will then be examined and validated in individual Taqman PCR assays in both human 
and murine cell lines. 
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4.2 Results 
4.2.1 Optimising a Method for Profiling MiRNAs Induced by SLPs from C. difficile 
MiRNAs are known to regulate immune signalling by targeting a variety of signalling 
proteins, regulatory molecules, cytokines, transcription factors and TLR receptors post 
immune stimulation (He et al., 2014). We hypothesise that SLPs from RT 001 and RT 
027 induce miRNAs and these profiles differ, which may explain the differences we see 
in TLR4 signalling. To test this hypothesis we had to first establish a protocol for 
detecting miRNAs. qPCR is the gold standard for examining miRNA expression and 
this technology is utilised in TLDA cards. TLDA cards are 384 well microfluidic cards 
preloaded with probes for different pools of known human miRNAs found in pool A 
and lesser characterised miRNAs found in pool B. Three endogenous small RNA 
controls are included on each of the pool A and B cards, thus enabling the screening of 
756 miRNAs from each sample. SLPs modulate TLR4 signalling therefore we wanted 
to examine miRNA profiles induced by SLPs via TLR4 signalling specifically, for that 
reason Hek TLR4/MD2/CD14 cells were used throughout the initial profiling studies. 
We also incorporated cells stimulated with LPS in our study as it is a well-known TLR4 
agonist that can activate both NF-κB & IRF3 signalling and miRNA activation by LPS 
has also been reported (Akashi et al., 2003; Taro Kawai & Akira, 2007; Laird et al., 
2009). Evidence from the literature shows that LPS induces miRNAs; miR-155, miR-
125, miR-9, the let-7 family, miR-145, miR-146a and miR-187 as little as eight hours 
post stimulation and they have been shown to modulate the immune response and target 
key molecules in the TLR4 signalling pathway (Curtale et al., 2013; Rossato et al., 
2012; Tili et al., 2007).  
We first needed to establish the time point we could assess miRNAs activation seeing as 
LPS can induce miRNAs that modulate the immune response as little as 8 hours post 
stimulation. We first had to establish if SLPs from RT 001 & RT 027 could activate NF-
κB and if SLPs from RT 027 could activate IRF3 signalling at this time point. We 
measured IL-8 and RANTES production in Hek TLR4/MD2/CD14 cells stimulated 
with LPS and SLPs from RT 001 and RT 027 for 8 hours. IL-8 and RANTES are 
indicative of NF-κB and IRF3 signalling respectively (Lin et al., 1999; Mukaida et al., 
1994). We measured human IL-8 and RANTES expression from the cell supernatants 
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using ELISA see Figure 4.2.1. There were low levels of IL-8 produced by the control 
Hek TLR4/MD2/CD14 cells, however IL-8 production was increased when cells were 
stimulated with LPS (p≤ 0.001) and SLPs from RT 001 (p≤ 0.001) and RT 027 (p≤ 
0.001) compared to the control cells. There were low levels of RANTES produced in 
Hek TLR4/MD2/CD14 cells, however production was increased in cells stimulated with 
LPS (p≤ 0.001) and SLPs from RT 027 (p≤ 0.01) compared to the control cells. There 
was no significant increase in RANTES produced in Hek TLR4/MD2/CD14 cells 
stimulated with SLPs from RT 001 compared to the control cells. In summary SLPs 
from RT 001 and RT 027 activated NF-κB and SLPs from RT 027 activated IRF3 
signalling at 8 hours, therefore we decided to profile miRNAs at this time point 
thereafter. 
Total RNA was extracted from cells using the using miRVana™ miRNA isolation kit 
and we did so according to manufacturer’s instructions. This method preserves the small 
RNA fraction containing miRNAs and includes the slightly longer endogenous small 
RNA control sequences. The RNA was quantified following isolation using the 
NanoDrop® ND-1000 Spectrophotometer. The purity of the RNA was also examined 
by measuring the 260 nm and 280 nm absorption wavelengths, where RNA with an 
A260/A280 ratio between 1.8- 2.1 was considered pure. RNA samples were 
subsequently run on 1% agarose gels where the 28S and 18S ribosomal RNA (rRNA) 
bands were assessed to confirm integrity. Two bands were seen on the gel, the first band 
was located between the 1500-2000 bp molecular markers indicative of the 18S rRNA 
band. A second band twice the intensity of the other was located between the 4000-5000 
bp molecular markers indicative of 28S rRNA band (see Appendix D). Total RNA of 
good quality was used exclusively throughout the studies. 
cDNA synthesis with and without downstream pre-amplification supports the analysis 
of miRNA with 1 to 1000 ng starting total RNA, however the manufacturer 
recommends downstream pre-amplification if the starting product is below 350 ng. Pre-
amplification PCR uniformly amplifies desired cDNA by increasing the amount of 
starting template (Noutsias et al., 2008). The increased amount of starting material 
boosts the sensitivity of miRNAs detected without biasing the estimation of miRNA 
expression ratio (Chen et al., 2009). We established the optimal quantity of input total 
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RNA for our study. A pre-amplification reaction with 350 ng total RNA increased the 
quantity of starting template seen by the detection of miRNAs at earlier cycle numbers 
see Figure 4.2.2. Once we optimised these conditions we ran Megaplex reverse 
transcription reactions (pool A and B), two pre-amplification reactions (pool A and B) 
and two TLDA cards (A and B) per sample from three biological replicates. Initially we 
screened control samples, samples stimulated with LPS and SLPs from RT 001.  
4.2.2 TLDA Card Analysis Parameters 
Following each run SDS files were exported from the Applied Biosystems 7900HT Fast 
Real time PCR machine and the qPCR data from pool A and B TLDA cards was 
analysed using ExpressionSuite software. The fluorescence threshold was set to 0.1 so 
that the experimental conditions lay within the exponential phase of the PCR reaction. 
When fluorescence crosses this value, the cycle is termed the "Threshold cycle" (Ct) 
and the higher the Ct, the smaller the initial amount of DNA. The max Ct for analysis 
was set to 37.0, anything beyond this Ct was deemed outside the limit of detection for 
this study. Each assay was pre-designed from Applied Biosystems™ and assay 
efficiency is guaranteed at 100%. A proper normalisation strategy is crucial for any 
qPCR data analysis, it minimises the effects of systematic technical variations and is a 
prerequisite for getting meaningful biological changes (Meyer, Kaiser, Wagner, Thirion, 
& Pfaffl, 2012). For large scale miRNA expression profiling studies, global 
normalisation out performs the normalisation strategies using endogenous controls 
(Mestdagh et al., 2009). Seeing as we generated a large data set global normalisation 
was carried out, the median Ct of common assays was used as the normaliser on a per 
sample basis. The normalised reporter ‘Rn’ value for each target was also integrated 
into these calculations. Relative gene expression was calculated and Benjamini-
Hochberg False Discovery Rate (FDR) was used to adjust p-values. Increasing the 
number of tests increases the probability of finding a significant p-value by chance and 
to avoid this effect the FDR adjusts the p-values according to the number of total tests. 
The statistics used in a t-test are defined as the difference of the arithmetric mean of two 
groups divided by the estimated standard deviation of that difference. The t-test statistic 
runs under the assumption that the given variable follow normal distribution (Goni, 
García, & Foissac, 2009; Li, 2012). Therefore we examined the overall Ct value 
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distribution for each sample from the data generated from the pool A and B TLDA 
cards see Figure 4.2.3. The box plot shows the Ct distribution for each treatment group 
with three biological replicates per group. The box contains the middle 50% of the data, 
the black horizontal line indicates the median Ct value and the black dot denotes the 
mean Ct. The end of the vertical lines indicates the minimum and maximum Ct values 
and the outliers are the points outside the ends of the whiskers. The overall Ct values 
follow normal distribution therefore we applied a student’s t-test where values of p≤ 
0.05 were considered statistically significant compared with the control cell group.  
4.2.3 Profiling Studies Using TLDA Cards Revealed 16 MiRNAs were Differentially 
Regulated in Response to LPS and SLPs from RT 001 
qPCR data analysis revealed 248 miRNAs were detected out of the 756 miRNAs 
analysed using pool A and B TLDA cards see Table 4.2.1, the other miRNAs were not 
expressed. There was also no expression in the NTC reactions on both A and B arrays 
(data not shown). Ct scatter plots showed there were differences in miRNA profiles 
between cells stimulated with LPS and SLPs from RT 001. We compared Ct values 
between each group and found they fell outside of the regression line- indicating they 
are not entirely linear see Figure 4.2.4. However in order to fully elucidate the 
difference between individual miRNA targets with statistically significant fold changes, 
the data was analysed using a volcano plot. According to the literature, there is a 
relationship between fold change and t-statistics with logarithm transformation (Li, 
2012). Therefore -log10 p-value was plotted against log2 fold change. For our study the 
fold change boundary was set to 1.0 and the p-value boundary was set to p≤ 0.05. 
miRNA targets above the central horizontal line had statistically relevant high 
magnitude fold changes. The top left quadrant displayed down regulated miRNAs, 
while the top right quadrant displayed miRNA targets that were up regulated.  
Four miRNAs were differentially regulated in response to LPS. The volcano plot 
showed that one miRNA was down regulated miR-586 (p≤ 0.05) while three miRNAs 
were upregulated miR-302c (p≤ 0.05), miR-374 (p≤ 0.05) and miR-543 (p≤ 0.01) see 
Figure 4.2.5. Twelve miRNAs were differentially regulated in response to SLPs from 
RT 001. The volcano plot showed three miRNAs were down regulated miR-1293 (p≤ 
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0.001), miR-422a (p≤ 0.01) and miR-874 (p≤ 0.05). Nine miRNAs were up regulated 
miR-1292 (p≤ 0.05), miR-148b (p≤ 0.001), miR-152 (p≤ 0.05), miR-24 (p≤ 0.05), miR-
215 (p≤ 0.05), miR-339-5p (p≤ 0.001), miR-432# (p≤ 0.05), miR550 (p≤ 0.05) and 
miR-590 (p≤ 0.05) see Figure 4.2.6. In total 16 miRNAs had significantly significant 
high magnitude fold changes in response to LPS and SLPs from RT 001, a summary of 
these results are shown in Table 4.2.2. 
4.2.4 Additional MiRNAs of Interest were Chosen for Further Validation Following a 
Review of the Literature and Re-examination of the Profiling Study 
We reviewed the literature for miRNAs known to regulate key elements of TLR4 
signalling including; signalling proteins, transcription factors, cytokines and regulatory 
molecules, to create a short list of potential miRNAs of interest. We also included 
miRNAs that are known to be induced by LPS and miRNAs induced during an immune 
response to infection. The short list comprised of let-7b, let-7c, let-7d, let-7e, let-7e#, 
miR-125a-5p, miR-132, miR-145, miR-146a miR-155, miR-187, miR-221, miR-221#, 
miR-9 and miR-9#. We then re-examined the profiling study to see if the short list of 
miRNAs were present in the initial experimental profiling study see Table 4.2.3. The 
miRNAs identified from the literature were in fact present but were over the 
significance value set in this experiment. MiR-155, miR-9, the let-7 family, miR-145, 
miR-146a and miR-187 have all been shown to be induced by LPS in the literature 
(Curtale et al., 2013; Rossato et al., 2012; Tili et al., 2007). Although not significantly 
expressed these miRNAs were shown to be induced by LPS in our study, thus validating 
our experimental method. We also found that there were differences in the expression of 
miRNAs between LPS and SLPs from RT 001, therefore we decided to include the 
short list of miRNAs from the literature for further analysis. The lists of 16 miRNAs 
identified from the experimental profiling study and the short list of 15 miRNAs from 
the literature were combined and custom TLDA cards containing the now 31 miRNAs 
of interest were commissioned. The endogenous control U6 snRNA was selected as it 
out performed the two other human small RNA endogenous controls RNU44 and 
RNU48 (see Appendix F). Therefore U6 snRNA was included as the endogenous 
control on the custom TLDA cards. 
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4.2.5 Custom TLDA Card Analysis Parameters 
New RNA samples were generated and included Hek TLR4/MD2/CD14 cells 
stimulated with LPS, SLPs from RT 001 and RT 027. qPCR data from the custom cards 
was analysed using ExpressionSuite software, where the threshold was set to 0.1 and the 
max Ct set to 37.0 as previously determined. There was also no miRNA expression 
detected in cards with NTC (data not shown). Due to the reduction in the number of 
total targets, U6 snRNA was used as the endogenous control instead of global 
normalisation and relative gene expression was calculated. We also examined the 
overall Ct value distribution for each sample from the custom cards see Figure 4.2.7. 
The box plot shows the Ct distribution for each treatment group from three biological 
replicates per group which also included 4 technical replicates. The overall Ct values 
followed normal distribution therefore we could apply a student’s t-test where values 
of p≤ 0.05 were considered statistically significant compared with the control cell 
group. 
4.2.6 Twenty-Four MiRNAs were Differentially Regulated by SLPs from RT 001 and 
RT 027 
qPCR data analysis revealed 28 miRNAs were detected out of the 31 miRNAs analysed 
using the custom TLDA cards see Table 4.2.4. Ct scatter plots analysis showed there 
were differences in miRNA profiles between cells stimulated with LPS, SLPs from RT 
001 and RT 027 see Figure 4.2.8 and Figure 4.2.9. When we compared Ct values 
between each group we found they fell outside of the regression line- indicating they 
were not entirely linear. The data was then visualised using a supervised heat map 
incorporating average linkage and Pearson’s correlation Figure 4.2.10. The heat map 
shows the corresponding relative miRNA expression levels and renders them in a green-
red scale. Green represents low expression levels while red represents high expression 
levels and black indicates an absence of detection. Each row represents a single miRNA 
and each column represents an individual sample. Cells stimulated with SLPs from RT 
027 had low expression for most of the miRNAs analysed and this was consistent 
between each of the biological replicates as shown by the green colour on the heat map. 
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A dendorgram is a tree diagram frequently used to illustrate the arrangement of the 
clusters produced by hierarchical clustering. According to the dendorgram on the y-axis 
shown with the heat map, miRNAs were clustered in one main clade with another 
smaller clade containing 2 branches. The first branch in the smaller clade contained 
branch tips for let-7e* and miR-1293, while the second branch contained tips for miR-
221* and miR-543. The larger main clade contained 7 distinct branches. The first, 
second and third branches contained a single branch tip for miR-586, miR550 and miR-
146a respectively. The fourth branch contained branch tips for miR-221, let-7c, let-7d, 
miR-9*, miR-9, miR-152, miR-432*, miR-148b and miR-339-5p. The fifth branch 
contained branch tips for miR-125a-5p, let-7e, let-7b and miR874. The sixth branch 
contained branch tips for miR-187, miR-215 and miR-24. The seventh branch contained 
branch tips for miR-1292, miR-145, miR-155, miR-422a, miR-132, miR-302c, miR-374 
and miR-590-5p. MiRNAs included within each clade and subsequent branch group, are 
more likely to be expressed together based on the experimental data in this study. 
In order to fully elucidate the difference between individual miRNA targets between 
treatment groups with statistically significant fold changes, the data was analysed using 
a volcano plot. Consequently -log10 p-value was plotted against log2 fold change, for our 
study the fold change boundary was set to 1.0 and the p-value boundary was set to p≤ 
0.05. Targets above the central horizontal line had statistically relevant high magnitude 
fold changes. The top left quadrant displayed down regulated miRNAs, while the top 
right quadrant displayed miRNA targets that were up regulated. Analysis showed 24 
miRNAs were differentially regulated in response to SLPs from RT 001 and RT 027. 
Two miRNAs, miR-145 (p≤ 0.05) and miR-146a (p≤ 0.001) were up regulated in 
response to SLPs from RT 001 see Figure 4.2.11. Twenty three miRNAs were down 
regulated in response to SLPs from RT 027 let-7b (p≤ 0.05), let-7c (p≤ 0.001), let-7d 
(p≤ 0.001), let-7e (p≤ 0.001), miR-125a-5p (p≤ 0.001), miR-1292 (p≤ 0.001), miR-132 
(p≤ 0.001), miR-145 (p≤ 0.001), miR-148b (p≤ 0.01), miR-152 (p≤ 0.05), miR-155 (p≤ 
0.05), miR-221 (p≤ 0.05), miR-24 (p≤ 0.05), miR339-5p (p≤ 0.001), miR-374 (p≤ 0.05), 
miR-422a (p≤ 0.05), miR-432* (p≤ 0.01), miR-543 (p≤ 0.01), miR-586 (p≤ 0.05), miR-
590 (p≤ 0.05), miR-9 (p≤ 0.05), miR-9* (p≤ 0.001) and miR-221 (p≤ 0.05) see Figure 
4.2.12. miR-145 was differentially regulated by both SLPs from RT 001 and RT 027.  
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4.2.7 Further Validation Confirmed let-7e, miR-155, miR-145 and miR-146a were 
Differentially Regulated in Response to SLPs from RT 001 and RT 027 
We choose four miRNAs let-7e, miR-155, miR-146a and miR-145 for further validation 
based on the differences observed between SLPs from RT 001 and RT 027 see Table 
4.2.5. Let-7e appeared to be down regulated in response to SLPs from RT 001, however 
it appeared to be even more down regulated when we compared the response to SLPs 
from RT 027. MiR-155 in response to SLPs from RT 001 remained at levels seen with 
control cells but appeared to be down regulated when we compared the response to 
SLPs from RT 027. MiR-146a and miR-145 were both up regulated in response to SLPs 
from RT 001 and appeared to be down regulated in response to SLPs from RT 027. 
New RNA samples were generated and included Hek TLR4/MD2/CD14 cells 
stimulated with LPS, SLPs from RT 001 and RT 027 from three biological replicates. 
Individual Taqman miRNA assays with three technical replicates per group were run for 
each miRNA examined and the qPCR data was analysed using ExpressionSuite 
software. The threshold was set to 0.1 and the max Ct set to 37.0, as previously 
determined. There was also no miRNA expression detected in assays containing NTC 
(data not shown). U6 snRNA was used as the endogenous control as previously 
determined and relative gene expression was calculated. The Mann Whitney U-test was 
used to test for significance between SLPs from RT 001 and RT 027. This statistical test 
was chosen because of the uncertainty of normal distribution due to the low number of 
miRNA targets in this experimental study (Goni et al., 2009).  
qPCR data from the individual miRNA assays confirmed the results seen with the 
custom TLDA cards, let-7e, miR-155, miR-145 and miR-146a were differentially 
regulated in response to SLPs from RT 001 and RT 027 see Figure 4.2.14. Stimulation 
with LPS did not significantly increase or decrease miR-145, it increased miR-146a to 
1.6 fold and it decreased let-7e and miR-155 to 0.6 and 0.7 fold respectively. 
Stimulation with SLPs from RT 001 did not significantly increase or decrease miR-155, 
it decreased let-7e and increased miR-146a and miR145 to 1.6 and 1.2 fold respectively. 
In all cases miRNAs were down regulated in response to SLPs from RT 027 compared 
to SLPs from RT 001, let-7e, miR-155, miR-146a and miR-145 were decreased to 0.1 
(p≤ 0.001), 0.03 (p≤ 0.001), 0.6 (p≤ 0.001) and 0.2 (p≤ 0.001) fold respectively. 
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4.2.8 Let-7e, miR-155, miR-145 and miR-146a were Differentially Regulated in 
JAWS II Cells 
In order to validate our results further we examined miRNA expression of let-7e, miR-
155, miR-146a and miR-145 in another cell line, we choose the murine dendritic cell 
line JAWS II as they behave in a similar way to BMDCs. JAWS II cells differ from 
BMDCs in that they fail to release the IL-12 cytokine family which include IL-12, IL-
23 and IL-27 and IL-35 (Collins, 2014; Jørgensen, Haase, & Michelsen, 2002; Zapala et 
al., 2011). To begin we had to determine if LPS, SLPs from RT 001 and RT 027 could 
induce an immune response in JAWS II cells. We measured murine IL-1β, TNF-α, IL-
27p28, MCP, IL-6, RANTES, MIP-2 and IL-12p70 in supernatents upon stimulation for 
8 hours using ELISA see Figure 4.2.14. IL-1β was not produced in control JAWS II 
cells. IL-1β was produced in JAWS II stimulated with LPS (p≤ 0.001), SLPs from RT 
001 (p≤ 0.001) and RT 027 (p≤ 0.001). TNF-α was not produced in JAWS II cells. 
TNF-α was produced in JAWS II stimulated with LPS (p≤ 0.001), SLPs from RT 001 
(p≤ 0.001) and RT 027 (p≤ 0.001). IL-27p28 was produced at negligible levels in 
control JAWS II cells, it did not increase when stimulated with LPS, SLPs from RT 001 
and from RT 027 as expected. MCP was produced at low levels in control JAWS II 
cells. MCP was produced in JAWS II cells stimulated with LPS (p≤ 0.001), SLPs from 
RT 001 (ns) and RT 027 (p≤ 0.001). IL-6 was not produced in control JAWS II cells. 
IL-6 was produced in JAWS II cells stimulated with LPS (p≤ 0.001), SLPs from RT 001 
(p≤ 0.001) and RT 027 (p≤ 0.001). RANTES was produced at low levels JAWS II cells. 
RANTES was produced in JAWS II cells stimulated with LPS (p≤ 0.001), SLPs from 
RT 001 (p≤ 0.001) and RT 027 (p≤ 0.001). MIP-2 was produced at low levels in control 
JAWs II cells. MIP-2 was produced in JAWS II cells stimulated with LPS (p≤ 0.001), 
SLPs from RT 001 (p≤ 0.001) and RT 027 (p≤ 0.001). IL-12p70 was produced at 
negligible levels in JAWS II cells and did not increase when stimulated with LPS, SLPs 
from RT 001 and RT 027 as expected.  
Once we established that SLPs from RT 001 and RT 027 could induce an immune 
response in JAWS II cells and there was a difference in the potency of this response. 
Total RNA was extracted using the mirVana isolation kit at the 8 hour time point 
previously determined. RNA samples were generated from three biological replicates. 
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Individual murine miRNA assays with three technical replicates per group from the 
biological replicates were run for each miRNA examined and the qPCR data was 
analysed using ExpressionSuite software. The threshold was set to 0.1 and the max Ct 
set to 37.0, as previously determined. There was also no miRNA expression detected in 
assays containing NTC (data not shown). The endogenous control snoRNA202 out 
performed the two other murine small RNA endogenous controls snoRNA234 and 
mammU6 (see Appendix F). snoRNA202 was used as the endogenous control and 
relative gene expression was calculated. The Mann Whitney U-test was used to test for 
significance between SLPs from RT 001 and RT 027. Stimulation with LPS did not 
significantly increase or decrease miR-146a, it increased miR-145, miR155 and let-7e to 
2.5, 60.0 and 1.7 fold respectively. Stimulation with SLPs from RT 001 did not 
significantly increase or decrease let-7e, however it increased miR-146a, miR-145 and 
miR-155 to 2.5, 25.0 and 1.2 fold respectively. In all cases miRNAs were down 
regulated in response to SLPs from RT 027 compared to SLPs from RT 001. Let-7e, 
miR-155, miR-146a and miR-145 were decreased to 0.5 (p≤ 0.05), 5.0 (p≤ 0.001), 0.2 
(p≤ 0.001) and 0.5 (p≤ 0.001) fold respectively see Figure 4.2.15.  
When we compared the expression of miR-146a, miR-145, miR-155 and let-7e we 
found they were significantly decreased in response to SLPs from RT 027 in both Hek 
TLR4/MD2/CD14 and JAWS II cells see Table 4.2.6. There were slight differences in 
the response to LPS and SLPs from RT 001 between cell types. MiR-146a expression 
was increased in response to LPS in Hek TLR4/MD2/CD14 cells, it was not increased 
or decreased in JAWS II cells, yet miR-146a was increased in response to SLPs from 
RT 001 in both cell types. MiR-145 was not increased or decreased in response to LPS 
in Hek TLR4/MD2/CD14 cells but it was increased in JAWS II cells. MiR-145 was 
increased in response to SLPs from RT 001 in Hek TLR4/MD2/CD14 cells yet it was 
not increased or decreased in JAWS II cells. MiR-155 was decreased in response to LPS 
in Hek TLR4/MD2/CD14 cells, in JAWS II cells it was significantly increased. MiR-
155 was not decreased nor increased in response to SLPs from RT 001 in Hek 
TLR4/MD2/CD14 cells, in JAWS II cells however it was increased. Let-7e was 
decreased in response to LPS in Hek TLR4/MD2/CD14 cells, in JAWS II cells it was 
increased. Let-7e was decreased in response to SLPs from RT 001 in Hek 
TL4/MD2/CD14 cells, in JAWS II cells it was increased.  
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Figure 4.2.1 SLPs from RT 001 and RT 027 induce IL-8 after 8 hours in Hek 
TLR4/MD2/CD14 cells, however SLPs from RT 001 fail to induce RANTES. Hek 
TLR4/MD2/CD14 cells were plated at 2x10
6
 cells/mL and allowed to adhere for 18 
hours to approximately 60% confluency. Cells were then stimulated with 100 ng/mL of 
LPS or 20 µg/mL SLPs from RT 001 and RT 027 for 8 hours. Supernatants were 
recovered and levels of human A) IL-8 and B) RANTES were measured using ELISA. 
The results show the mean (± SEM) measured in triplicate, one-way ANOVA followed 
by Newman-Keuls analysis was used to determine if differences were significantly 
different compared to the control, where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. The 
results are indicative of three independent experiments. 
A) 
B) 
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Figure 4.2.2 Starting RNA of 350 ng and a pre-amplification step are required for 
the detection of miRNA for use in this study. Hek TLR4/MD2/CD14 cells were 
plated at 2x10
6 
cells/mL and allowed to adhere for 18 hours to approximately 60% 
confluency. Cells were harvested and total RNA was extracted using miRVana™ 
miRNA isolation kit. 350 ng or 500 ng starting total RNA was converted to first strand 
cDNA using specific stem loop primers. The products were either added to PCR 
reaction mixes for the TLDA cards or used in a pre-amplification PCR reaction. 
Samples were added to each port on Applied Biosytems® Taqman® Low Density 
Array (TLDA) Human miRNA cards, pool A and pool B. The cards were sealed and ran 
on the Applied Biosystems 7900HT Fast Real Time PCR Machine. Amplification graph 
showing the ∆Rn V’s cycle A) 350 ng starting total RNA without pre-amplification B) 
500 ng starting total RNA without pre-amplification C) 350 ng starting total RNA with 
pre-amplification.  
A) 
B) 
C) 
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Figure 4.2.3. Overall Ct values follow normal distribution in miRNA profiling 
study with pool A & B TLDA cards. Hek TLR4/MD2/CD14 cells from three 
biological replicates were plated at 2x10
6
 cells/mL and allowed to adhere for 18 hours 
to approximately 60% confluency. Cells were stimulated with 100 ng/mL LPS or 20 
µg/mL SLPs from RT 001 for 8 hours. Cells were harvested and total RNA was 
extracted using miRVana™ miRNA isolation kit. 350 ng starting total RNA was 
converted to first strand cDNA using specific stem loop primers. The products were 
used in a pre-amplification PCR reaction. Samples were added to PCR reaction mixes 
and added to each well on Applied Biosytems® Taqman® Low Density Array (TLDA) 
Human miRNA cards, pool A and pool B. The cards were sealed and ran on the Applied 
Biosystems 7900HT Fast Real Time PCR Machine. The SDS files were exported and 
data from pool A and pool B cards were analysed using ExpressionSuite software 
v1.0.3. Box plot showing Ct distribution for each treated group from three biological 
replicates per group. The box contains the middle 50% of the data, the black horizontal 
line indicates the median Ct value and the black dot denotes the mean Ct. The ends of 
the vertical lines indicate the minimum and maximum Ct values and outliers are the 
points outside the ends of the whiskers.  
  
 125  
Table 4.2.1 qPCR analysis detected 254 miRNAs in Hek TLR4/MD2/CD14 cells 
from the 756 miRNAs analysed using the TLDA pool A & B cards. Hek 
TLR4/MD2/CD14 cells from three biological replicates were plated at 2x10
6 
cells/mL 
and allowed to adhere for 18 hours to approximately 60% confluency. Cells were 
stimulated with 100 ng/mL LPS or 20 µg/mL SLPs from RT 001 for 8 hours. Cells were 
harvested and total RNA was extracted using miRVana™ miRNA isolation kit. 350 ng 
starting total RNA was converted to first strand cDNA, the products of which were used 
in a pre-amplification PCR reaction. Samples were added to PCR reaction mixes and 
added to each well on Applied Biosytems® Taqman® Low Density Array (TLDA) 
Human miRNA cards, pool A and pool B. The cards were sealed and ran on the Applied 
Biosystems 7900HT Fast Real Time PCR Machine. The SDS files were exported and 
data from pool A and pool B cards analysed using ExpressionSuite software v1.0.3. The 
max Ct was set to 37.0 with a threshold of 0.1 and the reference group was set to the 
control cell group. Global normalisation was carried and relative gene expression values 
were calculated. The Benjamini-Hochberg false discovery rate was used to adjust p-
values and a student’s t-test was applied were values of p≤ 0.05 were considered 
statistically significant compared with the control group. 
Group Name Target Name RQ P-Value 
CTL dme-miR-7 1.0 1 
LPS dme-miR-7 0.7 0.586 
RT 001 dme-miR-7 0.8 0.62 
CTL hsa-let-7a 1.0 1 
LPS hsa-let-7a 0.7 0.321 
RT 001 hsa-let-7a 0.6 0.186 
CTL hsa-let-7b 1.0 1 
LPS hsa-let-7b 1.2 0.051 
RT 001 hsa-let-7b 0.9 0.732 
CTL hsa-let-7c 1.0 1 
LPS hsa-let-7c 0.6 0.142 
RT 001 hsa-let-7c 1.3 0.303 
CTL hsa-let-7d 1.0 1 
LPS hsa-let-7d 1.1 0.956 
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RT 001 hsa-let-7d 1.1 0.799 
CTL hsa-let-7e 1.0 1 
LPS hsa-let-7e 0.7 0.279 
RT 001 hsa-let-7e 0.7 0.432 
CTL hsa-let-7e# 1.0 1 
LPS hsa-let-7e# 1.2 0.533 
RT 001 hsa-let-7e# 0.9 0.895 
CTL hsa-miR-100 1.0 1 
LPS hsa-miR-100 0.8 0.621 
RT 001 hsa-miR-100 0.5 0.161 
CTL hsa-miR-103 1.0 1 
LPS hsa-miR-103 0.7 0.309 
RT 001 hsa-miR-103 0.6 0.254 
CTL hsa-miR-106a 1.0 1 
LPS hsa-miR-106a 0.9 0.516 
RT 001 hsa-miR-106a 1.2 0.634 
CTL hsa-miR-106b 1.0 1 
LPS hsa-miR-106b 0.7 0.306 
RT 001 hsa-miR-106b 1.0 0.713 
CTL hsa-miR-107 1.0 1 
LPS hsa-miR-107 0.4 0.167 
RT 001 hsa-miR-107 1.0 0.765 
CTL hsa-miR-10a 1.0 1 
LPS hsa-miR-10a 0.8 0.457 
RT 001 hsa-miR-10a 0.4 0.405 
CTL hsa-miR-10a# 1.0 1 
LPS hsa-miR-10a# 0.8 0.306 
RT 001 hsa-miR-10a# 1.1 0.689 
CTL hsa-miR-10b 1.0 1 
LPS hsa-miR-10b 0.5 0.153 
RT 001 hsa-miR-10b 0.8 0.468 
CTL hsa-miR-10b# 1.0 1 
LPS hsa-miR-10b# 1.9 0.263 
RT 001 hsa-miR-10b# 1.5 0.237 
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CTL hsa-miR-1180 1.0 1 
LPS hsa-miR-1180 0.9 0.311 
RT 001 hsa-miR-1180 1.0 0.824 
CTL hsa-miR-1201 1.0 1 
LPS hsa-miR-1201 0.8 0.685 
RT 001 hsa-miR-1201 1.1 0.453 
CTL hsa-miR-1208 1.0 1 
LPS hsa-miR-1208 0.6 0.091 
RT 001 hsa-miR-1208 0.6 0.098 
CTL hsa-miR-1225-3p 1.0 1 
LPS hsa-miR-1225-3p 0.3 0.133 
RT 001 hsa-miR-1225-3p 0.3 0.199 
CTL hsa-miR-1226# 1.0 1 
LPS hsa-miR-1226# 1.1 0.782 
RT 001 hsa-miR-1226# 1.2 0.443 
CTL hsa-miR-1227 1.0 1 
LPS hsa-miR-1227 0.7 0.308 
RT 001 hsa-miR-1227 1.0 0.784 
CTL hsa-miR-1233 1.0 1 
LPS hsa-miR-1233 0.7 0.741 
RT 001 hsa-miR-1233 1.3 0.282 
CTL hsa-miR-1243 1.0 1 
LPS hsa-miR-1243 1.0 0.93 
RT 001 hsa-miR-1243 0.4 0.144 
CTL hsa-miR-1248 1.0 1 
LPS hsa-miR-1248 1.1 0.703 
RT 001 hsa-miR-1248 1.3 0.315 
CTL hsa-miR-1254 1.0 1 
LPS hsa-miR-1254 0.9 0.624 
RT 001 hsa-miR-1254 1.0 0.912 
CTL hsa-miR-1255a 1.0 1 
LPS hsa-miR-1255a 1.2 0.968 
RT 001 hsa-miR-1255a 0.9 0.621 
CTL hsa-miR-1255b 1.0 1 
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LPS hsa-miR-1255b 0.7 0.357 
RT 001 hsa-miR-1255b 0.5 0.225 
CTL hsa-miR-125a-3p 1.0 1 
LPS hsa-miR-125a-3p 0.5 0.385 
RT 001 hsa-miR-125a-3p 1.1 0.89 
CTL hsa-miR-125b 1.0 1 
LPS hsa-miR-125b 0.5 0.233 
RT 001 hsa-miR-125b 0.6 0.439 
CTL hsa-miR-126 1.0 1 
LPS hsa-miR-126 0.7 0.49 
RT 001 hsa-miR-126 0.8 0.421 
CTL hsa-miR-126# 1.0 1 
LPS hsa-miR-126# 0.7 0.367 
RT 001 hsa-miR-126# 1.5 0.3 
CTL hsa-miR-1260 1.0 1 
LPS hsa-miR-1260 1.2 0.449 
RT 001 hsa-miR-1260 0.8 0.266 
CTL hsa-miR-1262 1.0 1 
LPS hsa-miR-1262 1.2 0.913 
RT 001 hsa-miR-1262 1.1 0.891 
CTL hsa-miR-1269 1.0 1 
LPS hsa-miR-1269 0.7 0.314 
RT 001 hsa-miR-1269 1.0 0.976 
CTL hsa-miR-1271 1.0 1 
LPS hsa-miR-1271 0.3 0.169 
RT 001 hsa-miR-1271 1.0 0.877 
CTL hsa-miR-1274a 1.0 1 
LPS hsa-miR-1274a 1.2 0.191 
RT 001 hsa-miR-1274a 1.1 0.338 
CTL hsa-miR-1274b 1.0 1 
LPS hsa-miR-1274b 1.2 0.714 
RT 001 hsa-miR-1274b 1.1 0.997 
CTL hsa-miR-1275 1.0 1 
LPS hsa-miR-1275 0.6 0.197 
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RT 001 hsa-miR-1275 0.6 0.157 
CTL hsa-miR-1276 1.0 1 
LPS hsa-miR-1276 1.2 0.69 
RT 001 hsa-miR-1276 2.0 0.149 
CTL hsa-miR-1282 1.0 1 
LPS hsa-miR-1282 0.9 0.599 
RT 001 hsa-miR-1282 1.1 0.997 
CTL hsa-miR-1285 1.0 1 
LPS hsa-miR-1285 0.2 0.065 
RT 001 hsa-miR-1285 0.9 0.887 
CTL hsa-miR-128a 1.0 1 
LPS hsa-miR-128a 0.6 0.084 
RT 001 hsa-miR-128a 0.9 0.788 
CTL hsa-miR-1290 1.0 1 
LPS hsa-miR-1290 1.1 0.64 
RT 001 hsa-miR-1290 0.9 0.832 
CTL hsa-miR-1291 1.0 1 
LPS hsa-miR-1291 1.3 0.305 
RT 001 hsa-miR-1291 0.7 0.258 
CTL hsa-miR-1292 1.0 1 
LPS hsa-miR-1292 1.13 0.330 
RT 001 hsa-miR-1292 1.4 0.03 
CTL hsa-miR-1293 1.0 1 
LPS hsa-miR-1293 1.17 0.413 
RT 001 hsa-miR-1293 0.20 0.002 
CTL hsa-miR-1296 1.0 1 
LPS hsa-miR-1296 1.1 0.866 
RT 001 hsa-miR-1296 1.1 0.68 
CTL hsa-miR-1303 1.0 1 
LPS hsa-miR-1303 0.7 0.343 
RT 001 hsa-miR-1303 1.0 0.793 
CTL hsa-miR-130b 1.0 1 
LPS hsa-miR-130b 0.8 0.531 
RT 001 hsa-miR-130b 1.1 0.735 
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CTL hsa-miR-130b# 1.0 1 
LPS hsa-miR-130b# 0.8 0.51 
RT 001 hsa-miR-130b# 0.7 0.31 
CTL hsa-miR-132 1.0 1 
LPS hsa-miR-132 1.0 0.902 
RT 001 hsa-miR-132 0.9 0.673 
CTL hsa-miR-132# 1.0 1 
LPS hsa-miR-132# 1.2 0.848 
RT 001 hsa-miR-132# 1.0 0.896 
CTL hsa-miR-144# 1.0 1 
LPS hsa-miR-144# 0.8 0.522 
RT 001 hsa-miR-144# 1.0 0.672 
CTL hsa-miR-145 1.0 1 
LPS hsa-miR-145 1.3 0.182 
RT 001 hsa-miR-145 0.5 0.268 
CTL hsa-miR-146b 1.0 1 
LPS hsa-miR-146b 0.6 0.34 
RT 001 hsa-miR-146b 0.2 0.092 
CTL hsa-miR-148a 1.0 1 
LPS hsa-miR-148a 1.6 0.54 
RT 001 hsa-miR-148a 0.9 0.709 
CTL hsa-miR-148a# 1.0 1 
LPS hsa-miR-148a# 0.5 0.065 
RT 001 hsa-miR-148a# 0.7 0.176 
CTL hsa-miR-148b 1.0 1 
LPS hsa-miR-148b 1.61 0.416 
RT 001 hsa-miR-148b 4.0 0.009 
CTL hsa-miR-148b# 1.0 1 
LPS hsa-miR-148b# 1.4 0.212 
RT 001 hsa-miR-148b# 1.0 0.935 
CTL hsa-miR-149 1.0 1 
LPS hsa-miR-149 1.1 0.61 
RT 001 hsa-miR-149 1.3 0.282 
CTL hsa-miR-151-3p 1.0 1 
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LPS hsa-miR-151-3p 1.5 0.716 
RT 001 hsa-miR-151-3p 0.3 0.214 
CTL hsa-miR-151-5p 1.0 1 
LPS hsa-miR-151-5p 0.9 0.948 
RT 001 hsa-miR-151-5p 1.7 0.794 
CTL hsa-miR-152 1.0 1 
LPS hsa-miR-152 1.53 0.818 
RT 001 hsa-miR-152 2.46 0.05 
CTL hsa-miR-155 1.0 1 
LPS hsa-miR-155 1.0 0.133 
RT 001 hsa-miR-155 1.0 0.202 
CTL hsa-miR-15a 1.0 1 
LPS hsa-miR-15a# 1.0 0.876 
RT 001 hsa-miR-15a# 0.8 0.333 
CTL hsa-miR-15b 1.0 1 
LPS hsa-miR-15b 0.7 0.075 
RT 001 hsa-miR-15b 0.9 0.496 
CTL hsa-miR-16 1.0 1 
LPS hsa-miR-16 0.7 0.353 
RT 001 hsa-miR-16 0.8 0.527 
CTL hsa-miR-16-1# 1.0 1 
LPS hsa-miR-16-1# 1.1 0.564 
RT 001 hsa-miR-16-1# 0.9 0.614 
CTL hsa-miR-17 1.0 1 
LPS hsa-miR-17 0.6 0.282 
RT 001 hsa-miR-17 0.7 0.368 
CTL hsa-miR-17# 1.0 1 
LPS hsa-miR-17# 1.2 0.747 
RT 001 hsa-miR-17# 1.5 0.308 
CTL hsa-miR-181a 1.0 1 
LPS hsa-miR-181a 1.1 0.308 
RT 001 hsa-miR-181a 0.6 0.096 
CTL hsa-miR-181a-2# 1.0 1 
LPS hsa-miR-181a-2# 0.8 0.795 
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RT 001 hsa-miR-181a-2# 0.9 0.775 
CTL hsa-miR-182 1.0 1 
LPS hsa-miR-182 0.9 0.42 
RT 001 hsa-miR-182 1.2 0.852 
CTL hsa-miR-1825 1.0 1 
LPS hsa-miR-1825 3.1 0.419 
RT 001 hsa-miR-1825 0.9 0.992 
CTL hsa-miR-183 1.0 1 
LPS hsa-miR-183 1.7 0.85 
RT 001 hsa-miR-183 0.7 0.193 
CTL hsa-miR-183# 1.0 1 
LPS hsa-miR-183# 1.0 0.82 
RT 001 hsa-miR-183# 1.1 0.651 
CTL hsa-miR-186 1.0 1 
LPS hsa-miR-186 0.9 0.413 
RT 001 hsa-miR-186 1.4 0.153 
CTL hsa-miR-18a 1.0 1 
LPS hsa-miR-18a 0.6 0.23 
RT 001 hsa-miR-18a 0.9 0.812 
CTL hsa-miR-18a# 1.0 1 
LPS hsa-miR-18a# 0.9 0.47 
RT 001 hsa-miR-18a# 1.3 0.237 
CTL hsa-miR-18b 1.0 1 
LPS hsa-miR-18b 0.3 0.08 
RT 001 hsa-miR-18b 1.5 0.263 
CTL hsa-miR-190b 1.0 1 
LPS hsa-miR-190b 1.2 0.563 
RT 001 hsa-miR-190b 2.2 0.210 
CTL hsa-miR-191 1.0 1 
LPS hsa-miR-191 0.7 0.736 
RT 001 hsa-miR-191 0.6 0.105 
CTL hsa-miR-191# 1.0 1 
LPS hsa-miR-191# 0.9 0.897 
RT 001 hsa-miR-191# 1.2 0.838 
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CTL hsa-miR-192 1.0 1 
LPS hsa-miR-192 1.0 0.745 
RT 001 hsa-miR-192 0.7 0.22 
CTL hsa-miR-192# 1.0 1 
LPS hsa-miR-192# 0.8 0.347 
RT 001 hsa-miR-192# 1.2 0.377 
CTL hsa-miR-193a-3p 1.0 1 
LPS hsa-miR-193a-3p 0.2 0.613 
RT 001 hsa-miR-193a-3p 0.6 0.13 
CTL hsa-miR-193a-5p 1.0 1 
LPS hsa-miR-193a-5p 1.2 0.832 
RT 001 hsa-miR-193a-5p 0.7 0.413 
CTL hsa-miR-193b 1.0 1 
LPS hsa-miR-193b 0.7 0.287 
RT 001 hsa-miR-193b 0.6 0.217 
CTL hsa-miR-193b# 1.0 1 
LPS hsa-miR-193b# 1.0 0.818 
RT 001 hsa-miR-193b# 1.6 0.292 
CTL hsa-miR-194 1.0 1 
LPS hsa-miR-194 0.6 0.645 
RT 001 hsa-miR-194 1.4 0.332 
CTL hsa-miR-196b 1.0 1 
LPS hsa-miR-196b 0.4 0.055 
RT 001 hsa-miR-196b 1.0 0.843 
CTL hsa-miR-197 1.0 1 
LPS hsa-miR-197 0.7 0.097 
RT 001 hsa-miR-197 0.7 0.141 
CTL hsa-miR-199a 1.0 1 
LPS hsa-miR-199a 1.3 0.417 
RT 001 hsa-miR-199a 2.6 0.177 
CTL hsa-miR-19a 1.0 1 
LPS hsa-miR-19a 1.9 0.596 
RT 001 hsa-miR-19a 1.1 0.692 
CTL hsa-miR-19a# 1.0 1 
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LPS hsa-miR-19a# 6.0 0.114 
RT 001 hsa-miR-19a# 2.1 0.253 
CTL hsa-miR-19b 1.0 1 
LPS hsa-miR-19b 1.0 0.927 
RT 001 hsa-miR-19b 0.7 0.281 
CTL hsa-miR-19b-1# 1.0 1 
LPS hsa-miR-19b-1# 0.1 0.266 
RT 001 hsa-miR-19b-1# 0.8 0.511 
CTL hsa-miR-200c 1.0 1 
LPS hsa-miR-200c 1.1 0.785 
RT 001 hsa-miR-200c 0.9 0.813 
CTL hsa-miR-20a 1.0 1 
LPS hsa-miR-20a 0.6 0.716 
RT 001 hsa-miR-20a 2.0 0.423 
CTL hsa-miR-20a# 1.0 1 
LPS hsa-miR-20a# 0.7 0.305 
RT 001 hsa-miR-20a# 0.8 0.337 
CTL hsa-miR-20b 1.0 1 
LPS hsa-miR-20b 0.8 0.713 
RT 001 hsa-miR-20b 0.9 0.816 
CTL hsa-miR-21 1.0 1 
LPS hsa-miR-21 0.3 0.205 
RT 001 hsa-miR-21 0.5 0.259 
CTL hsa-miR-21# 1.0 1 
LPS hsa-miR-21# 0.3 0.504 
RT 001 hsa-miR-21# 0.9 0.521 
CTL hsa-miR-210 1.0 1 
LPS hsa-miR-210 0.3 0.104 
RT 001 hsa-miR-210 0.7 0.157 
CTL hsa-miR-213 1.0 1 
LPS hsa-miR-213 0.8 0.456 
RT 001 hsa-miR-213 0.8 0.306 
CTL hsa-miR-215 1.0 1 
LPS hsa-miR-215 1.7 0.923 
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RT 001 hsa-miR-215 2.0 0.048 
CTL hsa-miR-218 1.0 1 
LPS hsa-miR-218 0.9 0.3 
RT 001 hsa-miR-218 1.1 0.657 
CTL hsa-miR-22# 1.0 1 
LPS hsa-miR-22# 0.7 0.468 
RT 001 hsa-miR-22# 1.0 0.976 
CTL hsa-miR-221 1.0 1 
LPS hsa-miR-221 0.7 0.285 
RT 001 hsa-miR-221 0.8 0.553 
CTL hsa-miR-222 1.0 1 
LPS hsa-miR-222 1.0 0.834 
RT 001 hsa-miR-222 0.9 0.913 
CTL hsa-miR-222# 1.0 1 
LPS hsa-miR-222# 0.9 0.737 
RT 001 hsa-miR-222# 1.4 0.67 
CTL hsa-miR-23b 1.0 1 
LPS hsa-miR-23b 0.5 0.589 
RT 001 hsa-miR-23b 0.8 0.503 
CTL hsa-miR-24 1.0 1 
LPS hsa-miR-24 1.53 0.876 
RT 001 hsa-miR-24 1.4 0.023 
CTL hsa-miR-24-2# 1.0 1 
LPS hsa-miR-24-2# 1.0 0.861 
RT 001 hsa-miR-24-2# 2.3 0.199 
CTL hsa-miR-25 1.0 1 
LPS hsa-miR-25 0.5 0.072 
RT 001 hsa-miR-25 0.6 0.12 
CTL hsa-miR-25# 1.0 1 
LPS hsa-miR-25# 0.9 0.696 
RT 001 hsa-miR-25# 1.0 0.813 
CTL hsa-miR-26a 1.0 1 
LPS hsa-miR-26a 1.1 0.3 
RT 001 hsa-miR-26a 1.2 0.521 
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CTL hsa-miR-26a-1# 1.0 1 
LPS hsa-miR-26a-1# 1.2 0.521 
RT 001 hsa-miR-26a-1# 0.8 0.313 
CTL hsa-miR-26a-2# 1.0 1 
LPS hsa-miR-26a-2# 0.7 0.685 
RT 001 hsa-miR-26a-2# 1.2 0.811 
CTL hsa-miR-26b 1.0 1 
LPS hsa-miR-26b 0.7 0.305 
RT 001 hsa-miR-26b 0.6 0.19 
CTL hsa-miR-26b# 1.0 1 
LPS hsa-miR-26b# 1.2 0.552 
RT 001 hsa-miR-26b# 0.9 0.786 
CTL hsa-miR-27a 1.0 1 
LPS hsa-miR-27a 0.5 0.226 
RT 001 hsa-miR-27a 0.9 0.725 
CTL hsa-miR-27a# 1.0 1 
LPS hsa-miR-27a# 1.3 0.151 
RT 001 hsa-miR-27a# 1.1 0.823 
CTL hsa-miR-27b 1.0 1 
LPS hsa-miR-27b 0.6 0.052 
RT 001 hsa-miR-27b 0.9 0.636 
CTL hsa-miR-27b# 1.0 1 
LPS hsa-miR-27b# 1.7 0.3 
RT 001 hsa-miR-27b# 0.9 0.647 
CTL hsa-miR-28 1.0 1 
LPS hsa-miR-28 0.5 0.055 
RT 001 hsa-miR-28 0.5 0.059 
CTL hsa-miR-28-3p 1.0 1 
LPS hsa-miR-28-3p 1.1 0.868 
RT 001 hsa-miR-28-3p 0.9 0.73 
CTL hsa-miR-29a 1.0 1 
LPS hsa-miR-29a 0.8 0.979 
RT 001 hsa-miR-29a 0.7 0.285 
CTL hsa-miR-29a# 1.0 1 
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LPS hsa-miR-29a# 0.6 0.346 
RT 001 hsa-miR-29a# 0.9 0.746 
CTL hsa-miR-29b 1.0 1 
LPS hsa-miR-29b 1.3 0.3 
RT 001 hsa-miR-29b 2.2 0.49 
CTL hsa-miR-29b-1# 1.0 1 
LPS hsa-miR-29b-1# 0.3 0.218 
RT 001 hsa-miR-29b-1# 0.8 0.3 
CTL hsa-miR-29b-2# 1.0 1 
LPS hsa-miR-29b-2# 1.2 0.547 
RT 001 hsa-miR-29b-2# 1.4 0.451 
CTL hsa-miR-29c 1.0 1 
LPS hsa-miR-29c 0.4 0.3 
RT 001 hsa-miR-29c 2.1 0.145 
CTL hsa-miR-301 1.0 1 
LPS hsa-miR-301 1.4 0.926 
RT 001 hsa-miR-301 0.4 0.129 
CTL hsa-miR-301b 1.0 1 
LPS hsa-miR-301b 0.4 0.138 
RT 001 hsa-miR-301b 0.6 0.297 
CTL hsa-miR-302a 1.0 1 
LPS hsa-miR-302a 0.1 0.207 
RT 001 hsa-miR-302a 0.0 0.191 
CTL hsa-miR-302c 1.0 1 
LPS hsa-miR-302c 2.68 0.028 
RT 001 hsa-miR-302c 1.53 0.139 
CTL hsa-miR-30a-3p 1.0 1 
LPS hsa-miR-30a-3p 0.8 0.3 
RT 001 hsa-miR-30a-3p 1.2 0.488 
CTL hsa-miR-30a-5p 1.0 1 
LPS hsa-miR-30a-5p 0.7 0.321 
RT 001 hsa-miR-30a-5p 0.9 0.817 
CTL hsa-miR-30b 1.0 1 
LPS hsa-miR-30b 1.0 0.926 
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RT 001 hsa-miR-30b 0.8 0.25 
CTL hsa-miR-30c 1.0 1 
LPS hsa-miR-30c 0.6 0.082 
RT 001 hsa-miR-30c 0.7 0.188 
CTL hsa-miR-30d 1.0 1 
LPS hsa-miR-30d 1.3 0.926 
RT 001 hsa-miR-30d 1.3 0.323 
CTL hsa-miR-30d# 1.0 1 
LPS hsa-miR-30d# 0.6 0.319 
RT 001 hsa-miR-30d# 0.9 0.727 
CTL hsa-miR-30e-3p 1.0 1 
LPS hsa-miR-30e-3p 0.8 0.236 
RT 001 hsa-miR-30e-3p 1.2 0.216 
CTL hsa-miR-31 1.0 1 
LPS hsa-miR-31 0.8 0.926 
RT 001 hsa-miR-31 0.8 0.161 
CTL hsa-miR-31# 1.0 1 
LPS hsa-miR-31# 0.8 0.405 
RT 001 hsa-miR-31# 0.8 0.321 
CTL hsa-miR-320 1.0 1 
LPS hsa-miR-320 0.8 0.245 
RT 001 hsa-miR-320 1.1 0.626 
CTL hsa-miR-320b 1.0 1 
LPS hsa-miR-320b 0.6 0.254 
RT 001 hsa-miR-320b 0.6 0.301 
CTL hsa-miR-324-3p 1.0 1 
LPS hsa-miR-324-3p 0.9 0.913 
RT 001 hsa-miR-324-3p 1.1 0.71 
CTL hsa-miR-324-5p 1.0 1 
LPS hsa-miR-324-5p 0.6 0.137 
RT 001 hsa-miR-324-5p 0.9 0.713 
CTL hsa-miR-328 1.0 1 
LPS hsa-miR-328 0.7 0.243 
RT 001 hsa-miR-328 0.8 0.16 
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CTL hsa-miR-335# 1.0 1 
LPS hsa-miR-335# 4.1 0.241 
RT 001 hsa-miR-335# 7.8 0.103 
CTL hsa-miR-338-5p 1.0 1 
LPS hsa-miR-338-5p 1.0 0.783 
RT 001 hsa-miR-338-5p 1.8 0.26 
CTL hsa-miR-339-3p 1.0 1 
LPS hsa-miR-339-3p 0.9 0.962 
RT 001 hsa-miR-339-3p 1.0 0.996 
CTL hsa-miR-339-5p 1.0 1 
LPS hsa-miR-339-5p 3.3 0.86 
RT 001 hsa-miR-339-5p 5.0 0.006 
CTL hsa-miR-33a 1.0 1 
LPS hsa-miR-33a 10.7 0.310 
RT 001 hsa-miR-33a 0.2 0.248 
CTL hsa-miR-340 1.0 1 
LPS hsa-miR-340 0.3 0.180 
RT 001 hsa-miR-340 0.4 0.052 
CTL hsa-miR-340# 1.0 1 
LPS hsa-miR-340# 1.3 0.252 
RT 001 hsa-miR-340# 1.2 0.328 
CTL hsa-miR-342-3p 1.0 1 
LPS hsa-miR-342-3p 0.7 0.091 
RT 001 hsa-miR-342-3p 0.8 0.203 
CTL hsa-miR-345 1.0 1 
LPS hsa-miR-345 1.2 0.585 
RT 001 hsa-miR-345 1.1 0.795 
CTL hsa-miR-34a 1.0 1 
LPS hsa-miR-34a 0.4 0.12 
RT 001 hsa-miR-34a 0.6 0.193 
CTL hsa-miR-34a# 1.0 1 
LPS hsa-miR-34a# 1.2 0.595 
RT 001 hsa-miR-34a# 0.8 0.571 
CTL hsa-miR-34b 1.0 1 
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LPS hsa-miR-34b 0.2 0.178 
RT 001 hsa-miR-34b 0.5 0.388 
CTL hsa-miR-34c 1.0 1 
LPS hsa-miR-34c 1.2 0.938 
RT 001 hsa-miR-34c 1.5 0.851 
CTL hsa-miR-365 1.0 1 
LPS hsa-miR-365 0.5 0.073 
RT 001 hsa-miR-365 0.8 0.526 
CTL hsa-miR-374 1.0 1 
LPS hsa-miR-374 2.0 0.03 
RT 001 hsa-miR-374 2.9 0.05 
CTL hsa-miR-374b# 1.0 1 
LPS hsa-miR-374b# 1.7 0.545 
RT 001 hsa-miR-374b# 0.9 0.656 
CTL hsa-miR-375 1.0 1 
LPS hsa-miR-375 0.6 0.173 
RT 001 hsa-miR-375 0.5 0.213 
CTL hsa-miR-378 1.0 1 
LPS hsa-miR-378 3.0 0.938 
RT 001 hsa-miR-378 0.5 0.353 
CTL hsa-miR-383 1.0 1 
LPS hsa-miR-383 0.8 0.355 
RT 001 hsa-miR-383 0.9 0.638 
CTL hsa-miR-409-3p 1.0 1 
LPS hsa-miR-409-3p 1.8 0.208 
RT 001 hsa-miR-409-3p 4.6 0.938 
CTL hsa-miR-422a 1.0 1 
LPS hsa-miR-422a 0.69 0.08 
RT 001 hsa-miR-422a 0.2 0.010 
CTL hsa-miR-423-5p 1.0 1 
LPS hsa-miR-423-5p 0.8 0.406 
RT 001 hsa-miR-423-5p 0.7 0.201 
CTL hsa-miR-424# 1.0 1 
LPS hsa-miR-424# 1.0 0.895 
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RT 001 hsa-miR-424# 1.1 0.651 
CTL hsa-miR-425# 1.0 1 
LPS hsa-miR-425# 0.8 0.338 
RT 001 hsa-miR-425# 1.0 0.904 
CTL hsa-miR-425-5p 1.0 1 
LPS hsa-miR-425-5p 0.8 0.571 
RT 001 hsa-miR-425-5p 0.8 0.341 
CTL hsa-miR-432# 1.0 1 
LPS hsa-miR-432# 0.95 0.818 
RT 001 hsa-miR-432# 2.27 0.043 
CTL hsa-miR-454 1.0 1 
LPS hsa-miR-454 1.2 0.975 
RT 001 hsa-miR-454 0.2 0.092 
CTL hsa-miR-454# 1.0 1 
LPS hsa-miR-454# 1.2 0.588 
RT 001 hsa-miR-454# 1.1 0.68 
CTL hsa-miR-484 1.0 1 
LPS hsa-miR-484 0.8 0.248 
RT 001 hsa-miR-484 0.8 0.395 
CTL hsa-miR-497 1.0 1 
LPS hsa-miR-497 0.8 0.975 
RT 001 hsa-miR-497 0.8 0.445 
CTL hsa-miR-500 1.0 1 
LPS hsa-miR-500 0.9 0.697 
RT 001 hsa-miR-500 0.7 0.454 
CTL hsa-miR-501 1.0 1 
LPS hsa-miR-501 1.2 0.937 
RT 001 hsa-miR-501 0.9 0.645 
CTL hsa-miR-502-3p 1.0 1 
LPS hsa-miR-502-3p 0.6 0.502 
RT 001 hsa-miR-502-3p 0.5 0.394 
CTL hsa-miR-505# 1.0 1 
LPS hsa-miR-505# 0.9 0.531 
RT 001 hsa-miR-505# 1.0 0.977 
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CTL hsa-miR-516-3p 1.0 1 
LPS hsa-miR-516-3p 32.4 0.937 
RT 001 hsa-miR-516-3p 1.0 0.773 
CTL hsa-miR-517b 1.0 1 
LPS hsa-miR-517b 0.4 0.937 
RT 001 hsa-miR-517b 0.5 0.056 
CTL hsa-miR-518f 1.0 1 
LPS hsa-miR-518f 3.9 0.937 
RT 001 hsa-miR-518f 1.3 0.807 
CTL hsa-miR-520c-3p 1.0 1 
LPS hsa-miR-520c-3p 0.9 0.902 
RT 001 hsa-miR-520c-3p 1.0 0.75 
CTL hsa-miR-520d-3p 1.0 1 
LPS hsa-miR-520d-3p 4.6 0.937 
RT 001 hsa-miR-520d-3p 1.2 0.61 
CTL hsa-miR-532 1.0 1 
LPS hsa-miR-532 0.8 0.734 
RT 001 hsa-miR-532 0.9 0.497 
CTL hsa-miR-532-3p 1.0 1 
LPS hsa-miR-532-3p 0.5 0.288 
RT 001 hsa-miR-532-3p 0.6 0.338 
CTL hsa-miR-543 1.0 1 
LPS hsa-miR-543 2.6 0.010 
RT 001 hsa-miR-543 2.1 0.937 
CTL hsa-miR-545# 1.0 1 
LPS hsa-miR-545# 3.5 0.231 
RT 001 hsa-miR-545# 0.8 0.532 
CTL hsa-miR-548H 1.0 1 
LPS hsa-miR-548H 1.2 0.426 
RT 001 hsa-miR-548H 0.8 0.691 
CTL hsa-miR-548J 1.0 1 
LPS hsa-miR-548J 1.4 0.937 
RT 001 hsa-miR-548J 2.6 0.077 
CTL hsa-miR-548K 1.0 1 
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LPS hsa-miR-548K 0.9 0.937 
RT 001 hsa-miR-548K 1.5 0.418 
CTL hsa-miR-548L 1.0 1 
LPS hsa-miR-548L 1.2 0.937 
RT 001 hsa-miR-548L 0.4 0.056 
CTL hsa-miR-550 1.0 1 
LPS hsa-miR-550 0.9 0.912 
RT 001 hsa-miR-550 1.4 0.021 
CTL hsa-miR-551b# 1.0 1 
LPS hsa-miR-551b# 0.8 0.295 
RT 001 hsa-miR-551b# 1.0 0.811 
CTL hsa-miR-572 1.0 1 
LPS hsa-miR-572 2.3 0.190 
RT 001 hsa-miR-572 2.1 0.141 
CTL hsa-miR-574-3p 1.0 1 
LPS hsa-miR-574-3p 0.8 0.937 
RT 001 hsa-miR-574-3p 0.8 0.114 
CTL hsa-miR-577 1.0 1 
LPS hsa-miR-577 0.7 0.235 
RT 001 hsa-miR-577 0.9 0.657 
CTL hsa-miR-580 1.0 1 
LPS hsa-miR-580 0.7 0.156 
RT 001 hsa-miR-580 0.6 0.168 
CTL hsa-miR-586 1.0 1 
LPS hsa-miR-586 0.6 0.037 
RT 001 hsa-miR-586 0.6 0.143 
CTL hsa-miR-589 1.0 1 
LPS hsa-miR-589 1.9 0.255 
RT 001 hsa-miR-589 1.0 0.845 
CTL hsa-miR-590-3p 1.0 1 
LPS hsa-miR-590-3p 0.6 0.128 
RT 001 hsa-miR-590-3p 1.2 0.545 
CTL hsa-miR-590-5p 1.0 1 
LPS hsa-miR-590-5p 2.5 0.937 
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RT 001 hsa-miR-590-5p 2.0 0.015 
CTL hsa-miR-592 1.0 1 
LPS hsa-miR-592 0.9 0.798 
RT 001 hsa-miR-592 0.9 0.8 
CTL hsa-miR-597 1.0 1 
LPS hsa-miR-597 0.7 0.179 
RT 001 hsa-miR-597 0.9 0.876 
CTL hsa-miR-598 1.0 1 
LPS hsa-miR-598 0.7 0.057 
RT 001 hsa-miR-598 0.7 0.056 
CTL hsa-miR-605 1.0 1 
LPS hsa-miR-605 0.7 0.937 
RT 001 hsa-miR-605 0.5 0.078 
CTL hsa-miR-616 1.0 1 
LPS hsa-miR-616 0.8 0.391 
RT 001 hsa-miR-616 1.1 0.452 
CTL hsa-miR-624 1.0 1 
LPS hsa-miR-624 0.7 0.291 
RT 001 hsa-miR-624 0.4 0.178 
CTL hsa-miR-625# 1.0 1 
LPS hsa-miR-625# 0.8 0.294 
RT 001 hsa-miR-625# 1.1 0.766 
CTL hsa-miR-628-3p 1.0 1 
LPS hsa-miR-628-3p 3.4 0.075 
RT 001 hsa-miR-628-3p 0.7 0.515 
CTL hsa-miR-629 1.0 1 
LPS hsa-miR-629 0.6 0.578 
RT 001 hsa-miR-629 1.2 0.488 
CTL hsa-miR-638 1.0 1 
LPS hsa-miR-638 0.5 0.098 
RT 001 hsa-miR-638 1.0 0.775 
CTL hsa-miR-641 1.0 1 
LPS hsa-miR-641 0.9 0.685 
RT 001 hsa-miR-641 1.2 0.613 
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CTL hsa-miR-652 1.0 1 
LPS hsa-miR-652 0.8 0.937 
RT 001 hsa-miR-652 1.1 0.917 
CTL hsa-miR-660 1.0 1 
LPS hsa-miR-660 0.9 0.937 
RT 001 hsa-miR-660 0.9 0.956 
CTL hsa-miR-664 1.0 1 
LPS hsa-miR-664 1.2 0.513 
RT 001 hsa-miR-664 1.1 0.348 
CTL hsa-miR-708 1.0 1 
LPS hsa-miR-708 0.4 0.937 
RT 001 hsa-miR-708 0.8 0.394 
CTL hsa-miR-720 1.0 1 
LPS hsa-miR-720 1.3 0.214 
RT 001 hsa-miR-720 1.1 0.591 
CTL hsa-miR-744 1.0 1 
LPS hsa-miR-744 0.8 0.937 
RT 001 hsa-miR-744 0.8 0.187 
CTL hsa-miR-744# 1.0 1 
LPS hsa-miR-744# 0.7 0.188 
RT 001 hsa-miR-744# 0.8 0.449 
CTL hsa-miR-766 1.0 1 
LPS hsa-miR-766 0.8 0.428 
RT 001 hsa-miR-766 0.9 0.608 
CTL hsa-miR-769-3p 1.0 1 
LPS hsa-miR-769-3p 0.9 0.796 
RT 001 hsa-miR-769-3p 1.0 0.826 
CTL hsa-miR-769-5p 1.0 1 
LPS hsa-miR-769-5p 0.8 0.307 
RT 001 hsa-miR-769-5p 0.9 0.614 
CTL hsa-miR-872 1.0 1 
LPS hsa-miR-872 0.3 0.457 
RT 001 hsa-miR-872 0.7 0.487 
CTL hsa-miR-874 1.0 1 
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LPS hsa-miR-874 0.71 0.432 
RT 001 hsa-miR-874 0.58 0.032 
CTL hsa-miR-886-5p 1.0 1 
LPS hsa-miR-886-5p 0.9 0.937 
RT 001 hsa-miR-886-5p 0.8 0.19 
CTL hsa-miR-891a 1.0 1 
LPS hsa-miR-891a 1.4 0.937 
RT 001 hsa-miR-891a 0.7 0.451 
CTL hsa-miR-9# 1.0 1 
LPS hsa-miR-9# 0.8 0.455 
RT 001 hsa-miR-9# 0.9 0.795 
CTL hsa-miR-92a 1.0 1 
LPS hsa-miR-92a 0.6 0.937 
RT 001 hsa-miR-92a 0.6 0.119 
CTL hsa-miR-92a-1# 1.0 1 
LPS hsa-miR-92a-1# 1.3 0.165 
RT 001 hsa-miR-92a-1# 1.1 0.424 
CTL hsa-miR-93# 1.0 1 
LPS hsa-miR-93# 1.3 0.416 
RT 001 hsa-miR-93# 1.2 0.147 
CTL hsa-miR-935 1.0 1 
LPS hsa-miR-935 1.0 0.858 
RT 001 hsa-miR-935 1.0 0.945 
CTL hsa-miR-938 1.0 1 
LPS hsa-miR-938 1.2 0.487 
RT 001 hsa-miR-938 1.5 0.192 
CTL hsa-miR-942 1.0 1 
LPS hsa-miR-942 0.8 0.284 
RT 001 hsa-miR-942 1.2 0.389 
CTL hsa-miR-99a 1.0 1 
LPS hsa-miR-99a 0.7 0.180 
RT 001 hsa-miR-99a 1.5 0.053 
CTL hsa-miR-99b 1.0 1 
LPS hsa-miR-99b 0.3 0.351 
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RT 001 hsa-miR-99b 1.1 0.764 
CTL mmu-miR-129-3p 1.0 1 
LPS mmu-miR-129-3p 0.7 0.553 
RT 001 mmu-miR-129-3p 0.3 0.302 
CTL mmu-miR-140 1.0 1 
LPS mmu-miR-140 1.0 0.937 
RT 001 mmu-miR-140 0.8 0.497 
CTL rno-miR-29c# 1.0 1 
LPS rno-miR-29c# 1.0 0.883 
RT 001 rno-miR-29c# 1.1 0.937 
CTL rno-miR-7# 1.0 1 
LPS rno-miR-7# 1.6 0.180 
RT 001 rno-miR-7# 1.2 0.169 
CTL hsa-miR-1 1.0 1 
LPS hsa-miR-1 1.5 0.587 
RT 001 hsa-miR-1 1.2 0.436 
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Figure 4.2.4. Ct Scatter plot shows there are differences in miRNA profiles 
between Hek TLR4/MD2/CD14 cells stimulated with LPS and SLPs from RT 001. 
Hek TLR4/MD2/CD14 cells from three biological replicates were plated at 2x10
6 
cells/mL and allowed to adhere for 18 hours to approximately 60% confluency. Cells 
were stimulated with 100 ng/mL LPS or 20 µg/mL SLPs from RT 001 for 8 hours. Cells 
were harvested and total RNA was extracted using miRVana™ miRNA isolation kit. 
350 ng starting total RNA was converted to first strand cDNA using specific stem loop 
primers, the products of which were used in a pre-amplification PCR reaction. Samples 
were added to PCR reaction mixes and added to each well on Applied Biosytems® 
Taqman® Low Density Array (TLDA) Human miRNA cards, pool A and pool B. The 
cards were sealed and ran on the Applied Biosystems 7900HT Fast Real Time PCR 
Machine. The SDS files were exported and data from pool A and pool B cards analysed 
using ExpressionSuite software. The Ct scatter plot shows the relationship between A) 
CTL V’s LPS B) CTL V’s SLPs from RT 001 and C) LPS V’s SLPs from RT 001 for 
all miRNAs in the profiling study.  
A) 
C) 
B) 
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Figure 4.2.5. Volcano plot showing four miRNAs are significantly differentially 
regulated when Hek TLR4/MD2/CD14 cells were stimulated with LPS. Hek 
TLR4/MD2/CD14 cells from three biological replicates were plated at 2x10
6
 cells/mL 
and allowed to adhere for 18 hours to approximately 60% confluency. Cells were 
stimulated with 100 ng/mL LPS for 8 hours. Cells were harvested and total RNA was 
extracted using miRVana™ miRNA isolation kit. 350 ng starting total RNA was 
converted to first strand cDNA, the products of which were used in a pre-amplification 
PCR reaction. Samples were added to PCR reaction mixes and added to each well on 
pool A and pool B TLDA human miRNA cards. The cards were sealed and ran on the 
Applied Biosystems 7900HT Fast Real Time PCR Machine. The SDS files were 
exported and data from pool A and pool B cards analysed using ExpressionSuite 
software v1.0.3. The max Ct was set to 37.0 with a threshold of 0.1 and the reference 
group was set to the control cell group. Global normalisation was carried and relative 
gene expression calculated. The Benjamini-Hochberg false discovery rate was used to 
adjust p-values and a student’s t-test applied, values of p≤ 0.05 were considered 
statistically significant compared with the control group. The volcano plot displays -
log10 p-value Vs log2 fold change. The p-value and fold change boundaries were set at 
0.05 & 1.0. Targets above the horizontal line have statistically significant fold changes. 
The top left quadrant shows miRNAs targets that are down regulated while the top right 
quadrant shows miRNA targets that are up regulated. 
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Figure 4.2.6. Volcano plot showing 12 miRNAs were significantly differentially 
regulated when Hek TLR4/MD2/CD14 cells were stimulated with SLPs from RT 
001. Hek TLR4/MD2/CD14 cells from three biological replicates were plated at 2x10
6 
cells/mL and allowed to adhere for 18 hours to approximately 60% confluency. Cells 
were stimulated with 20 µg/mL SLPs from RT 001 for 8 hours. Cells were harvested 
and total RNA was extracted using miRVana™ miRNA isolation kit. 350 ng starting 
total RNA was converted to first strand cDNA, the products of which were used in a 
pre-amp PCR reaction. Samples were added to PCR reaction mixes and added to each 
well on pool A and pool B TLDA human miRNA cards. The cards were sealed and ran 
on the Applied Biosystems 7900HT Fast Real Time PCR Machine. The SDS files were 
exported and data from pool A and pool B cards analysed using ExpressionSuite 
software v1.0.3. The max Ct was set to 37.0 with a threshold of 0.1 and the reference 
group was set to the control cell group. Global normalisation was carried and relative 
gene expression calculated. The Benjamini-Hochberg false discovery rate was used to 
adjust p-values and a student’s t-test applied, values of p≤ 0.05 were considered 
statistically significant compared with the control group. The volcano plot displays -
log10 p-value Vs log2 fold change. The p-value and fold change boundaries were set at 
0.05 & 1.0. Targets above the horizontal line have statistically significant fold changes. 
The top left quadrant shows miRNAs targets that are down regulated while the top right 
quadrant shows miRNA targets that are up regulated. 
  
 151  
Table 4.2.2. Sixteen miRNAs have statistically significant fold changes when Hek 
TLR4/MD2/CD14 cells were stimulated with LPS and SLPs from RT 001. 
Summary of statistically significant miRNAs from Hek TLR4/MD2/CD14 cells 
stimulated with either LPS or SLPs from RT 001, their relative gene expression and p-
value. Data generated from pool A and pool B TLDA card analysis.  
miRNA RQ p-value Target 
miR-1292 1.4 0.03 RT 001 
miR-1293 0.2 0.002 RT 001 
miR-148b 4.0 0.004 RT 001 
miR-152 2.5 0.05 RT 001 
miR-215 2.0 0.05 RT 001 
miR-24 1.4 0.02 RT 001 
miR-302c 2.7 0.03 LPS 
miR-339 5.0 0.001 RT 001 
miR-374a 1.9 0.03 LPS 
miR-422 0.2 0.001 RT 001 
miR-432# 2.3 0.04 RT 001 
miR-543 2.6 0.01 LPS 
miR-550 1.4 0.02 RT 001 
miR-586 0.5 0.04 LPS 
miR-590-5p 2.0 0.02 RT 001 
miR-874 0.6 0.03 RT 001 
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Table 4.2.3. List of miRNAs to be included in custom TLDA cards based on a 
review of the literature and re-examination of the profiling study. We reviewed the 
literature and included miRNAs known to target; TLR receptors including TLR4, 
signalling proteins, transcription factors, cytokines and regulatory molecules. We also 
included miRNAs that are known to be induced by LPS and miRNAs induced during 
infections. We re-examined the profiling study to see if the miRNAs from the literature 
were present in the profiling study, most miRNAs were but just over the significance 
value.  
MiRNA Evidence from the literature Present 
 
Up or down 
regulation 
let-7b Barron, Sanchez, Kelly, & Clynes, 2011; 
Chen et al., 2005; Koh, Lee, Chang, & 
Nissom, 2009; Kumar, 2009; Oglesby, 
McElvaney, & Greene, 2010 
Y ↑ LPS 
↓ RT 001 
let -7c Kim, Gregersen, & Diamond, 2013; Li et 
al., 2009; Nelson et al., 2004 
Y 
 
↑ LPS 
↑ RT 001 
let-7d Krichevsky, 2003; Li et al., 2009 Y ↑ RT 001 
let-7e Li et al., 2009; Virtue, Wang, & Yang, 
2012; Wei et al., 2013 
Y 
 
↑ LPS 
↑ RT 001 
let-7e# Li et al., 2009; Virtue, Wang, & Yang, 
2012; Wei et al., 2013 
Y 
 
↑ LPS 
↑ RT 001 
miR-125a-5p Roderburg et al., 2011 Y 
 
↓ LPS 
↑ RT 001 
miR-132 Krichevsky, 2003; Nahid, Satoh, & Chan, 
2011; O’Connell et al., 2007; Quinn & 
O’Neill, 2011; Taganov, Boldin, Chang, & 
Baltimore, 2006 
Y ↑ LPS 
↑ RT 001 
miR-145 Bandrés et al., 2006; Quinn & O’Neill, 
2011; Starczynowski et al., 2010 
Y ↓ LPS 
↑ RT 001 
miR-146a Nahid et al., 2011; Starczynowski et al., 
2010; Taganov et al., 2006; Xie et al., 2013 
N N/A 
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miR-155 Ceppi et al., 2009; Dai et al., 2011; 
Kohlhaas et al., 2009; O’Connell, Taganov, 
Boldin, Cheng, & Baltimore, 2007; Quinn 
& O’Neill, 2011 
Y ↑ LPS 
↑ 001 
miR-187 Rossato et al., 2012 N N/A 
miR-221 Wu et al., 2007 Y 
 
↑ LPS 
↓ RT 001 
miR-221# Wu et al., 2007 Y ↑ LPS 
↑ RT 001 
miR-9/# Bazzoni et al., 2009 Y 
 
↑ LPS 
↑ RT 001 
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Figure 4.2.7 Overall Ct values follow normal distribution in miRNAs detected in 
custom TLDA cards. Hek TLR4/MD2/CD14 cells from three biological replicates 
were plated at 2x10
6 
cells/mL and allowed to adhere for 18 hours to approximately 60% 
confluency. Cells were stimulated with 100 ng/mL LPS or 20 µg/mL SLPs from RT 
001 and RT 027 for 8 hours. Cells were harvested and total RNA was extracted using 
miRVana™ miRNA isolation kit. 350 ng starting total RNA was converted to first 
strand cDNA, the products of which were used in a pre-amplification PCR reaction. 
Samples were added to PCR reaction mixes and added to each well on custom made 
TLDA cards. The cards were sealed and ran on the Applied Biosystems 7900HT Fast 
Real Time PCR Machine. The SDS files were exported and data the cards analysed 
using ExpressionSuite software v1.0.3. Box plot showing Ct distribution for each 
treated group from three biological replicates per group. The box contains the middle 
50% of the data, the black horizontal line indicates the median Ct value and the black 
dot denotes the mean Ct. The ends of the vertical lines indicate the minimum and 
maximum Ct values and outliers are the points outside the ends of the whiskers. 
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Table 4.2.4 qPCR data analysis detected 28 miRNAs in Hek TLR4/MD2/CD14 
cells stimulated with LPS, SLPs from RT 001 and RT 027 from the 31 miRNAs 
analysed on custom TLDA cards. Hek TLR4/MD2/CD14 cells from three biological 
replicates were plated at 2x10
6 
cells/mL and allowed to adhere for 18 hours to 
approximately 60% confluency. Cells were stimulated with 100 ng/mL LPS or 20 
µg/mL SLPs from RT 001 and RT 027 for 8 hours. Cells were harvested and total RNA 
was extracted using miRVana™ miRNA isolation kit. 350 ng starting total RNA was 
converted to first strand cDNA, the products of which were used in a pre-amplification 
PCR reaction. Samples were added to PCR reaction mixes and added to each well on 
the custom TLDA cards. The cards were sealed and ran on the Applied Biosystems 
7900HT Fast Real Time PCR Machine. The SDS files were exported and data from the 
custom cards were analysed using ExpressionSuite software v1.0.3. The max Ct was set 
to 37.0 with a threshold of 0.1 and the reference group was set to the control cell group. 
U6 snRNA was used to correct for variation of RNA input and relative gene expression 
was calculated. A Student’s t-test was applied and values of p≤ 0.05 were considered 
statistically significant compared to the control group. 
Group Target RQ p-value 
CTL hsa-let-7b 1.0 1.000 
LPS hsa-let-7b 0.9 0.646 
RT 001 hsa-let-7b 0.8 0.299 
RT 027 hsa-let-7b 0.05 0.030 
CTL hsa-let-7c 1.0 1.000 
LPS hsa-let-7c 0.8 0.621 
RT 001 hsa-let-7c 1.0 0.997 
RT 027 hsa-let-7c 0.1 0.007 
CTL hsa-let-7d 1.0 1.000 
LPS hsa-let-7d 0.7 0.359 
RT 001 hsa-let-7d 0.9 0.280 
RT 027 hsa-let-7d 0.1 0.001 
CTL hsa-let-7e 1.0 1.000 
LPS hsa-let-7e 0.6 0.088 
RT 001 hsa-let-7e 0.7 0.070 
RT 027 hsa-let-7e 0.1 0.0001 
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CTL hsa-miR-125a-5p 1.0 1.000 
LPS hsa-miR-125a-5p 0.8 0.271 
RT 001 hsa-miR-125a-5p 0.8 0.176 
RT 027 hsa-miR-125a-5p 0.4 0.007 
CTL hsa-miR-1292 1.0 1.000 
LPS hsa-miR-1292 0.7 0.564 
RT 001 hsa-miR-1292 0.8 0.451 
RT 027 hsa-miR-1292 0.2 0.007 
CTL hsa-miR-132 1.0 1.000 
LPS hsa-miR-132 1.0 0.722 
RT 001 hsa-miR-132 0.8 0.220 
RT 027 hsa-miR-132 0.1 0.001 
CTL hsa-miR-145 1.0 1.000 
LPS hsa-miR-145 1.0 0.956 
RT 001 hsa-miR-145 1.2 0.035 
RT 027 hsa-miR-145 0.2 0.001 
CTL hsa-miR-146a 1.0 1.000 
LPS hsa-miR-146a 1.6 0.227 
RT 001 hsa-miR-146a 1.6 0.009 
RT 027 hsa-miR-146a 0.6 0.068 
CTL hsa-miR-148b 1.0 1.000 
LPS hsa-miR-148b 0.9 0.803 
RT 001 hsa-miR-148b 0.9 0.661 
RT 027 hsa-miR-148b 0.1 0.010 
CTL hsa-miR-152 1.0 1.000 
LPS hsa-miR-152 0.8 0.652 
RT 001 hsa-miR-152 0.9 0.700 
RT 027 hsa-miR-152 0.1 0.012 
CTL hsa-miR-155 1.0 1.000 
LPS hsa-miR-155 0.7 0.375 
RT 001 hsa-miR-155 1.0 0.698 
RT 027 hsa-miR-155 0.03 0.0002 
CTL hsa-miR-215 1.0 1.000 
LPS hsa-miR-215 1.4 0.401 
RT 001 hsa-miR-215 1.3 0.362 
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RT 027 hsa-miR-215 0.2 0.027 
CTL hsa-miR-221 1.0 1.000 
LPS hsa-miR-221 0.8 0.482 
RT 001 hsa-miR-221 0.8 0.315 
RT 027 hsa-miR-221 0.03 0.021 
CTL hsa-miR-24 1.0 1.000 
LPS hsa-miR-24 1.2 0.395 
RT 001 hsa-miR-24 1.1 0.212 
RT 027 hsa-miR-24 0.4 0.036 
CTL hsa-miR-339-5p 1.0 1.000 
LPS hsa-miR-339-5p 1.0 0.931 
RT 001 hsa-miR-339-5p 0.9 0.744 
RT 027 hsa-miR-339-5p 0.2 0.0003 
CTL hsa-miR-374 1.0 1.000 
LPS hsa-miR-374 0.7 0.282 
RT 001 hsa-miR-374 0.7 0.264 
RT 027 hsa-miR-374 0.2 0.019 
CTL hsa-miR-422a 1.0 1.000 
LPS hsa-miR-422a 0.5 0.320 
RT 001 hsa-miR-422a 0.8 0.843 
RT 027 hsa-miR-422a 0.1 0.013 
CTL hsa-miR-432* 1.0 1.000 
LPS hsa-miR-432* 1.1 0.646 
RT 001 hsa-miR-432* 1.1 0.531 
RT 027 hsa-miR-432* 0.1 0.010 
CTL hsa-miR-543 1.0 1.000 
LPS hsa-miR-543 1.2 0.557 
RT 001 hsa-miR-543 0.7 0.360 
RT 027 hsa-miR-543 0.1 0.003 
CTL hsa-miR-586 1.0 1.000 
LPS hsa-miR-586 0.6 0.198 
RT 001 hsa-miR-586 0.6 0.070 
RT 027 hsa-miR-586 0.05 0.015 
CTL hsa-miR-590-5p 1.0 1.000 
LPS hsa-miR-590-5p 0.9 0.823 
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RT 001 hsa-miR-590-5p 0.9 0.883 
RT 027 hsa-miR-590-5p 0.2 0.015 
CTL hsa-miR-9 1.0 1.000 
LPS hsa-miR-9 0.8 0.747 
RT 001 hsa-miR-9 0.8 0.405 
RT 027 hsa-miR-9 0.1 0.019 
CTL hsa-miR-9* 1.0 1.000 
LPS hsa-miR-9* 0.9 0.871 
RT 001 hsa-miR-9* 0.9 0.627 
RT 027 hsa-miR-9* 0.2 0.001 
CTL hsa-miR-1293 1.0 1 
LPS hsa-miR-1293 1.3 0.491 
RT 001 hsa-miR-1293 1.228 0.624 
RT 027 hsa-miR-1293 0.179 0.08 
CTL hsa-miR-221* 1.0 1 
LPS hsa-miR-221* 1.4 0.412 
RT 001 hsa-miR-221* 1.2 0.612 
RT 027 hsa-miR-221* 0.04 0.06 
CTL hsa-miR-221 1.0 1 
LPS hsa-miR-221 0.8 0.482 
RT 001 hsa-miR-221 0.8 0.315 
RT 027 hsa-miR-221 0.03 0.021 
CTL hsa-miR-550 1.0 1 
LPS hsa-miR-550 1.2 0.379 
RT 001 hsa-miR-550 1.0 0.792 
RT 027 hsa-miR-550 0.05 0.02 
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Figure 4.2.8 Ct Scatter plot shows there are differences in miRNA profiles between 
Hek TLR4/MD2/CD14 cells stimulated with LPS, SLPs from RT 001 and RT 027 
compared to the control. Hek TLR4/MD2/CD14 cells from three biological replicates 
were plated at 2x10
6 
cells/mL and allowed to adhere for 18 hours to approximately 60% 
confluency. Cells were stimulated with 100 ng/mL LPS or 20 µg/mL SLPs from RT 
001 and RT 027 for 8 hours. Cells were harvested and total RNA was extracted using 
miRVana™ miRNA isolation kit. 350 ng starting total RNA was converted to first 
strand cDNA, the product of which was used in a pre-amp PCR reaction. Samples were 
added to PCR reaction mixes and added to each well on custom made TLDA cards. The 
cards were sealed and ran on the Applied Biosystems 7900HT Fast Real Time PCR 
Machine. The SDS files were exported and data from the cards was analysed using 
ExpressionSuite software v1.0.3. The Ct scatter plot shows the relationship between A) 
CTL V’s LPS B) CTL V’s SLPs from RT 001 and C) CTL V’s SLPs from RT 027 for 
all miRNAs in the profiling study with custom cards. Ct values are not entirely linear as 
they fall outside of the line.  
A) 
B) 
C) 
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Figure 4.2.9 Ct Scatter plot shows there are differences in miRNA profiles between 
Hek TLR4/MD2/CD14 cells stimulated with LPS, SLPs from RT 001 and RT 027 
compared to each other. Hek TLR4/MD2/CD14 cells from three biological replicates 
were plated at 2x10
6 
cells/mL and allowed to adhere for 18 hours to approximately 60% 
confluency. Cells were stimulated with 100 ng/mL LPS or 20 µg/mL SLPs from RT 
001 and RT 027 for 8 hours. Cells were harvested and total RNA was extracted using 
miRVana™ miRNA isolation kit. 350 ng starting total RNA was converted to first 
strand cDNA, the product of which was used in a pre-amp PCR reaction. Samples were 
added to PCR reaction mixes and added to each well on custom made TLDA cards. The 
cards were sealed and ran on the Applied Biosystems 7900HT Fast Real Time PCR 
Machine. The SDS files were exported and data from the cards was analysed using 
ExpressionSuite software v1.0.3. The Ct scatter plot shows the relationship between A) 
LPS V’s SLPs from RT 001 B) LPS V’s SLPs from RT 027 and C) SLPs from RT 001 
V’s SLPs from RT 027 for all miRNAs in the profiling study with custom cards. Ct 
values are not entirely linear as they fall outside of the line. 
A) 
B) 
C) 
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Figure 4.2.10 Visual representation of miRNAs differentially regulated when Hek 
TLR4/MD2/CD14 cells were stimulated with LPS and SLPs from RT 001 and RT 
027. Hek TLR4/MD2/CD14 cells from three biological replicates were plated at 2x10
6 
cells/mL and allowed to adhere for 18 hours to approximately 60% confluency. Cells 
were stimulated with 100 ng/mL LPS or 20 µg/mL SLPs from RT 001 and RT 027 for 8 
hours. Cells were harvested and total RNA was extracted using miRVana™ miRNA 
isolation kit. 350 ng starting total RNA was converted to first strand cDNA, the product 
of which was used in a pre-amp PCR reaction. Samples were added to PCR reaction 
mixes and added to each well on custom TLDA cards. The cards were sealed and ran on 
the Applied Biosystems 7900HT Fast Real Time PCR Machine. The SDS files were 
exported and data from the cards was analysed using ExpressionSuite software. The 
profiles of 31 miRNAs were visualised using a supervised heat map (average linkage 
and Pearson’s correlation). The heat map shows the corresponding relative miRNA 
expression levels rendered in a green-red colour scale, red represents high expression 
level, green represents low expression level and black being absence of detection. Each 
row represents a single miRNA and each column represents an individual sample. 
Dendograms indicate the correlation between groups of samples and miRNAs. 
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Figure 4.2.11 MiR-145 and miR-146a were significantly up regulated when Hek 
TLR4/MD2/CD14 cells were stimulated with SLPs from RT 001. Hek 
TLR4/MD2/CD14 cells from three biological replicates were plated at 2x10
6 
cells/mL 
and allowed to adhere for 18 hours to approximately 60% confluency. Cells were 
stimulated with 20 µh/mL SLPs from RT 001 for 8 hours. Cells were harvested and 
total RNA was extracted using miRVana™ miRNA isolation kit. 350 ng starting total 
RNA was converted to first strand cDNA, the products of which were used in a pre-amp 
PCR reaction. Samples were added to PCR reaction mixes and added to custom TLDA 
cards. The cards were sealed and ran on the Applied Biosystems 7900HT Fast Real 
Time PCR Machine. The SDS files were exported and data from the custom cards 
analysed using ExpressionSuite software. The max Ct was set to 37.0 with a threshold 
of 0.1 and the reference group was set to the control cell group. U6 snRNA was used to 
correct for variation of RNA input and relative gene expression was calculated. A 
student’s t-test was applied and values of p≤ 0.05 were considered statistically 
significant compared to the control group. The volcano plot displays -log10 p-value Vs 
log2 fold change. The p-value and fold change boundaries were set at 0.05 & 1.0. 
Targets above the horizontal line have statistically significant fold changes. The top left 
quadrant shows miRNAs targets that are down regulated while the top right quadrant 
shows miRNA targets that are up regulated. 
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Figure 4.2.12 Twenty three miRNAs were significantly down regulated when Hek 
TLR4/MD2/CD14 cells were stimulated with SLPs from RT 027. Hek 
TLR4/MD2/CD14 cells from three biological replicates were plated at 2x10
6 
cells/mL 
and allowed to adhere for 18 hours to approximately 60% confluency. Cells were 
stimulated with 20 µg/mL SLPs from RT 027 for 8 hours. Cells were harvested and 
total RNA was extracted using miRVana™ miRNA isolation kit. 350 ng starting total 
RNA was converted to first strand cDNA, the products of which were used in a pre-amp 
PCR reaction. Samples were added to PCR reaction mixes and added to custom TLDA 
cards. The cards were sealed and ran on the Applied Biosystems 7900HT Fast Real 
Time PCR Machine. The SDS files were exported and data from the custom cards 
analysed using ExpressionSuite software. The max Ct was set to 37.0 with a threshold 
of 0.1 and the reference group was set to the control cell group. U6 snRNA was used to 
correct for variation of RNA input and relative gene expression was calculated. A 
student’s t-test was applied and values of p≤ 0.05 were considered statistically 
significant compared to the control group. The volcano plot displays -log10 p-value Vs 
log2 fold change. The p-value and fold change boundaries were set at 0.05 & 2.0. 
Targets above the horizontal line have statistically significant fold changes. The top left 
quadrant shows miRNAs targets that are down regulated while the top right quadrant 
shows miRNA targets that are up regulated. 
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Table 4.2.5 Four miRNAs of interest were chosen for further validation based on 
the differences between expression in response to SLPs from RT 001 and RT 027. 
23 miRNAs had statistically significant folds changes when Hek TLR4/MD2/CD14 
cells were stimulated with SLPs from RT 001 and RT 027. The miRNAs highlighted in 
yellow are of most interest to us based on the possible differences between SLPs from 
RT 001 and RT 027 therefore let-7e, miR-155, miR-146a and miR-145 were chosen for 
further validation.  
 RT 001 RT 027 
let -7e ↓ ↓↓ 
miR-155 ↔ ↓ 
miR-146a ↑ ↓ 
miR-145 ↑ ↓ 
Let-7b ↓ ↓↓ 
Let-7c ↔ ↓ 
let-7d ↓ ↓↓ 
miR-125a-5p ↓ ↓↓ 
miR-1292 ↓ ↓↓ 
miR-132 ↓ ↓↓ 
miR-148b ↓ ↓↓ 
miR-152 ↓ ↓↓ 
miR-215 ↑ ↓↓ 
miR-221 ↓ ↓↓ 
miR-24 ↑ ↓ 
miR-339-5p ↓ ↓↓ 
miR-374 ↓ ↓↓ 
miR-422a ↓ ↓↓ 
miR-432 ↑ ↓ 
miR-543 ↑ ↓ 
miR-586 ↓ ↓↓ 
miR-590-5p ↓ ↓↓ 
miR-9 ↓ ↓↓ 
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Figure 4.2.13 MiR-146a, miR-145, miR-155 and let-7e are differentially regulated 
in Hek TLR4/MD2/CD14 cells stimulated with SLPs from RT 001 and RT 027. 
Hek TLR4/MD2/CD14 cells from three biological replicates were plated at 2x10
6 
cells/mL and allowed to adhere for 18 hours to approximately 60% confluency. Cells 
were stimulated with 100 ng/mL LPS, 20 µg/mL SLPs from RT 001 and RT 027 for 8 
hours. Cells were harvested and total RNA was extracted using miRVana™ miRNA 
isolation kit. 350 ng starting total RNA was converted to first strand cDNA, the 
products of which were used in a pre-amplification PCR reaction. Samples were added 
to PCR reaction mixes for individual Taqman miRNA assays and added to wells on a 96 
well PCR plate. The plate was run on the Applied Biosystems 7900HT Fast Real Time 
PCR Machine. The SDS files were exported and data from the PCR plate analysed 
using ExpressionSuite software. The max Ct was set to 37.0 with a threshold of 0.1 and 
the reference group was set to the control cell group. U6 snRNA was used to correct for 
variation of RNA input and relative gene expression was calculated. Results show the 
mean (± SEM) from three biological replicates with 3 technical replicates each. The 
Mann Whitney U-test was used to test for significance comparing miRNAs induced by 
SLPs from RT 001 with SLPs from RT 027 where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 
0.001.  
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Figure 4.2.14 SLPs from RT 001 and RT 027 induce the production of murine IL-1 
β, TNFα, MCP, IL-6, RANTES and MIP-2 in JAWS II cells. JAWS II Cells were 
plated at 1x10
6
 cells/mL and stimulated with 100 ng/ml of LPS or 20 µg/mL SLPs from 
RT 001 and RT 027. Supernatants were recovered after 18 hours and assessed for levels 
of cytokines and chemokines using ELISA. The results show the mean (± SEM) 
measured in triplicate, one-way ANOVA followed by Newman-Keuls analysis was used 
to determine if differences between treatment groups were significantly different 
compared to the control, where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. The results are 
indicative of three independent experiments. 
  
 168  
miR-146a
CT
L
LP
S
RT
 00
1
RT
 02
7
0
1
2
3
**
R
Q
miR-155
CT
L
LP
S
RT
 00
1
RT
 02
7
0
20
40
60
80
**
R
Q
let-7e
CT
L
LP
S
RT
 00
1
RT
 02
7
0.0
0.5
1.0
1.5
2.0
2.5
*
R
Q
miR-145
CT
L
LP
S
RT
 00
1
RT
 02
7
0.0
0.5
1.0
1.5
2.0 **
R
Q
JawII cells
 
Figure 4.2.15 MiR-146a and miR-145, miR-155 and let-7e are differentially 
regulated in JAWS II cells stimulated with SLPs from RT 001 and RT 027. JAWS 
II cells from three biological replicates were plated at 2x10
6 
cells/mL. Cells were 
stimulated with 100 ng/mL LPS, 20 µg/mL SLPs from RT 001 and RT 027 for 8 hours. 
Cells were harvested and total RNA was extracted using miRVana™ miRNA isolation 
kit. 350 ng starting total RNA was converted to first strand cDNA, the products of 
which were used in a pre-amp PCR reaction. Samples were added to PCR reaction 
mixes for individual Taqman miRNA assays and added to wells on a 96 well PCR plate. 
The plate was run on the Applied Biosystems 7900HT Fast Real Time PCR Machine. 
The SDS files were exported and data from the PCR plate analysed using 
ExpressionSuite software. The max Ct was set to 37.0 with a threshold of 0.1 and the 
reference group was set to the control cell group. snoRNA202 was used to correct for 
variation of RNA input and relative gene expression was calculated. Results show the 
mean (± SEM) from three biological replicates with 3 technical replicates each. The 
Mann Whitney U-test was used to test for significance comparing miRNAs induced by 
SLPs from RT 001 with SLPs from RT 027 where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 
0.001. The results are indicative of three independent experiments. 
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Table 4.2.6 Expression of miR-146a, miR-145, miR-155 and let-7e in response to 
SLPs from RT 027 is similar in Hek TLR4/MD2/CD14 cells and JAWS II cells. 
Summary of qPCR data from Hek TLR4/MD2/CD14 cells and JAWS II cells stimulated 
with LPS, SLPs from RT 001 and RT 027. 
 Hek TLR4/MD2/CD14 JAWS II 
LPS RT 001 RT 027 LPS RT 001 RT 027 
miR-146a ↑ ↑ ↓↓ ↔ ↑ ↓↓ 
miR-145 ↔ ↑ ↓ ↑ ↔ ↓↓ 
miR-155 ↓ ↔ ↓ ↑↑ ↑ ↓ 
let-7e ↓ ↓ ↓↓ ↑ ↔ ↓ 
  
 170  
4.3 Discussion 
TLR signalling plays an important role in detecting pathogens and initiating the 
inflammatory response. It has now emerged that these TLR pathways are highly 
regulated by miRNAs and there is evidence to suggest they function as 
immunomodulators (Coll & O’Neill, 2010; He et al., 2014). Differences in miRNA 
expression profiles have been observed depending on the TLR stimulus used, treatment 
time, technology used and the cell type. MiRNAs have been shown to be involved in 
innate immunity by regulating TLR signalling and ensuing cytokine response by 
targeting a variety of signalling proteins, regulatory molecules and transcription factors 
(Dalal & Kwon, 2010; He et al., 2014; Sonkoly et al., 2008). MiRNAs also regulate 
central elements of the adaptive immune response such as antigen presentation, T cell 
receptor signalling and the interferon system (Cullen, 2006; Sonkoly et al., 2008). There 
is mounting evidence that miRNAs orchestrate immune regulation and host responses to 
pathogens during infection (Sonkoly et al., 2008). 
Until recently little was known about the recognition of C. difficile by the immune 
system, however research from our laboratory showed that SLPs from C. difficile 
activate TLR4, with subsequent activation of downstream signalling pathways known to 
be important in the immune response to infection (Collins et al., 2014; Ryan et al., 
2011). SLPs from ribotype 001 fail to fully activate all signalling pathways via TLR4 
(Ryan et al., 2011). In the previous chapter we showed that SLPs isolated from ribotype 
001 activate NF-κB signalling and they do not activate IRF3 downstream of TLR4. On 
the other hand SLPs from ribotype 027 activate both NF-κB and IRF3 signalling. The 
severity of C. difficile infection may be dependent on the strain present (Goorhuis et al., 
2007; Rupnik et al., 2009). Some ribotypes are more ‘hypervirulent’ than others, 
ribotype 027 is associated with more severe diarrhoea, higher mortality and more 
recurrences. In comparison ribotype 001 is associated with milder infection and 
clearance of the bacteria (Clements et al., 2010; Dawson et al., 2009; Goorhuis et al., 
2007; Loo et al., 2005). Given the role of miRNAs in the regulation of TLR4 signalling 
and during infection, we hypothesise that SLPs induce miRNAs and that profiles may 
differ between ribotypes. These miRNAs may modulate TLR4 signalling ultimately 
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leading to changes in the immune response to C. difficile, which may explain the 
differences in clinical symptoms between different ribotypes. The aim of this chapter 
was to profile and compare miRNA expression regulated by SLPs from ribotypes 001 
and 027. 
SLPs modulate TLR4 signalling therefore we wanted to examine miRNA profiles 
induced by SLPs via TLR4 signalling specifically, for that reason Hek 
TLR4/MD2/CD14 cells were used throughout the initial profiling studies. We also 
incorporated cells stimulated with LPS in our study as it is a known TLR4 agonist that 
activates NF-κB and IRF3 signalling (Akashi et al., 2003; Taro Kawai & Akira, 2007; 
Laird et al., 2009). Evidence from the literature shows, LPS induces miRNAs such as 
miR-155, miR-125, miR-9, the let-7 family, miR-145, miR-146a and miR-187. These 
miRNAs have been shown to modulate the immune response including key molecules 
involved in the TLR4 signalling pathway 6-8 hours post immune stimulation in vitro 
(Curtale et al., 2013; Rossato et al., 2012; Tili et al., 2007). We wanted to ensure that 
samples generated reflected the correct signalling profile at this 8 hour time point as 
seen when stimulated at 18 hours in our previous chapter. As expected, SLPs from 
ribotype 001 and 027 activated NF-κB signalling. SLPs from ribotype 027 activated 
IRF3 signalling but SLPs from ribotype 001 failed to induce this response. The profile 
at gene level was reflected in the production of human IL-8 and RANTES cytokines. 
Once we were confident we were generating the correct signalling profile, we went on 
to profile miRNAs at this 8 hour time point. Initially we profiled control untreated cells 
and compared them to cells stimulated with LPS and SLPs from ribotype 001. 
Over the last number of years various strategies have been developed to identify and 
characterise miRNAs, quantitatively and qualitatively. Methods include cloning, 
hybridisation, deep sequencing, northern blotting, microarrays and qPCR (Lhakhang & 
Chaudhry, 2012). Each method has their advantages and disadvantages but the approach 
we choose for this study was qPCR, it is the gold standard for miRNA detection due to 
its sensitivity, specificity, and wide dynamic range. Also the less abundant miRNAs 
routinely escape detection with the other technologies (Chen et al., 2005; Lim, Glasner, 
Yekta, Burge, & Bartel, 2003). We used Taqman® Low Density Array (TLDA) cards 
with preloaded primers for pool A v2 and pool B v3 human miRNAs to look at mature 
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miRNA expression. Multiple stem-loop reverse transcription primers produce cDNA for 
multiple miRNAs therefore increasing the number of miRNAs being reverse transcribed 
within a single reverse transcription reaction (Fiedler, Carletti, & Christenson, 2010). 
This method allowed us to use a small amount of starting material and examine 756 
miRNA targets between the two sets of cards. Pre-amplification uniformly amplifies 
desired cDNA by increasing the amount of starting template and this enhances the 
sensitivity of qPCR especially for low abundance genes (Noutsias et al., 2008). The 
substantially higher cDNA amounts expands the number of the target genes which can 
be analysed without biasing the estimation of miRNA expression ratio (Chen et al., 
2009). We optimised the assay to see if pre-amplification was necessary for our study, 
we ran cards with and without pre-amplification product. We saw an increase in the 
amount of cDNA, so as not to lose any of the low abundance miRNAs we used the pre-
amplification reaction for all samples thereafter. 
We generated a large data set and how this data was managed was very important. We 
implemented strict quality control (QC) guidelines and thresholds to eliminate false 
positive/negative results. In this study we had three biological replicates so we had to 
compare samples between cards. The purpose of normalisation is to reduce variation 
within a dataset, enabling a better appreciation of the biological variation (Mestdagh et 
al., 2009). A proper normalisation strategy is crucial for any qPCR data analysis, it 
minimises the effects of systematic technical variations and is a prerequisite for getting 
meaningful biological changes (Meyer et al., 2012). For large scale miRNA expression 
profiling studies, global normalisation out performs the normalisation strategies using 
endogenous controls (Mestdagh et al., 2009). After careful consideration we thought 
this was the best approach under the circumstances due to the large data set, constraints 
with the number of technical and the biological replicates for this initial screen. Taqman 
assays are designed to include a passive internal reference dye and a reporter dye which 
are amplified simultaneously in the presence of a target sequence using a labelled 
fluorophore, which emits light at a different wavelength than the fluorophore used for 
the target sequence assay. The two fluorophores are detected in different channels by 
the real-time PCR instrument (Jothikumar, Hill, & Narayanan, 2009). The normalised 
reporter ‘Rn’ value is taken into account during analysis. The Rn value is calculated by 
dividing the fluorescence of the passive dye by the fluorescence of the reporter dye to 
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normalise the reaction. This improves the precession of the data and accounts for 
variability in the optics, uneven illumination and the amount of condensation present 
(Jothikumar et al., 2009). Once we had applied the QC checks and carried out the global 
normalisation, we set our reference group as the untreated control cell group.  
The relative gene expression was calculated using the ΔΔct method to calculate fold 
change (RQ) (Livak & Schmittgen, 2001). Increasing the number of tests increases the 
probability of finding a significant p-value by chance and to avoid this effect the 
Benjamini-Hochberg False Discovery Rate (FDR) was used to adjust p-values 
according to the number of total tests. The statistics used in a t-test are defined as the 
difference of the arithmetric mean of two groups divided by the estimated standard 
deviation of that difference. The t-test statistic runs under the assumption that the given 
variable follow normal distribution (Goni et al., 2009; Li, 2012). Therefore we 
examined the overall Ct value distribution for each sample from the data generated from 
the TLDA cards. The overall Ct values followed normal distribution therefore we 
applied a student’s t-test where values of p≤ 0.05 were considered statistically 
significant compared with the control cell group. 
qPCR data analysis revealed 248 miRNAs were detected out of the 756 miRNAs 
analysed. In order to fully elucidate differences between individual miRNA targets with 
statistically significant fold changes we utilised volcano plots. MiR-155, miR-9, the let-
7 family, miR-145, miR-146a and miR-187 have all been shown to be induced by LPS 
in the literature (Curtale et al., 2013; Rossato et al., 2012; Tili et al., 2007). Although 
not significantly expressed these miRNAs were shown to be regulated by LPS in our 
study, thus validating our experimental method. We cannot rely on RQ values alone to 
evaluate differential expression of our data. According to the literature RQ is a 
reasonable measure of effect size however, it is widely considered to be inadequate 
because as it does not incorporate variance and offers no associated level of confidence 
(Allison, Cui, Page, & Sabripour, 2006; Hsiao, Worrall, Olefsky, & Subramaniam, 
2004; Miller, Galecki, & Shmookler-Reis, 2001). There is a relationship however 
between RQ and test statistics when both are transformed logarithmically (Li, 2012). 
We identified the miRNA targets for this study by examining the upper right and left 
quadrant of the volcano plot for statistically significant targets with large magnitude 
  
 174  
fold changes. Three miRNAs miR-543, miR302 and miR-374a were up regulated in 
response to LPS and miR-586 was down regulated. None of these miRNAs have been 
shown before to be differentially expressed in response to LPS or via TLR4 signalling 
in human or murine cells before, therefore we have potentially uncovered novel 
miRNAs that regulate this signalling pathway. We also identified for the first time novel 
miRNAs that were up regulated in response to SLPs from ribotype 001; miR-339-5p, 
miR148b, miR590-5p, miR-24, miR-550a, miR-1292, miR-432#, miR-215 and miR152. 
On the other hand miR-422a, miR-874 and miR1293 were down regulated in response 
to SLPs from ribotype 001 compared to the control cells. In the literature miR-148a/b 
has been shown to inhibit the expression of calcium/calmodulin-dependent protein 
kinase II, and thus they can regulate TLR-signalling pathways (He et al., 2014). Some 
of the other miRNAs were found in other models of disease and present in epithelial 
cells in the gut, for instance miR-215 has been associated with colon cancer (Song et al., 
2010). However the 16 miRNAs identified from the experimental profiling study 
needed to be validated further.  
We began by reviewing the literature for miRNAs known to regulate key elements of 
TLR4 signalling including: signalling proteins, transcription factors, cytokines and 
regulatory molecules, to create a short list of potential miRNAs of interest. MiRNAs 
that were known to be induced by LPS and induced during an immune response to 
infection were also included. We re-examined the profiling study to see if the short list 
of miRNAs were present in the initial experimental profiling study. The miRNAs 
identified from the literature were in fact present but were over the significance value 
set in this experiment. Custom TLDA cards were commissioned and targets on these 
cards included the 16 miRNAs from the experimental profiling study and the 15 
miRNAs from the review of the literature. The approach to data analysis had to be 
altered due to the decrease in the total number of tests from 756 to 31. We used the 
endogenous control U6 snRNA for data normalisation. New samples were generated 
and stimulated with LPS, SLPs from ribotype 001 and 027. We were also able to 
increase the number of technical replicates thus reducing potential variation. qPCR data 
analysis showed miR-145 and miR-146a were significantly up regulated in response to 
SLPs from ribotype 001. On the other hand there was a striking global down regulation 
of let-7b, let-7c, let-7d, let-7e, miR-125a-5p, miR-1292, miR-132, miR-145, miR-148b, 
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miR-152, miR-155, miR-221, miR-24, miR339-5p, miR-374, miR-422a, miR-432*, 
miR-543, miR-586, miR-590, miR-9, miR-9* and miR-221 in response to SLPs from 
ribotype 027. Hierarchical clustering analysis showed that miRNAs induced in response 
to SLPs from ribotype 001 and 027 were grouped together in distinctive clades. 
MiRNAs contained within these branches were more likely to be expressed together 
based on the experimental data in this study, this will have to be further validated in 
future work. 
Four miRNAs; let-7e, miR-155, miR-146a and miR-145- were chosen for further 
validation based on the differences between expression in response to SLPs from 
ribotype 001 and 027. Again we used U6 snRNA for data analysis however we used the 
Mann Whitney U-test when testing for significance. This statistical test was chosen 
because of the uncertainty of normal distribution due to low number of miRNA targets 
in this experimental study (Goni et al., 2009). qPCR data using individual Taqman 
assays confirmed that each of the miRNAs were down regulated in response to SLPs 
from ribotype 027 and that miR-146a and miR-145 were up regulated in response to 
SLPs from ribotype 001. We then validated these results in another cell line. We choose 
the murine dendritic cell line JAWS II as they behave in a similar way to BMDCs. 
JAWS II cells differ from BMDCs in that they fail to release the IL-12 cytokine family 
which include IL-12, IL-23 and IL-27 and IL-35 (Collins et al., 2014; Jørgensen et al., 
2002; Zapala et al., 2011). We observed that RANTES was produced in JAWS II cells 
when stimulated with SLPs from ribotype 001, however, the trend was the same in that 
ribotype 027 produced more RANTES compared to ribotype 001 as seen in the Hek 
TLR4/MD2/CD14 cells. JAWS II cells stimulated with SLPs from ribotype 001 and 027 
induced the production of murine cytokine and chemokines indicating the SLPs induced 
an immune response in these cells. We used snoRNA202 to correct for variation in 
RNA input, this is a murine small RNA endogenous control and was used as it showed 
the least variation across samples. qPCR data analysis showed that miR-146a, miR-145, 
miR-155 and let-7e were down regulated in response to SLPs from ribotype 027 and 
this was comparable to the response seen in the human Hek TLR/MD2/CD14 cell line. 
There were slight differences in the levels at which these miRNAs were expressed 
between the cell lines. However we showed that there were distinct miRNA profiles 
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regulated by SLPs from ribotype 001 and 027, which differed between ribotypes at this 
8 hour time point. 
Our data shows that SLPs from ribotype 001 and 027 down regulate let-7e in both 
human and murine cells. Evidence from the literature shows, the mRNA encoding 
TLR4 is regulated by members of the let-7 miRNA family and can be targeted by other 
isoforms of the let-7 family, such as let-7i. Down regulation of let-7i expression was 
shown to increase TLR4 expression by human epithelial cells after Cryptosporidium 
parvum infection or LPS treatment (Chen, Splinter, O’Hara, & LaRusso, 2008). In 
mouse peritoneal macrophages, the induction of let-7e expression decreases cell surface 
expression of TLR4, furthermore the transfection of macrophages with antisense 
miRNA to let-7e leads to an increased LPS induced cytokine response (Androulidaki et 
al., 2009). It is possible that the SLPs from both ribotypes utilise let-7e to activate TLR4 
signalling and increase cell surface marker expression leading to the production of 
cytokines. Our data also showed that miR-146a and miR-145 were up regulated in 
human and murine cells lines in response to SLPs from ribotype 001, in comparison 
these miRNAs were down regulated by SLPs from ribotype 027. MiRNA expression 
has been shown to contribute to disease. For example, loss of miR-145 and miR-146a 
transcripts within the 5q locus identified these miRNAs as key mediators of 5q 
syndrome, a haematopoietic malignancy that progresses to acute myeloid leukaemia 
(Starczynowski et al., 2010). Studies have shown that when miR-145 and miR-146a are 
absent their targets Mal, IRAK1 and TRAF6 are up regulated (Izar, Mannala, Mraheil, 
Chakraborty, & Hain, 2012; Taganov et al., 2006). It is possible that the down 
regulation of miR-145 and miR-146a induced in response to SLPs from ribotype 027 
leads to up regulation of Mal, IRAK1 and TRAF6- all three are implicated in NF-κB 
signalling pathways. This may account for the increased potency of the immune 
response to ribotype 027 compared to the immune response to ribotype 001. 
Lastly our data showed that miR-155 was down regulated in both human and murine 
cell lines in response to SLPs from ribotype 027 compared to SLPs from ribotype 001. 
The role of miR-155 in the TLR response is more complex (O’Neill et al., 2011). 
Studies using inhibition or over expression of miR-155 has shown that miR-155 
negatively regulates the expression of cytokines and chemokines such as IL-1 and 
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CXCL8 (Ceppi et al., 2009; Tang et al., 2010; Xiao et al., 2009). On the other hand, 
miR-155 is required for the expression of certain cytokines and type I IFNs 
(Androulidaki et al., 2009; O’Connell et al., 2007; Wang et al., 2010; Zhou et al., 2010). 
An effect that is probably mediated by the targeted suppression of suppressor of 
cytokine signalling 1 (SOCS1) and/or SHIP1, two negative regulators of cytokine-
mediators and TLR signalling pathways (Androulidaki et al., 2009; Wang et al., 2010; 
Yoshimura, Naka, & Kubo, 2007). IL-10, which is an important regulator of both innate 
and adaptive immune responses, can inhibit LPS induced expression of miR-155 
(McCoy et al., 2010; O’Connell, Rao, Chaudhuri, & Baltimore, 2010). IL-10 is known 
to dampen the innate immune response by down regulating TLR-induced pro-
inflammatory gene expression in macrophages and DCs after pathogen infection and 
can inhibit the proliferation of and cytokine production by CD4
+ 
T cells (O’Neill et al., 
2011). In the previous chapter we showed that SLPs from ribotype 027 induced the 
production of IL-10 in BMDCs. It is possible that the IL-10 produced by SLPs from 
ribotype 027 inhibits the expression of miR-155 and this warrants further investigation. 
In the previous chapter we also showed that SLPs from ribotype 001 appeared to 
produce much less IL-10 and IL-1β in BMDCs compared to SLPs from ribotype 027. 
Therefore it is possible that miR-155 expression was uninhibited by IL-10 and thus able 
to negatively regulate the expression of IL-1β. Consequently we have potentially 
identified a novel mechanism in which SLPs modulate TLR4 signalling in response to 
C. difficile infection in vitro. 
This profiling study and subsequent validation studies with the SLPs from ribotype 001 
and 027 only give us a snapshot into the signalling occurring at this particular point in 
time in vitro. Evidence from the literature shows that these miRNAs play key roles in 
modulating TLR4 and they have roles orchestrating the immune response to infection. 
In the next chapter we hope to elucidate further the role miR-146a, miR-145, miR-155 
and let-7e in NF-κB and IRF3 signalling. We hope to validate these miRNAs targets in 
vivo in a C. difficile infection model and use bioinformatics tools to search for 
biologically relevant miRNA gene interactions induced when SLPs activate TLR4 
signalling. 
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Chapter 5: Validation of miRNA Targets 
in a C. difficile Infection Model and 
Analysis of miRNA Functionality 
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5.1 Introduction 
To date 28,645 miRNA hairpin precursors corresponding to 35,828 mature miRNAs in 
223 species have been determined, 2588 mature miRNAs are currently annotated in the 
human genome (Eulalio & Mano, 2015). It has been estimated that up to 30% of all 
human genes are regulated by miRNAs in many cell types (Bartel, 2009; Fabian et al., 
2010; Yates et al., 2013). MiRNAs have been shown to be involved in innate immunity 
by regulating TLR signalling and ensuing cytokine response by targeting a variety of 
signalling proteins, regulatory molecules and transcription factors (Dalal & Kwon, 
2010; He et al., 2014; Sonkoly et al., 2008). They can also regulate central elements of 
the adaptive immune response such as antigen presentation, T cell receptor signalling 
and the interferon system (Cullen, 2006; Sonkoly et al., 2008). There is also mounting 
evidence that miRNAs orchestrate immune regulation and the host response to 
pathogens during infection. In chapter three we showed that SLPs from ribotype 001 
and 027 activate NF-κB and the potency of the response differed between ribotypes. 
SLPs from ribotype 027 activated IRF3 signalling but SLPs from ribotype 001 failed to 
induce this response. In chapter four we identified 24 miRNAs that were differentially 
regulated by SLPs from ribotype 001 and 027 using qPCR. We validated the expression 
of miR-146a, miR-145, miR-155 and let-7e in a human and murine cell line. 
Despite their clear importance as a class of regulatory molecule, determining the 
biological relevance of individual miRNAs has proven challenging (Vidigal & Ventura, 
2014). The implication of miRNAs in human diseases warrants a critical need to 
identify miRNA regulated genes in a biologically relevant context (Tarang & Weston, 
2014). The function of specific miRNAs have been predominantly inferred from over 
expression studies in animals and cultured cells, or from studies that used antisense 
molecules as a means of disrupting their pairing to targets (Vidigal & Ventura, 2014). 
The aim of the first part of this chapter is to determine the functionality of miR-146a, 
miR-145, miR-155 and let-7e in NF-κB and IRF3 signalling using chemically 
synthesised miRNA mimics. Nonetheless the most commonly used cellular assays are 
based on the principle of studying the functional consequences of artificially 
manipulating miRNAs levels. However, as the biological concentrations of these 
miRNAs in vivo may be several orders of magnitude different than in vitro conditions, it 
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is essential that the results of target recognition are recapitulated in appropriate animal 
models (Tarang & Weston, 2014). We had access to a bank of RNA samples derived 
from colonic tissue from a C. difficile infection model. Mice were treated with a cocktail 
of antibiotics before being infected with 10
3
 C. difficile spores from ribotype 001 and 
027. The colon was harvested at two time points during infection and RNA was 
extracted from the distal colon (Lynch 2014, unpublished). The aim of the next part of 
this chapter is to examine the expression of miR-146a, miR-145, miR-155 and let-7e 
from the colonic tissue generated in the C. difficile infection model. 
 
Figure 5.1.1 Diagram depicting seed match between miRNA and target mRNA  
(Peterson et al., 2014) 
Experimental data is not enough to give a comprehensive view of miRNA biology. It is 
thought that to get a more complete view, experimental data must be combined with 
computational predications (Bentwich et al., 2005; Ghosh, Chakrabarti, & Mallick, 
2007; Sachidanandam, 2005). MiRNA target prediction programs on the market today 
use algorithms to model how miRNAs target specific mRNAs based on four common 
features. A seed match occurs when adenosine pairs with uracil and guanine pairs with 
cytosine between a miRNA and its target sequence at the first two to eight nucleotides 
at the 5’ end moving toward the 3’end of the sequence see Figure 5.1.1 (Lewis et al., 
2003; Peterson et al., 2014). Conservation refers to the maintenance of a sequence 
across species on regions in the 3’ UTR, the 5’ UTR, the miRNA, or any combination 
of the three (Peterson et al., 2014). The binding of a miRNA to a candidate target 
mRNA is considered more likely if it is stable. Stability can be estimated by calculating 
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ΔG or free energy, negative ΔG means there is less energy available to bind thus 
stability is deemed to be increased. Site accessibility is a measure of the ease with 
which a miRNA can locate and hybridise with an mRNA target. Following 
transcription, mRNA assumes a secondary structure which can interfere with a miRNAs 
ability to bind to a target site. To assess the likelihood that an mRNA is the target of a 
miRNA, the predicted amount of energy required to make a site accessible to a miRNA 
can be evaluated (Mahen, Watson, Cottrell, & Fedor, 2010). 
An increasing collection of prediction tools are available, each with a distinct approach 
to miRNA target prediction (Peterson et al., 2014). It is thought that in order to find true 
miRNA targets they must be flagged in more than two prediction tools (Madden et al., 
2010; Sun et al., 2010). Two recent reviews outlined the features of numerous miRNA 
prediction tools and DIANA stood out from other prediction tools due to its range of 
capabilities, ease of use, relatively current input data and maintenance of the software 
(Eulalio & Mano, 2015; Peterson et al., 2014). DIANA miRPath highlights targets that 
are also predicted by two well-known prediction tools and this database is capable of 
detecting pathways targeted by single or multiple miRNAs. DIANA miRPath utilises 
complex algorithms incorporating all four of the common features; seed match, 
conservation, free energy, and site accessibility. It can also select between in silico 
predicted miRNA gene targets and experimentally validated targets. MiRNA and 
pathway information are then related back to biologically relevant genes and pathways 
found in Kyoto Encyclopaedia of Genes and Genomes (KEGG) (Paraskevopoulou et al., 
2013; Vlachos et al., 2012).  
MiRNAs regulate many different targets, individual 3’ UTRs also contain binding sites 
for multiple miRNAs, allowing for elaborate and complicated networks in which 
redundancy and cooperation between miRNAs determine the effect on gene expression 
(Bartel, 2009; Martinez & Walhout, 2009; Obermayer & Levine, 2014; van Rooij, 
2011). The number and distribution of miRNA binding sites are particularly important. 
Studies have demonstrated that two sites in the same or different miRNAs can act 
synergistically and that the distance between neighbouring miRNA binding sites affects 
the strength of the targets down regulation (Koscianska, Witkos, Kozlowska, 
Wojciechowska, & Krzyzosiak, 2015). Specifically, optimal down regulation was 
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observed when the distance between the 3’ end of the first miRNA site and the 5’ end of 
the subsequent miRNA was > 7 and < 40 nt and when the 5’ ends of both miRNA seeds 
were separated by between 13 and 35 nt. Therefore the target site’s activity depends on 
its surrounding context (Grimson et al., 2007; Saetrom et al., 2007). TargetScan allows 
the user to input gene names and search for predicted miRNA binding sites in the 
3’UTR of the gene of interest. The output screen shows the position of the predicted 
miRNA binding sites and ranks them by the probability of conserved targeting (PCT). 
The conservation of the predicted binding site in the 3’ UTR is determined following 
the analysis of possible subsequence’s (Lewis et al., 2005). Since one 3’ UTR can 
contain multiple target sites, an aggregate PCT is provided, the closer the PCT score is to 
1.0 the more likely it is to be conserved (Friedman et al., 2009). Therefore the final aim 
of the last part of this chapter is to use bioinformatics to identify miRNA regulated 
genes in a biologically relevant context using DIANA miRPath and to see if these genes 
contain predicted miRNA binding sites in TargetScan for the 24 miRNAs that were 
identified experimentally, given that miRNAs work in complex networks. 
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5.2 Results 
5.2.1 Optimising miRNA Mimics for Luciferase Gene Reporter Assays 
At the beginning of chapter four we hypothesised that miRNAs may be induced in 
response to SLPs from C. difficile and that these miRNA profiles differed between 
ribotypes. Subsequently we confirmed this hypothesis and found that 24 miRNAs were 
differentially regulated in response to SLPs from RT 001 and RT 027. We choose four 
miRNAs for further validation and found miR-146a, miR-155, let-7e and miR-145 were 
differentially regulated in response to SLPs from RT 001 and RT 027 in both a human 
and murine cell line. We also hypothesised that the miRNAs induced by SLPs modulate 
TLR4 signalling, given that in Chapter 3 SLPs from RT 027 activated IRF3 signalling 
but SLPs from RT 001 failed to induce this response. A common method to determine 
miRNA functionality is to transfect cells with both luciferase reporter constructs and 
increasing the amounts of the miRNA of interest with chemically synthesised miRNA 
mimics (van Rooij, 2011). The advantage of introducing a miRNA is that if the miRNA 
actually targets the binding site in the 3’UTR region, there will be a dose-dependent 
decrease in gene expression and this can be determined from the luciferase read out. To 
accurately assess whether miRNA/mRNA regulation occurs, transfection experiments 
should be performed in the cell type of interest where all endogenously expressed 
cofactors are present (Bartel, 2009). In chapter 3 we established a luciferase reporter 
gene assay for NF-κB and IRF3 using Hek TLR4/MD2/CD14 cells. These cells contain 
the machinery necessary for TLR4 signalling and they express all essential endogenous 
cofactors. We decided to utilise the already established luciferase gene reporter assay to 
assess if the miRNAs of interest modulate both arms of the TLR4 signalling pathway by 
transfecting miRNA mimics for these 4 miRNAs in Hek TLR4/MD2/CD14 cells along 
with plasmid DNA for NF-κB and IRF3. Seeing as IL-8 and RANTES cytokine 
production was well aligned with NF-κB and IRF3 signalling in chapter 3, we decided 
to include ELISA analysis in our study.  
We began by optimising the concentration of each of the miRNA mimics to transfect 
into Hek TLR4/MD2/CD14 cells, initially we used cells stimulated with LPS as a model 
to study this. Hek TLR4/MD2/CD14 cells were transfected with plasmid DNA required 
for NF-κB and IRF3 signalling. At the time of transfection increasing amounts of 
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miRNA mimics for miR-146a, miR-145, let-7e and miR-155 were added to the 
transfection mixes (0-100 nM). 24 hours post transfection cells were stimulated with 
LPS for 24 hours and IL-8 & RANTES were measured from cell supernatants using 
ELISA. We first examined the effect of miRNA mimics over expressing miR-146a. Hek 
TLR4/MD2/CD14 cells produced minimal levels of IL-8 however when stimulated with 
LPS, IL-8 production was increased to 2390 pg/mL. Transfection of 1 nM, 5 nM, 10 
nM, 50 nM and 100 nM miR-146a mimic did not affect IL-8 production when cells 
were stimulated with LPS, levels remained at approximately 2400 pg/mL. In contrast 
miRNA mimics over expressing miR-146a decreased RANTES production in a dose 
dependent manner in response to LPS see Figure 5.2.1. Hek TLR4/MD2/CD14 cells 
produced minimal levels of RANTES which was increased to 100 pg/mL when cells 
were stimulated with LPS. Transfection of 1 nM, 5 nM, 10 nM, 50 nM and 100 nM 
miR-146a mimic decreased RANTES production to 55 pg/mL (p≤ 0.001), 45 pg/mL (p≤ 
0.001), 40 pg/mL (p≤ 0.001) 30 pg/mL (p≤ 0.001) and 20 pg/mL (p≤ 0.001) 
respectively when cells were stimulated with LPS.  
We then examined the effect of miRNA mimics over expressing miR-145. Hek 
TLR4/MD2/CD14 cells produced minimal levels of IL-8, however when stimulated 
with LPS, IL-8 production was increased to 1500 pg/mL. Transfection of 1 nM, 5 nM, 
10 nM, 50 nM and 100 nM miR-146a mimic did not affect IL-8 production when cells 
were stimulated with LPS, levels remained at approximately 1300 pg/mL. In contrast 
miRNA mimics over expressing miR-145 decreased RANTES production in a dose 
dependent manner in response to LPS see Figure 5.2.2. Hek TLR4/MD2/CD14 cells 
produced minimal levels of RANTES, this was increased to 100 pg/mL when cells were 
stimulated with LPS. Transfection of 1 nM, 5 nM, 10 nM, 50 nM and 100 nM miR-145 
mimic decreased RANTES production to 50 pg/mL (p≤ 0.001), 35 pg/mL (p≤ 0.001), 
35 pg/mL (p≤ 0.001), 54 pg/mL (p≤ 0.001) and 20 pg/mL (p≤ 0.001) respectively when 
cells were stimulated with LPS.  
We then studied the effect of miRNA mimics over expressing miR-155. Hek 
TLR4/MD2/CD14 cells produced minimal levels of IL-8 however when stimulated with 
LPS, IL-8 production was increased to 2600 pg/mL. Transfection of 1 nM, 5 nM, 10 
nM, 50 nM and 100 nM miR-155 mimic did not affect IL-8 production when cells were 
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stimulated with LPS, levels remained at approximately 2400 pg/mL. In contrast miRNA 
mimics over expressing miR-155 decreased RANTES production in a dose dependent 
manner in response to LPS see Figure 5.2.3. Hek TLR4/MD2/CD14 cells produced 
minimal levels of RANTES, this was increased to 40 pg/mL RANTES. Transfection of 
1 nM, 5 nM, 10 nM, 50 nM and 100 nM miR-155 mimic decreased RANTES 
production to 22 pg/mL (p≤ 0.001), 25 pg/mL (p≤ 0.001), 20 pg/mL (p≤ 0.001), 10 
pg/mL (p≤ 0.001) and 8 pg/mL (p≤ 0.001) respectively when cells were stimulated with 
LPS. 
Lastly we examined the effect of miRNA mimics over expressing let-7e. Hek 
TLR4/MD2/CD14 cells produced minimal levels of IL-8 however when stimulated with 
LPS, IL-8 production was increased to 2500 pg/mL. Transfection of 1 nM, 5 nM, 10 
nM, 50 nM and 100 nM let-7e mimic did not affect IL-8 production when cells were 
stimulated with LPS, levels remained at approximately 2600 pg/mL. In contrast miRNA 
mimics over expressing let-7e decreased RANTES production in response to LPS see 
Figure 5.2.4. Hek TLR4/MD2/CD14 cells produced minimal levels of RANTES, this 
was increased to 140 pg/mL when cells were stimulated with LPS. Transfection of 1 
nM, 50 nM and 100 nM let-7e mimic decreased RANTES production to 60 pg/mL (p≤ 
0.05), 106 pg/mL (ns) and 80 pg/mL (p≤ 0.05) respectively when cells were stimulated 
with LPS. 10 nM let-7e mimic did not significantly decrease or increase RANTES 
production when cells were stimulated with LPS. On the other hand 5 nM let-7e mimic 
increased RANTES production to 195 pg/mL (p≤ 0.05) when cells were stimulated with 
LPS.  
Given that 100 nM of each of the miRNA mimics affected RANTES production we 
choose this concentration for all further studies. Negative control miRNA mimics 
consist of random sequences of miRNA mimic molecules that do not produce 
identifiable effects on known miRNA functions. We incorporated 100 nM of the 
negative control miRNA mimic into our study to make sure results were specific and 
not due to the effects of transient transfection. In contrast the positive control miRNA 
mimic miR-1 is known to down regulate many genes at the mRNA level and has been 
used as a positive control miRNA mimic in previous studies (Wendlandt et al., 2012). 
We needed to establish if the miRNA mimics had the ability to bind to the 3’UTR 
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region of our NF-κB and IRF3 constructs to see if they were suitable for our study. 
Therefore we incorporated this positive control miR-1 miRNA mimic into our study.  
We also wanted to make sure that cellular viability of the Hek TLR4/MD2/CD14 cells 
would not be affected by transient transfection with plasmid DNA and the miRNA 
mimics followed by cell stimulation. We used an “MTS” cytotoxicity assay to measure 
cell viability. Hek TLR4/MD2/CD14 cells were transfected with plasmid DNA required 
for NF-κB and IRF3. Both sets of plasmid DNA were co-transfected with constitutively 
expressed TK renilla luciferase and 100 nM of each of the miRNA mimics including the 
positive and negative control miRNA mimics. 24 hours post transfection cells were 
stimulated with LPS, SLPs from RT 001 and RT 027 for 24 hours. Cellular viability 
was then assessed using the Cell titer 96 Aqueous One solution containing MTS. 
Results were expressed as a percentage of untreated cells and cells treated with 10% 
DMSO were used as a positive control see Figure 5.2.5. Percentage viability did not fall 
below 75%, therefore transient transfection and stimulation did not have any significant 
cytotoxic effects on the Hek TLR4/MD2/CD14 cells.  
Luciferase activity in Hek TLR4/MD2/CD14 cells transfected with NF-κB and IRF3 
were measured. Both sets of plasmid DNA were co-transfected with constitutively 
expressed TK renilla luciferase and 100 nM of the positive and negative control miRNA 
mimics. 24 hours post transfection cells were stimulated with LPS or SLPs from RT 001 
and RT 027 for 24 hours. Lysates were generated and assayed for firefly and renilla 
activities see Figure 5.2.6. Transfection with each of the positive and negative control 
miRNA mimics did not affect NF-κB signalling, fold change remained at 1.0. NF-κB 
was increased in cells stimulated with LPS to 7.5 fold. Transfection of 100 nM positive 
control mimic decreased NF-κB expression to 4.0 fold (p≤ 0.001), while NF-κB 
expression remained at 7.5 fold with the addition of 100 nM negative control mimic. 
NF-κB increased in cells stimulated with SLPs from RT 001 to 4.5 fold. Transfection of 
100 nM positive control mimic decreased NF-κB expression to 1.5 fold (p≤ 0.05), while 
NF-κB expression remained at 4.5 fold with the transfection of 100 nM negative control 
mimic. NF-κB expression was increased in cells stimulated with SLPs from RT 027 to 
8.3 fold. Transfection of 100 nM positive control mimic decreased NF-κB expression to 
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3.0 fold (p≤ 0.001), while NF-κB expression remained at 8.3 fold with the transfection 
of 100 nM negative control miRNA mimic.  
A similar pattern emerged when we examined IRF3 expression, transfection with each 
of the positive and negative control miRNA mimics did not affect IRF3 signalling 
alone, fold change remained at 1.0. IRF3 was increased in cells stimulated with LPS to 
7.7 fold. Transfection of 100 nM positive control mimic decreased IRF3 expression to 
1.4 fold (p≤ 0.001), while IRF3 expression remained at 7.7 fold with the transfection of 
100 nM negative control mimic. There was minimal IRF3 expression in cells stimulated 
with SLPs from RT 001, however this was not significantly increased compared to the 
control cells. Transfection of 100 nM positive control mimic appeared to decrease IRF3 
expression to 0.1 fold (ns), while IRF3 expression remained at the same levels as the 
control with the transfection of 100 nM negative control mimic. IRF3 expression was 
increased in cells stimulated with SLPs from RT 027 to 6.0 fold. Transfection of 100 
nM positive control mimic decreased IRF3 expression to 0.5 fold (p≤ 0.001), while 
IRF3 expression remained at 6.0 fold with the transfection of 100 nM negative control 
miRNA mimic. 
The profile at gene level was also reflected in IL-8 and RANTES production. 
Transfection with each of the positive and negative control miRNA mimics did not 
significantly affect IL-8 production. Control cells produced 640 pg/mL, which was 
decreased to 370 pg/mL (ns) with the addition of the positive control mimic and 
remained close to 640 pg/mL with the transfection of the negative control mimic. IL-8 
was increased to 2500 pg/mL in response to LPS. Transfection of 100 nM positive 
control mimic decreased IL-8 production to 1000 pg/mL (p≤ 0.001), while IL-8 
production remained at 2500 pg/mL with the transfection of 100 nM negative control 
mimic. IL-8 was increased to 1500 pg/mL in response to SLPs from RT 001. 
Transfection of 100 nM positive control mimic decreased IL-8 production to 930 pg/mL 
(p≤ 0.05), while IL-8 production remained at 1500 pg/mL with the transfection of 100 
nM negative control mimic. IL-8 was increased to 2700 pg/mL in response to SLPs 
from RT 027. Transfection of 100 nM positive control mimic decreased IL-8 production 
to 1000 pg/mL (p≤ 0.001), while IL-8 production remained at 2500 pg/mL with the 
transfection of 100 nM negative control miRNA mimic. A similar pattern emerged 
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when we examined RANTES production. Transfection alone with each of the positive 
and negative control miRNA mimics did not significantly affect RANTES production. 
Control cells produced 70 pg/mL, which was decreased to 32 pg/mL (ns) with the 
transfection of the positive control mimic but remained close to 70 pg/mL with the 
transfection of the negative control mimic. RANTES production was increased to 350 
pg/mL in response to LPS. Transfection of 100 nM positive control mimic decreased 
RANTES production to 50 pg/mL (p≤ 0.001), while RANTES production remained at 
400 pg/mL with the transfection of 100 nM negative control mimic. There were low 
levels of RANTES detected in cells stimulated with SLPs from RT 001, however this 
was not significant compared to the control cells. Transfection of 100 nM positive 
control mimic decreased RANTES production to 50 pg/mL (p≤ 0.05), while RANTES 
production remained at similar levels with the transfection of 100 nM negative control 
mimic. RANTES production increased to 400 pg/mL in response to SLPs from RT 027. 
Transfection of 100 nM positive control mimic decreased RANTES production to 70 
pg/mL (p≤ 0.001), while RANTES production remained at similar levels 350 pg/mL 
with the transfection of 100 nM negative control miRNA mimics.  
The positive control miRNA mimic over expressing miR-1 bound to sites in the 3’UTR 
region of our NF-κB and IRF3 constructs thus modulating signalling when cells were 
stimulated with LPS, SLPs from RT 001 and RT 027. The results were not due to the 
effects of transient transfection as this was confirmed by the use of the negative control. 
Therefore we could use this method to assess if the four miRNAs of interest modulated 
NF-κB and IRF3 signalling in response to LPS, SLPs from RT 001 and RT 027. We 
over expressed each of the miRNAs of interest using specific mimics and measured 
luciferase activity and cytokine production. 
5.2.2 Mimics Over Expressing miR-146a, miR-145, miR-155 and let-7e Individually 
Target IRF3 Signalling in Response to LPS but not in Response to SLPs from RT 001 
and RT 027 
Firstly the effect of over expressing miR-146a on NF-κB and IRF3 signalling was 
examined see Figure 5.2.8. Transfection with the miRNA mimic over expressing miR-
146a alone did not induce NF-κB or IRF3 signalling, expression remained at 1.0 fold 
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consistent with the control Hek TLR4/MD2/CD14 cells. NF-κB was increased to 7.2 
fold in response to LPS and these levels remained the same with the transfection of 100 
nM miR-146a mimic. NF-κB was increased to 4.5 fold in response to SLPs from RT 
001 and these levels remained the same with the transfection of 100 nM miR-146a 
mimic. NF-κB was increased to 7.3 fold in response to SLPs from RT 027 and these 
levels remained the same with the transfection of 100 nM miR-146a mimic. Conversely 
IRF3 expression increased to 7.7 fold in response to LPS, however the transfection of 
miR-146a mimic decreased IRF3 expression to 4.5 fold (p≤ 0.001) in response to LPS. 
IRF3 expression was not significantly increased or decreased in response to SLPs from 
RT 001 and levels remained at 1.5 fold with the transfection of 100 nM miR-146a 
mimic. IRF3 expression increased to 6.0 fold in response to SLPs from RT 027 and 
levels remained the same with the transfection of 100 nM miR-146a mimic. The profile 
as gene level was also reflected in the production of IL-8 and RANTES see Figure 
5.2.9. Transfection with the miR-146a mimic alone did not affect IL-8 and RANTES 
production, as they remained at levels consistent with the control Hek 
TLR4/MD2/CD14 cells. IL-8 production was increased to 2600 pg/mL in response to 
LPS and the levels remained around the same levels with the transfection of 100 nM 
miR-146a mimic. IL-8 production was increased to 1500 pg/mL in response to SLPs 
from RT 001 and the levels remained the same with the transfection of 100 nM miR-
146a mimic. IL-8 production was increased to 2700 pg/mL in response to SLPs from 
RT 027 and levels decreased to 2500 pg/mL with the transfection of 100 nM miR-146a 
mimic, however this decrease was not significant. RANTES expression increased to 390 
pg/mL in response to LPS, while production decreased to 55 pg/mL (p≤ 0.001) with the 
transfection of 100 nM miR-146a mimic. RANTES production did not either increase or 
decrease in response to SLPs from RT 001 and levels remained the same with the 
transfection of 100 nM miR-146a mimic. RANTES production increased to 450 pg/mL 
in response to SLPs from RT 027 and levels remained the same with the transfection of 
100 nM miR-146a mimic.  
Next, the effects of over expressing miR-145 on NF-κB and IRF3 signalling were 
examined see Figure 5.2.10. Transfection with the miRNA mimic over expressing miR-
145 alone did not induce NF-κB or IRF3 signalling, expression remained at 1.0 fold 
consistent with the control Hek TLR4/MD2/CD14 cells. NF-κB was increased to 6.8 
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fold in response to LPS and these levels remained the same with the transfection of 100 
nM miR-145 mimic. NF-κB was increased to 4.7 fold in response to SLPs from RT 001 
and decreased to 3.9 fold with the transfection of 100 nM miR-145 mimic however this 
decrease was not significant. NF-κB was increased to 7.3 fold in response to SLPs from 
RT 027 and these levels remained the same with the transfection of 100 nM miR-145 
mimic. On the other hand IRF3 expression increased to 7.7 fold in response to LPS, 
however the transfection of miR-145 mimic decreased IRF3 expression to 4.5 fold (p≤ 
0.001) in response to LPS. IRF3 expression did not increase or decrease in response to 
SLPs from RT 001 and levels remained at 1.5 fold with the transfection of 100 nM miR-
145 mimic. IRF3 expression increased to 6.0 fold in response to SLPs from RT 027 and 
levels remained the same with the transfection of 100 nM miR-145 mimic. The profile 
as gene level were also reflected in the production of IL-8 and RANTES see Figure 
5.2.11. Transfection with the miR-145 mimic did not affect IL-8 and RANTES 
production, as they remained at levels consistent with the control Hek 
TLR4/MD2/CD14 cells. IL-8 production was increased to 2500 pg/mL in response to 
LPS and the levels remained the same with the transfection of 100 nM miR-145 mimic. 
IL-8 production was increased to 1500 pg/mL in response to SLPs from RT 001 and the 
levels remained the same with the transfection of 100 nM miR-145 mimic. IL-8 
production was increased to 2700 pg/mL in response to SLPs from RT 027 and levels 
remained the same with the transfection of 100 nM miR-145. RANTES expression 
increased to 390 pg/mL in response to LPS, while production decreased to 53 pg/mL 
(p≤ 0.001) with the transfection of the 100 nM miR-145 mimic. RANTES production 
did not increase or decrease in response to SLPs from RT 001 and levels remained the 
same with the transfection of the 100 nM miR-145 mimic. RANTES production 
increased to 450 pg/mL in response to SLPs from RT 027 and increased to 520 pg/mL 
with the transfection of 100 nM miR-145 mimic however this increase was not 
significant.  
The effect of over expressing miR-155 on NF-κB and IRF3 signalling was then studied 
see Figure 5.2.12. Transfection with the miRNA mimic over expressing miR-155 alone 
did not induce NF-κB or IRF3 signalling, expression remained at 1.0 fold consistent 
with the control Hek TLR4/MD2/CD14 cells. NF-κB was increased to 7.2 fold in 
response to LPS and these levels remained the same with the transfection of 100 nM 
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miR-155 mimic. NF-κB was increased to 4.7 fold in response to SLPs from RT 001 and 
these levels remained the same with the transfection of 100 nM miR-155 mimic. NF-κB 
was increased to 7.3 fold in response to SLPs from RT 027 and these levels remained 
the same with the transfection of 100 nM miR-155 mimic. On the other hand IRF3 
expression increased to 7.7 fold in response to LPS, however the transfection of miR-
155 mimic decreased IRF3 expression to 5.4 fold (p≤ 0.001) in response to LPS. IRF3 
expression was not increased or decreased in response to SLPs from RT 001 and levels 
remained at 1.5 fold with the transfection of the 100 nM miR-155 mimic. IRF3 
expression increased to 6.0 fold in response to SLPs from RT 027 and decreased to 5.5 
fold with the transfection of the 100 nM miR-155 mimic however this decrease was not 
significant. The profile as gene level was also reflected in the production of IL-8 and 
RANTES see Figure 5.2.13. Transfection with the miR-155 mimic did not affect IL-8 
and RANTES production, as they remained at levels consistent with the control Hek 
TLR4/MD2/CD14 cells. IL-8 production was increased to 2500 pg/mL in response to 
LPS and the levels remained the same with the transfection of 100 nM miR-155 mimic. 
IL-8 production was increased to 1500 pg/mL in response to SLPs from RT 001 and the 
levels remained the same with the transfection of 100 nM miR-155 mimic. IL-8 
production was increased to 2700 pg/mL in response to SLPs from RT 027 and 
decreased to 2300 pg/mL with the transfection of 100 nM miR-155 mimic however this 
decrease was not significant. RANTES expression increased to 350 pg/mL in response 
to LPS, while production decreased to 40 pg/mL (p≤ 0.001) with the transfection of 100 
nM miR-155 mimic. RANTES production did not increase or decrease in response to 
SLPs from RT 001 and levels remained the same with the transfection of 100 nM miR-
155 mimic. RANTES production increased to 450 pg/mL in response to SLPs from RT 
027 and levels remained the same with the transfection of 100 nM miR-155 mimic.  
Lastly the effect of over expressing let-7e on NF-κB and IRF3 signalling was studied 
see Figure 5.2.14. Transfection with miRNA mimic over expressing let-7e alone did 
not induce NF-κB or IRF3 signalling, expression remained at 1.0 fold consistent with 
the control Hek TLR4/MD2/CD14 cells. NF-κB was increased to 6.8 fold in response to 
LPS and these levels remained the same with the transfection of 100 nM let-7e mimic. 
NF-κB was increased to 4.7 fold in response to SLPs from RT 001 and these levels 
remained the same with the transfection of the 100 nM let-7e mimic. NF-κB was 
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increased to 7.3 fold in response to SLPs from RT 027 and these levels remained the 
same with the transfection of 100 nM let-7e mimic. On the other hand IRF3 expression 
increased to 7.7 fold in response to LPS, however the transfection of let-7e mimic 
decreased IRF3 expression to 6.0 fold (p≤ 0.001) in response to LPS. IRF3 expression 
was not increased or decreased in response to SLPs from RT 001 and levels remained at 
1.5 fold with the transfection of 100 nM let-7e mimic. IRF3 expression increased to 6.0 
fold in response to SLPs from RT 027 and levels remained the same with the 
transfection of 100 nM let-7e mimic. The profile as gene level was also reflected in the 
production of IL-8 and RANTES see Figure 5.2.15. Transfection with let-7e mimic did 
not affect IL-8 and RANTES production, as they remained at levels consistent with the 
control Hek TLR4/MD2/CD14 cells. IL-8 production was increased to 2500 pg/mL in 
response to LPS and the levels remained the same with the transfection of 100 nM let-
7e mimic. IL-8 production was increased to 1500 pg/mL in response to SLPs from RT 
001 and the levels remained the same with the transfection of 100 nM let-7e mimic. IL-
8 production was increased to 2700 pg/mL in response to SLPs from RT 027 and levels 
remained the same with the transfection of 100 nM let-7e mimic. RANTES expression 
increased to 350 pg/mL in response to LPS, while production decreased to 160 pg/mL 
(p≤ 0.001) with the transfection of the 100 nM let-7e mimic. RANTES production did 
not increase or decrease in response to SLPs from RT 001 and levels remained the same 
with the addition of the 100 nM let-7e mimic. RANTES production increased to 420 
pg/mL in response to SLPs from RT 027 and levels remained the same with the 
transfection of the 100 nM let-7e mimic.  
Therefore miRNA mimics over expressing miR-146a, miR-145, miR-155 and let-7e 
reduced IRF3 signalling in response to LPS, this was also reflected in RANTES 
production. We could not relate miRNA function of the individual miRNAs to IRF3 
signalling in response to SLPs from RT 001 and RT 027 in this experiment. LPS and 
SLPs from ribotype 027 signal through the same receptor and activate NF-κB and IRF3 
downstream of TLR4. However miR-146a, miR-145, miR-155 and let-7e appear to 
regulate IRF3 signalling differently in response to LPS compared with SLPs from 
ribotype 027. 
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5.2.3 MiRNAs were Enriched from RNA Derived from Colonic Tissue from an in 
vivo C. difficile Infection Model 
Up until now we have exclusively looked at miRNAs regulated in response to SLPs 
from RT 001 and RT 027 in a human and murine cell line. We identified four miRNAs 
of interest miR-146a, miR-145, miR-155 and let-7e. The next part of this chapter was to 
examine these miRNAs in colonic tissue from an in vivo C. difficile infection model, 
where mice had been infected with C. difficile spores from RT 001 and RT 027. Total 
RNA samples derived from colonic tissue had already been generated by Dr. Mark 
Lynch, a member of the Immunolodulation Research group (DCU), as part of his PhD 
research project. C57BL/6J mice were infected with C. difficile using an antibiotic-
induced model of mouse infection (Chen et al., 2008). There were four animals per 
treatment group: control group n=4, group treated with RT 001 n=4 and group treated 
with RT 027 n=4. Mice were treated for three days with an antibiotic mixture of 
Kanamycin (400 μg/mL), Gentamicin (35 μg/mL), Colistin (850 U/mL), Metronidazole 
(215 μg/mL) and Vancomycin (45 μg/mL) in the drinking water. Mice were 
subsequently given autoclaved water. On day 5, mice were injected intraperitoneally 
with Clindamycin (10 mg/kg). Mice were infected with 10
3
 C. difficile spores on day six 
by oral gavage. The colon was harvested from uninfected and infected mice after day 
three and seven of infection. Squares of tissue from the distal colon roughly 5 mm
3
 were 
cut for the preparation of RNA. Total RNA was extracted using the NucleoSpin® RNA 
II Total RNA Isolation Kit (Macherey-Nagel) as per manufacturer’s instructions. The 
RNA was quantified using a NanoDrop Spectrophotometer and then stored in the -80°C 
freezer until ready for use (Lynch 2014, unpublished). Firstly we had to determine if 
total RNA generated contained miRNAs and small RNA endogenous controls for our 
study. 
Small RNAs were enriched from 50 μg total RNA from samples generated in the C. 
difficile infection model using the mirVana™ miRNA Isolation Kit (Ambion) as per 
manufacturer’s instructions. The RNA was quantified following isolation using the 
NanoDrop® ND-1000 Spectrophotometer. The purity of the RNA was also examined 
by measuring the 260 nm and 280 nm absorption wavelengths, where RNA with an 
A260/A280 ratio between 1.8-2.1 was considered pure. RNA samples were 
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subsequently run on 1% agarose gels where the 28S and 18S rRNA bands were assessed 
to confirm integrity. Two bands were seen on the gel indicative of the 18S rRNA and 
28S rRNA band (see Appendix D). 100 ng enriched RNA was converted to first strand 
cDNA from each of the four biological replicates per treatment group and the products 
of which were used in a pre amplification reaction. Individual murine TaqMan miRNA 
assays with three technical replicates per group were run for each miRNAs and 
endogenous controls examined. The qPCR data was analysed using ExpressionSuite 
software, the threshold was set to 0.1 and the max Ct set to 37.0, as previously 
determined. There was also no miRNA expression detected in assays containing NTC 
(data not shown). We found that the RNA samples contained each of the three small 
RNA endogenous controls. snoRNA202 was chosen as the endogenous control for this 
study as it out performed snoRNA234 and mammU6 in samples from day 3 and day 7 
(see Appendix F). Relative gene expression was calculated and the student’s t-test was 
used to test for significance between mice treated with RT 001 and RT 027. Murine 
miR-146a, miR-145, miR-155 and let-7e were present in samples derived from colonic 
tissue from the in vivo C. difficile infection model. 
5.2.4 MiR-146a, miR-145, miR-155 and let-7e were Differentially Regulated in 
Colonic Tissue During C. difficile Infection with RT 001 and RT 027 
MiR-146a was differentially regulated in colonic tissue from mice infected with RT 001 
and RT 027, three and seven days post infection see Figure 5.2.16. Colonic tissue from 
control mice contained low levels of miR-146a. Three days post infection, colonic 
tissue from mice infected with RT 001 had a 1.4 fold increase in miR-146a compared to 
tissue from control mice. Colonic tissue from mice infected with RT 027 had a 0.7 fold 
decrease in miR-146a compared to tissue from control mice. MiR-146a was 
significantly decreased (p≤ 0.05) in colonic tissue from mice infected with RT 027 
compared with colonic tissue from mice infected with RT 001, three days post infection. 
However miRNA profiles changed seven days post infection. Colonic tissue from mice 
infected with RT 001 had a 1.2 fold increase in miR-146a compared to tissue from 
control mice. Whereas colonic tissue from mice infected with RT 027 had a 9.4 fold 
increase in miR-146a compared to tissue from control mice. MiR-146a was 
significantly increased (p≤ 0.001) in colonic tissue from mice infected with RT 027 
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compared with colonic tissue from mice infected with RT 001, seven days post 
infection. 
MiR-145 was differentially regulated in colonic tissue from mice infected with RT 001 
and RT 027, three and seven days post infection see Figure 5.2.17. Colonic tissue from 
control mice contained low levels of miR-145. Three days post infection, miR-145 
expression remained the same in colonic tissue from mice infected with RT 001 as in 
tissue from control mice. Colonic tissue from mice infected with RT 027 had a 0.2 fold 
decrease in miR-145 compared to tissue from control mice. MiR-145 was significantly 
decreased (p≤ 0.01) in colonic tissue from mice infected with RT 027 compared with 
colonic tissue from mice infected with RT 001, three days post infection. However 
miRNA profiles changed seven days post infection. Colonic tissue from mice infected 
with RT 001 had a 0.7 fold decrease in miR-145 compared to tissue from control mice. 
Whereas colonic tissue from mice infected with RT 027 had a 4.6 fold increase in miR-
145 compared to tissue from control mice. MiR-145 was significantly increased (p≤ 
0.001) in colonic tissue from mice infected with RT 027 compared with colonic tissue 
from mice infected with RT 001, seven days post infection. 
MiR-155 was differentially regulated in colonic tissue from mice infected with RT 001 
and RT 027, three days post infection see Figure 5.2.18. Colonic tissue from control 
mice contained low levels of miR-155. Three days post infection, colonic tissue from 
mice infected with RT 001 had a 25.6 fold increase in miR-155 compared to tissue from 
control mice. Colonic tissue from mice infected with RT 027 had a 1.7 fold increase in 
miR-155 compared to tissue from control mice. MiR-155 was significantly decreased 
(p≤ 0.01) in colonic tissue from mice infected with RT 027 compared with colonic 
tissue from mice infected with RT 001, three days post infection. However miRNA 
profiles changed seven days post infection. Colonic tissue from mice infected with RT 
001 had a 1.3 fold increase in miR-155 compared to tissue from control mice. Colonic 
tissue from mice infected with RT 027 had a 1.5 fold increase in miR-155 compared to 
tissue from control mice. MiR-155 expression was not significantly different when we 
compared its expression in colonic tissue from mice infected with RT 027 with colonic 
tissue from mice infected with RT 001, seven days post infection. 
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Let-7e was differentially regulated in colonic tissue from mice infected with RT 001 
and RT 027, three days post infection see Figure 5.2.19. Colonic tissue from control 
mice contained low levels of let-7e. Three days post infection, colonic tissue from mice 
infected with RT 001 had a 3.2 fold increase in let-7e compared to tissue from control 
mice. Colonic tissue from mice infected with RT 027 had a 1.2 fold increase in let-7e 
compared to tissue from control mice. Let -7e was significantly decreased (p≤ 0.01) in 
colonic tissue from mice infected with RT 027 compared with colonic tissue from mice 
infected with RT 001, three days post infection. However miRNA profiles changed 
seven days post infection. Colonic tissue from mice infected with RT 001 had a 1.3 fold 
increase in let-7e compared to tissue from control mice. Colonic tissue from mice 
infected with RT 027 had a 1.6 fold increase in let-7e compared to tissue from control 
mice. Let-7e expression was not significantly different when we compared its 
expression in colonic tissue from mice infected with RT 027 with colonic tissue from 
mice infected with RT 001, seven days post infection. 
5.2.5 Bioinformatics Analysis Reveals miRNAs Induced by SLPs from RT 001 and 
RT 027 Target Genes Involved in Essential Cell Signalling Pathways 
In chapter three we identified 24 miRNAs that were differentially regulated by SLPs 
from RT 001 and RT 027. We validated our results and showed miR-146a, miR-145, 
miR-155 and let-7e were differentially regulated in response to SLPs from RT 001 and 
RT 027 in a human and murine cell line. At the beginning of this chapter we were 
unable to link miR-146a, miR-145, miR-155 and let-7e individually to NF-κB and IRF3 
signalling downstream of TLR4 in response to SLPs from RT 001 and RT 027. 
However we confirmed that miR-146a, miR-145, miR-155 and let-7e were 
differentially regulated in colonic tissue during C. difficile infection with whole bacteria 
from RT 001 and RT 027. It is still possible that miRNA expression induced by SLPs 
modulate infection with RT 001 and RT 027. We know from the literature that miRNAs 
regulate many different targets, individual 3’ UTRs also contain binding sites for 
multiple miRNAs, allowing for elaborate and complicated networks in which 
redundancy and cooperation between miRNAs determine the effect on gene expression 
(Bartel, 2009; Martinez & Walhout, 2009; Obermayer & Levine, 2014; van Rooij, 
2011). We decided to utilise bioinformatics to identify possible miRNA/pathway/gene 
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interactions from the list of 24 miRNAs we showed were differentially regulated by 
SLPs from RT 001 and RT 027 experimentally. 
In the literature it is suggested that to select consensus targets, they must be identified 
by different prediction tools (Sun et al., 2010). We choose DIANA miRPath to carry out 
our searches as this prediction tool highlights targets that are also predicted by miRanda 
and TargetScan, two well-known prediction tools and targets which have also been 
verified experimentally in TarBase v6.0 (Paraskevopoulou et al., 2013; Vlachos et al., 
2012). DIANA miRPath uses miRNA names according to version 18 of miRBase, 
therefore we made sure we had the correct miRNA name for our targets according to 
this version. We inputted the list of miRNAs into miRConvertor on another database 
called miRSystem and crossed references the miRNA accession of each of our 24 
miRNAs of interest (see Appendix G). DIANA miRPath v2.0 is a free web-server 
which utilises miRNA targets in coding regions and 3’UTR regions provided by the 
DIANA-microT-CDS algorithm. The lists of 24 miRNAs of interest were inputted into 
the prediction tool where a posteriori analysis was performed. The significance levels 
between all possible miRNA pathway pairs were calculated using enrichment analysis. 
The previously calculated significance levels where combined with this to provide a 
merged p-value for each pathway by applying Fisher’s combined probability method. 
DIANA miRPath predicted that the 24 miRNAs of interest targeted 2551 genes in 146 
different pathways found in KEGG pathway database, 54 of these pathways had p-
values where p≤ 0.05 (see Appendix G). DIANA miRPath generated a heat map 
showing the 24 miRNAs versus 54 of the pathways where miRNA/gene/pathway 
interactions where p≤ 0.05. Darker colours represent lower significance values and the 
adjacent dendrograms depict hierarchical clustering. We identified miRNAs clustered 
together in two main clades exhibiting similar pathway targeting patterns see Figure 
5.2.20. The first clade contained two branches which were further sub divided, group 1 
contained branch tips for miR-221-3p, miR-1292, miR-215, miR-145-5p, miR-125a-5p, 
miR-432-3p, miR-146a-5p, miR-24-3p, miR-590-5p, let-7d-5p miR-422a, miR-339-5p 
and miR-586. Group 2 contained branch tips for let-7b-5p, let-7c, let-7e-5p and miR-
374a-5p. The second clade contained two branches which were further sub divided, 
group 1 contained branch tips for miR-148b-3p, miR-152, miR-9-3p, miR-155, miR-
132-3p, miR-543 while group 2 contained a single branch tip for miR-9-5p. 
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The top five KEGG pathways were selected for further analysis from the list of 54 
pathways generated in DIANA miRPath where miRNA/gene/pathway interactions had 
p-values of p≤ 0.05 see Table 5.2.1. DIANA miRPath predicted 15 genes were targeted 
by 6 of the miRNAs in ECM receptor interactions (p≤ 1E-16), Figure 5.2.21 shows an 
image generated in KEGG from this data. Genes highlighted in orange such as 
COL4A1, LAMA4, ITGA5, ITGA9, ITGA7 and ITGB6 present predicted targets for 
multiple miRNAs while genes highlighted in green were predicted not to be targeted by 
the miRNAs of interest. DIANA miRPath predicted 42 genes were targeted by 9 of the 
miRNAs in TGF-β signalling (p≤ 1E-16). Figure 5.2.22 shows an image generated in 
KEGG from this data. Genes highlighted in yellow such as GDF5, BMPR1A, SMAD7, 
SMURF2, LTBP1, SMAD3, SMAD2, CREBP, ROCK2, PPP2CB, RPS6KB1, FST, 
ACVR2A and PITX2 represent predicted targets for an individual miRNA. Genes 
highlighted in orange such as NOG, SMAD5, ID4, MAPK4, SKP1, DCN, TGFB2, 
TGFB1, TGFB2, ZFYVE, E2F5, TFDPs, INHRA, ACVR2A and ACVR1C represent 
predicted targets for multiple miRNAs and genes highlighted in green were predicted 
not to be targeted by the miRNAs of interest. DIANA miRPath predicted 98 genes were 
targeted by 10 of the miRNAs in MAPK signalling (p≤ 1E-16). Figure 5.2.23 shows an 
image generated in KEGG from this data. Genes highlighted in yellow such as 
CACNB4, CHUK, RELA, NTF3, NTRK2, RASGRP1, RPSKA1, FGFR1, PDGFRB, 
STMN1, PLA2G4E, RAF1, GNA12, MYC, DUSP5, PPP2R1, TRAF6, AKT1, 
MAPK1, MAX, MAP2K AND GADD4 represent predicted targets for an individual 
miRNA. Genes highlighted in orange such as NGF, BDNF, FGF7, SOS1, KRAS, 
RASA, RASGRP2, RAP1, MAPK1, ELK4, SRF, FOS, IL1A, FASLG, TGFBR, 
CASP3, PAK2, MAP4K, FLNA, CRK, NFATC, HSPA8, MAP2K and TAOK1 
represent predicted targets for multiple miRNAs and genes highlighted in green were 
predicted not to be targeted by the miRNAs of interest.  
DIANA miRPath predicted 121 genes were targeted by 11 of the miRNAs in PI3K-Akt 
signalling pathway (p≤ 1E-16). Figure 5.2.24 shows an image generated in KEGG from 
this data. Genes highlighted in yellow such as EFNA1, PKN2, PRKCA, RAF2, IL2, 
ITGA8, PTK, AKT2, RELA, CHUK, CREB2, FASLG, PPP2CB and GSK3B represent 
predicted targets for an individual miRNA. Genes highlighted in orange such as 
LAMA4, TEK, IL6R, ITGB1, PTEN, PIK3CA, SOS1, KRAS, PRKA, TSC1, EIF4E, 
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RPS6KB1, SGK3, MAPK1, MYB, PIK2CA, CDKN1A and FOXO3 represent 
predicted targets for multiple miRNAs and genes highlighted in green were predicted 
not to be targeted by the miRNAs of interest. DIANA miRPath predicted 74 genes were 
targeted by 10 miRNAs in Focal adhesion (p≤ 1.1E-16). Figure 5.2.25 shows an image 
generated in KEGG from this data. Genes highlighted in yellow such as ITGA6, 
ITGB1, RASGRF, ROCK2, SRC, VCL, MYLK, AKT3, PAK4, CTNNB1, SHC1 and 
RAF1 represent predicted targets for an individual miRNA. Genes highlighted in orange 
such as LAMA4, ARHGAP2, PPP1CB, ACTB, FLNA, CAV2, PTK2, PTEN, PIK3CA, 
VAV3, CCND2, CRK, RAP1B, MAPK8, IGF1, FLT1, MAPK4 and XIAP represent 
predicted targets for multiple miRNAs and genes highlighted in green were predicted 
not to be targeted by the miRNAs of interest. 
5.2.6 Forty-nine Genes Crossed Two or More Pathways from the Top Five Analysed, 
Most Genes had Predicted Binding sites in the 3’UTR regions for the miRNAs of 
Interest according to TargetScan 
DIANA miRPath analysis identified 350 genes in total from the top 5 KEGG pathways 
that were targeted by the miRNAs of interest. The number and distribution of miRNA 
binding sites is particularly important. Studies have demonstrated that two sites in the 
same or different miRNAs can act synergistically and that the distance between 
neighbouring miRNA binding sites affects the strength of the target down regulation 
(Koscianska et al., 2015). Specifically, optimal down-regulation was observed when the 
distance between the 3’ end of the first miRNA site and the 5’ end of the subsequent 
one was > 7 and < 40 nt and when the 5’ ends of both miRNA seeds were separated by 
between 13 and 35 nt (Grimson et al., 2007; Saetrom et al., 2007). However, miRNA 
target interactions are not only bidirectional but rather form complex networks as 
previously mentioned, therefore the target site’s activity will depend on its surrounding 
context (Saetrom et al., 2007). The online tool TargetScan searches for conserved seed 
regions of 7 and 8 nucleotides in length as well as for 3' compensated sites in 3'-UTRs. 
It ranks its predicted results based on further miRNA/mRNA binding properties 
including seed pairing, stability and target site abundance. Therefore we inputted each 
of the 350 genes into the TargetScan database to confirm if there were possible binding 
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sites in the 3’UTR regions of each gene for any of the 24 miRNAs which were 
expressed in response to SLPs from RT 001 and RT 027.  
We identified the individual positions within the 3’UTR region, the type of seed match 
and the probability of conserved targeting PCT (see Appendix G). Upon analysis of the 
gene lists we noticed that some genes came up as targets in more than one pathway. 
Therefore we cross referenced the gene lists from the 5 pathways and found 49 genes 
crossed two or more pathways see Table 5.2.2. MAPK1 was found in four of the five 
KEGG pathways; Focal adhesion, PI3K-AKT, TGF-β and MAPK signalling, however it 
did not contain any predicted miRNA binding sites for the miRNAs of interest 
according to TargetScan. The following genes; ITGA9, COL27A1, ITGB6, ITGA5, 
COL3A1, ITGA11, COL2A1, COL4A2, COL1A1, ITGA7, COL4A6, COL5A2, 
COL4A1 and LAMA4, were found in three of the five pathways; ECM-receptor 
interactions, PI3K-AKT signalling and focal adhesion. All genes except COL27A1, 
ITGB6 and ITGA7 contained possible binding sites for the miRNAs of interest. 
AKT1 and SOS2 were found in three of the five pathways; Focal adhesion, PI3K-AKT 
and MAPK signalling. SOS1 contained possible binding sites for the miRNAs of 
interest however AKT1 did not. The following genes; FGF12, NFKB1, NRAS, CHUK, 
KRAS, SOS1, FGF9, FGF18, NGF, RASGRF1, RELA and FGFR1, were found in two 
of the five pathways; PI3K-AKT and MAPK signalling. All genes except NFKB1 and 
FGF18 contained possible binding sites for the miRNAs of interest. RAP1A and 
MAPK8 were found in two of the five pathways; focal adhesion and MAPK signalling, 
neither genes contained possible binding sites for the miRNAs of interest. ROCK1, 
ITGB8 and ROCK2 were found in two of the five pathways; Focal adhesion and TGF-β 
signalling. ROCK2 and ITGB8 contained possible binding sites for the miRNAs of 
interest, while ROCK1 did not. The following genes; COL4A5, RAF1, PIK3R3, PDK1, 
VEGFC, ITGA2, COL1A2, AKT3, COL11A1, PTEN and COL4A4, were found in two 
of the five pathways; focal adhesion and PI3K-AKT signalling. All genes except 
VEGFC, ITGA2, AKT3 and COL4A4 contained possible binding sites for the miRNAs 
of interest. The following genes; PPP2CB, RPS6KB1, PPP2CA and RPS6KB2, were 
found in two of the five pathways; PI3K-Akt and TGF-β signalling. All genes except 
PPP2CA and RPS6KB2 contained possible binding sites for the miRNAs of interest.  
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Analysis showed that some genes were found in the PI3K-Akt signalling pathway only 
and all genes except PRLR, PPP2R2C, HSP90AA1, IL17R, PPP2R5A, IL4, IL2, 
THEM4, PPP2R3C, CHRM2, ANGPT1 and FN1 contained possible binding sites for 
the miRNAs of interest see Table 5.2.3. Genes found in the TGF-β signalling pathway 
only are shown in Table 5.2.4 and All genes except ID2, SMAD9, SMURF2, BMP5, 
INHBA, DCN, BMP2, TFDP1, BMPR1A and CREBBP contained possible binding 
sites for the miRNAs of interest. Genes found to be involved in focal adhesion included; 
ACTB, SHC1, COL24A1, PPP1CC, PAK7, VCL, CAV2, PPP1R12A, CTNNB1, 
DIAPH1, SRC, PAK4, MYLK3, BIRC3, VAV3, ARHGAP5, MYLK, XIAO and 
PPP1CB. All genes except PPP1CC, PAK7, CTNNB1, DIAPH1, MYLK3 and BIRC3 
contained possible binding sites for the miRNAs of interest see Table 5.2.5. Analysis 
showed that some genes were found in the MAPK signalling pathway only. All genes 
except NTRK2, DUSP22, CACNA1G, PTPRQ, DUSP14, RASGRF2, LAMTOR3, 
RASGRP2, MAP2K6, NFATC2, MYC, HSPA8, MECOM, STMN1, MAP3K2, 
PPM1B, CACNA2D1, PLA2G4E, MAP3K7 and MAPKAPK2 contained possible 
binding sites for the miRNAs of interest see Table 5.2.6. All 15 genes that were 
identified as being targeted in the ECM receptor were found in two or more of the other 
five KEGG pathways. 
5.2.7 Genes with Predicted Binding Sites for the miRNAs of Interest are found in 
Distinctive Groups, Examples from IL-6, NRAS, SMAD2, SOS1 and TRAF6 
We selected 5 genes from each of the top 5 KEGG pathways for a more in depth look at 
the position of potential binding sites for the 24 miRNAs of interest in the 3’UTR 
region of each of the genes. The IL-6 receptor gene contained possible binding sites for 
several of the miRNAs which were differentially regulated by SLPs from RT 001 and 
RT 027 see Figure 5.2.26. MiR-125a-5p contained a predicted binding site at position 
836-842 (5’-3’) on the IL6R 3’UTR (PCT 0.73). MiR-590-5p and miR-155-5p were 
predicted to be located further downstream on the IL6R gene to miR-125a-5p but in 
close proximity to each other. MiR-590-5p and miR-155-5p were predicted at position 
2954-2961 (PCT 0.78) and 3300-3307 (PCT 0.45) respectively. The 3’ end of miR-590-5p 
was 353 nt away from the 5’ end of miR-155, while the 5’ end of both miRNAs were 
346 nt away. MiR-9-5p, let-7b-5p, let-7c-5p, let-7d-5p and let-7e-5p were predicted to 
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be located further downstream on the IL6R gene from miR-590-5p and miR-155-5p, but 
in close proximity to each other. MiR-9-5p was predicted at position 4164-4170 (PCT 
0.56) and let-7b/c/d/e-5p were all predicted to be at positions 4077-4083 (PCT 0.94). The 
3’ end of miR-9-5p was 81 nt away from each of the 5’ ends of let-7b/c/d/e-5p, while 
the 5’ end of miR-9-5p was 87 nt away from the 5’ ends of let-7b/c/d/e-5p. MiRNA 
binding sites were clustered in three distinct locations on the 3’UTR region of the IL-6 
receptor gene.  
The NRAS gene contained possible binding sites for eight miRNAs which were 
differentially regulated by SLPs from RT 001 and RT 027 see Figure 5.2.27. MiR-152-
3p, miR-148b-3p, miR-146a-5p, let-7b-5p, let-7c-5p, let-7d-5p and let-7e-5p had 
predicted binding sites in close proximity to each other. MiR-152-3p and miR-148b-3p 
were predicted to be located at position 45-52 (5’-3’) on NRAS (PCT 0.88). MiR-146a-
5p was predicted to be located at position 172-179 (PCT <0.1). The 3’ end of miR-152-
3p and miR-148b-3p were 134 nt away from the 5’ end of miR-146a-5p, while the 5’ 
ends of miR-152-3p and miR-148b-3p were 127 nt away from miR-146a-5p. Let-
7b/c/d/e-5p were predicted to be located at position 186-192 (PCT > 0.99). The 3’ end of 
miR-152-3p and miR-148b-3p were 147 nt away from let-7b/c/d/e-5p, while the 3’ end 
of miR-146a-5p was 20 nt away from let-7b/c/d/e-5p. The 5’ end of miR-152-3p and 
miR-148b were 140 nt away from let-7b/c/d/e-5p, while the 5’ end of miR-146a-5p was 
13 nt away from let-7b/c/d/e-5p. Second binding sites were predicted for let-7b/c/d/e-5p 
further downstream on the NRAS gene at positions 2592-2598 (PCT 0.87). MiR-145-5p 
had predicted binding site further downstream on the NRAS gene at position 3599-3606 
(PCT 0.84). MiRNA binding sites were clustered in three distinct locations on the 3’UTR 
region of the NRAS gene and there may be synergy between miR-146a-5p and let-
7b/c/d/e-5p between positions 172-192 on the NRAS gene. 
The SMAD2 gene contained possible binding sites for ten miRNAs which were 
differentially regulated by SLPs from RT 001 and RT 027 see Figure 5.2.28. MiR-132-
3p and miR-125a-5p had predicted binding sites in close proximity to each other. MiR-
132-3p was predicted to be located at position 77-83 (5’-3’) on SMAD2 (PCT 0.46). 
MiR-125a-5p was predicted to be located at position 977-963 (PCT 0.80). The 3’ end of 
miR-132-3p was 851 nt away from the 5’ end of miR-125a-5p, while the 5’ end of miR-
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132-3p was 900 nt away from the 5’ end of miR-125a-5p. Predicted binding sites for 
let-7b-5p, let-7c-5p, let-7d-5p and let-7e-5p were located further downstream from miR-
132-3p and miR-125a-5p on the SMAD2 gene. Let-7b/c/d/e-5p had predicted binding 
sites located at position 3772-3778 (PCT 0.79). Predicted binding sites for miR-145-5p, 
miR-152-3p, miR-148b and miR-155-5p were located further downstream from 
7b/c/d/e-5p on the SMAD2 gene. MiR-145-5p had predicted binding sites located at 
position 7056-7062 (PCT 0.38). MiR-152-3p and miR-148b-3p had predicted binding 
sites at positions 8334-8340 (PCT 0.65). The 3’ end of miR-145-5p was 1284 nt away 
from the 5’ end of miR-152-3p and miR-148b-3p, while the 5’ end of miR-145-5p was 
1278 nt away from the 5’ end of miR-152-3p and miR-148b-3p. A predicted binding 
site for miR-155-5p was located at position 8694-8701 (PCT 0.78). The 3’ end of miR-
145-5p was 1645 nt away from the 5’ end of miR-155-5p, while the 3’ ends of miR-
152-3p and miR-148-3p were 364 nt away from the 5’ end of miR-155-5p. The 5’ end 
of miR-145-5p was 1639 nt away from the 5’ end of miR-155-5p, while the 5’ ends of 
miR-152-3p and miR-148-3p were 361 nt away from the 5’ end of miR-155-5p. 
MiRNA binding sites were clustered in three distinct locations on the 3’UTR region of 
the SMAD2 gene. 
The SOS1 gene contained possible binding sites for five miRNAs which were 
differentially regulated by SLPs from RT 001 and RT 027 see Figure 5.2.29. MiR-152-
3p, miR-148b-3p, miR-9-5p and miR-132-3p had predicted binding sites in close 
proximity to each other. MiR-152-3p and miR-148b-3p were predicted to be located at 
position 58-65 (5’-3’) on SOS1 (PCT 0.59). MiR-9-5p had a predicted binding site 
located at position 597-604 (PCT 0.87). The 3’ ends of miR-152-3p and miR-148b-3p 
were 539 nt away from the 5’ end of miR-9-5p, while the 5’ ends of miR-152-3p and 
miR-148b-3p were 539 nt away from the 5’ end of miR-9-5p. MiR-132-3p had a 
predicted binding site located at position 798-804 (PCT 0.38). The 3’ ends of miR-152-
3p and miR-148b-3p were 739 nt away from the 5’ end of miR-132-3p, while the 3’ end 
of miR-9-5p was 207 nt away from the 5’ end of miR-132-3p. The 5’ ends of miR-152-
3p and miR-148b-3p were 739 nt away from the 5’ end of miR-132-3p, while the 5’ end 
of miR-9-5p was 200 nt away from miR-132-3p. MiR-155-5p was located further 
downstream than miR-152-3p, miR-148b-3p, miR-9-5p and miR-132-3p on the SOS 1 
gene. MiR-155-5p had a predicted binding site located at position 3666-3672 (PCT 0.36). 
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miRNA binding sites were clustered in two distinct locations on the 3’UTR region of 
the SOS1 gene. The TRAF6 gene contained possible binding sites for two miRNAs 
which were differentially regulated by SLPs from RT 001 and RT 027 see Figure 
5.2.30. Unlike the other genes the miRNAs were clustered in one group on the 3’UTR 
region. There were three predicted binding sites for miR-146a-5p located at positions 
473-480 (PCT< 0.1), 538-545 (PCT< 0.1) and 1272-1279 (PCT< 0.1) respectively. MiR-
125a-5p had a predicted binding site located at position 1276-1283 (PCT 0.60). The 3’ 
ends of miR-146a-5p were 810, 745 and 11 nt away from the 5’ end of miR-125a-5p, 
while the 5’ ends of the miR-146a-5p were 803, 738 and 4 nt away from the 5’ end of 
miR-125a-5p. There may be synergy between miR-146a-5p and miR-125a-5p between 
positions 1272-1283 on the 3’ UTR region of TRAF6. 
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Figure 5.2.1 MiRNA mimic over expressing miR-146a decrease RANTES 
production in a dose dependent but do not effect IL-8 production in response to 
LPS. Hek TLR4/MD2/CD14 cells were plated at 1x10
6
 cells/mL and allowed to adhere 
for 18 hours to approximately 60% confluency. The cells were then transfected with 
NF-κB (80 ng) or pFA-IRF3 (30 ng) and pFR-regulated firefly luciferase (60 ng). Both 
sets of plasmid DNA were co-transfected with constitutively expressed TK renilla 
luciferase (20 ng) and +/- 0-100 nM miR-146a mimic. 24 hours post transfection cells 
were stimulated with 100 ng/mL for 18 hours. Cells supernatants were collected and 
human A) IL-8 and B) RANTES was measured by ELISA. The results show the mean 
(± SEM) measured in triplicate, one-way ANOVA followed by Newman-Keuls analysis 
was used to determine if differences between groups were significantly different 
compared to cells stimulated with LPS, where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. 
The results are indicative of three independent experiments. 
A) 
B) 
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Figure 5.2.2 MiRNA mimic over expressing miR-145 decrease RANTES 
production in a dose dependent manner but do not significantly affect IL-8 
production in response to LPS. Hek TLR4/MD2/CD14 cells were plated at 1x10
6
 
cells/mL and allowed to adhere for 18 hours to approximately 60% confluency. The 
cells were then transfected with NF-κB (80 ng) or pFA-IRF3 (30 ng) and pFR-regulated 
firefly luciferase (60 ng). Both sets of plasmid DNA were co-transfected with 
constitutively expressed TK renilla luciferase (20 ng) and +/- 0-100 nM miR-145 
mimic. 24 hours post transfection cells were stimulated with 100 ng/mL for 18 hours. 
Cells supernatants were collected and human A) IL-8 and B) RANTES was measured 
by ELISA. The results show the mean (± SEM) measured in triplicate, one-way 
ANOVA followed by Newman-Keuls analysis was used to determine if differences 
between groups were significantly different compared to cells stimulated with LPS, 
where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. The results are indicative of three 
independent experiments. 
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Figure 5.2.3 MiRNA mimic over expressing miR-155 decrease RANTES 
production in a dose dependent manner but does not affect IL-8 production in 
response to LPS. Hek TLR4/MD2/CD14 cells were plated at 1x10
6
 cells/mL and 
allowed to adhere for 18 hours to approximately 60% confluency. The cells were then 
transfected with NF-κB (80 ng) or pFA-IRF3 (30 ng) and pFR-regulated firefly 
luciferase (60 ng). Both sets of plasmid DNA were co-transfected with constitutively 
expressed TK renilla luciferase (20 ng) and +/- 0-100 nM miR-155 mimic. 24 hours 
post transfection cells were stimulated with 100 ng/mL for 18 hours. Cells supernatants 
were collected and human A) IL-8 and B) RANTES was measured by ELISA. The 
results show the mean (± SEM) measured in triplicate, one-way ANOVA followed by 
Newman-Keuls analysis was used to determine if differences between groups were 
significantly different compared to cells stimulated with LPS, where * p≤ 0.05, ** p≤ 
0.01 and *** p≤ 0.001. The results are indicative of three independent experiments. 
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Figure 5.2.4 1nM and 100 nM miRNA mimic over expressing let-7e decreases 
RANTES production but do not effect IL-8 production when stimulated with LPS. 
Hek TLR4/MD2/CD14 cells were plated at 1x10
6
 cells/mL and allowed to adhere for 18 
hours to approximately 60% confluency. The cells were then transfected with NF-κB 
(80 ng) or pFA-IRF3 (30 ng) and pFR-regulated firefly luciferase (60 ng). Both sets of 
plasmid DNA were co-transfected with constitutively expressed TK renilla luciferase 
(20 ng) and +/- 0-100 nM let-7e mimic. 24 hours post transfection cells were stimulated 
with 100 ng/mL LPS for 18 hours. Cells supernatants were collected and human A) IL-8 
and B) RANTES was measured by ELISA. The results show the mean (± SEM) 
measured in triplicate, one-way ANOVA followed by Newman-Keuls analysis was used 
to determine if differences between groups were significantly different compared to 
cells stimulated with LPS, where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. The results 
are indicative of three independent experiments. 
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Figure 5.2.5 Transfection of plasmid DNA, miRNA mimics and stimulation with 
LPS and SLPs from RT 001 and RT 027 do not notably affect viability of the Hek 
TLR4/MD2/CD14 cells. Hek TLR4/MD2/CD14 cells were plated at 1x10
6
 cells/mL 
and allowed to adhere for 18 hours to approximately 60% confluency. The cells were 
then transfected with NF-κB (80 ng) or pFA-IRF3 (30 ng) and pFR-regulated firefly 
luciferase (60 ng). Both sets of plasmid DNA were co-transfected with constitutively 
expressed TK renilla luciferase (20 ng) and +/- 100 nM of each of the miRNA mimics. 
24 hours post transfection cells were stimulated with 100 ng/mL LPS or SLPs from RT 
001/ RT 027 for 18 hours. Cellular viability was then assessed using an MTS assay. 
Cells treated with 10% DMSO were used as a positive control. Results are expressed as 
a percentage of untreated cells with the mean ± SEM of triplicate assays. Data 
represents three independent experiments. 
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Figure 5.2.6 The positive control miRNA mimic decreased NF-κB and IRF3 gene 
expression in response to LPS and SLPs from RT 001 and 027. Hek 
TLR4/MD2/CD14 cells were plated at 1x10
6
 cells/mL and allowed to adhere for 18 
hours to approximately 60% confluency. The cells were transfected with A) NF-κB (80 
ng) or B) pFA-IRF3 (30 ng) and pFR-regulated firefly luciferase (60 ng). Both sets of 
plasmid DNA were co-transfected with constitutively expressed TK renilla luciferase 
(20 ng) and +/- 100 nM positive or negative control miRNA mimic. 24 hours post 
transfection cells were stimulated with 100 ng/mL LPS or 20µg/mL SLPs from RT 
001/RT 027 for 18 hours. Lysates were generated and assayed for firefly and renilla 
luciferase activity. The Renilla luciferase plasmid was used to normalise for transfection 
efficiency in all experiments. The results show the mean (± SEM) measured in 
triplicate, one-way ANOVA followed by Newman-Keuls analysis was used to 
determine if differences between groups were significantly different, where * p≤ 0.05, 
** p≤ 0.01 and *** p≤ 0.001. The results are indicative of three independent 
experiments. 
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Figure 5.2.7 The positive control miRNA mimic decreased IL-8 and RANTES 
cytokine production in response to LPS and SLPs from RT 001 and 027. Hek 
TLR4/MD2/CD14 cells were plated at 1x10
6
 cells/mL and allowed to adhere for 18 
hours to approximately 60% confluency. The cells were then transfected with NF-κB 
(80 ng) or pFA-IRF3 (30 ng) and pFR-regulated firefly luciferase (60 ng). Both sets of 
plasmid DNA were co-transfected with constitutively expressed TK renilla luciferase 
(20 ng) and +/- 100 nM positive/negative control miRNA mimics. 24 hours post 
transfection cells were stimulated with 100 ng/mL LPS or SLPs from RT 001/ RT 027 
for 18 hours. Cells supernatants were collected and human A) IL-8 and B) RANTES 
was measured by ELISA. The results show the mean (± SEM) measured in triplicate, 
one-way ANOVA followed by Newman-Keuls analysis was used to determine if 
differences between groups were significantly different compared to cells stimulated 
with LPS, where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. The results are indicative of 
three independent experiments. 
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Figure 5.2.8 MiR-146a targets IRF3 signalling in response to LPS but not in 
response to SLPs from RT 001 and RT 027. Hek TLR4/MD2/CD14 cells were plated 
at 1x106 cells/mL and allowed to adhere for 18 hours to approximately 60% 
confluency. The cells were transfected with A) NF-κB (80 ng) or B) pFA-IRF3 (30 ng) 
and pFR-regulated firefly luciferase (60 ng). Both sets of plasmid DNA were co-
transfected with constitutively expressed TK renilla luciferase (20 ng) and +/- 100 nM 
miR-146a mimic. 24 hours post transfection cells were stimulated with 100 ng/mL LPS 
or 20µg/mL SLPs from RT 001/RT 027 for 18 hours. Lysates were generated and 
assayed for firefly and renilla luciferase activity. The Renilla luciferase plasmid was 
used to normalise for transfection efficiency in all experiments. The results show the 
mean (± SEM) measured in triplicate, one-way ANOVA followed by Newman-Keuls 
analysis was used to determine if differences between groups were significantly 
different, where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. The results are indicative of 
three independent experiments. 
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Figure 5.2.9 MiR-146a targets RANTES production in response to LPS but not in 
response to SLPs from RT 001 and RT 027. Hek TLR4/MD2/CD14 cells were plated 
at 1x10
6
 cells/mL and allowed to adhere for 18 hours to approximately 60% confluency. 
The cells were then transfected with NF-κB (80 ng) or pFA-IRF3 (30 ng) and pFR-
regulated firefly luciferase (60 ng). Both sets of plasmid DNA were co-transfected with 
constitutively expressed TK renilla luciferase (20 ng) and +/- 100 nM miR146a mimic. 
24 hours post transfection cells were stimulated with 100 ng/mL LPS or SLPs from RT 
001/ RT 027 for 18 hours. Cells supernatants were collected and human A) IL-8 and B) 
RANTES was measured by ELISA. The results show the mean (± SEM) measured in 
triplicate, one-way ANOVA followed by Newman-Keuls analysis was used to 
determine if differences between groups were significantly different compared to cells 
stimulated with LPS, where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. The results are 
indicative of three independent experiments. 
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Figure 5.2.10 MiR-145 targets IRF3 signalling in response to LPS but not in 
response to SLPs from RT 001 and RT 027. Hek TLR4/MD2/CD14 cells were plated 
at 1x10
6
 cells/mL and allowed to adhere for 18 hours to approximately 60% confluency. 
The cells were transfected with A) NF-κB (80 ng) or B) pFA-IRF3 (30 ng) and pFR-
regulated firefly luciferase (60 ng). Both sets of plasmid DNA were co-transfected with 
constitutively expressed TK renilla luciferase (20 ng) and 100 nM miR-146a mimic. 24 
hours post transfection cells were stimulated with 100 ng/mL LPS or 20 µg/mL SLPs 
from RT 001/RT 027 for 18 hours. Lysates were generated and assayed for firefly and 
renilla luciferase activity. The Renilla luciferase plasmid was used to normalise for 
transfection efficiency in all experiments. The results show the mean (± SEM) measured 
in triplicate, one-way ANOVA followed by Newman-Keuls analysis was used to 
determine if differences between groups were significantly different, where * p≤ 0.05, 
** p≤ 0.01 and *** p≤ 0.001. The results are indicative of three independent 
experiments. 
A) 
B) 
  
 215  
IL-8
0
1000
2000
3000
4000
Hek TLR4/MD2/CD14
p
g
/m
l
RANTES
0
100
200
300
400
500
600
LPS 100 ng/mL- - + + - - --
- - - - + + -- RT 001  20 g/mL
RT 027  20 g/mL
miR-145 mimic 100 nM
- - - - - - ++
- + - + - + +-
***
p
g
/m
l
 
Figure 5.2.11 MiR-145 targets RANTES production in response to LPS but not in 
response to SLPs from RT 001 and RT 027. Hek TLR4/MD2/CD14 cells were plated 
at 1x10
6
 cells/mL and allowed to adhere for 18 hours to approximately 60% confluency. 
The cells were then transfected with NF-κB (80 ng) or pFA-IRF3 (30 ng) and pFR-
regulated firefly luciferase (60 ng). Both sets of plasmid DNA were co-transfected with 
constitutively expressed TK renilla luciferase (20 ng) and +/- 100 nM miR145 mimic. 
24 hours post transfection cells were stimulated with 100 ng/mL LPS or SLPs from RT 
001/ RT 027 for 18 hours. Cells supernatants were collected and human A) IL-8 and B) 
RANTES was measured by ELISA. The results show the mean (± SEM) measured in 
triplicate, one-way ANOVA followed by Newman-Keuls analysis was used to 
determine if differences between groups were significantly different compared to cells 
stimulated with LPS, where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. The results are 
indicative of three independent experiments. 
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Figure 5.2.12 MiR-155 targets IRF3 signalling in response to LPS but not in 
response to SLPs from RT 001 and RT 027. Hek TLR4/MD2/CD14 cells were plated 
at 1x10
6
 cells/mL and allowed to adhere for 18 hours to approximately 60% confluency. 
The cells were transfected with A) NF-κB (80 ng) or B) pFA-IRF3 (30 ng) and pFR-
regulated firefly luciferase (60 ng). Both sets of plasmid DNA were co-transfected with 
constitutively expressed TK renilla luciferase (20 ng) and 100 nM miR-155 mimic. 24 
hours post transfection cells were stimulated with 100 ng/mL LPS or 20µg/mL SLPs 
from RT 001/RT 027 for 18 hours. Lysates were generated and assayed for firefly and 
renilla luciferase activity. The Renilla luciferase plasmid was used to normalise for 
transfection efficiency in all experiments. The results show the mean (± SEM) measured 
in triplicate, one-way ANOVA followed by Newman-Keuls analysis was used to 
determine if differences between groups were significantly different, where * p≤ 0.05, 
** p≤ 0.01 and *** p≤ 0.001. The results are indicative of three independent 
experiments. 
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Figure 5.2.13 MiR-155 targets RANTES production in response to LPS but not in 
response to SLPs from RT 001 and RT 027. Hek TLR4/MD2/CD14 cells were plated 
at 1x10
6
 cells/mL and allowed to adhere for 18 hours to approximately 60% confluency. 
The cells were then transfected with NF-κB (80 ng) or pFA-IRF3 (30 ng) and pFR-
regulated firefly luciferase (60 ng). Both sets of plasmid DNA were co-transfected with 
constitutively expressed TK renilla luciferase (20 ng) and +/- 100 nM miR-155 mimic. 
24 hours post transfection cells were stimulated with 100 ng/mL LPS or SLPs from RT 
001/ RT 027 for 18 hours. Cells supernatants were collected and human A) IL-8 and B) 
RANTES was measured by ELISA. The results show the mean (± SEM) measured in 
triplicate, one-way ANOVA followed by Newman-Keuls analysis was used to 
determine if differences between groups were significantly different compared to cells 
stimulated with LPS, where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. The results are 
indicative of three independent experiments. 
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Figure 5.2.14 Let-7e targets IRF3 signalling in response to LPS but not in response 
to SLPs from RT 001 and RT 027. Hek TLR4/MD2/CD14 cells were plated at 1x10
6
 
cells/mL and allowed to adhere for 18 hours to approximately 60% confluency. The 
cells were transfected with A) NF-κB (80 ng) or B) pFA-IRF3 (30 ng) and pFR-
regulated firefly luciferase (60 ng). Both sets of plasmid DNA were co-transfected with 
constitutively expressed TK renilla luciferase (20 ng) and 100 nM let-7e mimic. 24 
hours post transfection cells were stimulated with 100 ng/mL LPS or 20µg/mL SLPs 
from RT 001/RT 027 for 18 hours. Lysates were generated and assayed for firefly and 
renilla luciferase activity. The Renilla luciferase plasmid was used to normalise for 
transfection efficiency in all experiments. The results show the mean (± SEM) measured 
in triplicate, one-way ANOVA followed by Newman-Keuls analysis was used to 
determine if differences between groups were significantly different, where * p≤ 0.05, 
** p≤ 0.01 and *** p≤ 0.001. The results are indicative of three independent 
experiments. 
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Figure 5.2.15 Let-7e targets RANTES production in response to LPS but not in 
response to SLPs from RT 001 and RT 027. Hek TLR4/MD2/CD14 cells were plated 
at 1x10
6
 cells/mL and allowed to adhere for 18 hours to approximately 60% confluency. 
The cells were then transfected with NF-κB (80 ng) or pFA-IRF3 (30 ng) and pFR-
regulated firefly luciferase (60 ng). Both sets of plasmid DNA were co-transfected with 
constitutively expressed TK renilla luciferase (20 ng) and +/- 100 nM let-7e mimic. 24 
hours post transfection cells were stimulated with 100 ng/mL LPS or SLPs from RT 
001/ RT 027 for 18 hours. Cells supernatants were collected and human A) IL-8 and B) 
RANTES was measured by ELISA. The results show the mean (± SEM) measured in 
triplicate, one-way ANOVA followed by Newman-Keuls analysis was used to 
determine if differences between groups were significantly different compared to cells 
stimulated with LPS, where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. The results are 
indicative of three independent experiments. 
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Figure 5.2.16 MiR-146a is differentially regulated in colonic tissue of mice treated 
with RT 027 at day 3 and day 7 of infection. Total RNA derived from colonic tissue 
from an in vivo model of C. difficile was enriched for miRNAs using the mirVana 
Isolation kit, there were 4 animals per treatment group: control group n=4, group treated 
with RT 001 n=4 and group treated with RT 027 n=4. 100 ng RNA enriched for 
miRNAs was converted to first strand cDNA, the products of which were used in a pre-
amp PCR reaction. Samples were added to PCR reaction mixes for individual Taqman 
miRNA assays and added to wells on a 96 well PCR plate. The plate was run on the 
Applied Biosystems 7900HT Fast Real Time PCR Machine. The SDS files were 
exported and data from the PCR plate was analysed using ExpressionSuite software. 
The max Ct was set to 37.0 with a threshold of 0.1 and the reference group was set to 
the control group. snoRNA202 was used to correct for variation of RNA input and 
relative gene expression was calculated. The results show the mean (± SEM) measured 
in triplicate, a student’s t-test was used to test for significance by comparing samples of 
colonic tissue of mice treated with RT 001 with RT 027 where * p≤ 0.05, ** p≤ 0.01 
and *** p≤ 0.001. 
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Figure 5.2.17 MiR-145 is differentially regulated in colonic tissue of mice treated 
with RT 027 at day 3 and day 7 of infection. Total RNA derived from colonic tissue 
from an in vivo model of C. difficile was enriched for miRNAs using the mirVana 
Isolation kit, there were 4 animals per treatment group: control group n=4, group treated 
with RT 001 n=4 and group treated with RT 027 n=4. 100 ng RNA enriched for 
miRNAs was converted to first strand cDNA, the products of which were used in a pre-
amp PCR reaction. Samples were added to PCR reaction mixes for individual Taqman 
miRNA assays and added to wells on a 96 well PCR plate. The plate was run on the 
Applied Biosystems 7900HT Fast Real Time PCR Machine. The SDS files were 
exported and data from the PCR plate was analysed using ExpressionSuite software. 
The max Ct was set to 37.0 with a threshold of 0.1 and the reference group was set to 
the control group. snoRNA202 was used to correct for variation of RNA input and 
relative gene expression was calculated. The results show the mean (± SEM) measured 
in triplicate, a student’s t-test was used to test for significance by comparing samples of 
colonic tissue of mice treated with RT 001 with RT 027 where * p≤ 0.05, ** p≤ 0.01 
and *** p≤ 0.001. 
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Figure 5.2.18 MiR-155 is differentially regulated in colonic tissue of mice treated 
with RT 001 at day 3 of infection. Total RNA derived from colonic tissue from an in 
vivo model of C. difficile was enriched for miRNAs using the mirVana Isolation kit, 
there were 4 animals per treatment group: control group n=4, group treated with RT 001 
n=4 and group treated with RT 027 n=4. 100 ng RNA enriched for miRNAs was 
converted to first strand cDNA, the products of which were used in a pre-amp PCR 
reaction. Samples were added to PCR reaction mixes for individual Taqman miRNA 
assays and added to wells on a 96 well PCR plate. The plate was run on the Applied 
Biosystems 7900HT Fast Real Time PCR Machine. The SDS files were exported and 
data from the PCR plate was analysed using ExpressionSuite software. The max Ct was 
set to 37.0 with a threshold of 0.1 and the reference group was set to the control group. 
snoRNA202 was used to correct for variation of RNA input and relative gene 
expression was calculated. The results show the mean (± SEM) measured in triplicate, a 
student’s t-test was used to test for significance by comparing samples of colonic tissue 
of mice treated with RT 001 with RT 027 where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 
0.001. 
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Figure 5.2.19 Let-7e is differentially regulated in colonic tissue of mice treated with 
RT 001 at day 3 of infection. Total RNA derived from colonic tissue from an in vivo 
model of C. difficile was enriched for miRNAs using the mirVana Isolation kit, there 
were 4 animals per treatment group: control group n=4, group treated with RT 001 n=4 
and group treated with RT 027 n=4. 100 ng RNA enriched for miRNAs was converted 
to first strand cDNA, the products of which were used in a pre-amp PCR reaction. 
Samples were added to PCR reaction mixes for individual Taqman miRNA assays and 
added to wells on a 96 well PCR plate. The plate was run on the Applied Biosystems 
7900HT Fast Real Time PCR Machine. The SDS files were exported and data from the 
PCR plate was analysed using ExpressionSuite software. The max Ct was set to 37.0 
with a threshold of 0.1 and the reference group was set to the control group. 
snoRNA202 was used to correct for variation of RNA input and relative gene 
expression was calculated. The results show the mean (± SEM) measured in triplicate, a 
student’s t-test was used to test for significance by comparing samples of colonic tissue 
of mice treated with RT 001 with RT 027 where * p≤ 0.05, ** p≤ 0.01 and *** p≤ 
0.001. 
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Figure 5.2.20. Heat map showing pathways interactions from miRNAs differentially regulated by SLPs from RT 001 and RT 027. The target 
list generated from experimental data of miRNAs differentially regulated by SLPs from RT 001 and RT 027 was inputted into DIANA-miRPath v2.0 
database. A posteriori analysis was performed where the significance levels between all possible miRNA pathway pairs were calculated using 
enrichment analysis. The previously calculated significance levels where combined to provide a merged p-value for each pathway, by applying 
Fisher’s combined probability method. The heat map shows miRNAs versus 54 of the pathways where miRNA gene interactions where p≤ 0.05. 
Darker colours represent lower significance values and the adjacent dendrograms depict hierarchical clustering. We can identify miRNAs clustered 
together by exhibiting similar pathway targeting patterns. 
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Table 5.2.1 MiRNAs differentially regulated by SLPs from RT 001 and RT 027 are 
involved in essential cell signalling pathways. Table showing the top 5 KEGG 
pathways where gene/miRNA/pathway interactions are likely to occur. The list of 24 
miRNAs differentially regulated by SLPs from RT 001 and RT 027 were inputted into 
DIANA-miRPath v2.0 database where a posteriori analysis was performed. The 
significance levels between all possible miRNA pathways pairs were calculated using 
enrichment analysis. The previously calculated significance levels where combined to 
provide a merged p-value for each pathway, by applying Fisher’s combined probability 
method. 
KEGG pathway p-value #genes #miRNAs 
ECM- receptor Interaction  <1E-16 15 6 
TGF-beta signalling pathway <1E-16 42 9 
MAPK signalling pathway <1E-16 98 10 
PI3K-Akt signalling pathway <1E-16 121 11 
Focal adhesion 1.1E-16 74 10 
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Figure 5.2.21 MiRNAs differentially regulated by SLPs from RT 001 and RT 027 
may modulate genes involved in ECM-receptor interaction. The target list generated 
from experimental data of miRNAs differentially regulated by SLPs from RT 001 and 
RT 027 was inputted into DIANA-miRPath. A posteriori analysis was performed where 
the significance levels between all possible miRNA pathway pairs were calculated using 
enrichment analysis. The previously calculated significance levels where combined to 
provide a merged p-value for each pathway, by applying Fisher’s combined probability 
method. The resulting gene lists were converted into KEGG images. Genes highlighted 
in orange represent predicted targets for multiple miRNAs, whereas genes highlighted 
in green are not targeted by the miRNAs of interest in this pathway. 
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Figure 5.2.22. MiRNAs differentially regulated by SLPs from RT 001 and RT 027 
may modulate genes involved in TGF-β signalling pathway. The target list generated 
from experimental data of miRNAs differentially regulated by SLPs from RT 001 and 
RT 027 was inputted into DIANA-miRPath. A posteriori analysis was performed where 
the significance levels between all possible miRNA pathway pairs were calculated using 
enrichment analysis. The previously calculated significance levels where combined to 
provide a merged p-value for each pathway, by applying Fisher’s combined probability 
method. The resulting gene lists were converted into KEGG images. Genes highlighted 
in yellow represent predicted targets for an individual miRNA, genes highlighted in 
orange represent predicted targets for multiple miRNAs and genes highlighted in green 
are not targeted by the miRNAs of interest in this pathway. 
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Figure 5.2.23 MiRNAs differentially regulated by SLPs from RT 001 and RT 027 
may modulate genes involved in the MAPK signalling pathway. The target list 
generated from experimental data of miRNAs differentially regulated by SLPs from RT 
001 and RT 027 was inputted into DIANA-miRPath. A posteriori analysis was 
performed where the significance levels between all possible miRNA pathway pairs 
were calculated using enrichment analysis. The previously calculated significance levels 
where combined to provide a merged p-value for each pathway, by applying Fisher’s 
combined probability method. The resulting gene lists were converted into KEGG 
images. Genes highlighted in yellow represent predicted targets for an individual 
miRNA, genes highlighted in orange represent predicted targets for multiple miRNAs 
and genes highlighted in green are not targeted by the miRNAs of interest in this 
pathway. 
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Figure 5.2.24 MiRNAs differentially regulated by SLPs from RT 001 and RT 027 
may modulate genes involved in the PI3K-Akt signalling. The target list generated 
from experimental data of miRNAs differentially regulated by SLPs from RT 001 and 
RT 027 was inputted into DIANA-miRPath. A posteriori analysis was performed where 
the significance levels between all possible miRNA pathway pairs were calculated using 
enrichment analysis. The previously calculated significance levels where combined to 
provide a merged p-value for each pathway, by applying Fisher’s combined probability 
method. The resulting gene lists were converted into KEGG images. Genes highlighted 
in yellow represent predicted targets for an individual miRNA, genes highlighted in 
orange represent predicted targets for multiple miRNAs and genes highlighted in green 
are not targeted by the miRNAs of interest in this pathway. 
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Figure 5.2.25 MiRNAs differentially regulated by SLPs from RT 001 and RT 027 
may modulate genes involved in focal adhesion. The target list generated from 
experimental data of miRNAs differentially regulated by SLPs from RT 001 and RT 
027 was inputted into DIANA-miRPath. A posteriori analysis was performed where the 
significance levels between all possible miRNA pathway pairs were calculated using 
enrichment analysis. The previously calculated significance levels where combined to 
provide a merged p-value for each pathway, by applying Fisher’s combined probability 
method. The resulting gene lists were converted into KEGG images. Genes highlighted 
in yellow represent predicted targets for an individual miRNA, genes highlighted in 
orange represent predicted targets for multiple miRNAs and genes highlighted in green 
are not targeted by the miRNAs of interest in this pathway 
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Table 5.2.2 Forty-nine genes crossed two or more of the top 5 KEGG pathways 
and not all genes had predicted binding sites for the 24 miRNAs of interest. Gene 
lists generated in DIANA-miRPath, from the top 5 KEGG pathways were compared. 
Table showing the gene, the pathways it belongs to and if the gene contained a predicted 
biding site in its 3’UTR region according to TargetScan. TargetScan assesses miRNA 
seed complementarity and conservation. 
Gene ECM-
receptor  
PI3K  TGF-β  MAPK  Focal 
adhesion 
miRNA seed 
regions in 
3’UTR  
MAPK1 - √ √ √ √ - 
ITGA9 √ √ - - √ miR-148b 
miR-152 
miR-125a-5p 
COL27A1 √ √ - - √ - 
ITGB6 √ √ - - √ - 
ITGA5 √ √ - - √ miR-148b 
miR-152 
COL3A1 √ √ - - √ let-7 b/c/d/e 
ITGA11 √ √ - - √ let-7 b/c/d/e 
miR-148b 
miR-152 
COL2A1 √ √ - - √ miR-148b 
COL4A2 √ √ - - √ let-7 b/c/d/e 
miR-9 
COL1A1 √ √ - - √ let-7 b/c/d/e 
ITGA7 √ √ - - √ - 
COL4A6 √ √ - - √ let-7 b/c/d/e 
COL5A2 √ √ - - √ let-7 b/c/d/e 
COL4A1 √ √ - - √ miR-148b 
miR-152 
miR-590-5p 
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let-7 b/c/d/e  
LAMA4 √ √ - - √ miR-148b 
miR-152 
AKT1 - √ - √ √ - 
SOS2 - √ - √ √ miR-148b 
miR-152 
FGF12 - √ - √ - miR-9 
NFKB1 - √ - √ - - 
NRAS - √ - √ - miR-148b 
miR-145 
miR-146a 
let-7 b/c/d/e 
RAP1A - - - √ √ - 
CHUK - √ - √ - let-7 b/c/d/e 
KRAS - √ - √ - miR-155 
MAPK8 - - - √ √ - 
SOS1 - √ - √ - miR-9 
miR148-b 
miR152 
miR-155 
FGF9 - √ - √ - miR-155 
miR-9 
FGF18 - √ - √ - - 
NGF - √ - √ - let-7 b/c/d/e 
RASGRF1 - √ - √ - miR-125a-5p 
RELA - √ - √ - miR-155 
FGFR1 - √ - √ - miR-125a-5p 
ROCK1 - - √ - √ miR148-b 
miR152 
miR-145 
ITGB8 - - √ - √ miR-145 
miR-221 
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miR-152 
miR-148b 
let-7 b/c/d/e  
COL4A5 - √ - - √ let-7 b/c/d/e 
ROCK2 - - √ - √ - 
RAF1 - √ - - √ miR-125a-5p 
PIK3R3 - √ - - √ miR-152 
miR-148b 
miR-9 
miR-24 
PDK1 - √ - - √ miR-155 
VEGFC - √ - - √ - 
ITGA2 - √ - - √ - 
COL1A2 - √ - - √ let-7 b/c/d/e 
PPP2CB - √ √ - - miR-132 
AKT3 - √ - - √ - 
COL11A1 - √ - - √ let-7 b/c/d/e 
PTEN - √ - - √ miR-152 
miR-148b 
RPS6KB1 - √ √ - - miR-145 
PPP2CA - √ √ - - miR125a-5p 
RPS6KB2 - √ √ - - - 
COL4A4 - √ - - √ - 
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Table 5.2.3 Some genes in the PI3K-Akt signalling pathway had predicted binding 
sites for the 24 miRNAs of interest. Table showing the list of gens generated from 
DIANA miRPath and if the gene contained a predicted biding site in its 3’UTR region 
according to TargetScan, for the list of 24 miRNAs differentially regulated by SLPs 
from RT 001 and RT 027. TargetScan assesses miRNA seed complementarity and 
conservation, see Appendix G for the exact position of the predicted binding sites in the 
3’UTR regions for each gene.  
Gene Conserved miRNA seed regions in 3’UTR 
PRLR - 
GSK3B miR-132 
miR-9 
miR-24 
TSC1 let-7 b/c/d/e 
PDGFRA miR-24 
PPP2R5E miR-132 
miR-148b 
miR-152 
MYB miR-155 
PRKAA2 miR-125a-5p 
miR-146a 
let-7 b/c/d/e 
PPP2R2C - 
CREB5 miR-9 
miR-132 
miR-145 
YWHAG miR-132 
miR-125a-5p 
miR-221 
miR-145 
HSP90AA1 - 
CREB1 miR-155 
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miR-125a-5p 
ANGPT2 miR-145 
miR-125a-5p 
CDKN1B miR-221 
miR-24 
miR-148b 
miR-152 
YWHAB miR-148b 
miR-152 
GNB1 miR-145 
PPP2R5C miR-125a-5p 
miR-132 
CDK6 miR-148b 
miR-152 
miR-145 
let-7 b/c/d/e 
IL7R - 
PPP2R5A - 
GHR let-7 b/c/d/e 
IL4 - 
IL2 - 
THEM4 - 
EIF4E miR-9 
CCNE2 miR-9 
PPP2R2A miR-9 
miR-221 
let-7 b/c/d/e 
PIK3R1 miR-221 
miR-590-5p 
miR-155 
YWHAZ miR-155 
PPP2R3C - 
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KITLG miR-132 
miR-9 
INSR let-7 b/c/d/e 
PRKAA1 miR-148b 
miR-152 
FGF2 miR-148b 
miR-152 
CHRM2 - 
BCL2L1 let-7 b/c/d/e 
CREB3L2 miR-9 
ANGPT1 - 
FOXO3 miR-132 
miR-155 
miR-9 
FN1 - 
PKN2 miR-145 
miR-155 
let-7 b/c/d/e 
CDKN1A let-7 b/c/d/e 
miR-132 
SGK3 miR-132 
miR-9 
miR-155 
CSF1R miR-24 
miR-155 
OSMR let-7 b/c/d/e 
CSF1 miR-148b 
miR-152 
GNG5 let-7 b/c/d/e 
TEK miR-148b 
miR-152 
BCL2L11 miR-24 
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miR-221 
miR-148b 
miR-152 
miR-9 
IL6R miR-590-5p 
miR-125a-5p 
miR-155 
miR-9 
let-7 b/c/d/e 
EFNA1 miR-145 
miR-9 
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Table 5.2.4 Some genes in the TGF-β signalling pathway had predicted binding 
sites for the 24 miRNAs of interest. Table showing the list of gens generated from 
DIANA miRPath and if the gene contained a predicted biding site in its 3’UTR region 
according to TargetScan, for the list of 24 miRNAs differentially regulated by SLPs 
from RT 001 and RT 027. TargetScan assesses miRNA seed complementarity and 
conservation, see Appendix G for the exact position of the predicted binding sites in the 
3’UTR regions for each gene.  
Gene Conserved miRNA seed regions in 
3’UTR 
ID2 - 
SMAD2 miR-125a-5p 
let-7 b/c/d/e  
miR-145 
miR-155 
miR-148b 
miR-152 
SMAD6 - 
INHBB miR-148b 
miR-152 
miR-145 
miR-9 
SMAD9 - 
SMURF2 - 
BMPR1B miR-125a-5p 
BMP5 - 
PITX2 miR-590-5p 
SMAD3 miR-145 
INHBA - 
ID4 miR-9 
ACVR1 miR-148b 
miR-152 
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SKP1 miR-148b 
miR-152 
miR-145 
miR-221 
ZFYVE16 miR-221 
DCN - 
E2F5 miR-132 
let-7 b/c/d/e 
miR-132 
SMAD5 miR-145 
miR-148b 
miR-152 
miR-132 
miR-24 
miR-155 
ACVR2A miR-145 
miR-155 
let-7 b/c/d/e 
GDF6 miR-148b 
miR-152 
miR-155 
let-7 b/c/d/e 
BMP2 - 
TFDP1 - 
ACVR1C let-7 b/c/d/e  
miR-125a-5p 
miR-9 
GDF5 miR-132 
TGFB2 miR-145 
miR-590-5p 
miR-148b 
miR-152 
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EP300 miR-132 
BMPR1A - 
LTBP1 miR-148b  
miR-152 
SMAD7 miR-590-5p 
NOG miR-148b 
miR-152 
CREBBP - 
BMPR2 miR-125a-5p 
miR-590-5p 
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Table 5.2.5 Some genes involved in Focal adhesion had predicted binding sites for 
the 24 miRNAs of interest. Table showing the list of gens generated from DIANA 
miRPath and if the gene contained a predicted biding site in its 3’UTR region according 
to TargetScan, for the list of 24 miRNAs differentially regulated by SLPs from RT 001 
and RT 027. TargetScan assesses miRNA seed complementarity and conservation, see 
Appendix G for the exact position of the predicted binding sites in the 3’UTR regions 
for each gene.  
Gene Conserved miRNA seed regions in 
3’UTR 
ACTB miR-145 
SHC1 miR-9 
COL24A1 let-7 b/c/d/e 
PPP1CC - 
PAK7 - 
VCL miR-590-5p 
miR-9 
CAV2 miR-148b 
miR-152 
miR-145 
PPP1R12A miR-148b 
miR-152 
CTNNB1 - 
DIAPH1 - 
SRC miR-9 
PAK4 miR-9 
miR-145 
miR-24 
MYLK3 - 
BIRC3 - 
VAV3 miR-125a-5p 
miR-155 
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let-7 b/c/d/e 
miR-9 
MYLK miR-155 
miR-9 
miR-24 
XIAP miR-146a 
PPP1CB miR-148b 
miR-152 
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Table 5.2.6 Some genes in the MAPK signalling pathway had predicted binding 
sites for the 24 miRNAs of interest. Table showing the list of gens generated from 
DIANA miRPath and if the gene contained a predicted biding site in its 3’UTR region 
according to TargetScan, for the list of 24 miRNAs differentially regulated by SLPs 
from RT 001 and RT 027. TargetScan assesses miRNA seed complementarity and 
conservation, see Appendix G for the exact position of the predicted binding sites in the 
3’UTR regions for each gene.  
Gene Conserved miRNA seed regions in 
3’UTR 
FOS miR-221 
miR-155 
NTRK2 - 
NTF3 miR-221 
miR-590-5p 
DUSP22 -  
CACNA1G - 
PTPRQ - 
GNA12 miR-132 
IL1R1 miR-24 
RASA2 miR-145 
miR-9 
miR-125a-5p 
miR-590-5p 
ELK4 miR-145 
let-7 b/c/d/e  
miR-221 
MAP3K3 miR-9 
miR-145 
miR-125a-5p 
let-7 b/c/d/e  
miR-132 
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MAP2K7 miR-125a-5p 
miR-9 
DUSP14 - 
CACNB4 miR-221 
miR-155 
let-7b/c/d/e 
DUSP6 miR-9 
miR-145 
miR-125a-5p 
RASGRF2 - 
LAMTOR3 - 
MAP4K3 let-7 b/c/d/e 
RPS6KA1 miR-125a-5p 
RASGRP2 - 
GADD45A miR-148b 
miR-152 
MAP3K4 miR-148b 
miR-152 
MAP3K1 miR-9 
let-7 b/c/d/e 
MAP3K13 let-7 b/c/d/e 
TAB2 let-7 b/c/d/e  
miR-155 
BDNF miR-155 
MAP3K11 miR-145 
miR-125a-5p 
TAOK1 miR-155 
miR-24 
let-7 b/c/d/e  
miR-145 
miR-221 
MAP2K6 - 
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FGF11 miR-24 
let-7 b/c/d/e 
PPP3CA miR-145 
miR-590-5p 
let-7 b/c/d/e 
NLK miR-24 
miR-221 
miR-148b 
miR-152 
let-7 b/c/d/e 
CASP3 let-7 b/c/d/e 
RASGRP1 let-7 b/c/d/e 
RAPGEF2 miR-145 
miR-155 
NFATC2 - 
TRAF6 miR-146a 
miR-125a-5p 
MYC - 
PPM1A miR-125a-5p 
CACNB1 miR-125a-5p 
CACNA1E miR-24 
let-7 b/c/d/e  
miR-9 
DUSP8 miR-590-5p 
miR-9 
miR-24 
miR-148b 
miR-152 
PPP3R1  miR-221 
HSPA8 - 
MAX - 
FAS let-7 b/c/d/e 
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RPS6KA3 let-7 b/c/d/e  
miR-155 
miR-590-5p 
miR-145 
MAPK12 miR-125a-5p 
MECOM - 
STMN1 - 
MAP3K2 - 
PPM1B - 
CACNA2D1 - 
CACNB2 miR-125a-5p 
miR-145 
miR-9 
MEF2C miR-590-5p 
miR-9 
let-7 b/c/d/e 
IL1A miR-24 
MAP2K4 miR-145 
PLA2G4E - 
MAP3K7 - 
SRF miR-9 
miR-125a-5p 
MAPKAPK2 - 
DUSP1 let-7 b/c/d/e 
MAPK10 miR-590-5p 
miR-221 
PDGFRB miR-24 
miR-9 
CACNB3 miR-125a-5p 
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Figure 5.2.26 The IL-6 receptor gene contains possible 3’UTR binding sites for miR-125, miR-590, miR-155, miR-9 and let-7 b/c/d/e which 
were differentially regulated by SLPs from RT 001 and RT 027. These miRNAs were clustered in three distinct groups. The target list generated 
from experimental data of miRNAs differentially regulated by SLPs from RT 001 and RT 027 was inputted into DIANA-miRPath. A posteriori 
analysis was performed where the significance levels between all possible miRNA pathway pairs were calculated using enrichment analysis. The 
previously calculated significance levels where combined to provide a merged p-value for each pathway, by applying Fisher’s combined probability 
method. Gene lists from the PI3K-Akt signalling pathway were inputted into TargetScan were seed match conservation and PCT scores were 
determined.  
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Figure 5.2.27 The NRAS gene contains possible 3’UTR binding sites for miR-152, miR-148b, miR-146a, let-7 b/c/d/e and miR-145 which are 
differentially regulated by SLPs from RT 001 and RT 027. These miRNAs were clustered in three distinct groups and let-7 b/c/d/e had 2 
possible binding sites. The target list generated from experimental data of miRNAs differentially regulated by SLPs from RT 001 and RT 027 was 
inputted into DIANA-miRPath. A posteriori analysis was performed where the significance levels between all possible miRNA pathway pairs were 
calculated using enrichment analysis. The previously calculated significance levels where combined to provide a merged p-value for each pathway, by 
applying Fisher’s combined probability method. Gene lists from the PI3K-Akt signalling pathway and MAPK signalling pathway were inputted into 
TargetScan were seed match conservation and PCT scores were determined.  
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Figure 5.2.28 The SMAD2 gene contains possible 3’UTR binding sites for miR-132, miR-125a, let-7 b/c/d/e, miR-145, miR-152, miR-148b and 
miR-155 which are differentially regulated by SLPs from RT 001 and RT 027. These miRNAs were clustered in three distinct groups. The 
target list generated from experimental data of miRNAs differentially regulated by SLPs from RT 001 and RT 027 was inputted into DIANA-miRPath. 
A posteriori analysis was performed where the significance levels between all possible miRNA pathway pairs were calculated using enrichment 
analysis. The previously calculated significance levels where combined to provide a merged p-value for each pathway, by applying Fisher’s combined 
probability method. Gene lists from the TGF-β signalling pathway were inputted into TargetScan were seed match conservation and PCT scores were 
determined. 
  250  
 
Figure 5.2.29 The SOS1 gene contains possible 3’UTR binding sites for miR-152, miR-148b, miR-9, miR-132 and miR-155 which are 
differentially regulated by SLPs from RT 001 and RT 027. These miRNAs were clustered in two distinct groups. The target list generated from 
experimental data of miRNAs differentially regulated by SLPs from RT 001 and RT 027 was inputted into DIANA-miRPath. A posteriori analysis was 
performed where the significance levels between all possible miRNA pathway pairs were calculated using enrichment analysis. The previously 
calculated significance levels where combined to provide a merged p-value for each pathway, by applying Fisher’s combined probability method. Gene 
lists from the MAPK and PI3K-Akt signalling were inputted into TargetScan were seed match conservation and PCT scores were determined. 
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Figure 5.2.30 The TRAF6 gene contains possible 3’UTR binding sites for miR-146a and miR-125a which are differentially regulated by SLPs 
from RT 001 and RT 027. These miRNAs were clustered in one group and miR-146a has 3 possible binding sites. The target list generated from 
experimental data of miRNAs differentially regulated by SLPs from RT 001 and RT 027 was inputted into DIANA-miRPath. A posteriori analysis was 
performed where the significance levels between all possible miRNA pathway pairs were calculated using enrichment analysis. The previously 
calculated significance levels where combined to provide a merged p-value for each pathway, by applying Fisher’s combined probability method. Gene 
lists from the MAPK signalling were inputted into TargetScan were seed match conservation and PCT scores were determined. 
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5.3 Discussion 
A pathogen must successfully infiltrate the host’s tissues by attaching to cells and 
suppressing the cell’s natural functions for its own end, all while avoiding the host’s 
immune system and other defences (Krachler, Woolery, & Orth, 2011). Some strains of 
C. difficile can do this more effectively than others and there are differences in the 
severity of infection between ribotypes 001 and 027, as previously outlined. In order to 
protect against invading pathogens, organ specific and systemic immunological host 
responses are activated by PAMPS via membrane associated TLRs and cytoplasmic 
Nod-like receptors (Staedel & Darfeuille, 2013). TLR4 was the first mammalian TLR to 
be discovered, it detects LPS which is one of the best studied components of bacteria 
that can activate an immune response (Ruslan Medzhitov et al., 1997). TLR4 is 
distinctive among TLRs in that it activates the MyD88-dependent and MyD88-
independent signalling pathways (Akira & Takeda, 2004). Activation of both arms of 
the TLR4 signalling pathway is required for full bacterial clearance. Downstream 
signalling following activation of TLR4 with LPS ultimately leads to the activation of 
transcription factors such as AP-1, NF-κB and IRF3 and the induction of pro-
inflammatory cytokines, IFN and IFN-inducible genes (Mogensen, 2009). NF-κB 
activates innate and adaptive immunity aimed at eliminating the detected pathogen and 
developing a long lasting protection against future infection (Staedel & Darfeuille, 
2013). Other studies have shown the importance of IRF3 and type I IFNs in the 
modulation of host defence and bacterial clearance (O’Connell et al., 2004).  
The inflammatory response to infection must be tightly regulated in order to achieve 
pathogen clearance and at the same time avoid detrimental consequences of deregulated 
gene expression (Staedel & Darfeuille, 2013). The discovery in eukaryotic cells of small 
non-coding RNAs known as miRNAs has greatly expanded our understanding of the 
mechanisms that regulate gene expression (Friedman, Farh, Burge, & Bartel, 2009). 
MiRNAs have been shown to be involved in innate immunity by regulating TLR 
signalling and ensuing cytokine response by targeting a variety of signalling proteins, 
regulatory molecules and transcription factors (Dalal & Kwon, 2010; He et al., 2014; 
Sonkoly et al., 2008). There is also mounting evidence that miRNAs orchestrate 
immune regulation and the host response to pathogens during infection. Despite their 
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clear importance as a class of regulatory molecule, determining the biological relevance 
of individual miRNAs has proven challenging (Vidigal & Ventura, 2014). The 
implication of miRNAs in human diseases warrants a critical need to identify miRNA 
regulated genes in a biologically relevant context (Tarang & Weston, 2014). It is 
currently estimated that the human genome encodes thousands of miRNAs, targeting 
approximately 60% of all protein coding genes (Friedman et al., 2009). MiRNAs, 
similar to mRNA, are expressed in a time and tissue specific manner, and are involved 
in many fundamental biological processes.  
The function of specific miRNAs have been predominantly inferred from over 
expression studies in cultured cells or from studies that use antisense molecules as a 
means of disrupting their pairing to target mRNA (Vidigal & Ventura, 2014). A 
common method to determine miRNA functionality is to transfect cells with both 
luciferase reporter constructs and increasing the amounts of the miRNA of interest with 
chemically synthesised miRNA mimics (van Rooij, 2011). The advantage of 
introducing a miRNA is that if the miRNA actually targets the binding site in the 
3’UTR region, there will be a dose dependent decrease in gene expression and this can 
be determined from a luciferase gene reporter assay read out. In chapter three we 
established a luciferase gene reporter assay to examine the expression of NF-κB and 
IRF3 signalling in Hek TLR4/MD2/CD14 cells. We showed that SLPs from ribotype 
001 and 027 activate NF-κB and the potency of the response differed between 
ribotypes. SLPs from ribotype 027 activate IRF3 signalling but SLPs from ribotype 001 
fail to induce this response. In chapter four we identified 24 miRNAs that were 
differentially regulated by SLPs from ribotype 001 and 027 using qPCR. We validated 
the expression of miR-146a, miR-145, miR-155 and let-7e in human and murine cell 
lines. The aim of the first part of this chapter was to determine the functionality of; 
miR-146a, miR-145, miR-155 and let-7e, in NF-κB and IRF3 signalling in response to 
SLPs following TLR4 activation, using chemically synthesised miRNA mimics in the 
already established luciferase gene reporter assay.  
Initial findings suggested that miR-146a, miR-145, miR-155 and let-7e individually 
targeted RANTES production in response to TLR4 activation with LPS. MiRNA 
mimics over expressing miR-146a, miR-145 and miR-155 decreased RANTES 
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production in a dose dependent manner, while miRNA mimics over expressing let-7e 
decreased RANTES production with 1 and 100 nM, in response to LPS. On the other 
hand IL-8 production was not affected by the individual miRNA mimics in response to 
TLR4 activation with LPS. Seeing as transfection with 100 nM of each miRNA mimic 
affected RANTES production we choose this concentration for all further studies. We 
incorporated positive and negative control miRNA mimics into our study and showed 
that miRNA mimics had the ability to bind to constructs leading to decreased NF-κB/ 
IRF3 gene expression as well as IL-8/RANTES cytokine production. We also showed 
that the outcome was not due to the effects of transient transfection alone and the 
combination of transient transfection with cell stimulation did not have any significant 
cytotoxic effects on the cells. Consequently we were unable to link the individual 
miRNAs to NF-κB and IRF3 signalling. Over expressing miR-146a, miR-145, miR-155 
and let-7e did not decrease IRF3 signalling or RANTES production in response to SLPs 
from ribotype 001 and 027. We confirmed however that miR-146a, miR-145, miR-155 
and let-7e targeted IRF3 gene expression and RANTES production specifically in 
response to TLR4 activation with LPS. NF-κB and IL-8 production was not affected 
when the miRNAs were over expressed in response to LPS, SLPs from ribotype 001 
and 027.  
Interestingly both LPS and SLPs from ribotype 027 activate the same TLR4 receptor 
and lead to downstream activation of NF-κB and IRF3 signalling. Yet there are distinct 
differences in the miRNAs induced and how they target essential signalling molecules 
in regard to IRF3 signalling. This has not yet been reported in the literature to the best 
of our knowledge. These proteins seemingly activate the same signalling pathways 
however our study highlights that miRNAs regulate this further and thus warrants 
further investigation. It is possible that miRNAs that target IRF3 signalling in response 
to SLPs from ribotype 001 and 027 require the cooperation of other miRNAs to 
effectively target this signalling pathway. Evidence from the literature shows that 
miRNAs rarely act in isolation and they have been shown to be incorporated into 
various negative feedback and feed forward loops (Tsang, Zhu, & Oudenaarden, 2007). 
Recently studies have shown that transcriptional regulation by transcription factors and 
post-transcriptional regulation by miRNAs are often highly coordinated (Cai, Zhou, & 
Liu, 2013; Martinez & Walhout, 2009; Tsang et al., 2007). In negative feedback loops a 
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transcription factor suppresses a miRNA and the transcription factor itself is negatively 
regulated by the miRNA. Evidence from the literature has also shown that this type of 
feedback loop behaves like a switch, even without cooperative binding of the 
transcription factor (Cai et al., 2013). MiRNAs regulate many different targets, 
individual 3’UTRs also contain binding sites for multiple miRNAs, allowing for 
elaborate and complicated networks in which redundancy and cooperation between 
miRNAs determine the effect on gene expression (Bartel, 2009; Martinez-Sanchez & 
Murphy, 2013; Obermayer & Levine, 2014; van Rooij, 2011).  
Nonetheless the most commonly used cellular assays are based on the principle of 
studying the functional consequences of artificially manipulating miRNA levels. 
However, as the biological concentrations of these miRNAs in vivo may be several 
orders of magnitude different than in vitro conditions, it is essential that the results of 
target recognition are recapitulated in appropriate animal models (Tarang & Weston, 
2014). We had access to a bank of RNA samples derived from colonic tissue from a C. 
difficile infection model. Mice were treated with a cocktail of antibiotics before being 
infected with 10
3
 C. difficile spores from ribotype 001 and 027. The colon was 
harvested at two time points post infection and RNA was extracted from the distal 
colon. Data previously generated in our laboratory from this infection model linked 
infection with ribotype 027 with more severe disease. Animals infected with this 
ribotype showed greater weight loss, more tissue damage, and higher bacterial load 
relative to control and mice infected with ribotype 001. Mice infected with ribotype 001 
were able to effectively recover after seven days, with lowered CFU counts and weights 
comparable to control mice. Histology of colonic tissue supported this analysis, 
revealing mice infected with ribotype 001 had healthy gut morphology seven days after 
infection, while mice infected with ribotype 027 had more severe and persistent damage 
(Lynch 2014, unpublished). The aim of the next part of this chapter was to examine the 
expression of miR-146a, miR-145, miR-155 and let-7e from the colonic tissue 
generated in the C. difficile infection model, seeing as we validated these miRNAs in 
both a human and murine cell lines in the previous chapter.  
We found that the total RNA derived from the C. difficile infection model contained 
each of the miRNAs and small RNA endogenous controls. Our results suggest a role for 
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miR-146a, miR-145, miR-155 and let-7e in C. difficile infection. Our data showed that 
miR-146a and miR-145 were differentially regulated in colonic tissue of mice infected 
with ribotype 001 and 027, three and seven days post infection. These miRNAs were 
down regulated in colonic tissue of mice infected with ribotype 027 three days post 
infection. This data aligned with in vitro results, however at day 7 these miRNAs were 
up regulated. Our data shows that miR-145 and miR-146a were down regulated at day 3 
of infection in response to ribotype 027. In comparison miR-145 and miR-146a were up 
regulated in the tissue of mice infected with ribotype 001 at day 3 of infection. On the 
other hand miR-155 and let-7e were differentially regulated in colonic tissue from mice 
infected with ribotype 001 and 027 three days post infection. Both miRNAs were up 
regulated in colonic tissue of mice infected with ribotype 001 three days post infection, 
this was significantly different to the levels induced by mice infected with ribotype 027. 
These miRNA levels in mice infected with ribotype 001 and 027 appeared to return to 
levels comparable to levels seen in the control mice seven days post infection. The 
infection data does not align with in vitro data in that we do not see a down regulation 
of these miRNAs, therefore expression may not be linked to the SLPs alone. However 
we did see differential regulation of miR-155 and let-7e between both ribotypes 
suggesting they may have other important roles in regulating the host immune response 
to C. difficile. Research from our laboratory previously found that IL-10 was increased 
in mice infected with ribotype 027 at day 3 of infection in this model (Lynch 2014, 
unpublished). In contrast IL-10 was not produced in response to ribotype 001 at day 3 
of infection possibly allowing the increase in miR-155 expression at this point in 
infection- this data also aligns with in vitro experiments. Therefore there may be a link 
between the induction of IL-10 and miR-155 expression in response to C. difficile. 
The implication of miRNAs in human diseases warrants a critical need to identify 
miRNA regulated genes in a biologically relevant context (Tarang & Weston, 2014). 
Identification of miRNA target genes has been a great challenge and computational 
algorithms have been the major driving force in predicting miRNA targets (Bentwich et 
al., 2005; Jens & Rajewsky, 2014; Kuhn et al., 2008; Lewis et al., 2005). Experimental 
data is not enough to give a comprehensive view of miRNA biology, it is thought that to 
get a more complete view experimental data must be combined with computational 
predications (Bentwich et al., 2005; Ghosh et al., 2007; Sachidanandam, 2005). In 
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chapter four we identified 24 miRNAs that were differentially regulated by SLPs from 
ribotypes 001 and 027 experimentally using qPCR. Seeing as miRNAs may work in 
complex networks we decided to utilise bioinformatics to identify possible 
miRNA/pathway/gene interactions from the list of 24 miRNAs to identify biologically 
relevant miRNA target genes. DIANA miRPath is thought to stand out from other 
prediction tools due to its range of capabilities, ease of use, relatively current input data 
and maintenance of the software (Peterson et al., 2014). Our data shows that SLPs from 
ribotypes 001 and 027 may regulate miRNAs that target genes involved in these 
essential cell signalling processes. The bioinformatics search identified 54 pathways in 
which the 24 miRNAs of interest were predicted to target genes in pathways found in 
KEGG. The top 5 pathways; ECM, MAPK signalling, PI3K-AKT signalling, TGF-β 
signalling and focal adhesion- were predicted to be involved in essential cell signalling 
processes targeting 350 genes.  
MAPKs are serine-threonine kinases that mediate intracellular signalling associated 
with a variety of cellular activities including; cell proliferation, differentiation, survival, 
death, and transformation (Kim & Choi, 2010). Our data shows that 98 genes were 
predicted to be targeted by 10 of the miRNAs of interest in the MAPK signalling 
pathway. The genes targeted consisted of key kinases that regulate this pathway and 
other genes that are known to modulate the immune response. We also show that 121 
genes were predicted to be targeted by 11 of the miRNAs in the PI3K-Akt signalling 
pathway. This pathway plays an important role in a variety of cellular processes, 
including migration, survival and proliferation. For this reason, the pathway is targeted 
by many pathogens to reinforce or destroy focal adhesions, which play an integral role 
in phagocytosis (Krachler et al., 2011). Activation of PI3K can also activate small 
GTPases, such as Ras and Rac, which are linked to proliferation. Focal adhesions lie at 
the convergence of integrin adhesion, signalling and the actin cytoskeleton. Our data 
shows 74 genes were predicted to be targeted by 10 of the miRNAs in the focal 
adhesion pathway. Cells modify focal adhesions in response to changes in the molecular 
composition and physical forces present in their ECM thus modulation of focal 
adhesion can regulate cell proliferation, survival, migration and invasion (Wozniak, 
Modzelewska, Kwong, & Keely, 2004). MiRNAs regulated in response to ribotype 001 
and 027 potentially alter cell fate. Evidence from the literature has shown that altering 
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cell fate may be vital in the fine tuning of the immune response against infection (Kim 
& Choi, 2010; Liu, Drescher, & Chen, 2009). 
As well as nonspecific hydrophobic and electrostatic forces, bacteria use surface 
proteins with specific affinity for plasma proteins and components of the ECM to 
physically interact with host cells and mucins via a number of different adhesins. Our 
data also shows that 15 genes were predicted to be targeted by 6 of the miRNAs of 
interest in ECM receptor signalling pathway. The ECM is not generally exposed in the 
gut of healthy individuals and thus is not accessible for interaction with bacteria. 
However, these molecules become exposed after a tissue trauma following a mechanical 
or chemical injury or after an infection- thus aiding the adherence of the bacteria to 
epithelial cells (Dubreuil, Giudice, & Rappuoli, 2002). The genes targeted by the 
miRNAs of interest were integrins which are involved in cell surface adhesion and 
collagens which form structural elements in the ECM. It is possible that down 
regulation of miRNAs induced by ribotype 027 preserve the expression of ECM genes 
allowing the bacteria to adhere to epithelial cells. In contrast miRNAs regulated in 
response to ribotype 001 may bind to the 3’UTR of genes involved in the ECM 
preventing expression thus leading to reduced bacterial adherence. We also identified 42 
genes that were predicted to be targeted by 9 miRNAs of interest in the TGF-β 
signalling pathway.  
Members of the TGF-β family exert a wide range of biological effects on a large variety 
of cell types, for example they regulate cell growth, differentiation, matrix production 
and apoptosis. Many of them have important functions during embryonic development 
in pattern formation and tissue specification; in the adult they are involved in processes 
such as tissue repair and modulation of the immune system (Heldin, Miyazono, & ten 
Dijke, 1997). The genes targeted by the miRNAs of interest were SMAD proteins and 
other growth factors. SMAD3 inhibits activated macrophages and is essential in 
suppressing the inflammatory response by sequestering p300 an essential co-activator 
from the target promoter (Werner et al., 2000). SMAD3 contains a predicted binding 
site for miR-145 and in chapter four we showed that miR-145 was up regulated in 
response to SLPs from ribotype 001, however it is down regulated in response to SLPs 
from ribotype 027 in Hek TLR4/MD2/CD14 cells. It is possible that miR-145 induced 
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by SLPs from ribotype 001 bind to the 3’UTR region of SMAD3 preventing it’s 
expression, thus stopping SMAD3 from suppressing the inflammatory response leading 
to more efficient bacterial clearance. In contrast miR-145 is down regulated in response 
to SLPs from ribotype 027, therefore SMAD3 may be free to suppress the inflammatory 
response allowing for the persistence of infection seen with ribotype 027. Hence we 
have identified possible biologically relevant genes that are predicted to be targeted by 
the miRNAs induced in response to ribotype 001 and 027 and must therefore be 
validated experimentally in future work. 
MiRNAs can be transcribed from intergenic regions, where an individual gene or cluster 
of miRNAs form an independent transcriptional unit, or from introns of coding genes. 
38% of murine miRNAs fall within introns of mRNAs (Chiang et al., 2010). In most 
cases the miRNA is processed from the intron of the host transcript thus the miRNAs 
and host gene are co-ordinately expressed. Additionally, multiple miRNA hairpins are 
often encoded as clusters within a single primary transcript. These clusters can encode 
multiple miRNA seed families (Gurtan & Sharp, 2013). While expression between 
clustered miRNAs is strongly correlated, it is not absolute thus indicating regulation at 
the level of processing (Chiang et al., 2010). The clustered organisation of miRNAs 
suggests shared biological function among related miRNAs present in the same primary 
transcript (Gurtan & Sharp, 2013). MiRNAs regulate a plethora of target mRNAs, the 
simultaneous targeting of individual transcripts by multiple miRNAs and the 
redundancy of miRNA mediated control of gene expression- particularly for miRNAs 
sharing common seed sequences, are important factors that contribute to this complexity 
(Eulalio & Mano, 2015). The number and distribution of miRNA binding sites is 
particularly important. Studies have demonstrated that two sites in the same or different 
miRNAs can act synergistically and that the distance between neighbouring miRNA 
binding sites affects the strength of the targets down regulation (Koscianska, Witkos, 
Kozlowska, Wojciechowska, & Krzyzosiak, 2015). Specifically, optimal down 
regulation was observed when the distance between the 3’ end of the first miRNA site 
and the 5’ end of the subsequent one was > 7 and < 40 nt and when the 5’ ends of both 
miRNA seeds were separated by between 13 and 35 nt. Therefore the target site’s 
activity depends on its surrounding context (Grimson et al., 2007; Saetrom et al., 2007). 
We searched for the 24 miRNAs of interest in the 3’UTR gene in each of the 350 genes 
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identified by DIANA miRPath in TargetScan. Not all of the genes had predicted 3’UTR 
regions for the 24 miRNAs of interest according to TargetScan, however the majority 
did have possible predicted binding sites. We selected 5 genes IL-6R, NRAS, SMAD2, 
SOS1 and TRAF6 for further investigation.  
Through IL-6R, IL-6 signalling activates tyrosine kinases JAK1, JAK2, and TYK2, 
which leads to the phosphorylation of STAT1 and STAT3. STAT3 is an important 
regulator for a number of anti-apoptotic genes (Yao et al., 2014). NRAS is from a 
family of GTPase that control basic cellular functions including control of proliferation, 
differentiation and apoptosis and there is increasing evidence that it plays a role in the 
induction of T cells (Mor, Keren, Kloog, & George, 2008). SMAD2 plays a critical role 
in TGF-β signalling (Ungefroren et al., 2011). Targeted SOS1 deletion reveals a critical 
role in early T-cell development (Kortum et al., 2013). While TRAF6 a signalling 
adapter molecule plays a significant role in MyD88-dependent signalling, it is also 
important for DC maturation, cytokine production and has a T cell stimulatory capacity 
(Kobayashi, Walsh, & Choi, 2004). Our data shows that the miRNAs of interest were 
predicted to be found in distinctive groups in the 3’UTR region of each of the 5 genes. 
There were possible binding sites for miR-148b and miR-152 in the same location in 3 
out of the 5 genes. There were also possible binding sites for let-7b, let-7c, let-7d and 
let-7e in the same location in 4 out of 5 of the genes. There were also predicted 
cooperation between miR-146a and miR-125 in the TRAF6 gene, and the miRNAs were 
predicted to be separated by 11 nt possibly allowing for optimal down regulation. MiR-
155 were is close proximity to miR-550 in the 3’UTR region of the IL6 receptor gene 
while miR-145 and miR-146a were in close proximity in the 3’UTR region of the 
SMAD2 gene. This computational data shows that the miRNAs induced by SLPs from 
ribotype 001 and 027 may work together in distinctive miRNA clusters which regulate 
genes involved in a variety of cellular functions that may regulate the immune response 
and T cell function. 
In summary, LPS and SLPs from ribotype 027 activate the same TLR4 receptor and 
lead to downstream activation of NF-κB and IRF3 signalling. Yet there are distinct 
differences in the miRNAs regulated and how they target essential signalling molecules 
in regard to IRF3 signalling. This has not yet been reported in the literature to the best 
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of our knowledge. These proteins seemingly activate the same signalling pathways 
however our study highlights that miRNAs regulate this further and thus warrants 
further investigation. We were unable to link the individual miRNAs to NF-κB and 
IRF3 signalling- over expressing miR-146a, miR-145, miR-155 and let-7e did not 
decrease IRF3 signalling or RANTES production in response to SLPs from ribotype 
001 and 027. However our data suggests a role these miRNAs in CDI. There may also 
be a link between the induction of IL-10 and miR-155 expression in response to C. 
difficile and this novel finding has yet to be reported in the literature, it also warrants 
further investigation. The impact of the modulation of the immune response by the 
miRNAs may lead to biologically relevant changes at the cell level in a variety of 
processes such as the regulation of cell growth, differentiation, matrix production, 
apoptosis, proliferation, cytoskeletal dynamics, cell surface adhesion and collagens 
which form structural elements. Further work is needed to validate these results 
experimentally, however we identified genes that could be used in future work. We 
know from the literature that miRNAs regulate many different targets, individual 3’ 
UTRs also contain binding sites for multiple miRNAs, allowing for elaborate and 
complicated networks in which redundancy and cooperation between miRNAs 
determine the effect on gene expression (Bartel, 2009; Martinez-Sanchez & Murphy, 
2013; Obermayer & Levine, 2014; van Rooij, 2011). We have identified 24 miRNAs of 
interest that are found in distinctive groups in the 3’UTR region of the predicted genes, 
more work is needed to fully elucidate the complexities of these miRNAs in relation to 
these networks they induce in response to C. difficile. However the data generated in 
this study could be potentially used to help target therapeutics for the clearance of 
persistent CDI. 
.
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6.1 General Discussion 
C. difficile like other bacterial pathogens may manipulate cellular functions, signal 
transduction pathways and pro-inflammatory responses through the delivery of effectors 
into host cells to drive towards a protective anti-inflammatory response or a damaging 
pro-inflammatory response (Solomon, 2013; Staedel & Darfeuille, 2013). C. difficile is 
highly transmissible between humans, which is key to its survival and persistence 
(Deakin et al., 2012). CDI is now the leading cause of antibiotic-associated diarrhoea 
worldwide (Solomon, 2013). The bacterium’s ability to grow in the presence of 
antibiotics in recent years has enabled its rapid spread among patients (Rupnik et al., 
2009). Advances in molecular methods and improved animal models have facilitated an 
understanding of how this organism survives in the environment, adapts to the GI tract 
and accomplishes its unique pathogenesis (Carroll & Bartlett, 2011). The combination 
of more aggressive strains, the expansion of the pool of individuals at risk of CDI and 
the difference in severity of infection between strains, has led to a renewed effort to 
understand the molecular mechanisms associated with the pathogenesis of this disease. 
The severity of CDI can vary depending on the strain causing infection (Barbut et al., 
2007; Dawson et al., 2009; Warny et al., 2005). Some strains including ribotype 001 
may induce mild disease, while others such as ribotype 027 can induce severe colitis, 
leading to sepsis and in some cases even death. Many virulence factors have been 
examined over the years, with a particular interest in toxin production. Toxins mediate 
destruction of the epithelial cells leading to apoptosis and cell death, all of which have 
been studied in detail (Buffie & Pamer, 2013; Denève et al., 2009). Nonetheless the 
main mode of transmission of CDI is through the ingestion of C. difficile spores, 
although the timing and signals triggered to initiate germination following ingestion are 
not as well studied (Jump et al., 2007). Unlike most pathogens, C. difficile produce a 
metabolically dormant spore that is excreted by infected patients (Lawley, Croucher, et 
al., 2009). Infective spores persist in the environment because they are resistant to a 
wide range of physical and chemical stresses (Carlson et al., 2015; Paredes-Sabja et al., 
2014). Spores represent the infectious stage of C. difficile and diversity in germination 
characteristics of particular strains may also contribute to the observed differences in 
disease severity. Another important factor to consider is the attachment of C. difficile to 
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the mucosa, as this is an important step in disease pathogenesis (Péchiné et al., 2005). 
CWPs are extremely important components of the S-layer that have an essential role in 
facilitating adherence. The S-layer of most bacterial species are composed of one major 
protein, which is modified by glycosylation (Sara & Sleytr, 2000). However, C. difficile 
is unique in that a single gene encodes two SLPs which are derived from post-
translational cleavage of a single precursor slpA gene (Fagan et al., 2009). Mature SLPs 
contain a HMW protein which is highly conserved across strains of C. difficile, and a 
LMW protein which has been shown to be the dominant antigen (Drudy et al., 2004; Ní 
Eidhin et al., 2006; Sharp & Poxton, 1988).  
Mutation is the primary source of variation in any organism. Without it, natural 
selection cannot operate and organisms cannot adapt to novel environments (Gordo, 
Perfeito, & Sousa, 2011). Evidence from the literature suggests that sequence 
differences in essential genes between strains of bacteria may affect virulence. CagA is 
noted for its amino acid sequence diversity and can determine the outcome of infection 
between different strains of Helicobacter pylori (H. pylori) (Evans & Evans, 2001). 
LMW SLPs exhibit vast sequence variability between strains (Calabi et al., 2001; Ní 
Eidhin et al., 2006). A change in structure or specific motifs in LMW proteins may 
result in the host immune cells no longer being able to recognise C. difficile as a 
pathogen (Ausiello et al., 2006). Bioinformatic analysis carried out in our laboratory on 
mutations in the slpA gene from 16 ribotypes of C. difficile, showed amino acid residues 
undergo positive selection giving a fitness advantage to particular ribotypes enabling 
their survival (Lynch 2014, unpublished). Previous research from our laboratory also 
showed that intact SLPs from ribotype 001 containing both HMW and LMW proteins 
were required for DC activation and subsequently generated T helper cells required for 
bacterial clearance via TLR4 (Ryan et al., 2011). SLPs isolated from ribotype 001 
activate innate and adaptive immunity, suggesting an important role for SLPs in the 
recognition of C. difficile by the immune system (Collins et al., 2014; Ryan et al., 
2011). Given the known sequence differences in LMW SLPs and differences in clinical 
symptoms between strains of C. difficile, the aim of the first part of this study was to 
investigate the immune response of SLPs from various ribotypes of C. difficile, 
following TLR4 activation and the induction of downstream signalling. 
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Analysis revealed there are differences in the potency of the immune response between 
ribotypes. SLPs from a variety of C. difficile ribotypes induced the maturation of 
BMDCs, key immune cells. DC maturation is characterised by increased expression of 
cell surface markers such as CD40, CD80 and CD86 (Higgins et al., 2003; Lavelle et 
al., 2003). SLPs from the various ribotypes induced the expression of these surface 
markers in BMDCs and the response was similar to that induced by LPS, a well-known 
TLR4 agonist (Akashi et al., 2003; Taro Kawai & Akira, 2007; Laird et al., 2009). DC 
maturation is also characterised by the production of cytokines such as IL-12p40, 
TNFα, IL-23 and IL-6. These cytokines play a central role in the modulation of the 
immune system and they can have pro-inflammatory or anti-inflammatory functions 
(Gerhard & Andus, 1998). It has been shown previously that SLPs can induce the 
production of pro-inflammatory cytokines in immune cells such as BMDCs, monocytes 
and macrophage (Ausiello et al., 2006; Bianco et al., 2011; Collins et al., 2014; Drudy 
et al., 2004; Madan & Petri Jr, 2012; Ryan et al., 2011; Vohra & Poxton, 2012) and our 
data agrees with what was been reported. However, our findings show differences in the 
potency of the immune response between ribotypes, with regard to the induction of IL-
1β, IL-12p70 and IL-10 in BMDCs, which has not yet been reported in the literature. 
The ability of SLPs from certain ribotypes to induce anti-inflammatory responses and 
others to induce more potent pro-inflammatory responses may account for the 
variability of symptoms and severity of disease experienced by patients who contract C. 
difficile. 
We have previously shown in our laboratory that SLPs from ribotype 001 activate 
TLR4 (Ryan et al., 2011). TLR4 initiates downstream signalling which in turn activates 
NF-κB and IRF3 via MyD88-dependant and -independent pathways (Akira & Takeda, 
2004). IRF3 induce type I IFNs which have an important role in bridging innate and 
adaptive immunity by mediating the induction of co-stimulatory molecules on antigen 
presenting cells in response to pathogen associated molecules (Hoebe & Beutler, 2004). 
Given the similarity of the response of SLPs from ribotype 001 with LPS and the 
induction of DC maturation, it was not surprising to us that the response activated TLR4 
signalling with downstream activation of p38 and NF-κB signalling (Collins et al., 
2014; Ryan et al., 2011). What was surprising was SLPs from ribotype 001 did not 
induce IRF3 signalling, which may have direct consequences for the immune response 
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elicited upon infection and subsequent clearance (Ryan et al., 2011). The aim of the 
next part of this study was to investigate if there were differences between SLPs from 
the different ribotypes in signalling downstream of TLR4. Analysis revealed that SLPs 
from ribotype 027 activate both NF-κB and IRF3 signalling, leading to the production 
of IL-8 and RANTES cytokines. SLPs from the other ribotypes examined activated NF-
κB and IL-8 production only. Therefore there are key signalling differences between 
SLPs from ribotype 027, which is known to be hypervirulent and other ribotypes of C. 
difficile such as 001. For the first time we show evidence that SLPs from C. difficile can 
activate differing signalling pathways downstream of TLR4. 
Both MyD88-dependent and independent mechanisms are required for the development 
of full host response to bacterial challenge and LPS can activate both signalling 
pathways (Carrigan et al., 2010). Yet clearance of ribotype 027 appears more difficult 
given the clinical symptoms of CDI, even though both arms of the TLR4 pathway are 
activated. MiRNAs are short double stranded RNA molecules approximately 19-23 nt 
in length that pair to protein coding genes. To date 28,645 miRNA hairpin precursors 
corresponding to 35,828 mature miRNAs in 223 species have been determined, 2588 
mature miRNAs are currently annotated in the human genome (Eulalio & Mano, 2015). 
It has been estimated that up to 30% of all human genes are regulated by miRNAs in 
many cell types (Bartel, 2009; Fabian et al., 2010; Yates et al., 2013). MiRNAs block 
mRNA translation, reduce mRNA stability or induce mRNA cleavage after imperfect 
binding to the miRNA recognition elements within the 3’ and 5’ UTR of target mRNA 
genes (Bartel, 2004). MiRNAs have been shown to be involved in innate immunity by 
regulating TLR signalling and ensuing cytokine responses by targeting a variety of 
signalling proteins, regulatory molecules and transcription factors (Dalal & Kwon, 
2010; He et al., 2014; Sonkoly et al., 2008). Until now, nobody has examined miRNAs 
regulated in response to SLPs. Given the role of miRNAs in the regulation of TLR4 
signalling and during infection, our hypothesis states that SLPs regulate miRNAs and 
that profiles may differ between ribotypes. These miRNAs may modulate TLR4 
signalling ultimately leading to changes in the immune response to C. difficile, which 
may explain the differences in clinical symptoms between different ribotypes. 
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We developed a protocol to examine miRNAs using qPCR and our initial profiling 
study examined miRNAs regulated in response to LPS and SLPs from ribotype 001. 
Our qPCR data analysis revealed 248 miRNAs were detected out of the 756 miRNAs 
analysed. MiR-155, miR-9, the let-7 family, miR-145, miR-146a and miR-187 have all 
been shown to be induced by LPS and shown to modulate the immune response, 
including key molecules involved in TLR4 in vitro (Curtale et al., 2013; Rossato et al., 
2012; Tili et al., 2007). These miRNAs were present in our initial profiling study thus 
validating our method. We identified novel miRNAs; miR-543, miR302 and miR-374a, 
which were up regulated while miR-586 were down regulated in response to LPS. 
These miRNAs have never before been shown to be involved in TLR4 signalling upon 
activation with LPS in vitro. We also identified novel miRNAs; miR-339-5p, miR148b, 
miR590-5p, miR-24, miR-550a, miR-1292, miR-432#, miR-215 and miR152, which 
were up regulated in response to SLPs from ribotype 001. On the other hand miR-422a, 
miR-874 and miR1293 were down regulated in response to SLPs from ribotype 001 
compared to the control cells. MiR-148b was the only miRNA from this list that was 
linked with regulating TLR signalling before (He et al., 2014; Liu et al., 2010). Some of 
the other miRNAs were found in other models of disease and present in epithelial cells 
in the gut. Given the limitations of the initial profiling study, we combined the 
experimental data with a list of miRNAs generated from the literature, for miRNAs 
known to regulate key elements of TLR4 signalling- as these miRNAs were present in 
the initial study but just over the significance value set in the experiment. The aim of the 
next part of this study was to examine the miRNA profiles regulated in response to 
SLPs from ribotype 001 and 027 using custom TLDA cards for the miRNAs of interest. 
Analysis revealed that miRNAs were differentially regulated in response to SLPs from 
ribotype 001 compared to ribotype 027. There was a striking down regulation of the 24 
miRNAs regulated in response to SLPs from ribotype 027 compared to ribotype 001. 
We chose 4 miRNAs; let-7e, miR-155, miR-146a and miR-145 for further validation 
based on the differences in expression of these miRNAs between ribotypes 001 and 
027. These miRNAs have been shown to regulate a variety of signalling molecules that 
modulate immune function and have been shown to play a vital role in infection. We 
validated these miRNAs further using qPCR for individual miRNAs in a human and 
murine cell line. There were slight differences in the levels at which these miRNAs 
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were expressed between cell lines. However, we showed that there were distinct 
miRNA profiles regulated by SLPs from ribotype 001 and 027, which differed between 
ribotypes at this 8 hour time point. There are potential limitations to the use of cell lines 
such as Hek TLR4/MD2/CD14 and JAWS II cells. MiRNAs in vivo may be several 
orders of magnitude different than in vitro conditions, therefore it is essential that the 
results are recapitulated in appropriate animal models (Tarang & Weston, 2014). We 
had access to a bank of RNA samples derived from colonic tissue from a C. difficile 
infection model. Mice were treated with a cocktail of antibiotics prior to inoculation 
with 10
3
 C. difficile spores from ribotype 001 and 027. The colon was harvested at two 
time points during infection (Lynch 2014, unpublished). The aim of the next part of this 
study was to validate miRNAs induced during early and late stage CDI from an in vivo 
model of C. difficile. 
Analysis revealed that miR-146a and miR-145 were differentially regulated in colonic 
tissue of mice infected with ribotype 001 and 027 during early and late stage of CDI. 
These miRNAs were down regulated in colonic tissue of mice infected with ribotype 
027 three days post infection. This data aligned with in vitro results, however at day 7 
these miRNAs were up regulated. MiR-146a and miR-145 may be regulated by the 
SLPs from C. difficile to module the host immune response during infection. Evidence 
from the literature suggests that miR-145 is strongly up regulated during colonic 
inflammation and it has been recently shown that blocking miR-145 leads to a strong 
anti-inflammatory response (Izar et al., 2012; Starczynowski et al., 2010). Regulation of 
miR-145 has also been associated with inflammation in ulcerative colitis allowing for 
more persistent disease (Pekow et al., 2012). It was also shown that miR-146a 
expression negatively regulates severe inflammation during the innate immune response 
and inhibition of miRNA-146a was found to increase IL-8 and RANTES release (Perry 
et al., 2008). Our data shows that miR-145 and miR-146a were down regulated at day 3 
of infection in response to ribotype 027. It is possible that ribotype 027 utilise miR-145 
to elicit a strong anti-inflammatory response and miR-146a to diminish the host immune 
response, to facilitate survival of the pathogen at this early stage of infection leading to 
more persistent and severe infection. In comparison miR-145 and miR-146a were up 
regulated in the tissue of mice infected with ribotype 001 at day 3 of infection, possibly 
allowing the host to clear the infection more effectively leading to the healthy gut 
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morphology seen previously with this animal model. Damage to the colonic tissue was 
evident in the gut morphology of tissue from mice infected with ribotype 027 at day 7 
of infection (Lynch 2014, unpublished). Tissue damage leads to increased inflammation 
which may account for the increase in miR-145 and miR-146a at this late stage of 
infection in our study. It was also noted that there was a decrease in miR-146a in 
response to ribotype 027 at day 3 which may possibly lead to increased IL-8 and 
RANTES production. This aligns with in vitro data, in which SLPs from ribotype 027 
appeared to produce high levels of IL-8 and RANTES. Therefore ribotype 027 may 
utilise miR-146a to modulate IL-8 and RANTES production thus affecting the adaptive 
immune response and the polarisation of CD4
+
 T cells. 
On the other hand, miR-155 and let-7e were differentially regulated in colonic tissue 
from mice infected with ribotype 001 and 027 only during early stage CDI. Both 
miRNAs were up regulated in colonic tissue of mice infected with ribotype 001 three 
days post infection. This was significantly different to the levels induced by mice 
infected with ribotype 027. These miRNA levels in mice infected with ribotype 001 and 
027 appeared to return to levels comparable to levels seen in the control mice seven 
days post infection. The infection data does not align with in vitro data in that, we do 
not see a down regulation of these miRNAs, therefore expression may not be linked to 
the SLPs alone. However, we did see differential regulation of miR-155 and let-7e 
between both ribotypes suggesting they may have other important roles in regulating the 
host immune response to C. difficile. Evidence from the literature suggests that mRNA 
encoding TLR4 are regulated by members of the let-7 miRNA family (Androulidaki et 
al., 2009). It is possible that let-7e induced in response to ribotype 001 at early stage of 
infection modulates TLR4, leading to enhanced bacterial clearance. This may account 
for the less potent immune response seen in vitro and also in clinical outcomes during 
CDI. 
Evidence from the literature shows that miR-155 functions as a novel negative regulator 
that helps to fine tune the inflammatory response of H. pylori infection (Xiao et al., 
2009). Another study showed that IL-10 inhibits the expression of miR-155 in response 
to LPS, leading to an increase in the expression of SHIP1 and SOCS1, known negative 
regulators of TLR signalling (Androulidaki et al., 2009; McCoy et al., 2010). Research 
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from our laboratory previously found that in this in vivo model IL-10 was increased in 
mice infected with ribotype 027 at day 3 of infection in this in vivo model (Lynch 2014, 
unpublished). It is also possible that miR-155 is inhibited by the release of IL-10 in 
response to ribotype 027. Evidence from the literature shows that IL-10 increases 
SHIP1, which acts to switch off the pro-inflammatory response (McCoy et al., 2010). In 
contrast, IL-10 was not produced in response to ribotype 001 at day 3 of infection, 
possibly allowing the increase in miR-155 expression at this point early stage of 
infection. This data also aligns with in vitro experiments. Therefore there may be a link 
between the induction of IL-10 and miR-155 expression in response to C. difficile. This 
novel finding has yet to be reported in the literature and it also warrants further 
investigation. The absence of miRNAs induced in response to ribotype 027 in our 
experiment may correlate to less efficient clearance by the host’s immune response and 
more persistent infection. 
MiRNAs induced in response to C. difficile from ribotype 001 and 027, may work 
together in complex networks. Evidence from the literature suggests that miRNAs 
regulate many different targets, individual 3’ UTRs also contain binding sites for 
multiple miRNAs, allowing for elaborate and complicated networks in which 
redundancy and cooperation between miRNAs determine the effect on gene expression 
(Bartel, 2009; Martinez-Sanchez & Murphy, 2013; Obermayer & Levine, 2014). We 
were unable to link the four individual miRNAs to NF-κB and IRF3 signalling in 
response to SLPs from C. difficile. Over expressing miR-146a, miR-145, miR-155 and 
let-7e did not decrease IRF3 signalling or induce the production of RANTES in 
response to SLPs from ribotype 001 and 027. We confirmed however, that miR-146a, 
miR-145, miR-155 and let-7e targeted IRF3 gene expression and RANTES production 
specifically in response to TLR4 activation with LPS. Whilst NF-κB and IL-8 
production was not affected when the miRNAs were over expressed in response to LPS 
and SLPs from ribotype 001 and 027.  
LPS and SLPs from ribotype 027 activate the same TLR4 receptor and lead to 
downstream activation of NF-κB and IRF3 signalling. Yet, there are distinct differences 
in the miRNAs induced and how they target essential signalling molecules in regard to 
IRF3 signalling. This has not yet been reported in the literature, to the best of our 
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knowledge. These proteins seemingly activate the same signalling pathways however 
our study highlights that miRNAs may regulate this further. It is also possible that 
miRNAs that target IRF3 signalling, in response to SLPs from ribotype 001 and 027 
require the cooperation of other miRNAs to effectively target IRF3 in this signalling 
pathway.  
We found that the 24 miRNAs of interest, as a group were predicted to target 350 genes 
involved in essential cell processes including; ECM, MAPK signalling, PI3K-AKT 
signalling, TGF-β signalling and focal adhesion. MiRNAs induced in response to 
ribotype 001 and 027 potentially alter cell fate. Evidence from the literature has shown 
that altering cell fate may be vital in the fine tuning of the immune response against 
infection (Kim & Choi, 2010; Liu et al., 2009). It is possible that down regulation of 
miRNAs, induced by ribotype 027 preserve the expression of ECM genes allowing the 
bacteria to adhere to epithelial cells. In contrast, miRNAs induced in response to 
ribotype 001 may bind to the 3’UTR of genes involved in the ECM preventing 
expression, thus leading to reduced bacterial adherence. The impact of the modulation 
of the immune response by the miRNAs may lead to biologically relevant changes at 
the cell level in a variety of processes such as the regulation of cell growth, 
differentiation, matrix production, apoptosis, proliferation, cytoskeletal dynamics, cell 
surface adhesion and collagens which form structural elements. More work is needed to 
validate these results experimentally, however we identified genes that could be used in 
future work.  
Furthermore, evidence from the literature suggests that miR-152 and miR-148b 
cooperatively target genes to impair the innate immune responses and antigen 
presentation, which was validated experimentally (Liu et al., 2010). MiR-152 and miR-
148b are two of the miRNAs out of our list of 24 miRNAs of interest. They are 
predicted to be located together in the 3’UTR regions of predicted genes in our top 5 
pathways during our bioinformatics search. Differing combinations of the 24 miRNAs 
of interest were found in distinct groups in the 3’UTR region of the predicted genes, 
which may account for our inability to link the miRNAs individually to NF-κB and 
IRF3 in our experiment. We have identified 24 miRNAs of interest that are found in 
distinctive groups in the 3’UTR region of the predicted genes, more work is needed to 
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fully elucidate the complexities of these miRNAs in relation to the networks they induce 
in response to C. difficile. 
Antibiotics are the classical way of dealing with fully symptomatic CDI, there are an 
increasing number of strains showing antibiotic resistant and a limited number of drugs 
that can be used to treat CDI. There is much evidence to suggest that C. difficile is 
evolving to occupy niche hospital populations and there has been rapid worldwide 
spread of ribotypes 027 and 078 (Dawson et al., 2009). Ribotypes 027 and 078 are 
known to be ‘hypervirulent’ and have been associated with more severe diarrhoea, 
higher mortality and more recurrences (Clements et al., 2010; Dawson et al., 2009; 
Goorhuis et al., 2007; Loo et al., 2005). The impact of CDI in healthcare settings 
throughout the developed world is considerable in terms of mortality, morbidity, and 
disease management (Cartman et al., 2010). The profile of patients presenting with CDI 
has also changed in the last decade. CDI affects populations previously considered at 
low risk, including patients without previous exposure to antibiotics, young individuals 
and pregnant women (Le Monnier, Zahar, & Barbut, 2014). Oral Metronidazole is often 
the antibiotic of choice in cases of mild-to-moderate CDI, and oral Vancomycin is often 
the choice for severe infections (Burke & Lamont, 2014). Unfortunately, the 
effectiveness of these antibiotic treatments is limited by a lack of response in some 
patients and high recurrence rates. A third antimicrobial agent, Fidaxomicin, was 
recently approved for the treatment of CDI (Mullane, 2014). A new drug, CRS3123 is 
currently in early stage clinical trials for the treatment of CDI. Initial results show it is a 
narrow spectrum agent resulting in a high concentration of drug in the GI tract. 
CRS3123 was demonstrated to have potent in vitro anti-bacterial activity against all C. 
difficile strains tested, including the hypervirulent ribotype 027 (Goldberg et al., 2015). 
The continued prevalence of antibiotic-resistant strains, along with the emergence of 
new hypervirulent strains, reveals the need for new alternative forms of treatment 
against CDI. 
There are some emerging therapies to treat CDI currently in development. Monoclonal 
antibodies that have selectivity for toxins A and B are being developed. Monoclonal 
antibodies were reported to be superior in reducing rates of recurrent CDI in humans 
than current treatments in a Phase II randomised, double-blind, placebo- controlled trial 
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(Lowy, Molrine, & Ambrosino, 2010). Although the results reduced rates of reoccurring 
CDI this sort of therapy has its limitations in the delivery of therapy, effectiveness of 
the response in already very sick patients and the high costs associated with the 
production of monoclonal antibodies. There are several phase II clinical trials and one 
phase III clinical trial in the United States that are testing vaccines against C. difficile 
using monoclonal antibodies against toxins (Goldberg et al., 2015). More recently the 
use of microbe based treatment such as Faecal Microbiota Transplantation (FMT) from 
healthy donors has been developed for treatment of CDI (Ihunnah et al., 2013). The 
goals of this procedure are to restore the normal balance of the intestinal flora and to 
provide natural competition for C. difficile, thereby decreasing its overgrowth. FMT 
treatment has been successful in reducing reoccurring CDI however there is insufficient 
experience to guarantee that there are no long-term adverse effects or risks involved in 
this treatment, including the transmission of other life threatening bacteria (Bowman, 
Broussard, & Surawicz, 2015; Goldberg et al., 2015).  
In recent times miRNAs are thought to be viable targets for therapeutics given that 
mature miRNA sequences are short and often completely conserved across multiple 
vertebrate species, making miRNAs easy targets for therapeutics (van Rooij, 2011; van 
Rooij & Kauppinen, 2014). MiRNAs typically have many targets within cellular 
networks, which, in turn, enable modulation of entire pathways in a disease state. 
MiRNAs may be utilised to restore the function of a miRNA using either synthetic 
double-stranded miRNAs or viral vector-based over expression. Two strategies have 
been used to deliver miRNA replacement therapies in vivo using formulated, synthetic, 
double-stranded miRNA mimics, and viral constructs over-expressing the lost or down-
regulated miRNA (van Rooij & Kauppinen, 2014). Intravenously and intratumorally 
injected miRNA mimics complexed with liposome nanoparticles (Pramanik et al., 
2011), polyethyleneimine (Ibrahim et al., 2011) or atelocollagen (Takeshita et al., 2010) 
have been used to restore the functions of various tumour-suppressive miRNAs in 
mouse cancer models. Notably, the first liposome-formulated mimic is currently being 
tested in a Phase I clinical trial in patients with primary liver cancer (van Rooij & 
Kauppinen, 2014). Other strategies have been utilised to enhance delivery of antimiR 
oligonucleotides and have become a well validated experimental tool for in vivo 
inhibition of miRNAs (Krützfeldt et al., 2005).  
  
 274  
This work is in its infancy, however given the results of our study this data could be 
used to develop a viable new method to treat CDI. It may be possible to target miRNAs 
which are down regulated during infection with persistent ribotypes such as 027 with 
miRNA mimics to allow bacterial clearance. Another option is to target miRNAs that 
are up regulated using antimiR oligonucleotides to inhibit miRNAs modulating 
important anti-inflammatory cytokines in less persistent ribotypes such as ribotype 001. 
Another option is to target the ECM, MAPK signalling, PI3K-Akt signalling, TGF-β 
signalling and focal adhesion which alter cell fate and adhesion of the bacteria in the 
gut. 
In conclusion, our study showed that there are differences in the potency of the immune 
response between ribotypes. There were key signalling differences between SLPs from 
ribotype 027, which is known to be hypervirulent and other ribotypes of C. difficile such 
as 001. For the first time we show evidence that SLPs from C. difficile can activate 
differing signalling pathways downstream of TLR4. Until now nobody examined 
miRNA profiles regulated in response to SLPs from C. difficile. We identified novel 
miRNAs induced in response to LPS, SLPs from ribotype 001 and ribotype 027 in vitro. 
These miRNAs were differentially regulated between ribotypes, there was a global 
down regulation of miRNAs in response to SLPs from ribotype 027 compared with 
ribotype 001. LPS and SLPs from ribotype 027 activate the same TLR4 receptor and 
lead to downstream activation of NF-κB and IRF3 signalling. Yet there are distinct 
differences in the miRNAs regulated and how they target essential signalling molecules 
in regard to IRF3 signalling. Our data suggests a role for miR-146a, miR-145, miR-155 
and let-7e in regulating the host immune response to C. difficile infection from an in 
vivo animal model. The absence of miRNAs induced in response to ribotype 027 may 
correlate to less efficient clearance by the host’s immune response and more persistent 
infection. The miRNAs regulated in response to C. difficile from ribotype 001 and 027 
are predicted to target essential cell processes and the impact of the modulation of the 
immune response by the miRNAs may lead to biologically relevant changes at the cell 
level in a variety of processes. More work is needed to fully elucidate the complexities 
of these miRNAs in relation to the networks they regulate in response to C. difficile. 
The effectiveness of current treatments is limited by a lack of response in some patients 
and the high recurrence rates. Current and emerging therapies to treat CDI currently 
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focus on the neutralisation of toxins, the development of vaccines and FMT. MiRNAs 
are emerging as viable targets for therapeutics and the data generated in this study may 
be used to develop a miRNA based therapy for the treatment of persistent CDI, allowing 
bacterial clearance by the host’s immune system without the need for antibiotics. 
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Appendix A- Buffers and Solutions  
5X Loading Buffer 
Bromophenol Blue 0.05% (w/v) 
DTT 0.25 M 
SDS  2% 
Glycerol 10% 
Trizma Base  125 mM 
The solution was dissolved in dH2O to the required volume. 250 µl 1 M DTT was added 
per 1 mL 5X loading buffer just before use. 3µl was added to 12 µl of each sample for 
SDS PAGE analysis. 
Separating Gel (12% (w/v)) 
Acrylamide/ Bisacrylamide (30% stock) 12.5% 
Tris HCL pH 6.8 1.5 M 
SDS 1% 
Ammonium persulphate 0.5% (w/v) 
TEMED 0.1% (v/v) 
The solution was dissolved in dH2O to the required volume. Ammonium persulphate 
and TEMED were added last. The gel was covered with Isopropanol to exclude air and 
aid polymerisation. 
Stacking Gel (5% (w/v)) 
Acrylamide/ Bisacrylamide (30% stock) 5% 
Tris HCL pH 8.8 0.5 M 
SDS 1% 
Ammonium persulphate 0.5% (w/v) 
TEMED 0.1% (v/v) 
The solution was dissolved in dH2O to the required volume. Ammonium persulphate 
and TEMED were added last.  
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Electrode Running Buffer 
Trizma Base 25 mM 
Glycine 200 nM 
SDS 17 mM 
The solution was dissolved in dH2O to the required volume. 
Coomassie Stain 
Brilliant Blue 0.2% 
Methanol 45% 
Acetic Acid 10% 
The solution was dissolved in dH2O to the required volume. 
Destain solution 
Methanol 25% 
Acetic Acid 10% 
The solution was dissolved in dH2O to the required volume. 
Complete RPMI Culture Media 
Heat inactivated FBS 10% 
Penicillin/Streptomycin/L-glutamine 100 µg/mL/ 100 µg/mL/ 2 nM 
Complete DMEM Culture Media 
Heat inactivated FBS 10% 
Penicillin/Streptomycin/L-glutamine 100 µg/mL/ 100 µg/mL/ 2 nM 
10 µg/mL Blasticidin was added to maintain the hTLR4a and 50 µg/mL HygroGold 
were added to maintain the plasmid coding for MD2 and CD14 during Hek 
TLR4/MD2/CD14 cell culture. 
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Complete α-MEM Culture Media 
Non-heat inactivated FBS 10% 
Penicillin/Streptomycin/L-glutamine 100 µg/mL/ 100 µg/mL/ 2 nM 
Gentamycin 50 µg/mL 
rGMCSF 5 ng/mL 
DuoSet ELISA Kits 
hIL-8 DY208 
hRANTES DY278 
IL-12p28 DY1834 
MCP-1 DY479 
mIL-10 DY417 
mIL-12p40 DY404 
mIL-12p70 DY419 
mIL-1β DY401 
mIL-23 DY1887 
mIL-6 DY406 
MIP-2 DY452 
mRANTES DY478 
mTNFα DY410 
10X Phosphate Buffered Saline (PBS) 
Na2HPO4.2H2O 8 mM 
KH2PO4 1.5 mM 
NaCL 137 nM 
KCL 2.7 nM 
The solution was dissolved in dH2O to the required volume and the pH was adjusted to 
pH 7.4. 
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10X Tris buffered Saline (TBS)  
NaCL 1.5 M 
Trizma Base 0.2 M 
The solution was dissolved in dH2O to the required volume and the pH was adjusted to 
pH 7.6. 
FACS Buffer 
FBS 2% 
NaN3 0.05% 
EDTA 0.5 M 
The solution was dissolved in PBS and filtered through a 0.2 µM filter before use. 
MiRNA mimics 
MC12601  mirVana
™
 miRNA mimic hsa-miR-155 
MC10722  mirVana
™
 miRNA mimic hsa-miR-146a 
MC12304 mirVana
™
 miRNA mimic hsa-let-7e 
MC11480 mirVana
™
 miRNA mimic hsa-miR-145 
4464058 mirVana
™
 miRNA mimic Negative Control #1 
4465062 mirVana
™
 miRNA mimic miR-1 Positive Control 
1X Luciferase Lysis buffer 
Luciferase cell culture lysis reagent 20% 
Sigma water 80% 
100 µl 1X solution was added to each well to lyse the cells for luciferase assay analysis. 
 
50X TAE Buffer 
Trizma Base 40 mM 
Glacial Acetic Acid 20 mM 
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EDTA 1 mM 
The solution was dissolved in dH2O to the required volume and the pH was adjusted to 
pH 8.5.  
Luciferase Assay Mixture 
Tricine 0.2 M 
MgSO4.7H2O 2.67 nM 
EDTA 0.1 mM 
DTT 33.3 mM 
ATP 530 µM 
Acetyl Co Enzyme A  270 µM 
D-Luciferin 30 mg 
NaOH 2 M 
((MgCO3)4Mg(OH)2.5H2O 50 mM 
The solution was dissolved in dH2O to the required volume. The NaOH and Magnesium 
Carbonate Hydroxide pentahydrate were added last and kept in the dark thereafter. The 
solution was aliquoted and kept in the -20°C. The solution was thawed to room 
temperature before use and 40 µl was added per well to measure luciferase activity. 
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Appendix B- SLP Characterisation 
BCA Standard curve
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C. difficile Ribotype SLP Concentration µg/mL 
RT 001 3335 
RT 005 883.2 
RT 014 2456 
RT 027 2100 
RT 031 848 
RT 078 7234 
Figure B.1 The protein concentration of each of the SLPs was measured using the 
BCA assay. A Bicinchoninic acid (BCA) assay was performed to determine protein 
concentrations for each of the SLPs used in this project. A) Standard curve were the 
standard concentration was plotted against absorbance at 562 nm. Graph includes the 
equation of the line and the r
2
 value B) Protein concentration of each of the SLPs in 
µg/mL. 20 µg/mL was used to stimulate cells for each experiment. 
A) 
B) 
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Figure B.2. Endotoxin activity was not detected in samples of purified SLPs. 
Endotoxin activity was measured in purified SLPs and LPS using the ToxinSensor™ 
ChromogeniLAL Endotoxin Assay Kit according to manufacturer’s specifications. 
Endotoxin activity was detected in LPS which was used as a positive control. Therefore 
any immune response was due to the SLPs and not due to contamination from other 
bacterial sources.  
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Appendix C- Plasmid DNA Constructs 
 
 
 
Figure C.1 pRL-TK, pFR, pcDNA3.1, pFA-IRF3 and NF-κB construct maps. 
Expression vectors used in the generation of plasmid DNA for transient transfections. 
Chemically competent DH5α E. coli transformed with NF-κB, pFA-IRF3, pFR and 
phRL-TK renilla ligated DNA were a gift from Prof. Paul Moynagh, The Institute of 
Immunology, National University of Ireland Maynooth, Maynooth, Co. Kildare. 
  
 320  
Appendix D- RNA Quality Assurance 
 
Figure D.1 RNA Isolation product analysis by gel Electrophoresis. After each RNA 
isolation, 1µg RNA from each sample was mixed with RNA loading buffer and loaded 
on 1% agarose gel along with GeneRuler 1 kb plus ladder. The gel was run for 45 
minutes at 150 volts and visualised using the G-box imaging system. The 28S:18S 
ribosomal RNA (rRNA) bands were assessed for integrity. 
Ladder 
28S 
18S 
5000 bp 
4000 bp 
3000 bp 
2000 bp 
55 KDa 
Control LPS RT 001 RT 027 
1500 bp 
Ladder 
5000 bp 
4000 bp 
3000 bp 
2000 bp 
1500 bp 
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Appendix E- Taqman Assays 
 
Figure E.1 Map of miRNA assays on TLDA Pool A v2 cards. Location of the 384 
miRNA assays on TLDA pool A v2 cards. Each card was pre loaded with 0.5 µl 20X 
Taqman microRNA Assays.  
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Table E.1 miRNA target sequence and assay position on pool A TLDA cards. 
Location, assay ID, assay name and target sequence of each of the 20X Taqman 
microRNA assays on the pool A v2 TLDA cards used in this study 
Well 
location 
Assay 
ID 
Assay Name Target Sequence 5’ → 3’ 
A1 000377 hsa-let-7a UGAGGUAGUAGGUUGUAUAGUU 
A2 000379 hsa-let-7c UGAGGUAGUAGGUUGUAUGGUU 
A3 002283 hsa-let-7d AGAGGUAGUAGGUUGCAUAGUU 
A4 002406 hsa-let-7e UGAGGUAGGAGGUUGUAUAGUU 
A5 000382 hsa-let-7f UGAGGUAGUAGAUUGUAUAGUU 
A6 002282 hsa-let-7g UGAGGUAGUAGUUUGUACAGUU 
A7 002222 hsa-miR-1 UGGAAUGUAAAGAAGUAUGUAU 
A8 000583 hsa-miR-9 UCUUUGGUUAUCUAGCUGUAUGA 
A9 000387 hsa-miR-10a UACCCUGUAGAUCCGAAUUUGUG 
A10 002218 hsa-miR-10b UACCCUGUAGAACCGAAUUUGUG 
A11 001973 U6 snRNA GTGCTCGCTTCGGCAGCACATATAC
TAAAATTGGAACGATACAGAGAAGA
TTAGCATGGCCCCTGCGCAAGGATG
ACACGCAAATTCGTGAAGCGTTCCA
TATTTT 
A12 001973 U6 snRNA GTGCTCGCTTCGGCAGCACATATAC
TAAAATTGGAACGATACAGAGAAGA
TTAGCATGGCCCCTGCGCAAGGATG
ACACGCAAATTCGTGAAGCGTTCCA
TATTTT 
A13 000389 hsa-miR-15a UAGCAGCACAUAAUGGUUUGUG 
A14 000390 hsa-miR-15b UAGCAGCACAUCAUGGUUUACA 
A15 000391 hsa-miR-16 UAGCAGCACGUAAAUAUUGGCG 
A16 002308 hsa-miR-17 CAAAGUGCUUACAGUGCAGGUAG 
A17 002422 hsa-miR-18a UAAGGUGCAUCUAGUGCAGAUAG 
A18 002217 hsa-miR-18b UAAGGUGCAUCUAGUGCAGUUAG 
A19 000395 hsa-miR-19a UGUGCAAAUCUAUGCAAAACUGA 
A20 000396 hsa-miR-19b UGUGCAAAUCCAUGCAAAACUGA 
A21 000580 hsa-miR-20a UAAAGUGCUUAUAGUGCAGGUAG 
A22 001014 hsa-miR-20b CAAAGUGCUCAUAGUGCAGGUAG 
A23 000397 hsa-miR-21 UAGCUUAUCAGACUGAUGUUGA 
A24 000398 hsa-miR-22 AAGCUGCCAGUUGAAGAACUGU 
B1 000399 hsa-miR-23a AUCACAUUGCCAGGGAUUUCC 
B2 000400 hsa-miR-23b AUCACAUUGCCAGGGAUUACC 
B3 000402 hsa-miR-24 UGGCUCAGUUCAGCAGGAACAG 
B4 000403 hsa-miR-25 CAUUGCACUUGUCUCGGUCUGA 
B5 000405 hsa-miR-26a UUCAAGUAAUCCAGGAUAGGCU 
B6 000407 hsa-miR-26b UUCAAGUAAUUCAGGAUAGGU 
B7 000408 hsa-miR-27a UUCACAGUGGCUAAGUUCCGC 
B8 000409 hsa-miR-27b UUCACAGUGGCUAAGUUCUGC 
B9 002446 hsa-miR-28-3p CACUAGAUUGUGAGCUCCUGGA 
B10 000411 hsa-miR-28 AAGGAGCUCACAGUCUAUUGAG 
B11 001973 U6 snRNA GTGCTCGCTTCGGCAGCACATATAC
TAAAATTGGAACGATACAGAGAAGA
  
 323  
TTAGCATGGCCCCTGCGCAAGGATG
ACACGCAAATTCGTGAAGCGTTCCA
TATTTT 
B12 001973 U6 snRNA GTGCTCGCTTCGGCAGCACATATAC
TAAAATTGGAACGATACAGAGAAGA
TTAGCATGGCCCCTGCGCAAGGATG
ACACGCAAATTCGTGAAGCGTTCCA
TATTTT 
B13 002112 hsa-miR-29a UAGCACCAUCUGAAAUCGGUUA 
B14 000413 hsa-miR-29b UAGCACCAUUUGAAAUCAGUGUU 
B15 000587 hsa-miR-29c UAGCACCAUUUGAAAUCGGUUA 
B16 000602 hsa-miR-30b UGUAAACAUCCUACACUCAGCU 
B17 000419 hsa-miR-30c UGUAAACAUCCUACACUCUCAGC 
B18 002279 hsa-miR-31 AGGCAAGAUGCUGGCAUAGCU 
B19 002109 hsa-miR-32 UAUUGCACAUUACUAAGUUGCA 
B20 002085 hsa-miR-33b GUGCAUUGCUGUUGCAUUGC 
B21 000426 hsa-miR-34a UGGCAGUGUCUUAGCUGGUUGU 
B22 000428 hsa-miR-34c AGGCAGUGUAGUUAGCUGAUUGC 
B23 000431 hsa-miR-92a UAUUGCACUUGUCCCGGCCUGU 
B24 001090 mmu-miR-93 CAAAGUGCUGUUCGUGCAGGUAG 
C1 000433 hsa-miR-95 UUCAACGGGUAUUUAUUGAGCA 
C2 000186 mmu-miR-96 UUUGGCACUAGCACAUUUUUGCU 
C3 000577 hsa-miR-98 UGAGGUAGUAAGUUGUAUUGUU 
C4 000435 hsa-miR-99a AACCCGUAGAUCCGAUCUUGUG 
C5 000436 hsa-miR-99b CACCCGUAGAACCGACCUUGCG 
C6 000437 hsa-miR-100 AACCCGUAGAUCCGAACUUGUG 
C7 002253 hsa-miR-101 UACAGUACUGUGAUAACUGAA 
C8 000439 hsa-miR-103 AGCAGCAUUGUACAGGGCUAUGA 
C9 002167 hsa-miR-105 UCAAAUGCUCAGACUCCUGUGGU 
C10 002169 hsa-miR-106a AAAAGUGCUUACAGUGCAGGUAG 
C11 001094 RNU44 CCUGGAUGAUGAUAGCAAAUGCUG
ACUGAACAUGAAGGUCUUAAUUAG
CUCUAACUGACU 
C12 000442 hsa-miR-106b UAAAGUGCUGACAGUGCAGAU 
C13 000443 hsa-miR-107 AGCAGCAUUGUACAGGGCUAUCA 
C14 002245 hsa-miR-122 UGGAGUGUGACAAUGGUGUUUG 
C15 001182 mmu-miR-124a UAAGGCACGCGGUGAAUGCC 
C16 002199 hsa-miR-125a-3p ACAGGUGAGGUUCUUGGGAGCC 
C17 002198 hsa-miR-125a-5p UCCCUGAGACCCUUUAACCUGUGA 
C18 000449 hsa-miR-125b UCCCUGAGACCCUAACUUGUGA 
C19 002228 hsa-miR-126 UCGUACCGUGAGUAAUAAUGCG 
C20 000452 hsa-miR-127 UCGGAUCCGUCUGAGCUUGGCU 
C21 002229 hsa-miR-127-5p CUGAAGCUCAGAGGGCUCUGAU 
C22 002216 hsa-miR-128a UCACAGUGAACCGGUCUCUUU 
C23 001184 mmu-miR-129-3p AAGCCCUUACCCCAAAAAGCAU 
C24 000590 hsa-miR-129 CUUUUUGCGGUCUGGGCUUGC 
D1 000454 hsa-miR-130a CAGUGCAAUGUUAAAAGGGCAU 
D2 000456 hsa-miR-130b CAGUGCAAUGAUGAAAGGGCAU 
D3 000457 hsa-miR-132 UAACAGUCUACAGCCAUGGUCG 
D4 002246 hsa-miR-133a UUUGGUCCCCUUCAACCAGCUG 
D5 002247 hsa-miR-133b UUUGGUCCCCUUCAACCAGCUA 
D6 001186 mmu-miR-134 UGUGACUGGUUGACCAGAGGGG 
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D7 000460 hsa-miR-135a UAUGGCUUUUUAUUCCUAUGUGA 
D8 002261 hsa-miR-135b UAUGGCUUUUCAUUCCUAUGUGA 
D9 000592 hsa-miR-136 ACUCCAUUUGUUUUGAUGAUGGA 
D10 001129 mmu-miR-137 UUAUUGCUUAAGAAUACGCGUAG 
D11 002284 hsa-miR-138 AGCUGGUGUUGUGAAUCAGGCCG 
D12 002313 hsa-miR-139-3p GGAGACGCGGCCCUGUUGGAGU 
D13 002289 hsa-miR-139-5p UCUACAGUGCACGUGUCUCCAG 
D14 002234 hsa-miR-140-3p UACCACAGGGUAGAACCACGG 
D15 001187 mmu-miR-140 CAGUGGUUUUACCCUAUGGUAG 
D16 000463 hsa-miR-141 UAACACUGUCUGGUAAAGAUGG 
D17 000464 hsa-miR-142-3p UGUAGUGUUUCCUACUUUAUGGA 
D18 002248 hsa-miR-142-5p CAUAAAGUAGAAAGCACUACU 
D19 002249 hsa-miR-143 UGAGAUGAAGCACUGUAGCUC 
D20 002278 hsa-miR-145 GUCCAGUUUUCCCAGGAAUCCCU 
D21 000468 hsa-miR-146a UGAGAACUGAAUUCCAUGGGUU 
D22 002361 hsa-miR-146b-3p UGCCCUGUGGACUCAGUUCUGG 
D23 001097 hsa-miR-146b UGAGAACUGAAUUCCAUAGGCU 
D24 002262 hsa-miR-147b GUGUGCGGAAAUGCUUCUGCUA 
E1 000470 hsa-miR-148a UCAGUGCACUACAGAACUUUGU 
E2 000471 hsa-miR-148b UCAGUGCAUCACAGAACUUUGU 
E3 002255 hsa-miR-149 UCUGGCUCCGUGUCUUCACUCCC 
E4 000473 hsa-miR-150 UCUCCCAACCCUUGUACCAGUG 
E5 000475 hsa-miR-152 UCAGUGCAUGACAGAACUUGG 
E6 001191 mmu-miR-153 UUGCAUAGUCACAAAAGUGAUC 
E7 000477 hsa-miR-154 UAGGUUAUCCGUGUUGCCUUCG 
E8 000480 hsa-miR-181a AACAUUCAACGCUGUCGGUGAGU 
E9 000482 hsa-miR-181c AACAUUCAACCUGUCGGUGAGU 
E10 002334 hsa-miR-182 UUUGGCAAUGGUAGAACUCACACU 
E11 001006 RNU48 GAUGACCCCAGGUAACUCUGAGUG
UGUCGCUGAUGCCAUCACCGCAGC
GCUCUGACC 
E12 002269 hsa-miR-183 UAUGGCACUGGUAGAAUUCACU 
E13 000485 hsa-miR-184 UGGACGGAGAACUGAUAAGGGU 
E14 002271 hsa-miR-185 UGGAGAGAAAGGCAGUUCCUGA 
E15 002285 hsa-miR-186 CAAAGAAUUCUCCUUUUGGGCU 
E16 001193 mmu-miR-187 UCGUGUCUUGUGUUGCAGCCGG 
E17 002106 hsa-miR-188-3p CUCCCACAUGCAGGGUUUGCA 
E18 000489 hsa-miR-190 UGAUAUGUUUGAUAUAUUAGGU 
E19 002299 hsa-miR-191 CAACGGAAUCCCAAAAGCAGCUG 
E20 000491 hsa-miR-192 CUGACCUAUGAAUUGACAGCC 
E21 002250 hsa-miR-193a-3p AACUGGCCUACAAAGUCCCAGU 
E22 002281 hsa-miR-193a-5p UGGGUCUUUGCGGGCGAGAUGA 
E23 002367 hsa-miR-193b AACUGGCCCUCAAAGUCCCGCU 
E24 000493 hsa-miR-194 UGUAACAGCAACUCCAUGUGGA 
F1 000494 hsa-miR-195 UAGCAGCACAGAAAUAUUGGC 
F2 002215 hsa-miR-196b UAGGUAGUUUCCUGUUGUUGGG 
F3 000497 hsa-miR-197 UUCACCACCUUCUCCACCCAGC 
F4 002273 hsa-miR-198 GGUCCAGAGGGGAGAUAGGUUC 
F5 000498 hsa-miR-199a CCCAGUGUUCAGACUACCUGUUC 
F6 002304 hsa-miR-199a-3p ACAGUAGUCUGCACAUUGGUUA 
F7 000500 hsa-miR-199b CCCAGUGUUUAGACUAUCUGUUC 
F8 000502 hsa-miR-200a UAACACUGUCUGGUAACGAUGU 
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F9 002251 hsa-miR-200b UAAUACUGCCUGGUAAUGAUGA 
F10 002300 hsa-miR-200c UAAUACUGCCGGGUAAUGAUGGA 
F11 002363 hsa-miR-202 AGAGGUAUAGGGCAUGGGAA 
F12 000507 hsa-miR-203 GUGAAAUGUUUAGGACCACUAG 
F13 000508 hsa-miR-204 UUCCCUUUGUCAUCCUAUGCCU 
F14 000509 hsa-miR-205 UCCUUCAUUCCACCGGAGUCUG 
F15 002290 hsa-miR-208b AUAAGACGAACAAAAGGUUUGU 
F16 000512 hsa-miR-210 CUGUGCGUGUGACAGCGGCUGA 
F17 002306 hsa-miR-214 ACAGCAGGCACAGACAGGCAGU 
F18 000518 hsa-miR-215 AUGACCUAUGAAUUGACAGAC 
F19 002220 hsa-miR-216a UAAUCUCAGCUGGCAACUGUGA 
F20 002326 hsa-miR-216b AAAUCUCUGCAGGCAAAUGUGA 
F21 002337 hsa-miR-217 UACUGCAUCAGGAACUGAUUGGA 
F22 000521 hsa-miR-218 UUGUGCUUGAUCUAACCAUGU 
F23 000522 hsa-miR-219 UGAUUGUCCAAACGCAAUUCU 
F24 000524 hsa-miR-221 AGCUACAUUGUCUGCUGGGUUUC 
G1 002276 hsa-miR-222 AGCUACAUCUGGCUACUGGGU 
G2 002295 hsa-miR-223 UGUCAGUUUGUCAAAUACCCCA 
G3 002099 hsa-miR-224 CAAGUCACUAGUGGUUCCGUU 
G4 002101 hsa-miR-296-3p GAGGGUUGGGUGGAGGCUCUCC 
G5 000527 hsa-miR-296 AGGGCCCCCCCUCAAUCCUGU 
G6 001015 hsa-miR-299-3p UAUGUGGGAUGGUAAACCGCUU 
G7 000600 hsa-miR-299-5p UGGUUUACCGUCCCACAUACAU 
G8 000528 hsa-miR-301 CAGUGCAAUAGUAUUGUCAAAGC 
G9 002392 hsa-miR-301b CAGUGCAAUGAUAUUGUCAAAGC 
G10 000529 hsa-miR-302a UAAGUGCUUCCAUGUUUUGGUGA 
G11 000338 ath-miR159a UUUGGAUUGAAGGGAGCUCUA 
G12 000531 hsa-miR-302b UAAGUGCUUCCAUGUUUUAGUAG 
G13 000533 hsa-miR-302c UAAGUGCUUCCAUGUUUCAGUGG 
G14 002277 hsa-miR-320 AAAAGCUGGGUUGAGAGGGCGA 
G15 002227 hsa-miR-323-3p CACAUUACACGGUCGACCUCU 
G16 002161 hsa-miR-324-3p ACUGCCCCAGGUGCUGCUGG 
G17 000539 hsa-miR-324-5p CGCAUCCCCUAGGGCAUUGGUGU 
G18 000542 hsa-miR-326 CCUCUGGGCCCUUCCUCCAG 
G19 000543 hsa-miR-328 CUGGCCCUCUCUGCCCUUCCGU 
G20 001101 hsa-miR-329 AACACACCUGGUUAACCUCUUU 
G21 000544 hsa-miR-330 GCAAAGCACACGGCCUGCAGAGA 
G22 002230 hsa-miR-330-5p UCUCUGGGCCUGUGUCUUAGGC 
G23 000545 hsa-miR-331 GCCCCUGGGCCUAUCCUAGAA 
G24 002233 hsa-miR-331-5p CUAGGUAUGGUCCCAGGGAUCC 
H1 000546 hsa-miR-335 UCAAGAGCAAUAACGAAAAAUGU 
H2 002156 hsa-miR-337-5p GAACGGCUUCAUACAGGAGUU 
H3 002252 hsa-miR-338-3p UCCAGCAUCAGUGAUUUUGUUG 
H4 002184 hsa-miR-339-3p UGAGCGCCUCGACGACAGAGCCG 
H5 002257 hsa-miR-339-5p UCCCUGUCCUCCAGGAGCUCACG 
H6 002258 hsa-miR-340 UUAUAAAGCAAUGAGACUGAUU 
H7 002623 hsa-miR-155 UUAAUGCUAAUCGUGAUAGGGGU 
H8 002619 hsa-let-7b UGAGGUAGUAGGUUGUGUGGUU 
H9 002260 hsa-miR-342-3p UCUCACACAGAAAUCGCACCCGU 
H10 002147 hsa-miR-342-5p AGGGGUGCUAUCUGUGAUUGA 
H11 002186 hsa-miR-345 GCUGACUCCUAGUCCAGGGCUC 
H12 000554 hsa-miR-361 UUAUCAGAAUCUCCAGGGGUAC 
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H13 002117 hsa-miR-362-3p AACACACCUAUUCAAGGAUUCA 
H14 001273 hsa-miR-362 AAUCCUUGGAACCUAGGUGUGAGU 
H15 001271 hsa-miR-363 AAUUGCACGGUAUCCAUCUGUA 
H16 001020 hsa-miR-365 UAAUGCCCCUAAAAAUCCUUAU 
H17 000555 hsa-miR-367 AAUUGCACUUUAGCAAUGGUGA 
H18 000557 hsa-miR-369-3p AAUAAUACAUGGUUGAUCUUU 
H19 001021 hsa-miR-369-5p AGAUCGACCGUGUUAUAUUCGC 
H20 002275 hsa-miR-370 GCCUGCUGGGGUGGAACCUGGU 
H21 002124 hsa-miR-371-3p AAGUGCCGCCAUCUUUUGAGUGU 
H22 000560 hsa-miR-372 AAAGUGCUGCGACAUUUGAGCGU 
H23 000561 hsa-miR-373 GAAGUGCUUCGAUUUUGGGGUGU 
H24 000563 hsa-miR-374 UUAUAAUACAACCUGAUAAGUG 
I1 001319 mmu-miR-374-5p AUAUAAUACAACCUGCUAAGUG 
I2 000564 hsa-miR-375 UUUGUUCGUUCGGCUCGCGUGA 
I3 000565 hsa-miR-376a AUCAUAGAGGAAAAUCCACGU 
I4 001102 hsa-miR-376b AUCAUAGAGGAAAAUCCAUGUU 
I5 000566 hsa-miR-377 AUCACACAAAGGCAACUUUUGU 
I6 001138 mmu-miR-379 UGGUAGACUAUGGAACGUAGG 
I7 000569 hsa-miR-380-3p UAUGUAAUAUGGUCCACAUCUU 
I8 000571 hsa-miR-381 UAUACAAGGGCAAGCUCUCUGU 
I9 000572 hsa-miR-382 GAAGUUGUUCGUGGUGGAUUCG 
I10 000573 hsa-miR-383 AGAUCAGAAGGUGAUUGUGGCU 
I11 002331 hsa-miR-409-5p AGGUUACCCGAGCAACUUUGCAU 
I12 001274 hsa-miR-410 AAUAUAACACAGAUGGCCUGU 
I13 001610 hsa-miR-411 UAGUAGACCGUAUAGCGUACG 
I14 002297 hsa-miR-422a ACUGGACUUAGGGUCAGAAGGC 
I15 002340 hsa-miR-423-5p UGAGGGGCAGAGAGCGAGACUUU 
I16 000604 hsa-miR-424 CAGCAGCAAUUCAUGUUUUGAA 
I17 001516 hsa-miR-425-5p AAUGACACGAUCACUCCCGUUGA 
I18 001024 hsa-miR-429 UAAUACUGUCUGGUAAAACCGU 
I19 001979 hsa-miR-431 UGUCUUGCAGGCCGUCAUGCA 
I20 001028 hsa-miR-433 AUCAUGAUGGGCUCCUCGGUGU 
I21 001030 hsa-miR-449 UGGCAGUGUAUUGUUAGCUGGU 
I22 001608 hsa-miR-449b AGGCAGUGUAUUGUUAGCUGGC 
I23 002303 hsa-miR-450a UUUUGCGAUGUGUUCCUAAUAU 
I24 002208 hsa-miR-450b-3p UUGGGAUCAUUUUGCAUCCAUA 
J1 002207 hsa-miR-450b-5p UUUUGCAAUAUGUUCCUGAAUA 
J2 001141 mmu-miR-451 AAACCGUUACCAUUACUGAGUU 
J3 002329 hsa-miR-452 AACUGUUUGCAGAGGAAACUGA 
J4 002318 hsa-miR-453 AGGUUGUCCGUGGUGAGUUCGCA 
J5 002323 hsa-miR-454 UAGUGCAAUAUUGCUUAUAGGGU 
J6 002244 hsa-miR-455-3p GCAGUCCAUGGGCAUAUACAC 
J7 001280 hsa-miR-455 UAUGUGCCUUUGGACUACAUCG 
J8 002338 hsa-miR-483-5p AAGACGGGAGGAAAGAAGGGAG 
J9 001821 hsa-miR-484 UCAGGCUCAGUCCCCUCCCGAU 
J10 001277 hsa-miR-485-3p GUCAUACACGGCUCUCCUCUCU 
J11 001036 hsa-miR-485-5p AGAGGCUGGCCGUGAUGAAUUC 
J12 002093 hsa-miR-486-3p CGGGGCAGCUCAGUACAGGAU 
J13 001278 hsa-miR-486 UCCUGUACUGAGCUGCCCCGAG 
J14 001279 hsa-miR-487a AAUCAUACAGGGACAUCCAGUU 
J15 001285 hsa-miR-487b AAUCGUACAGGGUCAUCCACUU 
J16 002357 hsa-miR-488 UUGAAAGGCUAUUUCUUGGUC 
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J17 002358 hsa-miR-489 GUGACAUCACAUAUACGGCAGC 
J18 001037 hsa-miR-490 CAACCUGGAGGACUCCAUGCUG 
J19 002360 hsa-miR-491-3p CUUAUGCAAGAUUCCCUUCUAC 
J20 001630 mmu-miR-491 AGUGGGGAACCCUUCCAUGAGG 
J21 002364 hsa-miR-493 UGAAGGUCUACUGUGUGCCAGG 
J22 002365 hsa-miR-494 UGAAACAUACACGGGAAACCUC 
J23 001663 mmu-miR-495 AAACAAACAUGGUGCACUUCUU 
J24 001953 mmu-miR-496 UGAGUAUUACAUGGCCAAUCUC 
K1 002427 hsa-miR-499-3p AACAUCACAGCAAGUCUGUGCU 
K2 001352 mmu-miR-499 UUAAGACUUGCAGUGAUGUUU 
K3 002428 hsa-miR-500 UAAUCCUUGCUACCUGGGUGAGA 
K4 002435 hsa-miR-501-3p AAUGCACCCGGGCAAGGAUUCU 
K5 001047 hsa-miR-501 AAUCCUUUGUCCCUGGGUGAGA 
K6 002083 hsa-miR-502-3p AAUGCACCUGGGCAAGGAUUCA 
K7 001109 hsa-miR-502 AUCCUUGCUAUCUGGGUGCUA 
K8 001048 hsa-miR-503 UAGCAGCGGGAACAGUUCUGCAG 
K9 002084 hsa-miR-504 AGACCCUGGUCUGCACUCUAUC 
K10 002089 hsa-miR-505 CGUCAACACUUGCUGGUUUCCU 
K11 001051 hsa-miR-507 UUUUGCACCUUUUGGAGUGAA 
K12 001052 hsa-miR-508 UGAUUGUAGCCUUUUGGAGUAGA 
K13 002092 hsa-miR-508-5p UACUCCAGAGGGCGUCACUCAUG 
K14 002235 hsa-miR-509-5p UACUGCAGACAGUGGCAAUCA 
K15 002241 hsa-miR-510 UACUCAGGAGAGUGGCAAUCAC 
K16 001823 hsa-miR-512-3p AAGUGCUGUCAUAGCUGAGGUC 
K17 001145 hsa-miR-512-5p CACUCAGCCUUGAGGGCACUUUC 
K18 002090 hsa-miR-513-5p UUCACAGGGAGGUGUCAU 
K19 002369 hsa-miR-515-3p GAGUGCCUUCUUUUGGAGCGUU 
K20 001112 hsa-miR-515-5p UUCUCCAAAAGAAAGCACUUUCUG 
K21 002416 hsa-miR-516a-5p UUCUCGAGGAAAGAAGCACUUUC 
K22 001150 hsa-miR-516b AUCUGGAGGUAAGAAGCACUUU 
K23 002402 hsa-miR-517a AUCGUGCAUCCCUUUAGAGUGU 
K24 001153 hsa-miR-517c AUCGUGCAUCCUUUUAGAGUGU 
L1 002397 hsa-miR-518a-3p GAAAGCGCUUCCCUUUGCUGGA 
L2 002396 hsa-miR-518a-5p CUGCAAAGGGAAGCCCUUUC 
L3 001156 hsa-miR-518b CAAAGCGCUCCCCUUUAGAGGU 
L4 002401 hsa-miR-518c CAAAGCGCUUCUCUUUAGAGUGU 
L5 001159 hsa-miR-518d CAAAGCGCUUCCCUUUGGAGC 
L6 002389 hsa-miR-518d-5p CUCUAGAGGGAAGCACUUUCUG 
L7 002395 hsa-miR-518e AAAGCGCUUCCCUUCAGAGUG 
L8 002388 hsa-miR-518f GAAAGCGCUUCUCUUUAGAGG 
L9 002415 hsa-miR-519a AAAGUGCAUCCUUUUAGAGUGU 
L10 002403 hsa-miR-519d CAAAGUGCCUCCCUUUAGAGUG 
L11 002370 hsa-miR-519e AAGUGCCUCCUUUUAGAGUGUU 
L12 001167 hsa-miR-520a AAAGUGCUUCCCUUUGGACUGU 
L13 001168 hsa-miR-520a# CUCCAGAGGGAAGUACUUUCU 
L14 002393 hsa-miR-520d-5p CUACAAAGGGAAGCCCUUUC 
L15 001121 hsa-miR-520g ACAAAGUGCUUCCCUUUAGAGUGU 
L16 001122 hsa-miR-521 AACGCACUUCCCUUUAGAGUGU 
L17 002413 hsa-miR-522 AAAAUGGUUCCCUUUAGAGUGU 
L18 002386 hsa-miR-523 GAACGCGCUUCCCUAUAGAGGGU 
L19 001982 hsa-miR-524-5p CUACAAAGGGAAGCACUUUCUC 
L20 002385 hsa-miR-525-3p GAAGGCGCUUCCCUUUAGAGCG 
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L21 001174 hsa-miR-525 CUCCAGAGGGAUGCACUUUCU 
L22 002382 hsa-miR-526b CUCUUGAGGGAAGCACUUUCUGU 
L23 002355 hsa-miR-532-3p CCUCCCACACCCAAGGCUUGCA 
L24 001518 hsa-miR-532 CAUGCCUUGAGUGUAGGACCGU 
M1 001286 hsa-miR-539 GGAGAAAUUAUCCUUGGUGUGU 
M2 002201 hsa-miR-541 UGGUGGGCACAGAAUCUGGACU 
M3 001284 hsa-miR-542-3p UGUGACAGAUUGAUAACUGAAA 
M4 002240 hsa-miR-542-5p UCGGGGAUCAUCAUGUCACGAGA 
M5 002265 hsa-miR-544 AUUCUGCAUUUUUAGCAAGUUC 
M6 002267 hsa-miR-545 UCAGCAAACAUUUAUUGUGUGC 
M7 001538 hsa-miR-548a CAAAACUGGCAAUUACUUUUGC 
M8 002412 hsa-miR-548a-5p AAAAGUAAUUGCGAGUUUUACC 
M9 001541 hsa-miR-548b CAAGAACCUCAGUUGCUUUUGU 
M10 002408 hsa-miR-548b-5p AAAAGUAAUUGUGGUUUUGGCC 
M11 001590 hsa-miR-548c CAAAAAUCUCAAUUACUUUUGC 
M12 002429 hsa-miR-548c-5p AAAAGUAAUUGCGGUUUUUGCC 
M13 001605 hsa-miR-548d CAAAAACCACAGUUUCUUUUGC 
M14 002237 hsa-miR-548d-5p AAAAGUAAUUGUGGUUUUUGCC 
M15 001535 hsa-miR-551b GCGACCCAUACUUGGUUUCAG 
M16 002345 hsa-miR-556-3p AUAUUACCAUUAGCUCAUCUUU 
M17 002344 hsa-miR-556-5p GAUGAGCUCAUUGUAAUAUGAG 
M18 001528 hsa-miR-561 CAAAGUUUAAGAUCCUUGAAGU 
M19 002347 hsa-miR-570 CGAAAACAGCAAUUACCUUUGC 
M20 002349 hsa-miR-574-3p CACGCUCAUGCACACACCCACA 
M21 002351 hsa-miR-576-3p AAGAUGUGGAAAAAUUGGAAUC 
M22 002350 hsa-miR-576-5p AUUCUAAUUUCUCCACGUCUUU 
M23 002398 hsa-miR-579 UUCAUUUGGUAUAAACCGCGAUU 
M24 002399 hsa-miR-582-3p UAACUGGUUGAACAACUGAACC 
N1 001983 hsa-miR-582-5p UUACAGUUGUUCAACCAGUUACU 
N2 002409 hsa-miR-589 UGAGAACCACGUCUGCUCUGAG 
N3 001984 hsa-miR-590-5p GAGCUUAUUCAUAAAAGUGCAG 
N4 001551 hsa-miR-597 UGUGUCACUCGAUGACCACUGU 
N5 001988 hsa-miR-598 UACGUCAUCGUUGUCAUCGUCA 
N6 001960 mmu-miR-615 UCCGAGCCUGGGUCUCCCUCUU 
N7 002353 hsa-miR-615-5p GGGGGUCCCCGGUGCUCGGAUC 
N8 002414 hsa-miR-616 AGUCAUUGGAGGGUUUGAGCAG 
N9 001593 hsa-miR-618 AAACUCUACUUGUCCUUCUGAGU 
N10 002430 hsa-miR-624 CACAAGGUAUUGGUAUUACCU 
N11 002431 hsa-miR-625 AGGGGGAAAGUUCUAUAGUCC 
N12 001560 hsa-miR-627 GUGAGUCUCUAAGAAAAGAGGA 
N13 002433 hsa-miR-628-5p AUGCUGACAUAUUUACUAGAGG 
N14 002436 hsa-miR-629 UGGGUUUACGUUGGGAGAACU 
N15 002088 hsa-miR-636 UGUGCUUGCUCGUCCCGCCCGCA 
N16 001592 hsa-miR-642 GUCCCUCUCCAAAUGUGUCUUG 
N17 001604 hsa-miR-651 UUUAGGAUAAGCUUGACUUUUG 
N18 002352 hsa-miR-652 AAUGGCGCCACUAGGGUUGUG 
N19 002292 hsa-miR-653 GUGUUGAAACAAUCUCUACUG 
N20 002239 hsa-miR-654-3p UAUGUCUGCUGACCAUCACCUU 
N21 001611 hsa-miR-654 UGGUGGGCCGCAGAACAUGUGC 
N22 001612 hsa-miR-655 AUAAUACAUGGUUAACCUCUUU 
N23 001515 hsa-miR-660 UACCCAUUGCAUAUCGGAGUUG 
N24 002322 hsa-miR-671-3p UCCGGUUCUCAGGGCUCCACC 
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O1 002327 hsa-miR-672 UGAGGUUGGUGUACUGUGUGUGA 
O2 002021 hsa-miR-674 GCACUGAGAUGGGAGUGGUGUA 
O3 002341 hsa-miR-708 AAGGAGCUUACAAUCUAGCUGGG 
O4 002324 hsa-miR-744 UGCGGGGCUAGGGCUAACAGCA 
O5 001990 hsa-miR-758 UUUGUGACCUGGUCCACUAACC 
O6 002354 hsa-miR-871 UAUUCAGAUUAGUGCCAGUCAUG 
O7 002264 hsa-miR-872 AAGGUUACUUGUUAGUUCAGG 
O8 002356 hsa-miR-873 GCAGGAACUUGUGAGUCUCCU 
O9 002268 hsa-miR-874 CUGCCCUGGCCCGAGGGACCGA 
O10 002204 hsa-miR-875-3p CCUGGAAACACUGAGGUUGUG 
O11 002225 hsa-miR-876-3p UGGUGGUUUACAAAGUAAUUCA 
O12 002205 hsa-miR-876-5p UGGAUUUCUUUGUGAAUCACCA 
O13 002372 hsa-miR-885-3p AGGCAGCGGGGUGUAGUGGAUA 
O14 002296 hsa-miR-885-5p UCCAUUACACUACCCUGCCUCU 
O15 002194 hsa-miR-886-3p CGCGGGUGCUUACUGACCCUU 
O16 002193 hsa-miR-886-5p CGGGUCGGAGUUAGCUCAAGCGG 
O17 002374 hsa-miR-887 GUGAACGGGCGCCAUCCCGAGG 
O18 002212 hsa-miR-888 UACUCAAAAAGCUGUCAGUCA 
O19 002202 hsa-miR-889 UUAAUAUCGGACAACCAUUGU 
O20 002209 hsa-miR-890 UACUUGGAAAGGCAUCAGUUG 
O21 002191 hsa-miR-891a UGCAACGAACCUGAGCCACUGA 
O22 002210 hsa-miR-891b UGCAACUUACCUGAGUCAUUGA 
O23 002195 hsa-miR-892a CACUGUGUCCUUUCUGCGUAG 
O24 000469 hsa-miR-147 GUGUGUGGAAAUGCUUCUGC 
P1 000511 hsa-miR-208 AUAAGACGAGCAAAAAGCUUGU 
P2 000514 hsa-miR-211 UUCCCUUUGUCAUCCUUCGCCU 
P3 000515 hsa-miR-212 UAACAGUCUCCAGUCACGGCC 
P4 002095 hsa-miR-219-1-3p AGAGUUGAGUCUGGACGUCCCG 
P5 002390 hsa-miR-219-2-3p AGAAUUGUGGCUGGACAUCUGU 
P6 000523 hsa-miR-220 CCACACCGUAUCUGACACUUU 
P7 002206 hsa-miR-220b CCACCACCGUGUCUGACACUU 
P8 002211 hsa-miR-220c ACACAGGGCUGUUGUGAAGACU 
P9 002190 hsa-miR-298 AGCAGAAGCAGGGAGGUUCUCCCA 
P10 000540 hsa-miR-325 CCUAGUAGGUGUCCAGUAAGUGU 
P11 000553 hsa-miR-346 UGUCUGCCCGCAUGCCUGCCUCU 
P12 002122 hsa-miR-376c AACAUAGAGGAAAUUCCACGU 
P13 000574 hsa-miR-384 AUUCCUAGAAAUUGUUCAUA 
P14 001023 hsa-miR-412 ACUUCACCUGGUCCACUAGCCGU 
P15 001029 hsa-miR-448 UUGCAUAUGUAGGAUGUCCCAU 
P16 001039 hsa-miR-492 AGGACCUGCGGGACAAGAUUCUU 
P17 001050 hsa-miR-506 UAAGGCACCCUUCUGAGUAGA 
P18 002155 hsa-miR-509-3-5p UACUGCAGACGUGGCAAUCAUG 
P19 001111 hsa-miR-511 GUGUCUUUUGCUCUGCAGUCA 
P20 001152 hsa-miR-517b UCGUGCAUCCCUUUAGAGUGUU 
P21 001163 hsa-miR-519c AAAGUGCAUCUUUUUAGAGGAU 
P22 001116 hsa-miR-520b AAAGUGCUUCCUUUUAGAGGG 
P23 001119 hsa-miR-520e AAAGUGCUUCCUUUUUGAGGG 
P24 001120 hsa-miR-520f AAGUGCUUCCUUUUAGAGGGUU 
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Figure E.2 Map of miRNA assays on TLDA Pool B v3 cards. Location of the 384 
miRNA assays on TLDA pool B v3 cards. Each card was pre loaded with 0.5 µl 20X 
Taqman microRNA Assays.  
  
 331  
Table E.2 miRNA target sequence and assay position on pool B TLDA cards. 
Location, assay ID, assay name and target sequence of each of the 20X Taqman 
microRNA assays on the pool B v3 TLDA cards used in this study 
Well 
location 
Assay 
ID 
Assay Name Target Sequence 5’ → 3’ 
A1 000268 dme-miR-7 UGGAAGACUAGUGAUUUUGUUGU 
A2 002909 hsa-miR-548I AAAAGUAAUUGCGGAUUUUGCC 
A3 000416 hsa-miR-30a-3p CUUUCAGUCGGAUGUUUGCAGC 
A4 000417 hsa-miR-30a-5p UGUAAACAUCCUCGACUGGAAG 
A5 000420 hsa-miR-30d UGUAAACAUCCCCGACUGGAAG 
A6 000422 hsa-miR-30e-3p CUUUCAGUCGGAUGUUUACAGC 
A7 000427 hsa-miR-34b UAGGCAGUGUCAUUAGCUGAUUG 
A8 000451 hsa-miR-126# CAUUAUUACUUUUGGUACGCG 
A9 000478 hsa-miR-154# AAUCAUACACGGUUGACCUAUU 
A10 000483 hsa-miR-182# UGGUUCUAGACUUGCCAACUA 
A11 001973 U6 snRNA GTGCTCGCTTCGGCAGCACATATACTAA
AATTGGAACGATACAGAGAAGATTAGC
ATGGCCCCTGCGCAAGGATGACACGCA
AATTCGTGAAGCGTTCCATATTTT 
A12 001973 U6 snRNA GTGCTCGCTTCGGCAGCACATATACTAA
AATTGGAACGATACAGAGAAGATTAGC
ATGGCCCCTGCGCAAGGATGACACGCA
AATTCGTGAAGCGTTCCATATTTT 
A13 000510 hsa-miR-206 UGGAAUGUAAGGAAGUGUGUGG 
A14 000516 hsa-miR-213 ACCAUCGACCGUUGAUUGUACC 
A15 000534 hsa-miR-302c# UUUAACAUGGGGGUACCUGCUG 
A16 000535 hsa-miR-302d UAAGUGCUUCCAUGUUUGAGUGU 
A17 000567 hsa-miR-378 CUCCUGACUCCAGGUCCUGUGU 
A18 000570 hsa-miR-380-5p UGGUUGACCAUAGAACAUGCGC 
A19 002910 hsa-miR-1257 AGUGAAUGAUGGGUUCUGACC 
A20 001011 hsa-miR-200a# CAUCUUACCGGACAGUGCUGGA 
A21 001026 hsa-miR-432 UCUUGGAGUAGGUCAUUGGGUGG 
A22 001027 hsa-miR-432# CUGGAUGGCUCCUCCAUGUCU 
A23 001043 hsa-miR-497 CAGCAGCACACUGUGGUUUGU 
A24 001046 hsa-miR-500 AUGCACCUGGGCAAGGAUUCUG 
B1 002927 hsa-miR-1238 CUUCCUCGUCUGUCUGCCCC 
B2 001106 hsa-miR-488 CCCAGAUAAUGGCACUCUCAA 
B3 001113 hsa-miR-517# CCUCUAGAUGGAAGCACUGUCU 
B4 001149 hsa-miR-516-3p UGCUUCCUUUCAGAGGGU 
B5 001158 hsa-miR-518c# UCUCUGGAGGGAAGCACUUUCUG 
B6 001166 hsa-miR-519e# UUCUCCAAAAGGGAGCACUUUC 
B7 001170 hsa-miR-520h ACAAAGUGCUUCCCUUUAGAGU 
B8 001173 hsa-miR-524 GAAGGCGCUUCCCUUUGGAGU 
B9 001178 mmu-let-7d# CUAUACGACCUGCUGCCUUUCU 
B10 001283 hsa-miR-363# CGGGUGGAUCACGAUGCAAUUU 
B11 001973 U6 snRNA  GTGCTCGCTTCGGCAGCACATATACTA
AAATTGGAACGATACAGAGAAGATTAG
CATGGCCCCTGCGCAAGGATGACACGC
AAATTCGTGAAGCGTTCCATATTTT 
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B12 001973 U6 snRNA GTGCTCGCTTCGGCAGCACATATACTAA
AATTGGAACGATACAGAGAAGATTAGC
ATGGCCCCTGCGCAAGGATGACACGCA
AATTCGTGAAGCGTTCCATATTTT 
B13 001338 rno-miR-7# CAACAAAUCACAGUCUGCCAUA 
B14 001510 hsa-miR-656 AAUAUUAUACAGUCAACCUCU 
B15 001511 hsa-miR-549 UGACAACUAUGGAUGAGCUCU 
B16 001512 hsa-miR-657 GGCAGGUUCUCACCCUCUCUAGG 
B17 001513 hsa-miR-658 GGCGGAGGGAAGUAGGUCCGUUGGU 
B18 001514 hsa-miR-659 CUUGGUUCAGGGAGGGUCCCCA 
B19 001519 hsa-miR-551a GCGACCCACUCUUGGUUUCCA 
B20 001520 hsa-miR-552 AACAGGUGACUGGUUAGACAA 
B21 001521 hsa-miR-553 AAAACGGUGAGAUUUUGUUUU 
B22 001522 hsa-miR-554 GCUAGUCCUGACUCAGCCAGU 
B23 001523 hsa-miR-555 AGGGUAAGCUGAACCUCUGAU 
B24 001525 hsa-miR-557 GUUUGCACGGGUGGGCCUUGUCU 
C1 001526 hsa-miR-558 UGAGCUGCUGUACCAAAAU 
C2 001527 hsa-miR-559 UAAAGUAAAUAUGCACCAAAA 
C3 001529 hsa-miR-562 AAAGUAGCUGUACCAUUUGC 
C4 001530 hsa-miR-563 AGGUUGACAUACGUUUCCC 
C5 001531 hsa-miR-564 AGGCACGGUGUCAGCAGGC 
C6 001533 hsa-miR-566 GGGCGCCUGUGAUCCCAAC 
C7 001534 hsa-miR-567 AGUAUGUUCUUCCAGGACAGAAC 
C8 001536 hsa-miR-569 AGUUAAUGAAUCCUGGAAAGU 
C9 001539 hsa-miR-586 UAUGCAUUGUAUUUUUAGGUCC 
C10 001540 hsa-miR-587 UUUCCAUAGGUGAUGAGUCAC 
C11 001094 RNU44 CCUGGAUGAUGAUAGCAAAUGCUGAC
UGAACAUGAAGGUCUUAAUUAGCUCU
AACUGACU 
C12 001542 hsa-miR-588 UUGGCCACAAUGGGUUAGAAC 
C13 001543 hsa-miR-589 UCAGAACAAAUGCCGGUUCCCAGA 
C14 001544 hsa-miR-550 UGUCUUACUCCCUCAGGCACAU 
C15 001545 hsa-miR-591 AGACCAUGGGUUCUCAUUGU 
C16 001546 hsa-miR-592 UUGUGUCAAUAUGCGAUGAUGU 
C17 001547 hsa-miR-593 AGGCACCAGCCAGGCAUUGCUCAGC 
C18 001550 hsa-miR-596 AAGCCUGCCCGGCUCCUCGGG 
C19 001553 hsa-miR-622 ACAGUCUGCUGAGGUUGGAGC 
C20 001554 hsa-miR-599 GUUGUGUCAGUUUAUCAAAC 
C21 001555 hsa-miR-623 AUCCCUUGCAGGGGCUGUUGGGU 
C22 001556 hsa-miR-600 ACUUACAGACAAGAGCCUUGCUC 
C23 001557 hsa-miR-624 UAGUACCAGUACCUUGUGUUCA 
C24 001558 hsa-miR-601 UGGUCUAGGAUUGUUGGAGGAG 
D1 001559 hsa-miR-626 AGCUGUCUGAAAAUGUCUU 
D2 001562 hsa-miR-629 GUUCUCCCAACGUAAGCCCAGC 
D3 001563 hsa-miR-630 AGUAUUCUGUACCAGGGAAGGU 
D4 001564 hsa-miR-631 AGACCUGGCCCAGACCUCAGC 
D5 001566 hsa-miR-603 CACACACUGCAAUUACUUUUGC 
D6 001567 hsa-miR-604 AGGCUGCGGAAUUCAGGAC 
D7 001568 hsa-miR-605 UAAAUCCCAUGGUGCCUUCUCCU 
D8 001569 hsa-miR-606 AAACUACUGAAAAUCAAAGAU 
D9 001570 hsa-miR-607 GUUCAAAUCCAGAUCUAUAAC 
D10 001571 hsa-miR-608 AGGGGUGGUGUUGGGACAGCUCCGU 
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D11 001573 hsa-miR-609 AGGGUGUUUCUCUCAUCUCU 
D12 001574 hsa-miR-633 CUAAUAGUAUCUACCACAAUAAA 
D13 001576 hsa-miR-634 AACCAGCACCCCAACUUUGGAC 
D14 001578 hsa-miR-635 ACUUGGGCACUGAAACAAUGUCC 
D15 001581 hsa-miR-637 ACUGGGGGCUUUCGGGCUCUGCGU 
D16 001582 hsa-miR-638 AGGGAUCGCGGGCGGGUGGCGGCCU 
D17 001583 hsa-miR-639 AUCGCUGCGGUUGCGAGCGCUGU 
D18 001584 hsa-miR-640 AUGAUCCAGGAACCUGCCUCU 
D19 001585 hsa-miR-641 AAAGACAUAGGAUAGAGUCACCUC 
D20 001586 hsa-miR-613 AGGAAUGUUCCUUCUUUGCC 
D21 001587 hsa-miR-614 GAACGCCUGUUCUUGCCAGGUGG 
D22 001589 hsa-miR-616 ACUCAAAACCCUUCAGUGACUU 
D23 001591 hsa-miR-617 AGACUUCCCAUUUGAAGGUGGC 
D24 001594 hsa-miR-643 ACUUGUAUGCUAGCUCAGGUAG 
E1 001596 hsa-miR-644 AGUGUGGCUUUCUUAGAGC 
E2 001597 hsa-miR-645 UCUAGGCUGGUACUGCUGA 
E3 001598 hsa-miR-621 GGCUAGCAACAGCGCUUACCU 
E4 001599 hsa-miR-646 AAGCAGCUGCCUCUGAGGC 
E5 001600 hsa-miR-647 GUGGCUGCACUCACUUCCUUC 
E6 001601 hsa-miR-648 AAGUGUGCAGGGCACUGGU 
E7 001602 hsa-miR-649 AAACCUGUGUUGUUCAAGAGUC 
E8 001603 hsa-miR-650 AGGAGGCAGCGCUCUCAGGAC 
E9 001606 hsa-miR-661 UGCCUGGGUCUCUGGCCUGCGCGU 
E10 001607 hsa-miR-662 UCCCACGUUGUGGCCCAGCAG 
E11 001006 RNU48 GAUGACCCCAGGUAACUCUGAGUGUGU
CGCUGAUGCCAUCACCGCAGCGCUCUG
ACC 
E12 001613 hsa-miR-571 UGAGUUGGCCAUCUGAGUGAG 
E13 001614 hsa-miR-572 GUCCGCUCGGCGGUGGCCCA 
E14 001615 hsa-miR-573 CUGAAGUGAUGUGUAACUGAUCAG 
E15 001617 hsa-miR-575 GAGCCAGUUGGACAGGAGC 
E16 001619 hsa-miR-578 CUUCUUGUGCUCUAGGAUUGU 
E17 001621 hsa-miR-580 UUGAGAAUGAUGAAUCAUUAGG 
E18 001622 hsa-miR-581 UCUUGUGUUCUCUAGAUCAGU 
E19 001623 hsa-miR-583 CAAAGAGGAAGGUCCCAUUAC 
E20 001624 hsa-miR-584 UUAUGGUUUGCCUGGGACUGAG 
E21 001625 hsa-miR-585 UGGGCGUAUCUGUAUGCUA 
E22 001818 rno-miR-29c# UGACCGAUUUCUCCUGGUGUUC 
E23 001986 hsa-miR-766 ACUCCAGCCCCACAGCCUCAGC 
E24 001987 hsa-miR-595 GAAGUGUGCCGUGGUGUGUCU 
F1 001992 hsa-miR-668 UGUCACUCGGCUCGGCCCACUAC 
F2 001993 hsa-miR-767-5p UGCACCAUGGUUGUCUGAGCAUG 
F3 001995 hsa-miR-767-3p UCUGCUCAUACCCCAUGGUUUCU 
F4 001996 hsa-miR-454# ACCCUAUCAAUAUUGUCUCUGC 
F5 001998 hsa-miR-769-5p UGAGACCUCUGGGUUCUGAGCU 
F6 002002 hsa-miR-770-5p UCCAGUACCACGUGUCAGGGCCA 
F7 002003 hsa-miR-769-3p CUGGGAUCUCCGGGGUCUUGGUU 
F8 002004 hsa-miR-802 CAGUAACAAAGAUUCAUCCUUGU 
F9 002005 hsa-miR-675 UGGUGCGGAGAGGGCCCACAGUG 
F10 002087 hsa-miR-505# GGGAGCCAGGAAGUAUUGAUGU 
F11 002094 hsa-miR-218-1# AUGGUUCCGUCAAGCACCAUGG 
F12 002096 hsa-miR-221# ACCUGGCAUACAAUGUAGAUUU 
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F13 002097 hsa-miR-222# CUCAGUAGCCAGUGUAGAUCCU 
F14 002098 hsa-miR-223# CGUGUAUUUGACAAGCUGAGUU 
F15 002100 hsa-miR-136# CAUCAUCGUCUCAAAUGAGUCU 
F16 002102 hsa-miR-34b CAAUCACUAACUCCACUGCCAU 
F17 002104 hsa-miR-185# AGGGGCUGGCUUUCCUCUGGUC 
F18 002105 hsa-miR-186# GCCCAAAGGUGAAUUUUUUGGG 
F19 002107 hsa-miR-195# CCAAUAUUGGCUGUGCUGCUCC 
F20 002108 hsa-miR-30c-1# CUGGGAGAGGGUUGUUUACUCC 
F21 002110 hsa-miR-30c-2# CUGGGAGAAGGCUGUUUACUCU 
F22 002111 hsa-miR-32# CAAUUUAGUGUGUGUGAUAUUU 
F23 002113 hsa-miR-31# UGCUAUGCCAACAUAUUGCCAU 
F24 002114 hsa-miR-130b# ACUCUUUCCCUGUUGCACUAC 
G1 002115 hsa-miR-26a-2# CCUAUUCUUGAUUACUUGUUUC 
G2 002116 hsa-miR-361-3p UCCCCCAGGUGUGAUUCUGAUUU 
G3 002118 hsa-let-7g# CUGUACAGGCCACUGCCUUGC 
G4 002119 hsa-miR-302b# ACUUUAACAUGGAAGUGCUUUC 
G5 002120 hsa-miR-302d# ACUUUAACAUGGAGGCACUUGC 
G6 002121 hsa-miR-367# ACUGUUGCUAAUAUGCAACUCU 
G7 002125 hsa-miR-374a# CUUAUCAGAUUGUAUUGUAAUU 
G8 002126 hsa-miR-23b# UGGGUUCCUGGCAUGCUGAUUU 
G9 002127 hsa-miR-376a# GUAGAUUCUCCUUCUAUGAGUA 
G10 002128 hsa-miR-377# AGAGGUUGCCCUUGGUGAAUUC 
G11 000338 ath-miR159a UUUGGAUUGAAGGGAGCUCUA 
G12 002129 hsa-miR-30b# CUGGGAGGUGGAUGUUUACUUC 
G13 002130 hsa-miR-122# AACGCCAUUAUCACACUAAAUA 
G14 002131 hsa-miR-130a# UUCACAUUGUGCUACUGUCUGC 
G15 002132 hsa-miR-132# ACCGUGGCUUUCGAUUGUUACU 
G16 002134 hsa-miR-148a# AAAGUUCUGAGACACUCCGACU 
G17 002135 hsa-miR-33a GUGCAUUGUAGUUGCAUUGCA 
G18 002136 hsa-miR-33a# CAAUGUUUCCACAGUGCAUCAC 
G19 002137 hsa-miR-92a-1# AGGUUGGGAUCGGUUGCAAUGCU 
G20 002138 hsa-miR-92a-2# GGGUGGGGAUUUGUUGCAUUAC 
G21 002139 hsa-miR-93# ACUGCUGAGCUAGCACUUCCCG 
G22 002140 hsa-miR-96# AAUCAUGUGCAGUGCCAAUAUG 
G23 002141 hsa-miR-99a# CAAGCUCGCUUCUAUGGGUCUG 
G24 002142 hsa-miR-100# CAAGCUUGUAUCUAUAGGUAUG 
H1 002143 hsa-miR-101# CAGUUAUCACAGUGCUGAUGCU 
H2 002144 hsa-miR-138-2# GCUAUUUCACGACACCAGGGUU 
H3 002145 hsa-miR-141# CAUCUUCCAGUACAGUGUUGGA 
H4 002146 hsa-miR-143# GGUGCAGUGCUGCAUCUCUGGU 
H5 002148 hsa-miR-144# GGAUAUCAUCAUAUACUGUAAG 
H6 002149 hsa-miR-145# GGAUUCCUGGAAAUACUGUUCU 
H7 002150 hsa-miR-920 GGGGAGCUGUGGAAGCAGUA 
H8 002151 hsa-miR-921 CUAGUGAGGGACAGAACCAGGAUUC 
H9 002152 hsa-miR-922 GCAGCAGAGAAUAGGACUACGUC 
H10 002154 hsa-miR-924 AGAGUCUUGUGAUGUCUUGC 
H11 002157 hsa-miR-337-3p CUCCUAUAUGAUGCCUUUCUUC 
H12 002158 hsa-miR-125b-2# UCACAAGUCAGGCUCUUGGGAC 
H13 002159 hsa-miR-135b# AUGUAGGGCUAAAAGCCAUGGG 
H14 002160 hsa-miR-148b# AAGUUCUGUUAUACACUCAGGC 
H15 002163 hsa-miR-146a# CCUCUGAAAUUCAGUUCUUCAG 
H16 002164 hsa-miR-149# AGGGAGGGACGGGGGCUGUGC 
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H17 002165 hsa-miR-29b-1# GCUGGUUUCAUAUGGUGGUUUAGA 
H18 002166 hsa-miR-29b-2# CUGGUUUCACAUGGUGGCUUAG 
H19 002168 hsa-miR-105# ACGGAUGUUUGAGCAUGUGCUA 
H20 002170 hsa-miR-106a# CUGCAAUGUAAGCACUUCUUAC 
H21 002171 hsa-miR-16-2# CCAAUAUUACUGUGCUGCUUUA 
H22 002172 hsa-let-7i# CUGCGCAAGCUACUGCCUUGCU 
H23 002173 hsa-miR-15b# CGAAUCAUUAUUUGCUGCUCUA 
H24 002174 hsa-miR-27b# AGAGCUUAGCUGAUUGGUGAAC 
I1 002176 hsa-miR-933 UGUGCGCAGGGAGACCUCUCCC 
I2 002177 hsa-miR-934 UGUCUACUACUGGAGACACUGG 
I3 002178 hsa-miR-935 CCAGUUACCGCUUCCGCUACCGC 
I4 002179 hsa-miR-936 ACAGUAGAGGGAGGAAUCGCAG 
I5 002180 hsa-miR-937 AUCCGCGCUCUGACUCUCUGCC 
I6 002181 hsa-miR-938 UGCCCUUAAAGGUGAACCCAGU 
I7 002182 hsa-miR-939 UGGGGAGCUGAGGCUCUGGGGGUG 
I8 002183 hsa-miR-941 CACCCGGCUGUGUGCACAUGUGC 
I9 002185 hsa-miR-335# UUUUUCAUUAUUGCUCCUGACC 
I10 002187 hsa-miR-942 UCUUCUCUGUUUUGGCCAUGUG 
I11 002188 hsa-miR-943 CUGACUGUUGCCGUCCUCCAG 
I12 002189 hsa-miR-944 AAAUUAUUGUACAUCGGAUGAG 
I13 002196 hsa-miR-99b# CAAGCUCGUGUCUGUGGGUCCG 
I14 002197 hsa-miR-124# CGUGUUCACAGCGGACCUUGAU 
I15 002200 hsa-miR-541# AAAGGAUUCUGCUGUCGGUCCCACU 
I16 002203 hsa-miR-875-5p UAUACCUCAGUUUUAUCAGGUG 
I17 002213 hsa-miR-888# GACUGACACCUCUUUGGGUGAA 
I18 002214 hsa-miR-892b CACUGGCUCCUUUCUGGGUAGA 
I19 002231 hsa-miR-9# AUAAAGCUAGAUAACCGAAAGU 
I20 002238 hsa-miR-411# UAUGUAACACGGUCCACUAACC 
I21 002243 hsa-miR-378 ACUGGACUUGGAGUCAGAAGG 
I22 002254 hsa-miR-151-3p CUAGACUGAAGCUCCUUGAGG 
I23 002259 hsa-miR-340# UCCGUCUCAGUUACUUUAUAGC 
I24 002263 hsa-miR-190b UGAUAUGUUUGAUAUUGGGUU 
J1 002266 hsa-miR-545# UCAGUAAAUGUUUAUUAGAUGA 
J2 002270 hsa-miR-183# GUGAAUUACCGAAGGGCCAUAA 
J3 002272 hsa-miR-192# CUGCCAAUUCCAUAGGUCACAG 
J4 002274 hsa-miR-200b# CAUCUUACUGGGCAGCAUUGGA 
J5 002286 hsa-miR-200c# CGUCUUACCCAGCAGUGUUUGG 
J6 002287 hsa-miR-155# CUCCUACAUAUUAGCAUUAACA 
J7 002288 hsa-miR-10a# CAAAUUCGUAUCUAGGGGAAUA 
J8 002293 hsa-miR-214# UGCCUGUCUACACUUGCUGUGC 
J9 002294 hsa-miR-218-2# CAUGGUUCUGUCAAGCACCGCG 
J10 002298 hsa-miR-129# AAGCCCUUACCCCAAAAAGUAU 
J11 002301 hsa-miR-22# AGUUCUUCAGUGGCAAGCUUUA 
J12 002302 hsa-miR-425# AUCGGGAAUGUCGUGUCCGCCC 
J13 002305 hsa-miR-30d# CUUUCAGUCAGAUGUUUGCUGC 
J14 002307 hsa-let-7a# CUAUACAAUCUACUGUCUUUC 
J15 002309 hsa-miR-424# CAAAACGUGAGGCGCUGCUAU 
J16 002310 hsa-miR-18b# UGCCCUAAAUGCCCCUUCUGGC 
J17 002311 hsa-miR-20b# ACUGUAGUAUGGGCACUUCCAG 
J18 002312 hsa-miR-431# CAGGUCGUCUUGCAGGGCUUCU 
J19 002314 hsa-miR-7-2# CAACAAAUCCCAGUCUACCUAA 
J20 002315 hsa-miR-10b# ACAGAUUCGAUUCUAGGGGAAU 
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J21 002316 hsa-miR-34a# CAAUCAGCAAGUAUACUGCCCU 
J22 002317 hsa-miR-181a-2# ACCACUGACCGUUGACUGUACC 
J23 002325 hsa-miR-744# CUGUUGCCACUAACCUCAACCU 
J24 002330 hsa-miR-452# CUCAUCUGCAAAGAAGUAAGUG 
K1 002332 hsa-miR-409-3p GAAUGUUGCUCGGUGAACCCCU 
K2 002333 hsa-miR-181c# AACCAUCGACCGUUGAGUGGAC 
K3 002336 hsa-miR-196a# CGGCAACAAGAAACUGCCUGAG 
K4 002339 hsa-miR-483-3p UCACUCCUCUCCUCCCGUCUU 
K5 002342 hsa-miR-708# CAACUAGACUGUGAGCUUCUAG 
K6 002343 hsa-miR-92b# AGGGACGGGACGCGGUGCAGUG 
K7 002346 hsa-miR-551b# GAAAUCAAGCGUGGGUGAGACC 
K8 002362 hsa-miR-202# UUCCUAUGCAUAUACUUCUUUG 
K9 002366 hsa-miR-193b# CGGGGUUUUGAGGGCGAGAUGA 
K10 002368 hsa-miR-497# CAAACCACACUGUGGUGUUAGA 
K11 002371 hsa-miR-518e# CUCUAGAGGGAAGCGCUUUCUG 
K12 002376 hsa-miR-543 AAACAUUCGCGGUGCACUUCUU 
K13 002378 hsa-miR-125b-1# ACGGGUUAGGCUCUUGGGAGCU 
K14 002379 hsa-miR-194# CCAGUGGGGCUGCUGUUAUCUG 
K15 002380 hsa-miR-106b# CCGCACUGUGGGUACUUGCUGC 
K16 002381 hsa-miR-302a# ACUUAAACGUGGAUGUACUUGCU 
K17 002384 hsa-miR-519b-3p AAAGUGCAUCCUUUUAGAGGUU 
K18 002387 hsa-miR-518f# CUCUAGAGGGAAGCACUUUCUC 
K19 002391 hsa-miR-374b# CUUAGCAGGUUGUAUUAUCAUU 
K20 002400 hsa-miR-520c-3p AAAGUGCUUCCUUUUAGAGGGU 
K21 002404 hsa-let-7b# CUAUACAACCUACUGCCUUCCC 
K22 002405 hsa-let-7c# UAGAGUUACACCCUGGGAGUUA 
K23 002407 hsa-let-7e# CUAUACGGCCUCCUAGCUUUCC 
K24 002410 hsa-miR-550 AGUGCCUGAGGGAGUAAGAGCCC 
L1 002411 hsa-miR-593 UGUCUCUGCUGGGGUUUCU 
L2 002417 hsa-let-7f-1# CUAUACAAUCUAUUGCCUUCCC 
L3 002418 hsa-let-7f-2# CUAUACAGUCUACUGUCUUUCC 
L4 002419 hsa-miR-15a# CAGGCCAUAUUGUGCUGCCUCA 
L5 002420 hsa-miR-16-1# CCAGUAUUAACUGUGCUGCUGA 
L6 002421 hsa-miR-17# ACUGCAGUGAAGGCACUUGUAG 
L7 002423 hsa-miR-18a# ACUGCCCUAAGUGCUCCUUCUGG 
L8 002424 hsa-miR-19a# AGUUUUGCAUAGUUGCACUACA 
L9 002425 hsa-miR-19b-1# AGUUUUGCAGGUUUGCAUCCAGC 
L10 002432 hsa-miR-625# GACUAUAGAACUUUCCCCCUCA 
L11 002434 hsa-miR-628-3p UCUAGUAAGAGUGGCAGUCGA 
L12 002437 hsa-miR-20a# ACUGCAUUAUGAGCACUUAAAG 
L13 002438 hsa-miR-21# CAACACCAGUCGAUGGGCUGU 
L14 002439 hsa-miR-23a# GGGGUUCCUGGGGAUGGGAUUU 
L15 002440 hsa-miR-24-1# UGCCUACUGAGCUGAUAUCAGU 
L16 002441 hsa-miR-24-2# UGCCUACUGAGCUGAAACACAG 
L17 002442 hsa-miR-25# AGGCGGAGACUUGGGCAAUUG 
L18 002443 hsa-miR-26a-1# CCUAUUCUUGGUUACUUGCACG 
L19 002444 hsa-miR-26b# CCUGUUCUCCAUUACUUGGCUC 
L20 002445 hsa-miR-27a# AGGGCUUAGCUGCUUGUGAGCA 
L21 002447 hsa-miR-29a# ACUGAUUUCUUUUGGUGUUCAG 
L22 002642 hsa-miR-151-5P UCGAGGAGCUCACAGUCUAGU 
L23 002643 hsa-miR-765 UGGAGGAGAAGGAAGGUGAUG 
L24 002658 hsa-miR-338-5P AACAAUAUCCUGGUGCUGAGUG 
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M1 002672 hsa-miR-620 AUGGAGAUAGAUAUAGAAAU 
M2 002675 hsa-miR-577 UAGAUAAAAUAUUGGUACCUG 
M3 002676 hsa-miR-144 UACAGUAUAGAUGAUGUACU 
M4 002677 hsa-miR-590-3P UAAUUUUAUGUAUAAGCUAGU 
M5 002678 hsa-miR-191# GCUGCGCUUGGAUUUCGUCCCC 
M6 002681 hsa-miR-665 ACCAGGAGGCUGAGGCCCCU 
M7 002743 hsa-miR-520D-
3P 
AAAGUGCUUCUCUUUGGUGGGU 
M8 002752 hsa-miR-1224-3P CCCCACCUCCUCUCUCCUCAG 
M9 002867 hsa-miR-1305 UUUUCAACUCUAAUGGGAGAGA 
M10 002756 hsa-miR-513C UUCUCAAGGAGGUGUCGUUUAU 
M11 002757 hsa-miR-513B UUCACAAGGAGGUGUCAUUUAU 
M12 002758 hsa-miR-1226# GUGAGGGCAUGCAGGCCUGGAUGGGG 
M13 002761 hsa-miR-1236 CCUCUUCCCCUUGUCUCUCCAG 
M14 002763 hsa-miR-1228# GUGGGCGGGGGCAGGUGUGUG 
M15 002766 hsa-miR-1225-3P UGAGCCCCUGUGCCGCCCCCAG 
M16 002768 hsa-miR-1233 UGAGCCCUGUCCUCCCGCAG 
M17 002769 hsa-miR-1227 CGUGCCACCCUUUUCCCCAG 
M18 002773 hsa-miR-1286 UGCAGGACCAAGAUGAGCCCU 
M19 002775 hsa-miR-548M CAAAGGUAUUUGUGGUUUUUG 
M20 002776 hsa-miR-1179 AAGCAUUCUUUCAUUGGUUGG 
M21 002777 hsa-miR-1178 UUGCUCACUGUUCUUCCCUAG 
M22 002778 hsa-miR-1205 UCUGCAGGGUUUGCUUUGAG 
M23 002779 hsa-miR-1271 CUUGGCACCUAGCAAGCACUCA 
M24 002781 hsa-miR-1201 AGCCUGAUUAAACACAUGCUCUGA 
N1 002783 hsa-miR-548J AAAAGUAAUUGCGGUCUUUGGU 
N2 002784 hsa-miR-1263 AUGGUACCCUGGCAUACUGAGU 
N3 002785 hsa-miR-1294 UGUGAGGUUGGCAUUGUUGUCU 
N4 002789 hsa-miR-1269 CUGGACUGAGCCGUGCUACUGG 
N5 002790 hsa-miR-1265 CAGGAUGUGGUCAAGUGUUGUU 
N6 002791 hsa-miR-1244 AAGUAGUUGGUUUGUAUGAGAUGGUU 
N7 002792 hsa-miR-1303 UUUAGAGACGGGGUCUUGCUCU 
N8 002796 hsa-miR-1259 AUAUAUGAUGACUUAGCUUUU 
N9 002798 hsa-miR-548P UAGCAAAAACUGCAGUUACUUU 
N10 002799 hsa-miR-1264 CAAGUCUUAUUUGAGCACCUGUU 
N11 002801 hsa-miR-1255B CGGAUGAGCAAAGAAAGUGGUU 
N12 002803 hsa-miR-1282 UCGUUUGCCUUUUUCUGCUU 
N13 002805 hsa-miR-1255A AGGAUGAGCAAAGAAAGUAGAUU 
N14 002807 hsa-miR-1270 CUGGAGAUAUGGAAGAGCUGUGU 
N15 002810 hsa-miR-1197 UAGGACACAUGGUCUACUUCU 
N16 002815 hsa-miR-1324 CCAGACAGAAUUCUAUGCACUUUC 
N17 002816 hsa-miR-548H AAAAGUAAUCGCGGUUUUUGUC 
N18 002818 hsa-miR-1254 AGCCUGGAAGCUGGAGCCUGCAGU 
N19 002819 hsa-miR-548K AAAAGUACUUGCGGAUUUUGCU 
N20 002820 hsa-miR-1251 ACUCUAGCUGCCAAAGGCGCU 
N21 002822 hsa-miR-1285 UCUGGGCAACAAAGUGAGACCU 
N22 002823 hsa-miR-1245 AAGUGAUCUAAAGGCCUACAU 
N23 002824 hsa-miR-1292 UGGGAACGGGUUCCGGCAGACGCUG 
N24 002827 hsa-miR-1301 UUGCAGCUGCCUGGGAGUGACUUC 
O1 002829 hsa-miR-1200 CUCCUGAGCCAUUCUGAGCCUC 
O2 002830 hsa-miR-1182 GAGGGUCUUGGGAGGGAUGUGAC 
O3 002832 hsa-miR-1288 UGGACUGCCCUGAUCUGGAGA 
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O4 002838 hsa-miR-1291 UGGCCCUGACUGAAGACCAGCAGU 
O5 002840 hsa-miR-1275 GUGGGGGAGAGGCUGUC 
O6 002841 hsa-miR-1183 CACUGUAGGUGAUGGUGAGAGUGGGC
A 
O7 002842 hsa-miR-1184 CCUGCAGCGACUUGAUGGCUUCC 
O8 002843 hsa-miR-1276 UAAAGAGCCCUGUGGAGACA 
O9 002844 hsa-miR-320B AAAAGCUGGGUUGAGAGGGCAA 
O10 002845 hsa-miR-1272 GAUGAUGAUGGCAGCAAAUUCUGAAA 
O11 002847 hsa-miR-1180 UUUCCGGCUCGCGUGGGUGUGU 
O12 002850 hsa-miR-1256 AGGCAUUGACUUCUCACUAGCU 
O13 002851 hsa-miR-1278 UAGUACUGUGCAUAUCAUCUAU 
O14 002852 hsa-miR-1262 AUGGGUGAAUUUGUAGAAGGAU 
O15 002854 hsa-miR-1243 AACUGGAUCAAUUAUAGGAGUG 
O16 002857 hsa-miR-663B GGUGGCCCGGCCGUGCCUGAGG 
O17 002860 hsa-miR-1252 AGAAGGAAAUUGAAUUCAUUUA 
O18 002861 hsa-miR-1298 UUCAUUCGGCUGUCCAGAUGUA 
O19 002863 hsa-miR-1290 UGGAUUUUUGGAUCAGGGA 
O20 002868 hsa-miR-1249 ACGCCCUUCCCCCCCUUCUUCA 
O21 002870 hsa-miR-1248 ACCUUCUUGUAUAAGCACUGUGCUAAA 
O22 002871 hsa-miR-1289 UGGAGUCCAGGAAUCUGCAUUUU 
O23 002872 hsa-miR-1204 UCGUGGCCUGGUCUCCAUUAU 
O24 002873 hsa-miR-1826 AUUGAUCAUCGACACUUCGAACGCAAU 
P1 002874 hsa-miR-1304 UUUGAGGCUACAGUGAGAUGUG 
P2 002877 hsa-miR-1203 CCCGGAGCCAGGAUGCAGCUC 
P3 002878 hsa-miR-1206 UGUUCAUGUAGAUGUUUAAGC 
P4 002879 hsa-miR-548G AAAACUGUAAUUACUUUUGUAC 
P5 002880 hsa-miR-1208 UCACUGUUCAGACAGGCGGA 
P6 002881 hsa-miR-548E AAAAACUGAGACUACUUUUGCA 
P7 002883 hsa-miR-1274A GUCCCUGUUCAGGCGCCA 
P8 002884 hsa-miR-1274B UCCCUGUUCGGGCGCCA 
P9 002885 hsa-miR-1267 CCUGUUGAAGUGUAAUCCCCA 
P10 002887 hsa-miR-1250 ACGGUGCUGGAUGUGGCCUUU 
P11 002888 hsa-miR-548N CAAAAGUAAUUGUGGAUUUUGU 
P12 002890 hsa-miR-1283 UCUACAAAGGAAAGCGCUUUCU 
P13 002893 hsa-miR-1247 ACCCGUCCCGUUCGUCCCCGGA 
P14 002894 hsa-miR-1253 AGAGAAGAAGAUCAGCCUGCA 
P15 002895 hsa-miR-720 UCUCGCUGGGGCCUCCA 
P16 002896 hsa-miR-1260 AUCCCACCUCUGCCACCA 
P17 002897 hsa-miR-664 UAUUCAUUUAUCCCCAGCCUACA 
P18 002901 hsa-miR-1302 UUGGGACAUACUUAUGCUAAA 
P19 002902 hsa-miR-1300 UUGAGAAGGAGGCUGCUG 
P20 002903 hsa-miR-1284 UCUAUACAGACCCUGGCUUUUC 
P21 002904 hsa-miR-548L AAAAGUAUUUGCGGGUUUUGUC 
P22 002905 hsa-miR-1293 UGGGUGGUCUGGAGAUUUGUGC 
P23 002907 hsa-miR-1825 UCCAGUGCCCUCCUCUCC 
P24 002908 hsa-miR-1296 UUAGGGCCCUGGCUCCAUCUCC 
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Figure E.3 Position of miRNA assays on Custom TLDA cards. Format for the 
custom made 384 well microRNA arrays made by Applied Biosystems™, containing 
our 31 miRNAs of interest and endogenous control U6 snRNA.  
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Table E.3 miRNA target sequences for custom TLDA cards. The assay position, 
assay ID, assay name and target sequence for each of the 20X Taqman microRNA 
assays pre loaded on the custom made TLDA cards. 
Position Assay 
ID 
Assay Name Target Sequence 5’ → 3’ 
1 002257 hsa-miR-339-5p UCCCUGUCCUCCAGGAGCUCACG 
2 000471 hsa-miR-148b UCAGUGCAUCACAGAACUUUGU 
3 002297 hsa-miR-422a ACUGGACUUAGGGUCAGAAGGC 
CTL 001973 U6 snRNA GTGCTCGCTTCGGCAGCACATATACT
AAAATTGGAACGATACAGAGAAGATT
AGCATGGCCCCTGCGCAAGGATGACA
CGCAAATTCGTGAAGCGTTCCATATTT
T 
4 001984 hsa-miR-590-5p GAGCUUAUUCAUAAAAGUGCAG 
5 000402 hsa-miR-24 UGGCUCAGUUCAGCAGGAACAG 
6 000533 hsa-miR-302c UAAGUGCUUCCAUGUUUCAGUGG 
7 000563 hsa-miR-374 UUAUAAUACAACCUGAUAAGUG 
8 002268 hsa-miR-874 CUGCCCUGGCCCGAGGGACCGA 
9 000518 hsa-miR-215 AUGACCUAUGAAUUGACAGAC 
10 000475 hsa-miR-152 UCAGUGCAUGACAGAACUUGG 
11 002623 hsa-miR-155 UUAAUGCUAAUCGUGAUAGGGGU 
12 000457 hsa-miR-132 UAACAGUCUACAGCCAUGGUCG 
13 000468 hsa-miR-146a UGAGAACUGAAUUCCAUGGGUU 
14 001193 mmu-miR-187 UCGUGUCUUGUGUUGCAGCCGG 
15 002278 hsa-miR-145 GUCCAGUUUUCCCAGGAAUCCCU 
16 002619 hsa-miR-let7b UGAGGUAGUAGGUUGUGUGGUU 
17 000379 hsa-miR- let 7c UGAGGUAGUAGGUUGUAUGGUU 
18 002283 hsa-miR- let 7d AGAGGUAGUAGGUUGCAUAGUU 
19 002406 hsa-miR- let 7e UGAGGUAGGAGGUUGUAUAGUU 
20 000583 hsa-miR-9 UCUUUGGUUAUCUAGCUGUAUGA 
21 002198 hsa-miR-125a-5p UCCCUGAGACCCUUUAACCUGUGA 
22 000524 hsa-miR-221 AGCUACAUUGUCUGCUGGGUUUC 
23 002096 hsa-miR-221# ACCUGGCAUACAAUGUAGAUUU 
24 002905 hsa-miR-1293 UGGGUGGUCUGGAGAUUUGUGC 
25 002376 hsa-miR-543 AAACAUUCGCGGUGCACUUCUU 
26 002410 hsa-miR-550 AGUGCCUGAGGGAGUAAGAGCCC 
27 002824 hsa-miR-1292 UGGGAACGGGUUCCGGCAGACGCUG 
28 001539 hsa-miR-586 UAUGCAUUGUAUUUUUAGGUCC 
29 001027 hsa-miR-432# CUGGAUGGCUCCUCCAUGUCU 
30 002407 hsa-miR- let 7e# CUAUACGGCCUCCUAGCUUUCC 
31 002231 hsa-miR-9# AUAAAGCUAGAUAACCGAAAGU 
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Table E.4. Human miRNA target sequences. Assay name, stem loop sequence and 
target sequence for each of the individual human 20X Taqman microRNA assays. 
Assay ID Assay Name Stem loop sequence for RT miRNA Target 
Sequence 5’ → 3’ 
000468 hsa-miR-146a-5p CCGAUGUGUAUCCUCAGCU
UUGAGAACUGAAUUCCAUG
GGUUGUGUCAGUGUCAGAC
CUCUGAAAUUCAGUUCUUC
AGCUGGGAUAUCUCUGUCA
UCGU 
UGAGAACUGAAUU
CCAUGGGUU 
002623 hsa-miR-155-5p CUGUUAAUGCUAAUCGUGA
UAGGGGUUUUUGCCUCCAA
CUGACUCCUACAUAUUAGC
AUUAACAG 
UUAAUGCUAAUCG
UGAUAGGGGU 
002406 
 
hsa-let-7e-5p CCCGGGCUGAGGUAGGAGG
UUGUAUAGUUGAGGAGGAC
ACCCAAGGAGAUCACUAUA
CGGCCUCCUAGCUUUCCCC
AGG 
UGAGGUAGGAGGU
UGUAUAGUU 
002278 hsa-miR-145a-5p CACCUUGUCCUCACGGUCC
AGUUUUCCCAGGAAUCCCU
UAGAUGCUAAGAUGGGGAU
UCCUGGAAAUACUGUUCUU
GAGGUCAUGGUU 
GUCCAGUUUUCCCA
GGAAUCCCU 
Table E.5 Murine miRNA target sequences. Assay name, stem loop sequence and 
target sequence for each of the individual murine 20X Taqman microRNA assays. 
Assay ID Assay Name Stem loop sequence for RT miRNA Target 
Sequence 5’ → 3’ 
000468 mmu-miR-146a AGCUCUGAGAACUGAAUU
CCAUGGGUUAUAUCAAUG
UCAGACCUGUGAAAUUCA
GUUCUUCAGCU 
UGAGAACUGAAU
UCCAUGGGUU 
002571 
 
mmu-miR-155 CUGUUAAUGCUAAUUGUG
AUAGGGGUUUUGGCCUCU
GACUGACUCCUACCUGUU
AGCAUUAACAG 
UUAAUGCUAAUU
GUGAUAGGGGU 
002406 mmu-let-7e-5p CGCGCCCCCCGGGCUGAG
GUAGGAGGUUGUAUAGUU
GAGGAAGACACCCGAGGA
GAUCACUAUACGGCCUCC
UAGCUUUCCCCAGGCUGC
GCC 
UGAGGUAGGAGG
UUGUAUAGUU 
002278 mmu-miR-145a-5p CUCACGGUCCAGUUUUCC
CAGGAAUCCCUUGGAUGC
UAAGAUGGGGAUUCCUGG
AAAUACUGUUCUUGAG 
GUCCAGUUUUCCC
AGGAAUCCCU 
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Table E.6 Endogenous control sequences. Assay ID, assay name and target sequence 
of endogenous controls for individual Taqman assays 
Assay 
ID 
Assay Name Target Sequence 5’ → 3’ 
001973 
 
U6 snRNA 
 
GTGCTCGCTTCGGCAGCACATATACTAAAATTGGAAC
GATACAGAGAAGATTAGCATGGCCCCTGCGCAAGGA
TGACACGCAAATTCGTGAAGCGTTCCATATTTT 
001094 RNU44 CCUGGAUGAUGAUAGCAAAUGCUGACUGAACAUGA
AGGUCUUAAUUAGCUCUAACUGACU 
001006 RNU48 GAUGACCCCAGGUAACUCUGAGUGUGUCGCUGAUG
CCAUCACCGCAGCGCUCUGACC 
001232 snoRNA202 GCTGTACTGACTTGATGAAAGTACTTTTGAACCCTTT
TCCATCTGATG 
001234 
 
snoRNA234 
 
CTTTTGGAACTGAATCTAAGTGATTTAACAAAAATTC
GTCACTACCACTGAGA 
001973 
 
MammuU6 GTGCTCGCTTCGGCAGCACATATACTAAAATTGGAAC
GATACAGAGAAGATTAGCATGGCCCCTGCGCAAGGA
TGACACGCAAATTCGTGAAGCGTTCCATATTTT 
 
  
 343  
 Appendix F- Endogenous Controls for qPCR 
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Figure F.1 Endogenous controls for microRNA individual Taqman assays. U6 
snRNA was identified as an endogenous control for sample generate from human Hek 
TLR4/MD2/CD14 cells. snoRNA202 was identified as an endogenous control for 
samples generated from murine JAWS II cells and murine samples from the infection 
model at day 3 and day 7. 
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Appendix G- Bioinformatics 
Table G.1 Database and Web links for bioinformatics tools used in this study 
Database Web link 
DIANA miRPath http://diana.imis.athena-
innovation.gr/DianaTools/index.php?r=mirpath/in
dex 
TargetScan Human http://www.targetscan.org/ 
miRNA Converter (miRSystem) http://mirsystem.cgm.ntu.edu.tw/ 
Table G.2 miRNA names according to version 18 and 20 of miRBASE. The lists of 
miRNAs were inputted into miR Convertor which is a feature of miRSystem to ensure 
we had up to date names for each of the miRNAs according to version 18 of miRBASE 
which is used by DIANA miRPath v2.0 for further analysis 
INPUT_ID ACCESSION VER_20 VER_18 
hsa-let-7b-5p MIMAT0000063 hsa-let-7b-5p hsa-let-7b-5p 
hsa-let-7c-5p MIMAT0000064 hsa-let-7c-5p hsa-let-7c 
hsa-let-7d-5p MIMAT0000065 hsa-let-7d-5p hsa-let-7d-5p 
hsa-let-7e-5p MIMAT0000066 hsa-let-7e-5p hsa-let-7e-5p 
hsa-miR-125a-5p MIMAT0000443 hsa-miR-125a-5p hsa-miR-125a-5p 
hsa-miR-1292-5p MIMAT0005943 hsa-miR-1292-5p hsa-miR-1292 
hsa-miR-132-3p MIMAT0000426 hsa-miR-132-3p hsa-miR-132-3p 
hsa-miR-145-5p MIMAT0000437 hsa-miR-145-5p hsa-miR-145-5p 
hsa-miR-146a-5p MIMAT0000449 hsa-miR-146a-5p hsa-miR-146a-5p 
hsa-miR-148b-3p MIMAT0000759 hsa-miR-148b-3p hsa-miR-148b-3p 
hsa-miR-152-3p MIMAT0000438 hsa-miR-152-3p hsa-miR-152 
hsa-miR-155-5p MIMAT0000646 hsa-miR-155-5p hsa-miR-155-5p 
hsa-miR-215-5p MIMAT0000272 hsa-miR-215-5p hsa-miR-215 
hsa-miR-221-3p MIMAT0000278 hsa-miR-221-3p hsa-miR-221-3p 
hsa-miR-24-3p MIMAT0000080 hsa-miR-24-3p hsa-miR-24-3p 
hsa-miR-339-5p MIMAT0000764 hsa-miR-339-5p hsa-miR-339-5p 
hsa-miR-374a-5p MIMAT0000727 hsa-miR-374a-5p hsa-miR-374a-5p 
hsa-miR-422a MIMAT0001339 hsa-miR-422a hsa-miR-422a 
hsa-miR-432-3p MIMAT0002815 hsa-miR-432-3p hsa-miR-432-3p 
hsa-miR-543 MIMAT0004954 hsa-miR-543 hsa-miR-543 
hsa-miR-586 MIMAT0003252 hsa-miR-586 hsa-miR-586 
hsa-miR-590-5p MIMAT0003258 hsa-miR-590-5p hsa-miR-590-5p 
hsa-miR-9-3p MIMAT0000442 hsa-miR-9-3p hsa-miR-9-3p 
hsa-miR-9-5p MIMAT0000441 hsa-miR-9-5p hsa-miR-9-5p 
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Table G.3 The 24 miRNAs of interest targeted 2551 genes in 146 different 
pathways according to KEGG, data generated from DIANA miRPath v2.0. The 
lists of 24 miRNAs of interest were inputted into the DIANA miRPath prediction tool 
where a posteriori analysis was performed. The significance levels between all possible 
miRNA pathway pairs according to KEGG were calculated using enrichment analysis. 
The previously calculated significance levels where combined with this to provide a 
merged p-value for each pathway by applying Fisher’s combined probability method. 
KEGG pathway p-value #genes #miRNAs 
Prion diseases <1E-16 3 3 
ECM-receptor interaction <1E-16 15 6 
TGF-beta signalling pathway <1E-16 42 9 
MAPK signalling pathway <1E-16 98 10 
Pathways in cancer <1E-16 117 10 
PI3K-Akt signalling pathway <1E-16 121 11 
Focal adhesion 1.11E-16 74 10 
Prostate cancer 1.11E-16 43 11 
Transcriptional misregulation in cancer 9.24E-13 68 11 
Wnt signalling pathway 2.42E-12 55 11 
Endometrial cancer 5.94E-11 24 9 
Glioma 8.23E-11 25 8 
Regulation of actin cytoskeleton 1.41E-10 69 8 
Neurotrophin signalling pathway 1.68E-10 46 9 
Hepatitis B 2.62E-10 44 11 
Renal cell carcinoma 4.26E-10 26 6 
Insulin signalling pathway 2.49E-09 49 11 
Chronic myeloid leukaemia 3.54E-09 27 8 
Amoebiasis 5.18E-09 20 5 
p53 signalling pathway 8.19E-09 25 7 
ErbB signalling pathway 1.10E-08 32 8 
Small cell lung cancer 1.56E-08 38 10 
Hypertrophic cardiomyopathy (HCM) 2.47E-08 29 7 
Glycosaminoglycan biosynthesis - chondroitin sulfate 2.73E-07 4 4 
B cell receptor signalling pathway 3.78E-07 25 7 
T cell receptor signalling pathway 1.08E-06 27 4 
mTOR signalling pathway 3.02E-06 25 8 
Dilated cardiomyopathy 1.11E-05 31 9 
Melanoma 1.50E-05 25 7 
Acute myeloid leukaemia 1.61E-05 21 7 
Non-small cell lung cancer 3.22E-05 18 7 
HTLV-I infection 4.30E-05 47 7 
Cytokine-cytokine receptor interaction 6.96E-05 32 6 
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Pathogenic Escherichia coli infection 7.38E-05 8 1 
Colorectal cancer 0.000181 24 6 
Long-term potentiation 0.000186 25 4 
Axon guidance 0.000288 38 4 
Basal cell carcinoma 0.001142 18 6 
Circadian rhythm 0.001693 15 5 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 0.002041 12 3 
Valine, leucine and isoleucine biosynthesis 0.002189 2 7 
Ubiquitin mediated proteolysis 0.003648 33 5 
GnRH signalling pathway 0.00863 20 4 
Adipocytokine signalling pathway 0.009211 12 4 
Dorso-ventral axis formation 0.009752 7 4 
Endocytosis 0.012588 35 3 
mRNA surveillance pathway 0.012739 23 3 
Lysine degradation 0.015693 10 5 
Pancreatic cancer 0.017541 19 4 
Gap junction 0.022004 14 3 
VEGF signalling pathway 0.02785 17 3 
Adherens junction 0.031416 27 5 
Jak-STAT signalling pathway 0.04341 23 4 
Protein digestion and absorption 0.053215 10 3 
Fc epsilon RI signalling pathway 0.055219 9 2 
Thyroid cancer 0.058518 10 5 
HIF-1 signalling pathway 0.065032 14 2 
Mucin type O-Glycan biosynthesis 0.066994 7 5 
Melanogenesis 0.069544 14 3 
Biosynthesis of unsaturated fatty acids 0.086606 4 1 
Dopaminergic synapse 0.089544 30 3 
Osteoclast differentiation 0.09518 32 4 
Phosphatidylinositol signalling system 0.096817 25 5 
RNA transport 0.13389 13 3 
Biotin metabolism 0.134585 1 2 
GABAergic synapse 0.157337 12 3 
Chemokine signalling pathway 0.171029 32 3 
ABC transporters 0.17257 6 2 
Type II diabetes mellitus 0.181815 5 3 
Cholinergic synapse 0.210517 27 4 
Inositol phosphate metabolism 0.213264 14 4 
Cell cycle 0.215188 14 3 
Renin-angiotensin system 0.240273 5 1 
Gastric acid secretion 0.248511 16 4 
Bacterial invasion of epithelial cells 0.293373 20 4 
Hedgehog signalling pathway 0.29584 12 3 
Calcium signalling pathway 0.379276 8 1 
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Amphetamine addiction 0.408419 18 3 
Protein processing in endoplasmic reticulum 0.42342 8 1 
Viral carcinogenesis 0.438084 27 3 
RNA degradation 0.46417 11 3 
Hepatitis C 0.465413 10 1 
Endocrine and other factor-regulated calcium reabsorption 0.488316 12 2 
Viral myocarditis 0.504112 8 4 
Apoptosis 0.514354 9 3 
Long-term depression 0.531543 16 3 
Pancreatic secretion 0.663237 12 2 
Aldosterone-regulated sodium reabsorption 0.668861 10 3 
Herpes simplex infection 0.691523 25 3 
Epstein-Barr virus infection 0.707393 13 1 
Vascular smooth muscle contraction 0.719352 5 2 
Retrograde endocannabinoid signalling 0.726176 13 2 
Toll-like receptor signalling pathway 0.726836 18 3 
Tight junction 0.761025 17 2 
Glutamatergic synapse 0.798927 20 2 
Shigellosis 0.835699 14 2 
Oocyte meiosis 0.864453 12 2 
Chagas disease (American trypanosomiasis) 0.900815 6 1 
Sphingolipid metabolism 0.934722 6 1 
African trypanosomiasis 0.93694 3 1 
Fanconi anemia pathway 0.958664 2 1 
Other glycan degradation 0.968731 2 3 
Amyotrophic lateral sclerosis (ALS) 0.969045 5 1 
Measles 0.970755 9 1 
Terpenoid backbone biosynthesis 0.979777 7 2 
Salivary secretion 0.980074 5 1 
RIG-I-like receptor signalling pathway 0.98462 5 1 
Glycerophospholipid metabolism 0.988557 8 1 
Notch signaling pathway 0.989326 4 1 
Butanoate metabolism 0.99052 4 1 
NOD-like receptor signalling pathway 0.99096 9 2 
Glycosaminoglycan biosynthesis - keratan sulfate 0.993582 3 3 
Sulfur relay system 0.993763 2 2 
NF-kappa B signalling pathway 0.993981 6 2 
Serotonergic synapse 0.994442 8 2 
Influenza A 0.995537 15 2 
Maturity onset diabetes of the young 0.995979 4 1 
Carbohydrate digestion and absorption 0.997374 5 1 
One carbon pool by folate 0.997636 5 2 
Cardiac muscle contraction 0.998475 2 1 
Circadian entrainment 0.998884 6 1 
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Nicotinate and nicotinamide metabolism 0.998966 2 1 
Leukocyte transendothelial migration 0.99939 8 1 
Fructose and mannose metabolism 0.999642 4 1 
Legionellosis 0.999699 4 1 
Nucleotide excision repair 0.999877 2 1 
Valine, leucine and isoleucine degradation 0.999898 1 1 
Pentose phosphate pathway 0.999953 4 2 
Alcoholism 0.999968 9 1 
Taurine and hypotaurine metabolism 0.99997 1 1 
Folate biosynthesis 0.999977 1 1 
Pantothenate and CoA biosynthesis 0.999992 3 1 
Type I diabetes mellitus 0.999994 4 1 
Vasopressin-regulated water reabsorption 0.999998 5 1 
Glycosylphosphatidylinositol(GPI)-anchor biosynthesis 0.999998 3 1 
Glycosphingolipid biosynthesis - globo series 0.999999 1 1 
DNA replication 0.999999 2 1 
Fat digestion and absorption 1 3 1 
Graft-versus-host disease 1 3 1 
Galactose metabolism 1 3 1 
Fatty acid elongation 1 1 1 
Tyrosine metabolism 1 2 1 
D-Glutamine and D-glutamate metabolism 1 1 1 
Lipoic acid metabolism 1 1 1 
Metabolism of xenobiotics by cytochrome P450 1 1 1 
Phagosome 1 6 1 
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Table G.4 Complete list of miRNAs of interest predicted from DIANA-miRPath 
v2.0 and crossed checked in TargetScan. Table showing Gene, conserved miRNAs 
from the 24 miRNAs of interest, the position in the gene, seed match and the probability 
of conserved targeting (PCT). 
Gene Conserved 
miRNA seed 
regions in 
3’UTR 
Position in Gene 
3’→5’ 
Seed Match PCT 
ITGA9 miR-125a-5p 
miR-148b 
miR-152 
281-287 
402-408 
402-408 
7mer-m8 
7mer-1A 
7mer-1A 
0.91 
0.85 
< 0.1 
ITGA5 miR-148b 
miR-152 
187-193, 902-909 
187-193, 902-909 
7mer-m8, 8mer 
7mer-m8, 8mer 
0.39, 0.71 
0.39, 0.71 
COL3A1 let-7 b/c/d/e 408-415 8mer 0.95 
ITGA11 let-7 b/c/d/e 
miR-148b 
miR-152 
784-790 
1082-1089 
1082-1089 
7mer-A1 
8mer 
8mer 
0.91 
0.86 
0.86 
COL2A1 miR-148b 82-89 8mer 0.80 
COL4A2 let-7 b/c/d/e  
miR-9 
49-55 
107-113 
7mer-A1 
7mer-m8 
0.95 
0.79 
COL1A1 let-7 b/c/d/e 789-795 7mer-m8 0.89 
COL4A6 let-7 b/c/d/e 265-272 8mer 0.95 
COL5A2 let-7 b/c/d/e 1051-1058 8mer 0.95 
COL4A1 miR-148b 
miR-152 
miR-590-5p 
let-7 b/c/d/e  
266-273 
266-273 
194-200 
88-94 
8mer 
8mer 
7mer-m8 
7mer-A1 
0.61 
0.61 
0.22 
0.85 
LAMA4 miR-148b 
miR-152 
41-47 
41-47 
7mer-A1 
7mer-A1 
0.78 
0.78 
SOS2 miR-148b 
miR-152 
miR-145-5p 
257-263, 300-307 
257-263, 300-307 
25-31 
7mer-m8, 8 mer 
7mer-m8, 8 mer 
7mer-A1 
0.48, 0.78 
0.48, 0.78 
0.58 
FGF12 miR-9 174-180 7mer-m8 0.54 
CHUK let-7 b/c/d/e 495-501 7mer-m8 0.44 
KRAS miR-155 205-211 7mer-m8 0.23 
FGF9 miR-155 
miR-9 
717-724 
1067-1073 
8mer 
7mer-m8 
0.34 
0.72 
NGF let-7 b/c/d/e 65-61 8mer 0.95 
RASGRF1 miR-125a-5p 1228-1234 7mer-m8 0.91 
RELA miR-155 1406-1413 8mer 0.59 
FGFR1 miR-125a-5p 417-423 7mer-m8 0.23 
ROCK1 miR148-b 
miR152 
miR-145 
867-873, 1414-1420 
867-873, 1414-1420 
1357-1363 
7mer-m8, 7mer-A1 
7mer-m8, 7mer-A1 
7mer-A1 
0.93 
0.86 
> 0.99 
ITGB8 miR-145 4500-4507 8mer 0.77 
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miR-221 
miR-152 
miR-148b 
let-7 b/c/d/e  
227-233 
290-296 
290-296 
1606-1612 
7mer-A1 
7mer-A1 
7mer-A1 
7mer-m8 
0.86 
0.83 
0.83 
0.91 
COL4A5 let-7 b/c/d/e 165-171 7mer-A1 0.79 
RAF1 miR-125a-5p 641-648 8mer < 0.1 
PIK3R3 miR-152 
miR-148b 
miR-9 
miR-24 
202-209 
202-209 
495-501 
1548-1555 
8mer 
8mer 
7mer-m8 
8mer 
0.58 
0.58 
0.91 
0.43 
PDK1 miR-155 2525-2532 8mer < 0.1 
COL1A2 let-7 b/c/d/e 378-385 8mer 0.95 
PPP2CB miR-132 262-268 7mer-m8 0.23 
COL11A1 let-7 b/c/d/e 748-754 7mer-A1 0.84 
PTEN miR-152 
miR-148b 
2254-2260, 3151-3158 
2254-2260, 3151-3158 
7mer-m8, 8mer 
7mer-m8, 8mer 
0.86, 0.88 
0.86, 0.88 
RPS6KB1 miR-145 
miR-24 
819-826 
1652-1685 
8mer 
7mer-A1 
0.59 
0.17 
PPP2CA miR125a-5p 476-482 7mer-A1 0.81 
GSK3B miR-132 
miR-9 
miR-24 
2665-2671 
3645-3651 
4111-4118 
7mer-A1 
7mer-m8 
8mer 
0.27 
0.72 
0.37 
TSC1 let-7 b/c/d/e 720-726 7mer-m8 0.89 
PDGFRA miR-24 2116-2123 8mer 0.42 
PPP2R5E miR-132 
miR-148b 
miR-152 
956-962 
3465-3472 
3465-3472 
7mer-m8 
8mer 
8mer 
0.27 
< 0.1 
< 0.1 
MYB miR-155 15-21 7mer-m8 0.23 
PRKAA2 miR-125a-5p 
miR-146a 
let b/c/d/e 
3542-3549 
3943-3950 
6617-66624 
8mer 
8mer 
8mer 
0.26 
< 0.1 
0.95 
CREB5 miR-9 
miR-132 
miR-145 
4013-4019, 5055-5061 
5493-6499 
4393-4400 
7mer-m8 
7mer-m8 
8mer 
0.70, 0.68 
0.28 
0.62 
YWHAG miR-132 
miR-125a-5p 
miR-221 
miR-145 
232-238 
940-947 
2737-2743 
1993-1999 
7mer-m8 
8mer 
7mer-m8 
7mer-A1 
0.44 
0.47 
0.10 
0.59 
CREB1 miR-155 
miR-125a-5p 
157-163 
5078-5084, 5900-5906 
7mer-A1 
7mer-m8 
0.56 
0.57, 0.78 
ANGPT2 miR-145 
miR-125a-5p 
331-338 
495-501 
8mer 
7mer-A1 
0.91 
0.53 
CDKN1B miR-221 
miR-24 
miR-148b 
miR-152 
201-208, 274-281 
1253-1260 
128-134 
128-134 
8mer 
8mer 
7mer-A1 
7mer-A1 
0.68 
0.84 
N/A 
N/A 
YWHAB miR-148b 1698-1705 
1698-1705 
8mer 
8met 
0.86 
0.86 
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GNB1 miR-145 28-34 7mer-A1 0.51 
PPP2R5C miR-125a-5p 
miR-132 
 1262-1268 
2232-2238 
7mer-m8 
7mer-m8 
0.73 
0.33 
CDK6 miR-148b 
miR-152 
miR-145 
let-7 b/c/d/e 
2270-2277 
2270-2277 
2388-2395, 9872-9878 
854-860 
8mer 
8mer 
8mer, 7mer-m8 
7mer-m8 
0.66 
0.66 
0.76, 0.65 
0.83 
GHR let-7 b/c/d/e 2246-2252 7mer-A1 0.95 
EIF4E miR-9 69-69 7mer-m8 0.92 
CCNE2 miR-9 677-684 8mer 0.61 
PPP2R2A miR-9 
miR-221 
let-7 b/c/d/e 
1404-1410 
452-458 
745-751 
7mer-A1 
7mer-A1 
7mer-m8 
0.58 
0.35 
0.80 
PIK3R1 miR-221 
miR-590-5p 
miR-155 
522-529 
861-867 
3718-3724 
8mer 
7mer-m8 
7mer-m8 
0.67 
0.51 
0.23 
YWHAZ miR-155 1353-1360 8mer 0.46 
KITLG miR-132 
miR-9 
18-24 
1647-1654 
7mer-A1 
8mer 
0.28 
< 0.1 
INSR let-7 b/c/d/e 2393-2400 8mer 0.96 
PRKAA1 miR-148b 
miR-152 
2069-2076 
2069-2076 
8mer 
8mer 
0.75 
0.75 
FGF2 miR-148b 
miR-152 
3114-3121 
3114-3121 
8mer 
8mer 
< 0.1 
< 0.1 
BCL2L1 let-7 b/c/d/e 945-952 8mer 0.81 
CREB3L2 miR-9 1253-1259 7mer-A1 0.82 
FOXO3 miR-132 
miR-155 
miR-9 
 162-169 
1497-1503 
3175-3181 
8mer 
7mer-m8 
7mer-m8 
0.77 
0.23 
0.86 
PKN2 miR-145 
miR-155 
let-7 b/c/d/e 
 205-211 
1969-1976 
1228-1234 
7mer-A1 
8mer 
7mer-A1 
0.66 
0.20 
0.83 
CDKN1A let-7 b/c/d/e 
miR-132 
943-950 
1365-1371 
8mer 
7mer-m8 
0.82 
0.12 
SGK3 miR-132 
miR-9 
miR-155 
287-293, 332-338 
998-1004 
249-256 
7mer-m8 
7mer-A1 
8mer 
0.55, 0.22 
0.72 
0.45 
CSF1R miR-24 
miR-155 
215-221, 584-590 
763-770 
7mer-m8, 7mer-A1 
8mer 
0.46, 0.17 
0.21 
OSMR let-7 b/c/d/e 756-763 8mer 0.95 
CSF1 miR-148b 
miR-152 
801-807, 902-909 
801-807, 902-909 
7mer-m8, 8mer 
7mer-m8, 8mer 
0.72, < 
0.1 
0.72, < 
0.1 
GNG5 let-7 b/c/d/e 149-155 7mer-m8 0.96 
TEK miR-148b 
miR-152 
894-901 
894-901 
8mer 
8mer 
0.29 
0.29 
BCL2L11 miR-24 442-449, 2678-2685 8mer 0.82, 0.84 
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miR-221 
miR-148b 
miR-152 
miR-9 
4052-4059 
3996-4002, 4094-4101 
3996-4002, 4094-4101 
1927-1934 
8mer 
7mer-A1, 8mer 
7mer-A1, 8mer 
8mer 
0.68 
0.76, 0.89 
0.76, 0.89 
0.90 
EFNA1 miR-145 
miR-9 
731-737 
273-279 
7mer-m8 
7mer-A1 
0.59 
0.80 
INHBB miR-148b 
miR-152 
miR-145 
miR-9 
1459-1466 
1459-1466 
1370-1376 
1575-1852 
8mer 
8mer 
7mer-m8 
8mer 
0.86 
0.86 
0.61 
0.91 
BMPR1B miR-125a-5p 141-148 8mer < 0.1 
PITX2 miR-590-5p 278-284 7mer-m8 0.50 
SMAD3 miR-145 1397-1404, 3925-3931 8mer, 7mer-m8 0.85, 0.60 
ID4 miR-9 1201-1207, 1248-
1254,2714-2721 
7mer-m8, 7mer-
A1, 8mer 
0.71, 0.68,  
< 0.1 
ACVR1 miR-148b 
miR-152 
miR-155 
449-455 
449-455 
304-310 
7mer-m8 
7mer-m8 
7mer-A1 
0.66 
0.66 
0.38 
SKP1 miR-148b 
miR-152 
miR-145 
miR-221 
51-57 
51-57 
420-427 
521-528 
7mer-m8 
7mer-m8 
8mer 
8mer 
0.92 
0.92 
0.55 
0.10 
ZFYVE16 miR-221 882-889 8mer 0.63 
E2F5 miR-132 
let-7 b/c/d/e 
miR-132 
18-25 
27-33 
18-25 
8mer 
7mer-m8 
8mer 
< 0.1 
0.84 
< 0.1 
SMAD5 miR-145 
miR-148b 
miR-152 
miR-132 
miR-155 
miR-24 
261-268 
532-538 
532-538 
1036-1043 
830-836 
2166-2172 
8mer 
7mer-m8 
7mer-m8 
8mer 
7mer-A1 
7mer-m8 
0.82 
0.32 
0.32 
0.10 
0.40 
0.41 
ACVR2A miR-145 
miR-155 
let-7 b/c/d/e 
40-46 
559-565 
589-595 
7mer-m8 
7mer-m8 
7mer-A1 
0.37 
0.23 
0.88 
GDF6 miR-148b 
miR-152 
miR-155 
let-7 b/c/d/e 
1825-1831 
1825-1831 
1994-2001 
2094-2101 
7mer-m8 
7mer-m8 
8mer 
8mer 
0.89 
0.89 
0.70 
0.96 
ACVR1C let-7 b/c/d/e  
miR-125a-5p 
miR-9 
90-97 
1965-1972 
6759-6765 
8mer 
8mer 
7mer-A1 
0.96 
0.35 
0.76 
GDF5 miR-132 508-515 8mer 0.14 
TGFB2 miR-145 
miR-590-5p 
miR-148b 
miR-152 
284-290, 2098-2105 
1282-1289 
2300-2307 
2300-2307 
7mer-A1, 8mer 
8mer 
8mer 
8mer 
0.94, 0.36 
0.78 
0.89 
0.89 
EP300 miR-132 1065-1072 8mer 0.65 
  
 353  
LTBP1 miR-148b  
miR-152 
34-40 
34-40 
7mer-m8 
7mer-m8 
0.62 
0.61 
SMAD7 miR-590-5p 1122-1129 8mer 0.80 
NOG miR-148b 
miR-152 
172-178 
172-178 
7mer-m8 
7mer-m8 
0.58 
0.58 
BMPR2 miR-125a-5p 
miR-590-5p 
6570-6576 
7554-7561, 7739-7745 
7mer-m8 
8mer, 7mer-m8 
0.81 
< 0.1, 
0.51 
ACTB miR-145 145-152 8mer 0.75 
  SHC1 miR-9 209-215, 1465-1471 7mer-m8 0.75, 0.90 
COL24A1 let-7 b/c/d/e 485-491 7mer-m8 0.91 
VCL miR-590-5p 
miR-9 
283-289, 1908-1915 
1680-1686 
7mer-m8, 8mer 
7mer-A1 
0.51, 0.36 
0.82 
CAV2 miR-148b 
miR-152 
miR-145 
750-756 
750-756 
1806-1813 
7mer-m8 
7mer-m8 
8mer 
0.44 
0.44 
0.55 
PPP1R12
A 
miR-148b 
miR-152 
1202-1208 
1202-1208 
7mer-m8 
7mer-m8 
0.63 
0.63 
SRC miR-9 419-425 7mer-A1 0.77 
PAK4 miR-9 
miR-145 
miR-24 
 22-29 
294-300 
470-477 
8mer 
7mer-A1 
8mer 
0.95 
0.91 
0.76 
VAV3 miR-125a-5p 
miR-155 
let-7 b/c/d/e 
miR-9 
235-241 
1357-1364 
1549-1555 
2032-2039 
7mer-A1 
8mer 
7mer-A1 
8mer 
0.74 
< 0.1 
0.95 
0.95 
MYLK miR-155 
miR-9 
miR-24 
179-185 
1017-1023 
485-491 
7mer-A1 
7mer-A1 
7mer-A1 
0.71 
0.75 
0.17 
XIAP miR-146a 
miR-155 
2795-2802 
3253-3259 
8mer 
7mer-m8 
< 0.1 
0.23 
PPP1CB miR-148b 
miR-152 
64-70 
64-70 
7mer-m8 
7mer-m8 
0.91 
0.91 
FOS miR-221 
miR-155 
203-210 
325-332 
8mer 
8mer 
0.62 
0.55 
NTF3 miR-221 
miR-590-5p 
52-59 
133-139 
8mer 
7mer-m8 
0.66 
0.50 
GNA12 miR-132 2521-2527 7mer-A1 0.28 
IL1R1 miR-24 2916-2922 7mer-A1 0.17 
RASA2 miR-145 
miR-9 
miR-125a-5p 
miR-590-5p 
24-31 
2497-2503 
627-633 
1369-1376 
8mer 
7mer-A1 
7mer-A1 
8mer 
0.88 
0.62 
0.81 
0.53 
ELK4 miR-145 
let-7 b/c/d/e  
miR-221 
3369-3676, 6526-6533 
2556-2562 
8492-8498 
8mer 
7mer-m8 
7mer-A1 
0.47, 0.89 
0.89 
0.48 
MAP3K3 miR-9 
miR-145 
560-567, 1804-1810 
760-766 
7mer-m8 
7mer-m8 
0.79, 0.35 
0.36 
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miR-125a-5p 
let-7 b/c/d/e  
miR-132 
597-603 
1201-1207 
1576-1583 
7mer-A1 
7mer-A1 
8mer 
0.54 
0.88 
0.74 
MAP2K7 miR-125a-5p 
miR-9 
644-650 
758-764, 1385-1391 
7mer-m8 
7mer-m8 
0.88 
0.88,0.56 
CACNB4 miR-221 
miR-155 
let-7 b/c/d/e 
5624-5271, 6086-6092 
2250-2256 
3640-3646 
8mer, 7mer-A1 
7mer-m8 
7mer-m8 
0.44, 0.35 
0.23 
0.48 
DUSP6 miR-9 
miR-145 
miR-125a-5p 
 423-429 
1018-1025 
952-958 
7mer-A1 
8mer 
7mer-A1 
0.82 
0.90 
0.81 
MAP4K3 let-7 b/c/d/e 1056-1063 8mer 0.94 
RPS6KA1 miR-125a-5p 777-783 7mer-m8 0.75 
GADD45A miR-148b 
miR-152 
32-39 
32-39 
8mer 
8mer 
0.64 
0.64 
MAP3K4 miR-148b 
miR-152 
384-391 
384-391 
8mer 
8mer 
0.79 
0.79 
MAP3K1 miR-9 
let-7 b/c/d/e 
2183-2189 
2152-2159 
7mer-m8 
8mer 
0.80 
0.94 
MAP3K13 let-7 b/c/d/e 848-855 8mer 0.71 
TAB2 let-7 b/c/d/e  
miR-155 
160-166 
818-825 
7mer-A1 
8mer 
0.87 
0.49 
BDNF miR-155 271-278 8mer 0.93 
MAP3K11 miR-145 
miR-125a-5p 
 56-62 
271-278 
7mer-A1 
8mer 
0.71 
0.93 
TAOK1 miR-24 
let-7 b/c/d/e  
miR-145 
miR-221 
miR-155 
1216-1223, 4409-4416 
2787-2793 
3493-3499, 4794-4801 
5695-5701 
7492-7498 
8mer 
7mer-m8 
8mer 
7mer-m8 
7mer-A1 
0.81, 0.44 
0.74 
0.65, 0.47 
0.10 
0.37 
FGF11 miR-24 
let-7 b/c/d/e 
388-395 
1192-1199 
8mer 
8mer 
0.58 
0.94 
PPP3CA miR-145 
miR-590-5p 
let-7 b/c/d/e 
736-743 
1129-1135 
638-644 
8mer 
7mer-m8 
7mer-A1 
0.76 
0.50 
0.81 
NLK miR-24 
miR-221 
miR-148b 
miR-152 
let-7 b/c/d/e 
miR-132 
411-417 
32-38 
879-885 
879-885 
1116-1133 
1349-1355 
7mer-A1 
7mer-m8 
7mer-m8 
7mer-m8 
7mer-m8 
7mer-A1 
0.17 
0.10 
0.59 
0.59 
0.90 
0.27 
CASP3 let-7 b/c/d/e  317-324 8mer 0.95 
RASGRP1 let-7 b/c/d/e 493-500 8mer 0.95 
RAPGEF2 miR-145 
miR-155 
1043-1049 
1731-1738 
7mer-m8 
8mer 
0.65 
0.15 
PPM1A miR-125a-5p 2583-2589 7mer-m8 0.85 
CACNB1 miR-125a-5p 1168-1175 8mer 0.84 
CACNA1 miR-24 2361-2368 8mer 0.35 
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CACNAE let-7 b/c/d/e  
miR-9 
1368-1374 
2032-2038 
7mer-A1 
7mer-m8 
0.91 
0.70 
DUSP8 miR-590-5p 
miR-9 
miR-24 
miR-148b 
miR-152 
1650-1657 
479-584 
401-407 
1790-1796 
1790-1796 
8mer 
7mer-m8 
7mer-m8 
7mer-m8 
7mer-m8 
0.81 
0.38 
0.74 
0.39 
0.39 
PPP3R1  miR-221 189-195, 343-349 7mer-A1, 7mer-m8 0.47, 0.10 
FAS let-7 b/c/d/e 879-886 8mer 0.73 
RPS6KA3 let-7 b/c/d/e  
miR-155 
miR-590-5p 
miR-145 
4432-4438 
312-318 
4486-4492 
3929-3935 
7mer-m8 
7mer-m8 
7mer-m8 
7mer-m8 
0.94 
0.23 
0.50 
0.44 
MAPK12 miR-125a-5p 378-385 8mer 0.75 
CACNB2 miR-125a-5p 
miR-145 
miR-9 
1164-1170 
1279-1285 
1510-1516 
7mer-A1 
7mer-A1 
7mer-m8 
0.55 
0.75 
0.52 
MEF2C miR-590-5p 
miR-9 
let-7 b/c/d/e 
192-198 
3788-3795 
3889-3895, 3906-3912 
7mer-m8 
8mer 
7mer-A1 
0.45 
0.89 
0.82, 0.79 
IL1A miR-24 105-111 7mer-m8 0.46 
MAP2K4 miR-145 340-346 7mer-A1 0.53 
SRF miR-9 
miR-125a-5p 
153-159 
2055-2061 
7mer-A1 
7mer-A1 
0.58 
0.37 
DUSP1 let-7 b/c/d/e 433-439 7mer-A1 0.95 
MAPK10 miR-590-5p 
miR-221 
604-610 
705-711 
7mer-m8 
7mer-m8 
0.45 
0.10 
PDGFRB miR-24 
miR-9 
232-239 
1763-1770 
8mer 
8mer 
0.56 
0.95 
CACNB3 miR-125a-5p 338-345 8mer 0.76 
 
